Abstract Supplement

8th IAS Conference on HIV Pathogenesis, Treatment & Prevention
19–22 July 2015, Vancouver, Canada

Scan this QR code with your mobile device to view the special issue online
A murine viral outgrowth assay to detect HIV in patients with undetectable viral loads

Kelly Metcalf Pate 1; Chris Pohlmeyer 2; Victoria Walker-Sperling 2; Jeremy Foote 1; Kevin Najarro 1; Catherine Cryer 1,3; Maria Salgado 2,4; Lucio Gama 1; Elizabeth Engle 1; Erin Shirk 1; Suzanne Queen 1; Stanley Chioma 2; Meghan Vermillion 1; Brandon Bullock 1; Ming Li 1; Claire Lyons 1,5; Robert Adams 1; Chris Zink 1; Janice Clements 1; Joseph Mankowski 1 and Joel Blankson 2

1Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, United States. 2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, United States. 3School of Veterinary Medicine, University of Pennsylvania, Philadelphia, United States. 4Institute IrsiCaixa, Universitat Autònoma de Barcelona, Badalona, Spain. 5Cummings School of Veterinary Medicine, Tufts University, North Grafton, United States.

Presenting author email: kpate5@jhmi.edu

Introduction: Sensitive assays are needed for detection of residual HIV in patients with undetectable plasma viral loads to determine if eradication strategies are effective. The gold standard quantitative viral outgrowth assay (QVOA) underestimates the magnitude of the viral reservoir, while sensitive PCR-based assays lack the ability to distinguish replication competent from defective virus. We sought to determine whether xenograft of leukocytes from HIV-1 infected patients with undetectable plasma viral loads into severely immuno-compromised mice would result in viral amplification and measurable viral loads within the aberrant murine host.

Methods: We evaluated whether xenograft of 1) peripheral blood mononuclear cells (PBMCs) from five HIV-1+ patients on suppressive antiretroviral therapy (ART), 2) PBMCs or purified resting CD4+ T cells from 5 HIV-1+ elite suppressors (ES), or 3) PBMCs from a Simian Immunodeficiency Virus (SIV)+ pigtailed macaque on suppressive ART, all with undetectable plasma viral loads, into NOD.Cg-PkrdcscidIl2rgtm1Wjl/SzJ (NSG) mice resulted in viral amplification in the mouse. Successful xenograft of mice was confirmed by flow cytometry. Human CD8+ T cells were depleted in humanized mice with depleting antibody, and CD4+ T cells were activated in a subset of mice with activating anti-CD3. Plasma viral loads in xenografted mice were quantified using qRT-PCR, and compared to plasma viral load and QVOA results from the human or macaque donor.

Results: With this murine viral outgrowth assay (MVOA), we amplified HIV-1 from all 10 HIV+ subjects with undetectable plasma viral load, including an ES from whom we were unable to recover virus by QVOA. We detected HIV in mice an average of 20 days after xenograft with PBMCs from patients on suppressive ART, and an average of 28 days after xenograft with PBMCs or resting CD4+ T cells from ES. For two of the mice xenografted with CD4+ T cells from ES, we detected HIV only after activation with anti-CD3. We similarly detected SIV in macaquized mice by seven days post-xenograft.

Conclusions: The MVOA has the potential to serve as a powerful tool to identify residual HIV-1 in patients with undetectable viral loads, such as those who have undergone promising cure therapies.
replication are still unclear, particularly in tissues. Here, we used the well-established model of SIV-infection in rhesus macaques (RMs) to investigate the existence of PTC in this model and the features associated with post-ART SIV control.

**Methods**: Fifteen RMs (B*08- and B*17) were infected (i.v.) with SIVmac239. All 15 animals initiated a five-drug ART regimen 60 days after infection, which was maintained for seven months. ART was then interrupted and RMs monitored for eight additional months. Blood (PB), lymph node (LN) and colorectal (RB) biopsies were collected throughout the study. Quantitative assessment of total SIV-DNA and RNA was performed on purified blood CD4 T cells and mucosal tissues by quantitative PCR; immunological parameters were determined by flow cytometry.

**Results**: ART suppressed SIV-RNA to < 60 copies/mL in all RMs. After ART interruption, six RMs controlled SIV viremia at < 10^3 copies/mL up to eight months off-ART (PTC), while nine RMs rebounded to pre-ART levels (non-controllers, NC). At pre-ART, PTC had significantly lower plasma viremia and SIV-DNA content, as well as higher CD4 T cell counts as compared to NC. Levels of intestinal CD4 T cells were similar, but PTC had higher frequencies of Th17 cells than NC. On-ART, PTC had significantly lower levels of residual plasma viremia (3 copies/mL, limit of detection) and SIV-DNA content (both in blood and colorectum). After ART interruption, SIV-DNA content rapidly increased in NC while it progressively decreased in PTC. Finally, in PTC control of SIV rebound associated with higher CD4 T cell levels and reduced immune activation in PB and RB during the entire off-ART period.

**Conclusions**: Lower set point viremia, reduced cell-associated SIV-DNA and preserved Th17 cell homeostasis associate with improved virologic response to ART and sustained viral control post-ART interruption in SIV-infected RMs.

**http://dx.doi.org/10.7448/IAS.18.5.20321**

**MOAA0103**

**Anti-HIV antibody responses reflect the quantifiable HIV reservoir size**

Sulggi Lee 1; Nicolas Chomont 2; Remi Fromentin 2; Robert Silicano 3; Janet Silicano 3; Douglas Richman 4; Una O’Doherty 5; Sarah Palmer 6; Peter Burbelo 7 and Steven Deeks 1

1Department of Medicine, University of California San Francisco, San Francisco, United States. 2Department of Immunology, University of Montreal, Montreal, Canada. 3Department of Medicine, Johns Hopkins University, Baltimore, United States. 4Department of Medicine, University of California San Diego, La Jolla, United States. 5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States. 6Department of Medicine, University of Sydney, Sydney, Australia. 7National Institute of Dental and Craniofacial Research, Clinical Dental Research Core, Bethesda, United States.

**Presenting author email**: sulggi.lee@ucsf.edu

**Introduction**: A major challenge to HIV eradication strategies is accurate measurement of the latent HIV reservoir. We assessed whether the host response to residual virus may be a sensitive measure of reservoir size by comparing anti-HIV antibody profiles in relation to several HIV reservoir assays.

**Methods**: Using a luciferase immunoprecipitation systems (LIPS) assay, we quantitatively analyzed seven anti-HIV antibody profiles from 61 patients who initiated long-term (> 3 years) antiretroviral therapy (ART) during chronic HIV infection. HIV antibody levels were evaluated in relation to 12 HIV reservoir measures: total, integrated and 2-LTR DNA (rtPCR, n = 48); unspliced RNA (rtPCR, n = 44), total and 2-LTR DNA (droplet digital PCR, n = 27); integrated DNA (aluPCR, n = 16); viral outgrowth assay (VOA, n = 27) and plasma HIV RNA (single copy assay, SCA, n = 27). Summary estimates of the overall association between HIV reservoir measures and HIV antibody levels adjusted for multiple comparisons were obtained using permutation testing.

**Results**: Participants were mostly male (96%) with a median age of 56, median nadir and proximal CD4 T cell counts of 210 and 670 cells/mm^3, respectively, and ART-suppression for a median of 11 years. Individual correlations showed that integrated and total HIV DNA levels by aluPCR and ddPCR were significantly associated with all antibody levels except p24 (nor matrix, for ddPCR, Figure 1). HIV reservoir size measured by viral outgrowth assay (VOA) was associated with gp120 and gp41 levels (r = 0.45, p = 0.02; r = 0.43, p = 0.02) while HIV RNA by SCA and HIV DNA by rtPCR were not correlated with any HIV antibody responses. Permutation testing

![Abstract MOAA0103 - Figure 1. Individual correlations matrix.](image-url)
Abstract MOAA0103 - Table 1. Adjusted summary correlations

| Anti-HIV antibody response | R   | P      |
|----------------------------|-----|--------|
| logpp120                   | 0.80| 0.009  |
| logpp41                    | 0.73| 0.042  |
| logrt                      | 0.82| 0.007  |
| logintegrase               | 0.70| 0.053  |
| loger                      | 0.60| 0.199  |
| logma                      | 0.54| 0.340  |
| logps24                    | 0.41| 0.679  |
| All                        | 0.82| 0.039  |

demonstrated a strong overall association between HIV reservoir size and anti-HIV antibody responses (r = 0.82, p = 0.04, Table 1), in particular with gp120 (r = 0.80, p = 0.009), gp41 (r = 0.73, p = 0.04) and reverse transcriptase (r = 0.82, p = 0.007). Further adjustment for age, proximal CD4+ T cell count and years of ART suppression did not significantly alter these results.

Conclusions: Anti-HIV antibody responses correlate with quantifiable reservoir size during chronic ART-mediated suppression. Epitope location (envelope proteins and reverse transcriptase, an enzyme involved in the early steps of viral replication) may determine the strength of this association. Future studies are needed to evaluate whether viral RNA or proteins are produced in cells with defective proviruses.

http://dx.doi.org/10.7448/IAS.18.5.20322

MOAA0104
Transcriptomics and metabolomics identify inflammatory profiles that segregate subjects with high and low inducible HIV reservoir
Khader Ghneime1; Jeff Ahlers2; Slim Fourati1; Carey Shive3; Mark Cameron3; Pranab Mukherjee1; Mahmoud Ghannoum4; Benigno Rodriguez5; Steven Deeks6; Michael Lederman4 and Rafick Sekaly7
1Department of Pathology, Case Western Reserve University, Cleveland, United States. 2VCTI-L, Port Saint Lucie, United States. 3Department of Medicine, University of California San Francisco, San Francisco, United States.
Presenting author email: khader.ghneime@case.edu

Introduction: To identify mechanisms that control immune reconstitution and the size of the inducible HIV reservoir, we performed whole blood transcriptional and metabolic profiling of subjects from the CLIF and UCSF SCOPE cohorts. These cohorts included subjects who increased CD4 counts post cART (IR) or stayed in the CLIF and UCSF SCOPE cohorts. These cohorts included subjects who increased CD4 counts post cART (IR) or stayed.

Methods: We performed unsupervised analysis of gene expression data using hierarchical clustering to identify class and supervised analysis using statistical filtering to identify gene signatures and pathway activity differentially expressed between classes. Multivariate analysis based on Sparse Partial Least Regression was used to determine if Group membership correlated with plasma metabolites measured by LC-MS/GC-MS. A gene-based classifier was developed to identify INR groups using the pamr package.

Results: Two groups of INR subjects were identified by whole blood gene expression and pathway analysis. INR-A had the highest levels of IL-6, VDCA14, FOXO3 and STAT1 expression, and highest levels of oxidative stress and mitochondrial dysfunction. Pathway analysis showed that INR-A failed to activate the NF-kB pathway, TLR-MyD88 signalling and proinflammatory modules yet upregulated expression of the p38 MAPK pathway, IRF-3, IRF-4 and IL-10 associated with a tolerogenic myeloid response. In contrast, INR-B was characterized by an unrestrained proinflammatory response including the upregulation of multiple TLRs, STAT1, IRF1 and IRF8 associated with Type I/II IFN responses. Plasma metabolites including carnitines, bacterial metabolites and cholesterol also segregated between the two INR groups and correlated with gene expression including FOXO3A and STAT1. TILDA, a measure of the inducible HIV reservoir; revealed that INR-A subjects had higher levels than INR-B and IR’s. As CD4 counts and plasma biomarkers of inflammation/immune activation fail to distinguish the two INR groups, we developed a 352 gene-based classifier that accurately identified patient groups (AUC of 0.81 by ROC analysis) in an independent test cohort (UCSF SCOPE) including those that had the highest levels of HIV reservoir.

Conclusions: Identifying pathways that control immune reconstitution and the size of the inducible HIV reservoir paves the way to the development of therapeutic strategies that can lead to eradication of HIV.

http://dx.doi.org/10.7448/IAS.18.5.20323

MOAA0105LB
HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally infected child
Pierre Frange1,2,3, Albert Baye4,5, Veronique Avettand-Fenoel1,2, Erainna Bellaton6; Diane Deschamps7,9; Mathieu Angin2; Sophie Caillat-Zucman10,11; Gilles Peytavin2,3; Jerome Le Chenadec14,15; Josiane Warszawski14,15; Christine Rouzioux12; Asier Saez-Cirion9 and ANRS Epf-Co10 Pediatric Cohort
1Assistance Publique – Hôpitaux de Paris (AP-HP), Laboratoire de Microbiologie Clinique, Hôpital Necker – Enfants malades, Paris, France. 2EA7327, Université Paris Descartes, Paris, France. 3AP-HP, Unité d’Immunologie, Hématologie et Rhumatologie Pédiatriques, Hôpital Necker – Enfants malades, Paris, France. 4AP-HP, Service de Pédiatrie générale, Hôpital Robert Debré, Paris, France. 5Université Paris 7 Denis Diderot, Paris, France. 6AP-HP, Service d’Hématologie pédiatrique, Hôpital Robert Debré, Paris, France. 7AP-HP, Hôpital Bichat – Claude Bernard, Paris, France. 8INSERM UMR1137 IAME Université Paris Diderot, Paris, France. 9Unite de HIV Infection and Persistence, Institut Pasteur, Paris, France. 10AP-HP, Laboratoire d’Immunologie, Hôpital Robert Debré, Paris, France. 11INSERM UMR1149, Université Paris Diderot, Paris, France. 12AP-HP, Laboratoire de Pharma-Toxicologie, Hôpital Bichat, Paris, France. 13IAME, INSERM UMR 1137, Université Paris Diderot, Paris, France. 14AP-HP, Service d’Epidémiologie et de Santé publique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. 15INSERM U1018, Université Paris Sud, Le Kremlin-Bicêtre, France.
Presenting author email: asier.saez-cirion@pasteur.fr

Introduction: Durable HIV-1 remission after interruption of combined antiretroviral therapy (cART) has been reported in some adults who started cART during primary HIV-1 infection. The in utero HIV-1-infected “Mississippi child” exhibited transient viral control after interrupting very early-initiated cART. However, viraemia rebounded 27 months later, leaving unclear the possibility of obtaining long-term post-treatment remission in vertically infected children. Here, we report the case of a perinatally HIV-1-infected adolescent who shows unprecedented virological remission more than 11 years after cART discontinuation.

Methods: HIV-RNA and CD4+ T-cell counts have been monitored since birth. Ultraviolet HIV-RNA, peripheral blood mononuclear cell (PBMC)-associated HIV-DNA, flow-cytometry-assessed frequency of HIV-specific CD8+ T cells, CD8+ T-cell-mediated HIV suppression, reactivation of the CD4+ T-cell reservoir were evaluated after 10 and 11 years of control off therapy. Plasma concentrations of antiretrovirals were determined by tandem mass spectrometry.
**MOAA0106B**

**Time-associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy – implications for clinical trials of cure interventions**

Christina Chang1,2, Paul Cameron1,2, Julian Elliott2; Alan Perelson3; Siddappa Byrareddy1; James Arthos2; Claudia Cicala3; Keith Reimann1; Tristram Parslow1; Philip Santangelo4; Francois Villinger5; Anthony Fauci6 and Abtaf Ansari7

1Department of Pathology & Laboratory Medicine, Emory University, Atlanta, United States. 2Laboratory of Immunoregulation, National Institute of Allergy & Infectious Diseases, National Institutes of Health (NIH), Bethesda, United States. 3Department of Mass Biologics, University of Massachusetts Medical School, Boston, United States. 4Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, United States. 5National Laboratory for Cancer Research, National Cancer Institute, Frederick, United States. 6National Cancer Institute, Frederick, United States. 7National Laboratory for Cancer Research, National Cancer Institute, Frederick, United States. 8Center for Integrative Medicine, University of California, San Francisco, United States. 9National Laboratory for Cancer Research, National Cancer Institute, Frederick, United States. Presenting author email: christina.chang@unimelb.edu.au

**Introduction:** Cell-associated unspliced (CA-US) HIV RNA is an important marker of the HIV reservoir and a common primary endpoint in clinical trials of latency reversing agents in HIV-infected subjects on antiretroviral therapy (ART). We observed large baseline variation in CA-US HIV RNA in a recent clinical trial of disulphiram subjects on suppressive ART prior to any intervention. B3 was collected immediately prior to administration of disulphiram. We measured CA-US HIV RNA and DNA by real-time PCR and plasma HIV RNA (using a single copy assay) by droplet digital PCR. Plasma cortisol and thyroid-stimulating hormone (TSH) levels were quantified by ELISA. PBMC were stained with live-dead dye and antibodies to CD3, CD4, CD8, CD45RA,CCR7, CD27, CD38, HLA-DR, acetylated lysine and acetylated histone-3 and were analyzed by flow cytometry. Data were assessed for normality and then analyzed with Wilcoxon matched-pairs signed rank tests and paired t-tests.

**Results:** CA-US RNA was higher in blood collected at B3 compared to B1 and B2 (median 85.63 vs. 28.14 and 34.87 copies/million CD4+ T-cell equivalents; both, p < 0.001). There were little differences in HIV DNA or plasma HIV RNA at these times. B3 was collected earlier in the day compared to B1 and B2 (mean 8.28 am vs. 11.38 am and 10.21 am; both, p < 0.001). Other parameters that were significantly higher at B3 compared to B1 and B2 were cortisol (p = 0.001 and 0.011); TSH (p = 0.023 and 0.004); CD8 + CD38 + HLA-DR – T cells (both, p < 0.001) and CD4 + CD38 + HLA-DR – T cells, which were elevated at B3 compared to B2 (p = 0.012). There were no significant differences in the percentage of T-cell subsets or histone acetylation in the blood collected at these time points.

**Conclusions:** Time-associated variation in CA-US HIV RNA seen in HIV-infected subjects on suppressive ART was not associated with significant alterations in CD4+ T-cell subset composition and was suggestive of circadian changes in HIV RNA transcription. Diurnal changes in CA-US HIV RNA may need to be considered in the design of future cure intervention trials.

http://dx.doi.org/10.7448/IAS.18.5.20567

**MOAA0202**

**Treatment with anti-α4β7 integrin antibody reduces virus-mediated gastrointestinal pathology by targeting distinct mucosal tissues**

Siddappa Byrareddy1; Jamie Arthos2; Claudia Cicala3; Keith Reimann1; Tristram Parslow1; Philip Santangelo4; Francois Villinger5; Anthony Fauci6 and Abtaf Ansari7

1Department of Pathology & Laboratory Medicine, Emory University, Atlanta, United States. 2Laboratory of Immunoregulation, National Institute of Allergy & Infectious Diseases, National Institutes of Health (NIH), Bethesda, United States. 3Department of Mass Biologics, University of Massachusetts Medical School, Boston, United States. 4Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, United States. Presenting author email: siddappa.n.byrareddy@emory.edu

**Introduction:** Our laboratory has recently demonstrated that in vivo administration of a monoclonal anti-α4β7 antibody (α4β7-mAb) during acute SIV infection following (1) intravenous, (2) intra-rectal or (3) repeated low-dose intra-vaginal SIV challenge lead to markedly lower gastro-intestinal tissue viral loads compared to rhesus macaques (RM) treated with a control mAb. The purpose of the present study was to compare the tissues that served as primary targets of viral infection in the α4β7-mAb versus control mAb-treated RM, in order to identify mechanisms by which α4β7-mAb antibody reduces virus-mediated gastrointestinal pathology.

**Methods:** Groups of 12–16 RM were administered a rhesus α4β7-mAb monoclonal antibody or an isotype-matched control rhesus IgG mAb (50 mg/kg) intravenously (i.v.) starting on day -1 and then every three weeks after infection. Each monkey was then repeatedly challenged with a low-dose SIVmac251 intra-vaginally or a single high-dose intrarectally.

**Results:** Intravenous administration of α4β7-mAb blocked the detection of α4β7 on CD4+ T cells in the blood, cervicovaginal tissue and gut-associated lymphoid tissue (GALT) throughout the period of mAb administration. Viral RNA was reduced in GALT biopsies of the α4β7-mAb treated RMs compared to those treated with control mAb.
treated (median 3.5 vs. 12.8 copies/ng DNA respectively, p = 0.006). Furthermore, in-depth analysis performed on a subset of animals (n = 4/group) indicated that proviral DNA was 5 to 25 fold more abundant in jejunum, ileum or colon of control-treated RMs compared to those treated with S47-mAb. In contrast, no difference in proviral loads in the spleen and lymph nodes from various sites was noted in the two groups. Immuno-PET/CT assisted analysis revealed that for animals with comparable plasma viral loads, the S47-mAb treated monkeys showed a lower signal in the large intestine. In addition, only the control treated monkeys showed a clear PET/CT signal in lymph nodes surrounding the genital tract suggesting that treatment with S47-mAb prevents viral replication in this tissue, leading to different patterns of tissue localization of the virus between the two groups.

Conclusions: The S47-mAb either protects or delays intravaginal SIV transmission, reduces gastrointestinal pathology following infection and results in both quantitative and qualitative differences in the level of viremia and tissue localization of virus.

http://dx.doi.org/10.7448/IAS.18.5.20324

MOAA0203
Oral microbiome in HIV-infected women: ageing, disease progression and opportunistic infections increase the pathogenic profile
Michael George1; Barbara Weiser2,3; Harold Burger2,3; Tyler Lewy1 and Kathryn Anastos4
1Department of Medical Microbiology and Immunology, University of California Davis School of Medicine, Davis, United States. 2School of Medicine, University of California Davis, Davis, United States. 3Sacramento Veterans Administration Medical Center, Sacramento, United States. 4Department of Medicine, Albert Einstein College of Medicine, Yeshiva University, Bronx, United States. Presenting author email: mdgeorge@ucdavis.edu

Introduction: A recent marked increase in the proportion of HIV-infected individuals older than 50 highlights the need to study the impact of ageing on HIV pathogenesis. HIV-associated non-AIDS (HANA) conditions, such as cardiovascular disease, diabetes, osteoporosis and dementia are more prevalent in older HIV-infected populations than young adults. The microbiome in saliva and the oral cavity has been studied as a window into pathogenesis in ageing populations. Although disruption of the oral microbiome (dysbiosis) has been linked to various human conditions and diseases associated with ageing, the role of age-related dysbiosis in the development of opportunistic infections and HANA conditions in HIV patients is not well understood.

Methods: We utilize 16S rRNA-based pyrosequencing to compare the salivary microbiome in three groups: chronically HIV-infected women aged 50 years old (ageing), or infected individuals older than 50 highlights the need to study the impact of ageing on HIV pathogenesis. HIV-associated non-AIDS (HANA) conditions, such as cardiovascular disease, diabetes, osteoporosis and dementia are more prevalent in older HIV-infected populations than young adults. The microbiome in saliva and the oral cavity has been studied as a window into pathogenesis in ageing populations. Although disruption of the oral microbiome (dysbiosis) has been linked to various human conditions and diseases associated with ageing, the role of age-related dysbiosis in the development of opportunistic infections and HANA conditions in HIV patients is not well understood. We also examine correlations between dysbiosis of the salivary microbiome that is enhanced in ageing individuals and characterized by increased abundance of pathogenic bacteria and a decline in healthy probiotic microbes. Higher proportions of Prevotella, Staphylococcus, Morrella, Peptostreptococcus, Ruminococcus and Orbacterium were detected in both ageing and young adult HIV infected women than in uninfected controls. Prevotella, Morrella and Orbacterium increases were higher in ageing than in young HIV patients. HIV infection in older patients was associated with greater salivary shedding of Epstein Barr Virus (EBV). Increased EBV shedding, higher peripheral HIV burden and reduced CD4+ T cell counts correlated with increases in Prevotella and decreases in probiotic Lactobacillus. Patients with opportunistic oral infections also showed enhanced salivary levels of Porphyromonas, Lachnospira and Actinobacillus, and reduced Streptococcus.

Conclusions: Age, severity of disease progression and emergence of opportunistic infections all contribute to various degrees in increasing the pathogenic footprint of the oral microbiome during chronic HIV infection. The study findings provide new insights into age-related dysbiosis of the salivary microbiome and its role in HIV pathogenesis and lay critical groundwork for future expanded investigations.

http://dx.doi.org/10.7448/IAS.18.5.20325

MOAA0204
Serum-derived bovine immunoglobulin isolate increases peripheral and mucosal CD4 T cell count in patients with HIV enteropathy
David Asmuth1; Ma Somsouk2; Peter Hunt3; Zhong Min Ma4,5,6, Christopher Miller3,7; Xiao Dong Li1,4; John Hinkle5; Audrey Shaw5; Eric Weaver6 and Gerald Klein3
1Internal Medicine, University of California Davis Medical Center, Sacramento, United States. 2Department of Medicine, University of California San Francisco, San Francisco, United States. 3Center for Comparative Medicine, University of California Davis, Davis, United States. 4Center for Comparative Medicine, Davis, United States. 5California National Primate Research Center, Davis, United States. 6EarlyPhase Sciences Inc., Cary, United States. 7Entera Health Inc., Cary, United States. 8Entera Health, Inc., Ankeny, United States. 9Entera Health, Inc., Cary, United States.

Introduction: A multi-centre trial in HIV-enteropathy was conducted to evaluate the impact of serum-derived bovine immunoglobulin isolate (SBI) on markers of peripheral and mucosal immunity and gastrointestinal (GI) symptoms as previously reported.

Methods: Patients (pts) on long-term suppressive antiretroviral treatment (ART) with HIV-enteropathy were randomized to receive SBI 2.5 vs. 5.0 g BID or placebo (PBO) during a four-week lead-in phase followed by SBI 2.5 vs. 5.0 g BID for 20 weeks. Evaluations included plasma biomarkers for inflammation, peripheral CD4 counts and pt-reported surveys on GI symptoms. Eight pts underwent duodenal biopsies to examine mucosal immunity.

Results: A total of 103 pts (SBI 2.5 g; n = 34; SBI 5.0 g; n = 33; PBO: n = 36 continued 2.3 vs. 5.0 g (n = 18 each)) were enrolled (31% female; 61% black; mean age 51 years). Mean duration of HIV, ART and enteropathy was over 15, 5 and 5 years, respectively. All cohorts showed a reduction in abnormal stool frequency (p = 0.0001) from baseline (BL) to week 4; however between group analysis was not significant. This reduction was maintained for pts receiving SBI through 24 weeks. The 2.5 and 5.0 g cohorts were combined for zonulin and CD4 analysis. The mean plasma zonulin levels significantly increased (p < 0.0001) for pts receiving SBI through 24 weeks.

Median peripheral CD4 counts increased significantly from BL to week 24 in patients in the lowest baseline CD4 quartile (308 to 386 cells/mL, p = 0.002), while no significant change was observed among subjects in the combined SBI cohorts during this time period. This compromised subgroup also experienced greater increases in CD4 counts at week-4 than PBO pts (median +42 vs. −17 cells/mL, p = 0.02). Duodenal CD4 densities increased from 217 to 329 cells/mm² (median increase of 145 cells/mm² (p = 0.02)) in biopsies obtained from eight pts, consistent with earlier findings. Duodenal crypt cells expressing Ki67 decreased in 6/7 pts from 41 to 24% (p = 0.08, n = 7) which correlated with the decreased number of Paneth cells per crypt (p = 0.048).

Conclusions: Serial SBI may be a novel strategy to restore mucosal immunity and systemic immune reconstitution among pts who have not achieved normal CD4 counts despite prolonged suppressive ART.

http://dx.doi.org/10.7448/IAS.18.5.20326
MOAA0205
HIV-exposure, gut microbiome, and vaccine responses in South African infants
Katie Viljoen1; Jerome Wendon1; Ulas Karaoz2; Eoin Brodie2; Nicola Mulder3; Gerrat Botha3; Elvis Kidzeru1; James Butcher1; Clive Gray1; Ken Rosenthal3; Alash'e Abimiku3; Bill Cameron2; Alain Stintzi1 and Heather Jaspan1,2,8,9

1Clinical Lab Sciences, Institute of Infectious Disease and Molecular Medicine, University of CapeTown, Cape Town, South Africa. 2Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 3Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 4Institute of Systems Biology, Ottawa, Canada. 5Institute for Molecular Medicine and Health, McMaster University, Hamilton, Canada. 6Institute of Human Virology, Baltimore, United States. 7Ottawa Hospital Research Institute, Ottawa, Canada. 8Seattle Children's Research Institute, Seattle, United States. 9Department of Pediatrics, University of Washington, Global Health, Seattle, United States.

Presenting author email: hbjaspan@gmail.com

Introduction: The gut microbiome is crucial for mucosal and systemic immune development. In mice, certain bacteria are required for induction of Th17 and Th17 cell development in the gut. Likewise, gut microbiota enhance immune responses to influenza vaccination in the mouse model. HIV-infected women have altered vaginal and gut microbiome, and HIV-exposed infants (HEU) and their mothers receive antibiotics for pneumocystis pneumonia prophylaxis, therefore HEU may have altered gut microbiota. HEU have higher morbidity and mortality than HIV-unexposed (HU) infants, and respond poorly to certain infant vaccinations. We hypothesized that the aetiology of this relative immune deficiency is mediated by gut dysbiosis.

Methods: HEU and HU infants were recruited at birth from informal settlements of Cape Town. Blood and stool were collected after informed consent was obtained. Stool DNA was extracted using MoBio PowerFecal DNA kit and 454 or Illumina sequencing was performed. Data was pre-processed using QIIME and UPARSE and imported into R for further analyses using phyloseq. Differential abundance testing was performed at Operational Taxonomic Unit (OTU) level using the R metagenomeSeq package. Whole blood was incubated with BCG, positive and negative controls, and proliferation and cytokine expression measured using multi-parameter flow cytometry.

Results: We found substantial differences in bacterial diversity between HEU and HU infants by Shannon index. Moreover, at all taxonomic levels, there were differences between the HIV exposure groups via PCoA analysis. Several OTUs of the phylum Firmicutes were differentially abundant between HEU and HU infants, three of which were of the genus Veillonella. Several key species were significantly correlated with both proliferative and cytokine responses to BCG. For example, at six weeks of age, significantly decreased abundance of Bacteroides species, and in particular B. fragilis, were present in infants with high CD4 + IL-2+, CD8 + ki67+ and CD8 + IL-17+ responses to BCG vaccination at six weeks of age.

Conclusions: Gut microbial composition could explain the immunological differences between HU and HEU infants. These differences should be considered in development of HIV vaccines for exposed neonates.

http://dx.doi.org/10.7448/IAS.18.5.20327

MOAB0101
Field evaluation of point-of-care testing for early infant diagnosis in Cape Town, South Africa
Max Kison1; Lorna DunnIng2; Marvin Hsiao2 and Landon Myer3

1Division of Neonatal Medicine, Department of Paediatrics & Child Health, University of Cape Town, Cape Town, South Africa. 2Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa. 3Division of Medical Virology, University of Cape Town, Cape Town, South Africa.

Introduction: Provision of rapid early infant HIV diagnosis (EID) service remains a challenge for prevention of mother-to-child transmission programmes globally. Point-of-care (POC) EID testing may improve access and turnaround times, but while several POC technologies are in development there are few data on implementation.

Methods: We conducted an implementation study of the Alere qDetect POC system for EID at two public sector health facilities. At a maternity hospital the POC device was used to test HIV-exposed neonates soon after birth; at a primary care clinic the device was used for routine six-week EID testing. At each site infants undergoing laboratory-based HIV PCR testing per local protocols were tested on the POC device by doctors or nurses with results available within one hour. Analysis examined the performance of POC versus laboratory testing of the same specimen, and semi-structured interviews with providers to assess implementation issues and acceptability.

Results: Overall 476 tests were conducted: 291 birth tests in the maternity hospital (mean child age, <1 day) and 195 six-week tests in primary care (mean child age, 51 days). Twelve percent of all tests resulted in an error with no differences by site; most error results
resolved with retesting. POC EID was more sensitive (100%; lower confidence limit, 40%) and specific (100%, lower confidence limit, 98%) among older children tested in primary care compared birth testing in hospital (92% (95% CI, 62–100%) and 99% (95% CI, 99–100%), respectively), though test performance improved with repeated lab testing and negative predictive value was high (>99%) at both sites. In interviews, providers felt that the ease of use of the device coupled with the rapid turnaround time of POC EID results facilitated decision-making in the management of infants, but many wanted to understand better the cause of errors on the POC device to assist in repeat testing.

**Conclusions:** POC EID testing performs well in field implementation in health care facilities and is highly acceptable to health care providers. While further research is needed to understand POC EID implementation at scale, the rapid turnaround time of POC testing may allow immediate identification and management of HIV-infected infants.

http://dx.doi.org/10.7448/IAS.18.5.20328

**MOAB0102**

**High rates of baseline NNRTI-resistance and virologic failure among ART naïve HIV-infected children in Mali**

Claudia S Crowell1; Almoustapha Issiaka Maiga2; Mariam Sylla2; Babafemi Taiwo3; Niaboula Koné4; Robert Leo Murphy5; Anne-Genevieve Marcelin6; Ban Traore7; Djeneba Bocar Fofana8 and Ellen G Chadwick9

1Department of Pediatric Infectious Diseases, University of Washington, Seattle Children’s Hospital, Seattle, United States.
2Faculty of Pharmacy, University of Sciences Techniques and Technologies of Bamako, Unité d’Épidémiologie Moléculaire de la Résistance du VIH aux ARV, SEREFO, Bamako, Mali.
3Département de Pédiatrie, Centre Hospitalier Universitaire Gabriel Toure, Bamako, Mali.
4Department of Infectious Diseases, Northwestern University, Chicago, United States.
5Department of Virology, Hôpital Pitié-Salpêtrière, Paris, France.
6Division of Pediatric Infectious Diseases, Lurie Children’s Hospital, Chicago, United States.

**Introduction:** Limited data exist on drug resistance and antiretroviral treatment (ART) outcomes in HIV-1 infected children in West Africa. We determined the prevalence of baseline resistance, and correlates of virologic failure (VF) and on-treatment resistance in a cohort of HIV-1 infected children in Mali.

**Methods:** Prospective observational study of HIV-1 infected children <10 years of age initiating first-line ART in Bamako, Mali. Assessments occurred at baseline and after six months of ART. Genotypic resistance testing on stored baseline and six-month samples occurred at study end. Reverse transcriptase and protease genes were sequenced using in-house methods. Resistance was defined as intermediate or high-level according to the Stanford HIV Genotypic Resistance Algorithm v7.0. Virologic failure was defined as viral load (VL) ≥1000 copies/mL. Clinical and immunological failures were based on WHO criteria. Logistic regression was used to evaluate factors associated with VF and resistance.

**Results:** A total of 150 children were enrolled; 60% male and mean age 3.4 years. Ninety-four percent reported no prevention of mother-to-child transmission (PMTCT) exposure. Median baseline CD4 count and VL were 633 cells/mm3 (IQR: 381–1039) and 675,651 copies/mL (IQR: 40,000–1,583,200). Initial ART regimens were lopinavir/ritonavir-based (43%) or non-nucleoside reverse transcriptase inhibitors (NNRTI) (efavirenz or nevirapine)-based (57%). Of 141 children with amplifiable baseline samples, 28 (19.86%) had NNRTI resistance, only two of whom had PMTCT exposure and none had protease inhibitor (PI) resistance. Mean age of children with baseline NNRTI resistance was 2.3 years. By six months of ART, 11 died, 8 were lost to follow-up and 6 had missing VL data. Among 125 remaining children, 41 (33%) had VF, 24 of whom (58%) had drug resistance (23 with NNRTI and one with PI mutations). A total of 93% of children with VF did not meet criteria for clinical or immunological failure. In multivariate analyses adjusting for age, gender, adherence and ART regimen, baseline NNRTI resistance was strongly associated withVF and six-month resistance (OR: 6.7, p = 0.001; OR: 20, p < 0.001).

**Conclusions:** Baseline NNRTI resistance was common in Malian children without prior NNRTI exposure and was associated with VF and a high resistance rate during ART. Clinical and immunologic criteria rarely detected VF. Our findings support WHO recommendations of PI-based regimens in all children <3 years, and virological monitoring.

http://dx.doi.org/10.7448/IAS.18.5.20329

**MOAB0103**

**T cell activation and treatment outcomes among infants receiving early ART**

Kristjana Hríðra Asbjörnsdóttir1; Jennifer A Sklyr2; Dalton Wamalwa2; Stephen De Rosa3,4,5; James P Hughes2; Ali Rowhani-Rahbar6; Bhavna H Chohan6; Sarah Benki-Nugent6; Kenneth Tapia7 and Grace C John-Stewart8,9,10

1Department of Epidemiology, University of Washington, Seattle, United States.
2Department of Global Health, University of Washington, Seattle, United States.
3Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
4Laboratory Medicine, University of Washington, Seattle, United States.
5Center for AIDS Research Immunology Core, University of Washington, Seattle, United States.
6Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, United States.
7Department of Biostatistics, University of Washington, Seattle, United States.
8Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
9Center for AIDS Research Biometrics Core, University of Washington, Seattle, United States.
10Department of Pediatrics and Medicine, University of Washington, Seattle, United States.

**Presenting author email:** kasbjorn@uw.edu

**Introduction:** Chronic immune activation is associated with HIV disease progression in adults; however, data in children, especially infants, are limited. We determined levels and correlates of T-cell activation and the effect of baseline activation on response to antiretroviral treatment (ART) in HIV-infected infants.

**Methods:** This investigation utilized specimens from the Optimizing Pediatric HAART study of early infant ART (NCT00428116). Kenyan infants less than five months of age were enrolled between 2007 and 2010 and started on ART. Peripheral blood mononuclear cell (PBMC) samples collected before ART initiation were analyzed using flow
cytometry and the activated [HLA-DR + /CD38high] T-cell percentage quantified. Factors associated with T-cell activation at baseline were identified using Mann-Whitney U tests or linear regression. The effect of baseline activation on survival, CD4 reconstitution and HIV-1 log_{10} viral load (VL) suppression was assessed using Cox proportional hazard models.

**Results:** Among 72 infants, median age at enrolment was 111 days, median VL was 6.6 log_{10} copies/mL and median CD4 was 19%. Most infants had symptomatic disease; 49% were WHO stage 3/4, median weight-for-age Z-score (WAZ) was −2.5 and median length-for-age Z-score (LAZ) was −2.1. Twenty infants died, including eight before ART initiation. Median CD8 + T-cell activation at baseline pre-ART was 17.0% (interquartile range [IQR] 10.4, 31.8) and median CD4 + T-cell activation was 3.3% (IQR 1.6, 5.8). At enrolment, CD8 + T-cell activation was associated with younger age (−0.15%/day [95% Confidence Interval (CI) −0.28, −0.01], p = 0.05) and weight-for-age Z-score (2.4%/WAZ standard deviation [95% CI 0.64−4.2], p = 0.02), but not with CD4% or VL. CD4 + T-cell activation at enrolment was inversely associated with CD4% (−0.20%/CD4% [95% CI −0.36, −0.05], p = 0.01). T-cell activation pre-ART was not associated with time to CD4% reconstitution or VL suppression. Low CD8 + T-cell activation (<5%) was associated with mortality (hazard ratio = 3.8 [95% CI 1.3, 11.4], p = 0.02).

**Conclusions:** Contrary to findings in adults, low CD8 + T-cell activation was strongly associated with mortality in this infant cohort. Among infants, low CD8 + T-cell activation in symptomatic HIV infection may be a marker of ineffective immune response.

http://dx.doi.org/10.7448/IAS.18.5.20330

**MOAB0104**

Changes in renal laboratory parameters and bone mineral density in treatment-naive HIV-1-infected adolescents initiating therapy with INSTI-based single-tablet regimens containing tenofovir alafenamide or tenofovir disoproxil fumarate

Hilda Kizito1; Aditya Gaur2; Wasana Prasitsuebsai3; Natella Rakhmanina4; Kulkanya Chokephaibulkit5; Jan Fourie6; Linda-Gail Bekker7; Yongwu Shao8; Sean Bennett9 and Eriq Quirk8

1Joint Clinical Research Centre, Kampala, Uganda. 2St. Jude Children’s Research Hospital, Memphis, United States. 3HIVNAT, Bangkok, Thailand. 4Children’s National Health System, Washington, United States. 5Siriraj Hospital, Bangkok, Thailand. 6Aptami Medical Centre, Dundee, South Africa. 7Desmond Tutu HIV Centre, Cape Town, South Africa. 8Gilead Sciences, Inc., Foster City, United States. Presenting author email: aditya.gaur@stjude.org

**Introduction:** EVG/C/D4/F/TAF (E/C/F/TAF) and EVG/C/D4/F/T (TDF/Tibilee, STB) are integrase inhibitor (INSTI) single-tablet regimens (STRs) in clinical development for HIV-1-infected adolescents. Exposures of all components have been shown to be within the range associated with antiviral activity in adults. Preliminary comparative safety data through 24 weeks are reported.

**Methods:** Treatment-naive 12 to <18-year-olds weighing ≥35 kg with HIV-1 RNA ≥1000 copies/mL, CD4 > 100 cells/μL and eGFR ≥90 mL/min/1.73 m² received E/C/F/TAF or STB once daily in two ongoing 48-week, single-arm, open-label trials. Adverse events (AE), laboratory tests, bone mineral density (BMD) by dual X-ray absorptiometry and height-age adjusted (HA) Z-scores were assessed through Week 24.

**Results:** The E/C/F/TAF and STB trials enrolled 50 and 33 adolescents, respectively (median age 15 vs. 16 years, 56% vs. 30% female, 88% vs. 76% Black, 22% vs. 27% with baseline HIV-1 RNA >100,000 copies/mL, median CD4 count 456 vs. 407 cells/μL, median eGFR 156 vs. 143 mL/min/1.73 m²). Most AEs in both trials were mild and unrelated to treatment, with no deaths or AEs leading to treatment discontinuation. At Week 24, the median increase in serum creatinine was +0.08 mg/dL in E/C/F/TAF participants, with and +0.10 mg/dL in STB participants, with median eGFR decreases of −17.0 and −18.0 mL/min/1.73 m², respectively, consistent with COBI’s inhibition of renal tubular creatinine secretion. Proteinuria (any grade) occurred in 26% of E/C/F/TAF participants vs. 52% of STB participants, with Grade 2 or higher proteinuria occurring in 4% vs. 21% of participants, respectively. Of those participants with BMI measurements at Week 24, the median increase in spine BMD was +1.98% in E/C/F/TAF participants, with a decrease of ≤4% in 34/41 participants (7%), versus a median decrease of −1.29% in the STB cohort, with a decrease of ≥4% in 6/20 participants (30%). Spine HA Z-scores decreased by −0.02 and −0.21 respectively.

**Conclusions:** Compared with STB, E/C/F/TAF exhibited similar effects on eGFR, a lower incidence and severity of proteinuria, and a median increase in spine mineralization. Both STRs were well-tolerated through 24 weeks. These findings support INSTI-based STRs as initial HIV-1 treatment in adolescents and suggest that TAF could offer safety advantages in paediatric populations.

http://dx.doi.org/10.7448/IAS.18.5.20331

**MOAB0105**

Treatment and resistance outcomes of Asian children on second-line antiretroviral therapy

Wasana Prasitsuebsai1; Sirinya Teeraananchai1; Khanh Huu Truong2; Jintanat Anaworanich3,4,5; Viet Chau Do6; Lam Van Nguyen7; Pope Kosalaraks8; Nia Kurniati4; Tavitiya Sudjaritruk10; Kulkanya Chokephaibulkit11; Thida Singtoryj12; Stephen J Kerr1,3,6; Annette H Sohn11 and TASER-Pediatrics Study

1HIV-NAT, Thai Red Cross – AIDS Research Centre, Bangkok, Thailand. 2Children’s Hospital 1, Ho Chi Minh City, Vietnam. 3HIV-NAT, SEARCH, Thai Red Cross – AIDS Research Centre, Bangkok, Thailand. 4University of Texas MD Anderson Cancer Centre and Department of Infectious Diseases, Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand. 5Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. 6Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 7Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 8TREAT Asia/amfAR, Foundation for AIDS Research, Bangkok, Thailand. 9Amsterdam Institute of Global Health and Development (AIGHD), Amsterdam, The Netherlands. Presenting author email: annette.sohn@amfar.org

**Introduction:** With limited paediatric third-line antiretroviral therapy (ART) in resource-limited settings, data on treatment efficacy and drug resistance following second-line failure are needed to guide future management.

**Methods:** HIV-infected children <18 years old who were taking or switching to second-line ART were enrolled from Indonesia, Thailand and Vietnam. Clinical and laboratory assessments were retrospectively and prospectively obtained from the time of second-line switch (baseline). Genotyping was performed upon virologic failure (VF; HIV-RNA >1000 copies/mL). Cox proportional hazards regression was used to evaluate factors predicting post-switch VF.

**Results:** A total of 277 children were enrolled; 41% were female. Baseline values included median (interquartile range; IQR) age 7.5 (5.3–10.3) years, CD4 count 300 (146–562) cells/μL, CD4 percentage 13 (7–20%), HIV-RNA 5 (4.4–5.5) log_{10} copies/mL. The median duration of first-line ART was 2.7 (1.7–4.2) years. Resistance
mutations at first-line failure were available for 156 of 277 children (all had prior non-nucleoside reverse transcriptase (NNRTI)-based regimens) and included ≥4 thymidine analogue mutations (TAMs; 18%), Q151 M (8%), M184 V (82%) and ≥1 NNRTI mutation (92%). Current second-line regimens contained lamivudine (90%), tenofovir (43%), zidovudine or abacavir (30%) and boosted lopinavir (LPV) or atazanavir (ATV; 98%). After a median of 3.3 (1.8–5.3) years on second-line, the median CD4 was 767 (556–1060) cells/mm³ and 26 (20–31%). Eighteen (7%) had WHO stage 3 or 4 events; 3 (2%) died from HIV-related illnesses. VF occurred in 73 (27%; incidence 7 per 100 person-years, 95% confidence interval (CI) 5.8–9.1), at which time 23% had <95% adherence by pill count. Fifty of 73 with second-line VF had ≥4 TAMs (10%), Q151 M (4%), M184 V (55%), and ≥1 major LPV (8%), ≥6 LPV (2%), and ≥1 major ATV mutations (4%). Age >11 years (hazard ratio (HR) 4.06; 95% CI 2.15–7.66) and HIV-RNA >5 log₁₀ copies/mL (HR 2.4; 95% CI 1.27–4.59) at second-line switch were predictors of VF.

Conclusions: One-fourth of children had VF while on second-line ART. However, <10% developed major mutations to protease inhibitors, which may have been related to poor adherence or duration of VF. Greater advocacy is needed to create access to third-line antiretrovirals in resource-limited settings.

http://dx.doi.org/10.7448/IAS.18.5.20332

MOAB0106

Week 48 safety and efficacy of a rilpivirine (TMC278)-based regimen in HIV-infected treatment-naive adolescents: PAINT phase II trial

Johan Lombaard¹; Torsak Bunupuradah²; Patricia Flynn³; John Ramapuran³; Francis Saa³; Herta Crauwels³; Annemie Hoogstoel⁴; Veerle Van Eygen⁵; Marija Stevens⁶ and Katia Boven⁷

¹Joshua Research, Bloemfontein, South Africa. ²Thai Red Cross AIDS Research Centre, Bangkok, Thailand. ³St. Jude Children’s Research Hospital, Memphis, United States. ⁴Kasturba Medical College Hospital, Mangalore, India. ⁵Joint Clinical Research Centre, Kampa, Uganda. ⁶Janssen Infectious Diseases BVBA, Beerse, Belgium. ⁷Janssen Research & Development LLC, Titusville, United States.

Presenting author email: kboven@its.jnj.com

Introduction: Rilpivirine 25 mg qd exposure was similar in adults and adolescents (Week 4 PAINT pharmacokinetic analysis). Week 48 safety and efficacy results are reported here.

Methods: PAINT (NCT00798864) is a Phase II, ongoing, open-label, single-arm trial of rilpivirine plus two investigator-selected NNRTIs in treatment-naive HIV-1-infected adolescents (≥12 to <18 years, from sites in India, Thailand, Uganda, South Africa, USA). After the adult approved indication, only patients with viral load (VL) <100,000 copies/mL were enrolled. Virologic response was defined as VL <50 copies/mL (time-to-loss-of-virologic-response (TLOVR) algorithm).

Results: Of 36 patients, 20 (56%) were female, 18 (50%) aged 12 to <15 years and 32 (89%) Black/African American; 28 (78%) had baseline (BL) VL <100,000 copies/mL; 24 (67%) received emtricitabine/tenofovir disoproxil fumarate (TDF), 8 (22%) lamivudine/TDF and 4 (11%) lamivudine/zidovudine. At Week 48, 26/36 (72%) patients overall, 22/28 (79%) with BLVL ≤100,000 copies/mL and 4/8 (50%) with BLVL >100,000 copies/mL achieved virologic response. Of the 10 non-responders (28%), eight were virologic failures (VFs), one was dosed although a protocol violator (screening NNRTI RAM) and withdrawn and one withdrew due to an AE (pulmonary tuberculosis). CD4¹ count increased by median (range) 250.5 (–135 to 740) cells/mm³. For 2/8 VFs, overall adherence (pill count) was <95% (one of these also had BLVL >100,000 copies/mL). Five of eight VFs developed rilpivirine RAMs, mostly E138K (n = 4), K101E (n = 2) and M230L (n = 2); 4/5 developed NTRTI RAMs, mostly M184V (n = 3). Mean (standard deviation) rilpivirine AUC₂₄h and C₀ were 2391 (991) ng.h/mL and 84 (39) ng/mL, respectively (population pharmacokinetic analysis). Most AEs were grade 1 or 2. Seven patients (19%) had grade 3 or 4 AEs regardless of causality, mainly malaria and depression (each n = 2 and not related to rilpivirine). AEs considered at least possibly related to rilpivirine occurred in 13 (36%) patients, mainly (excluding investigations) somnolence (n = 5, 14%) and nausea (n = 2, 6%).

Conclusions: This 48-week analysis supports use of rilpivirine 25 mg qd combined with other antiretrovirals in treatment-naive HIV-1-infected adolescents (≥12 to <18 years) with VL ≤100,000 copies/mL. Rilpivirine safety, virological and pharmacokinetic results were similar to those observed in adults.

http://dx.doi.org/10.7448/IAS.18.5.20333

MOAB0107LB

In utero tenofovir exposure is not associated with foetal long bone growth

Jennifer Jao¹;²; Landon Myer³; Tamsin Phillips⁴; Greg Petro⁵; Allison Zerbe⁶ and Elaine J Abrams⁶

¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States. ²Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, United States. ³Division of Epidemiology and Biostatistics, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. ⁴Division of Epidemiology and Biostatistics, University of Cape Town, Cape Town, South Africa. ⁵Division of Obstetrics & Gynaecology, University of Cape Town, Cape Town, South Africa. ⁶Division of Obstetrics & Gynaecology, University of Cape Town, Cape Town, South Africa. ⁷ICAP, Columbia University, New York, United States.

Presenting author email: jennifer.jao@mssm.edu

Introduction: Despite widespread use of tenofovir (TDF) in pregnant and breast-feeding women, few data have been published on foetal bone development or child growth after in utero TDF exposure.

Methods: We evaluated foetal long bone measurements in HIV-infected pregnant women/foetus dyads in Cape Town, South Africa. Measurements were conducted by a trained research sonographer using high-resolution ultrasound. Foetal femur (FLZ) and humerus (HLZ) lengths were compared by duration of in utero TDF exposure in three categories: 1) TDF-exposed since conception (TDF-C) versus 2) TDF-exposed for >4 weeks and initiated after first trimester (TDF-E), versus 3) TDF-exposed for <4 weeks or TDF-unexposed (TDF-U). Ultrasound performed at <10 weeks gestational age (GA), twin pregnancies and those resulting in intrauterine foetal demise were excluded. Linear mixed effects models were used to assess the effect of duration of TDF exposure category on FLZ and HLZ.

Results: A total of 1597 foetal ultrasounds (408 TDF-C, 581 TDF-E, 968 TDF-U) in 1030 women (73% of whom had ≥2 ultrasounds) were available for analysis. Women in the TDF-C group were older and had lower CD4 cell counts than women in the other categories but did not differ in anthropometry or history of low birth weight deliveries (Table). Median duration of TDF exposure was 26.9, 13.0 and 0 weeks, respectively, in the TDF-C, TDF-E and TDF-U groups. Mean FLZ and HLZ did not differ by TDF exposure category (FLZ: 0.321 vs. 0.300 vs. 0.303, p = 0.570, and HLZ: 0.130 vs. 0.318 vs. 0.048, p = 0.832). These relationships persisted after adjusting for maternal age, gestation, gravidity, socioeconomic status, CD4 cell count, HIV RNA level and maternal BMI (β = 0.038, p = 0.563 for TDF-C vs. TDF-U and β = -0.002, p = 0.964 for TDF-E vs. TDF-U foetal FLZ; β = 0.009, p = 0.903 for TDF-C vs. TDF-U and β = -0.006, p = 0.885 for TDF-E vs. TDF-U foetal HLZ). No other factors related to HIV disease severity were associated with foetal FLZ or HLZ.
Abstract MOAB0107LB  Table 1. Characteristics of women and foetal ultrasound measurement

| Characteristics of pregnant women | TDF-exposed since conception (n = 226) | TDF-exposed for >4 weeks and initiated after first trimester (n = 232) | TDF-exposed for <4 weeks or TDF-unexposed (n = 572) | p |
|-----------------------------------|----------------------------------------|-------------------------------------------------|-------------------------------------------------|---|
| Age of mother, years              | 31 (27–34)                             | 27 (23–32)                                      | 28 (25–32)                                      | <0.001 |
| GA, weeks                         | 20 (14–28)                             | 21 (14–28)                                      | 21 (16–27)                                      | 0.805 |
| Maternal BMI at enrolment, kg/m²  | 29.14 (25.81–33.91)                    | 28.50 (25.00–33.75)                             | 28.63 (25.15–34.24)                             | 0.790 |
| CD4 cell count, cells/mm³         | 399 (273–523)                          | 360 (239–478)                                   | 340 (232–507)                                   | 0.015 |
| Log HIV RNA level at enrolment    | 1.59 (1.59–1.59)                       | 4.13 (3.52–4.57)                                | 3.99 (3.37–4.65)                                | <0.001 |
| Number of women with >2 ultrasound scans | 147 (64.8)                     | 126 (54.3)                                      | 479 (83.6)                                      | 0.001 |
| Characteristics of ultrasound scans (n = 408) |                                   | (n = 581)                                      | (n = 968)                                      | p value |
| Femur length z score              | 0.32 (−0.03, 0.70)                     | 0.30 (−0.03, 0.63)                              | 0.33 (−0.07, 0.79)                              | 0.570 |
| Humerus length z score            | 0.13 (−0.29, 0.59)                     | 0.32 (−0.04, 0.59)                              | 0.05 (−0.33, 0.46)                              | 0.832 |

Conclusions: In utero TDF exposure does not appear to alter foetal long bone growth. These results are reassuring and support the continued use of TDF in HIV-infected pregnant women.

http://dx.doi.org/10.7448/IAS.18.5.20480

MOAB0201
The durability of isoniazid preventive therapy for tuberculosis: long-term follow-up from a prospective cohort of HIV-infected adults in South Africa
Colleen Hanrahan¹; Neil Martinson²; Grace Link-Barnes³; Reginah Msandiwa²; Richard Chaisson⁴ and Jonathan Golub⁴
¹Johns Hopkins Bloomberg School of Public Health, Baltimore, United States. ²Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. ³Center for TB Research, Johns Hopkins School of Medicine, Baltimore, United States. Presenting author email: chanrah1@jhmi.edu

Introduction: Isoniazid preventive therapy (IPT) has been demonstrated to reduce the risk of active tuberculosis (TB) in HIV-infected adults, but the effectiveness of shorter IPT regimens (6–9 months) rapidly wanes in high TB burden settings. We examined the long-term durability of six months of IPT among HIV-infected adults in South Africa.

Methods: We analyzed the experience of a prospective clinical cohort of HIV-infected adults at one urban and one rural hospital in South Africa. The exposures of interest were receipt of IPT and antiretroviral therapy (ART), and the primary outcome was incident TB. We used multivariate Poisson regression to examine the association of IPT and ART with risk of TB.

Results: From 2003 to 2010, 3465 HIV-infected adults were followed for 9908 person-years (PY) during which 372 incident TB cases were diagnosed (incidence rate (IR): 3.8/100PY; 95% CI: 3.4–4.2). A total of 776 participants received IPT (median treatment length: 5 months (IQR: 2–6)). During 1886 PY of follow-up after initiating IPT, 54 incident cases of TB were diagnosed (IR: 2.9/100 PY; 95% CI: 2.2–3.7), while during 8022 PY of follow-up without IPT exposure, 318 incident TB cases were diagnosed (IR: 4.0/100 PY; 95% CI: 3.6–4.4). After adjusting for age, sex, study site, ART use and CD4 count, IPT was associated with a 23% reduction in TB incidence over seven years of follow-up (adjusted IRR: 0.77; 95% CI: 0.7–1.0; p = 0.070). IPT appeared to be protective only for the first year following initial IPT exposure (aIRR: 0.46; 95% CI: 0.36–0.96; p = 0.042), after which the risk of TB was not significantly reduced.

Conclusions: In this prospective cohort of HIV-infected adults in South Africa, receipt of six months of IPT resulted in a marked (40%) reduction in risk for TB during the first year following IPT initiation, independent of ART status. No reduction in TB risk was observed beyond one year, confirming similar findings in settings of high TB burden. We demonstrate that IPT remains an important intervention for HIV-infected individuals, and that even a short regimen can provide crucial protection from TB of up to one year for those not yet initiated on highly active antiretroviral therapy.

http://dx.doi.org/10.7448/IAS.18.5.20334

Abstract MOAB0201  Table 1. Incidence of TB by time following IPT exposure

| Time interval | Cases/PY | Rate/100 PY | Cases/PY | Rate/100 PY | Unadjusted Incidence rate ratio (95% CI) |
|---------------|---------|------------|---------|------------|----------------------------------------|
| Overall       | 318/8022| 4.0 (3.6–4.4) | 54/1886 | 2.9 (2.2–3.7) | 0.72 (0.53–0.99) | 0.042 | 0.77 (0.57–1.0) | 0.070 |
| 0–1 year      | 151/2672| 5.7 (4.8–6.6) | 16/615  | 1.6 (1.6–4.2) | 0.46 (0.26–0.80) | 0.006 | 0.60 (0.36–0.98) | 0.042 |
| ≥1–2 years    | 75/2138 | 3.5 (2.8–4.4) | 20/519  | 3.9 (2.5–6.0) | 1.1 (0.63–1.9) | 0.740 | 1.1 (0.67–1.8) | 0.733 |
| ≥2–3 years    | 47/1362 | 3.5 (2.6–4.6) | 10/301  | 3.3 (1.8–6.2) | 0.96 (0.50–1.9) | 0.880 | 0.95 (0.51–1.8) | 0.880 |
| ≥3 years      | 45/1851 | 2.4 (18–3.3)  | 8/451   | 1.8 (0.89–3.7) | 0.73 (0.30–1.6) | 0.413 | 0.73 (0.34–1.6) | 0.394 |
MOAB0202

Treatment outcomes of drug-resistant TB patients in South Africa, disaggregated by HIV status, as reported in a national electronic drug-resistant TB register

Denise Hilary Evans1; Kate Schnippel1; Eric Budgell1; Kate Shearer1; Rebecca Berhanu2; Lawrence Long3 and Sydney Rosen3

1Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2Right to Care, Johannesburg, South Africa. 3Center for Global Health & Development, Boston University School of Public Health, Boston, United States.

Abstract MOAB0202 - Figure 1. Time to incident TB by IPT and HAART exposure.

Abstract MOAB0202 - Table 1. Summary of treatment outcomes of MDR-TB patients in South Africa (n = 13,692)

| HIV status | Total | Cured | Completed treatment | Died | Failed treatment | Lost to follow-up | Not evaluated |
|------------|-------|-------|---------------------|------|------------------|-------------------|--------------|
| HIV − ve   | 3739  | 803   | 341 (9.1%)          | 460  | 289 (7.7%)       | 773 (20.7%)       | 1073 (28.7%) |
| HIV + ve   | 7289  | 1356  | 576 (7.9%)          | 1243 | 390 (5.4%)       | 985 (13.5%)       | 2739 (37.5%) |
| Unknown    | 2664  | 328   | 184 (6.9%)          | 383  | 118 (4.4%)       | 236 (8.9%)        | 1415 (53.1%) |

TB treatment history

| Failed 1st | 3959  | 735   | 333 (8.4%)          | 567  | 186 (4.7%)       | 485 (12.3%)       | 1653 (41.7%) |
| Failed 2nd | 2516  | 495   | 197 (7.8%)          | 415  | 180 (7.2%)       | 352 (14.0%)       | 877 (34.8%)  |
| Other      | 384   | 36    | 23 (6.0%)           | 63   | 29 (7.6%)        | 64 (16.7%)        | 169 (44.0%)  |

LTF lost to follow-up; 1st first-line; 2nd second-line.
Mortality was substantially higher in the HIV positive (27.3% (26.0 and those co-infected with HIV (42.5% (41.0 negative patients (42.9% (41.0 42.4% (41.3.

http://dx.doi.org/10.7448/IAS.18.5.20335

may improve treatment results.

high in both groups but almost 1.5 times more in HIV co-infected

success was low (42%) and did not vary by HIV status. Mortality was

compared to HIV negatives (21.6 and 8.6% vs. 29.0 and 10.8%).

HIV positive patients were lost to follow-up or failed treatment

8.0/100 pys) group (adjusted hazard ratio 1.45 (1.30

treatment completed), failed, lost to follow-up and died. Person-time

accrued from treatment initiation until the earliest of outcome
date recorded or 24 months on treatment. Cox hazard models were

used to evaluate the relationship between HIV status and all-cause

mortality. Models were adjusted for age, gender and previous history

of TB treatment.

Results: In total, 13,692 confirmed MDR-TB patients initiated treat-
mant (median age 35.4 years; 53% male; 99% pulmonary TB). Eighty-one percent (11,028/13,692) had HIV status recorded; of these 66% (7289/11,028) were co-infected with HIV.

Among those with an outcome reported (8465/13,692; 62%), overall mortality and success rates were 24.6% (95% CI 23.7–25.6) and 42.4% (41.3–43.4), respectively. Success was similar between HIV negative patients (42.9% (41.0–44.8); 18.1/100 person-years (pys)) and those co-infected with HIV (42.5% (41.0–43.9); 15.5/100 pys).

Mortality was substantially higher in the HIV positive (27.3% (26.0–28.6); 10.1/100 pys) than the HIV negative (17.3% (15.9–18.7); 8.0/100 pys) group (adjusted hazard ratio 1.45 (1.30–1.62)). Fewer HIV positive patients were lost to follow-up or failed treatment compared to HIV negatives (21.6 and 8.6% vs. 29.0 and 10.8%).

Conclusions: In this analysis of the outcomes of MDR-TB treatment in the South African national database, the reported rate of treatment success was low (42%) and did not vary by HIV status. Mortality was high in both groups but almost 1.5 times more in HIV co-infected patients. New guidelines allowing decentralized (outpatient) treatment of some MDR-TB patients and newly available drug regimens may improve treatment results.

http://dx.doi.org/10.7448/IAS.18.5.20335

Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed

Anna Schultz4; Anne Marie Werlinrud Eifsen2; Frank A Post3; Alexander Panteleeev4; Hansjakob Furrer5,6; Robert Miller7; Marcelo H Llosso8; Javier Toibaro8; Aliaksandr Skrahin9; Jose M Miro10; Joan A Cayla `11; Enrico Girardi12; Mathias Bruyand13; Amanda Mocroft1; Ole Kirk2 and on behalf of the TB: HIV Study Group in EuroCoord

8Department of Infection and Population Health, University College London, London, United Kingdom. 7Department of Infectious Diseases and Rheumatology, CHIP, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 8Department of Sexual Health, King’s College Hospital, Caldecot Centre, London, United Kingdom. 9Department of HIV/TB, TB Hospital 2, St. Petersburg, Russian Federation. 10Bern University Hospital, Bern, Switzerland. 11Department of Infectious Diseases, University of Bern, Bern, Switzerland. 12Centre for Sexual Health and HIV Research, University College London, Mortimer Market Centre, London, United Kingdom. 6Department of Immunocompromised, Hospital J.M. Ramos Mejia, Buenos Aires, Argentina. 7Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus. 8Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain. 9Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Agencia de Salud Pública de Barcelona, Barcelona, Spain. 10Department of Infectious Diseases, INMI ‘L. Spallanzani’ Ospedale L Spallanzani, Rome, Italy. 11INSERM, ISPED, Centre Inserm U 897- Epidemiologie-Biostatistique, Bordeaux, France.

Presenting author email: a.schultze@ucl.ac.uk

Introduction: Management of TB in HIV patients in Eastern Europe (EE) is challenged by high MDR-TB prevalence, low rates of drug susceptibility testing (DST) and poor access to ART. We report 1-year mortality estimates from a multi-regional (EE, Western Europe (WE) and Latin America (LA)) cohort study.

Methods: Deaths within 12 months of starting TB therapy (baseline) among consecutive HIV patients with TB in 2011–2013 were classified as being TB-related or not. Risk factors for all-cause and TB-related death were assessed using standard survival analysis methods.

Results: Among 1410 patients starting TB therapy (EE = 835, WE = 319, LA = 256), 257 (18%) died within 12 months of baseline; 170 (66%) of these were TB-related. The cumulative probability of all-cause and TB-related death at 12 months was 29.5 and 11% (p < 0.001) and 22, 1 and 4% (p < 0.001) in EE, WE and LA respectively. In EE, fewer patients were on cART at 12 months (68% vs. 90% and 85%, p < 0.001), and many were treated without access to baseline DST (66% vs. 37% and 69%, p < 0.001). Among those with DST, the empirical treatment regimen (composed when DST results were not yet known) included <3 active TB drugs in 36, 7 and 9% (EE, WE, LA, p < 0.001); of those 81, 46 and 86% had MDR-TB. Patients who started <3 active drugs were at excess risk of dying from TB compared to patients starting ≥3 active drugs.

Abstract MOAB0203 Figure 1. TB-related death among HIV-positive patients according to the number of active drugs used as part of empiric TB therapy.
(aHR = 3.20, 95% CI = 1.82–5.66). Patients without DST results (and thus no option for targeting subsequent therapy) also had a greater risk of death (aHR = 2.33, 1.40–3.87). This appeared driven by deaths in EE (Figure, aHR = 2.37, 1.66–3.40, analyses restricted to EE), although a formal test for interaction with region was not significant (p = 0.44), potentially due to few deaths outside EE.

**Conclusions:** There is an elevated risk of death from TB in HIV patients managed in EE compared to WE and LA. This is partly explained by modifiable risk factors including low rates of DST, hampering the optimized choice of TB drugs in a setting of high MDR-TB prevalence. Our data call for urgent action to improve the care of HIV/TB patients in EE.

http://dx.doi.org/10.7448/IAS.18.5.20336

**MOAB0204**

**Missed opportunities in the TB/HIV cascade of care in 14 high burden TB/HIV African countries, 2012**

Annabel Baddeley1; Meg Doherty2; Avinash Kanchar1; Alberto Matteelli1; Hazim Bakir Timimi1 and Haileyesus Getahun1

1Global TB Programme, World Health Organization, Geneva, Switzerland. 2Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.

Presenting author email: baddeleya@who.int

**Introduction:** Despite being preventable and curable, tuberculosis (TB) remains the leading cause of morbidity and mortality of people living with HIV (PLHIV). The past decade has seen considerable scale-up of collaborative TB/HIV activities, however, implementation remains suboptimal. Closer inspection at each stage of the cascade of TB/HIV care is warranted to assess the gaps and to identify opportunities for strengthened service delivery in order to eliminate HIV-associated TB mortality.

**Methods:** Data were downloaded from the Global TB Programme Database on 22/01/2015 on the latest available TB treatment outcomes (2012 cohort), disaggregated by HIV status, from reporting high TB/HIV burden countries in the WHO African Region, along with related data on the implementation of collaborative TB/HIV activities. Data were analysed and missed opportunities identified.

**Results:** Fourteen countries reported the required outcome data, accounting for some 570,000 HIV-positive incident TB cases, (Table 1), or 63% of the African burden and 49% of the global burden in 2012. More than 50,000 reported HIV-positive TB cases died or were lost to follow-up, representing 18% of evaluated cases, compared with 11% of evaluated HIV-negative TB cases, (Figure 1).

Of the estimated HIV-positive TB cases almost 260,000 (46%) went unreported, (Table 1). Among registered TB patients, 11% (around 80,000) did not have an HIV test in the TB register. In eight countries that reported, there was a gap of over 1,700,000 reported as not having received a TB screen, (53% of the 3,300,000 people in HIV care). Among notified HIV-positive TB cases, 42% (nearly 130,000) were not reported as receiving ART. Only five of the 14 countries reported providing Isoniazid Preventive Therapy (IPT) to people newly registered in HIV care. In the four countries that reported a denominator, 69% (some 900,000) people newly enrolled in HIV care did not receive IPT.

**Conclusions:** This analysis highlights some considerable gaps in the care cascade, resulting from suboptimal implementation and/or recording and reporting. In order to prevent disproportionate TB mortality among PLHIV, countries are encouraged to scrutinize weaknesses in the care cascade at every level to enhance early detection of HIV-associated TB, timely ART initiation and scaled-up TB prevention.

http://dx.doi.org/10.7448/IAS.18.5.20337

**MOAB0205LB**

Empiric TB therapy does not decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating ART: results of ACTG A5274 (REMEMBER study)

Mina Hosseinipour1,2; Greg Bisson3; Sachiko Miyahara4; Xin Sun5; Agnes Moses1; Cynthia Riviere6; Fredrick K Kirui7; Sharlaaa Badal-Faesen8; David Lagat9; Mulinida Nyirenda10; Kogieleum Naidoo10; James Hakim11; Peter Muyenyi12; German Henostroza13; Paul D Leger7; Javier R Lama14; Lerato Mohapi15; Jorge Alave14; Vidya Mave16; Valdilea G Veloso17; Sandy Pillay18; Nagalingeswaran Kumarasamy19; Jing Bao20; Evelyn Hogg21; Lynne Jones22; Andrew Zolopa23; Johnstone Kumwenda9; Amita Gupta24 and Adult AIDS Clinical Trials Group 5274 Study Team

1UNC Project, Lilongwe, Malawi. 2School of Medicine, University of North Carolina, Chapel Hill, United States. 3University of
Pennsylvania Perelman School of Medicine, Department of Biostatistics and Epidemiology, Philadelphia, United States. 4Harvard School of Public Health, Department of Biostatistics, Harvard University, Boston, United States. 5Gheskio Centers, Port-au-Prince, Haiti. 6Clinical HIV Research Unit, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa. 7School of Medicine, Moi University, Eldoret, Kenya. 8Johns Hopkins Project, Blantyre, Malawi. 9Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. 10Department of Medicine, University of Zimbabwe, Harare, Zimbabwe. 11Joint Clinical Research Centre, Kampala, Uganda. 12Centre for Infectious Diseases Research, Lusaka, Zambia. 13Association Civil Impacta Saludy Educacion, Lima, Peru. 15Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa. 16Johns Hopkins Clinical Trials Unit, B.J. Medical College, Pune, India. 17Evandro Chagas National Institute of Infectious Diseases/Fiocruz, Rio de Janeiro, Brazil. 18University of KwaZulu-Natal, Durban, South Africa. 19YRCARE Medical Centre, VHS, Chennai, India. 20National Institutes of Health, Bethesda, United States. 21Social & Scientific Systems, Silver Spring, United States. 22Frontier Sciences, Buffalo, United States. 23School of Medicine, Johns Hopkins University, Baltimore, United States.

Presenting author email: mina_hosseinipour@med.unc.edu

Introduction: Strategies for reducing the high early mortality seen among patients initiating antiretroviral therapy ART in resource-limited settings (RLS) are urgently needed. We hypothesized that given the high burden of tuberculosis (TB) in these settings, empiric TB treatment among patients at high risk for death would reduce early mortality.

Methods: REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens) is a multicountry randomized clinical trial comparing two management strategies: ART + empiric 4 drug TB therapy (Empiric) vs. ART + isoniazid preventive therapy (IPT) in HIV-infected individuals with CD4 count < 500 cells/mm³. Participants were screened for TB prior to entry using symptom screen, locally available diagnostics per standard of care, and GeneXpert when available. The study was stratified according to CD4 count (< 25 vs. ≥ 25 cells/mm³) and poor prognostic factors (body mass index < 18.5, haemoglobin < 8 g/dl, recent hospitalization). The primary endpoint was survival (death or unknown status) at 24 weeks postrandization, and Kaplan–Meier estimates of the endpoint rates across arms were compared by the z-test.

Results: Of 1368 participants screened, 850 (62%) were randomized; 53% were male, 90% were black and median (quartiles) age was 36 (30–42) years. The median (quartiles) CD4 count at study entry was 18 cells/mm³ (9, 32). At week 24, both arms had the same primary endpoint rate of 5.2% (95% CI: 3.5–7.8%) for Empiric and 3.4–7.8% for IPT) with an absolute risk difference of —0.06% (95% CI: —0.05 to 2.94%). Primary endpoint rates were similar across arms for the stratification factors and for other secondary outcomes: viral load <400 copies/mL was achieved in 84% Empiric and 85% IPT; Grade 3 or 4 symptoms occurred in 12% Empiric and 11% IPT; Grade 3 or 4 laboratory abnormalities in 23% both arms; and new clinical events in 49% Empiric and 51% IPT.
Conclusions: Among highly TB screened participants with advanced HIV in RLS, empiric TB therapy did not reduce mortality at 24 weeks compared to IPT. The low mortality seen in both arms supports enhanced screening for TB prior to ART initiation and the routine use of IPT.

http://dx.doi.org/10.7448/IAS.18.5.20481

MOAC0101B
Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission
Myron Cohen1; Ying Chen2; Marybeth McCauley3; Theresa Gamble4; Mina Hosseinipour5,6; Nagalingswaran Kumaramany7; James Hakim8; Newton Kumwenda9; Tania Brum10; Beatriz Grinsztejn11; Sheela Godbole12; Suwat Chariyalertsak13; Breno Riegel Santos14; Kenneth Mayer15,16; Irving Hoffman17; Susan Ehlersman18; Estelle Piwowar-Manning19; San-San Ou20; Leslie Cottie21; Joseph Makhema20; Lisa Mills21; Ravindre Panchia22; Sharlaa Badal-Faesen23; Joseph Erron24; Joel Gallant24; Diane Havlir25; Susan Swindells26; Vanessa Ehlarrar27; David Burns28; Taha Taha29; Karin Nielsen30; Max Essex31,32; Thomas Fleming33 and HPTN 052 Study Group

1Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States. 2Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, United States. 3HPTN, HIV Prevention Trials Network, Washington, United States. 4HPTN, HIV Prevention Trials Network, Washington, United States. 5Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, United States. 6UNC Project-Malawi, Institute for Global Health and Infectious Diseases, Lilongwe, Malawi. 7Y.R. Gaitonade Center for AIDS Research and Education, Chennai, India. 8University of Zimbabwe, Harare, Zimbabwe. 9Johns Hopkins Project, College of Medicine, Blantyre, Malawi. 10Laboratorio de AIDS e Imunologia Molecular-IoC/Fiocruz, Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil. 11Istituto Nazionale di Ricerche su Evandro Chagas-INI-Fiocruz, Rio de Janeiro, Brazil. 12National AIDS Research Institute (ICMR), Pune, India. 13Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 14Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil. 15The Fenway Institute, Boston, United States. 16Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States. 17Institute of Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, United States. 18Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, United States. 19Fred Hutchinson Cancer Research Center, Seattle, United States. 20Botswana Harvard AIDS Institute, Gaborone, Botswana. 21KEMRI-Centers for Disease Control and Prevention, Kisumu, Kenya. 22Chris Hani Baragwanath Hospital, Soweto HPTN CRS, Soweto, South Africa. 23University of the Witwatersrand, Clinical HIV Research Unit, Johannesburg, South Africa. 24Southwest CARE Center, Albuquerque, United States. 25University of California, San Francisco, United States. 26University of Nebraska Medical Center, Omaha, United States. 27Clinical Prevention Research Branch/Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States. 28Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States. 29David Geffen UCLA School of Medicine, Los Angeles, United States. 30Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States. 31Harvard T.H. Chan School of Public Health AIDS Initiative, Boston, United States. 32Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 33Department of Biostatistics, University of Washington, Seattle, United States.

Presenting author email: mscohen@med.ucn.edu

Introduction: The HPTN 052 trial was designed to evaluate whether antiretroviral therapy reduces sexual transmission of HIV. The trial started in April 2005 and ended in May 2015.

Methods: HPTN 052 enrolled 1763 HIV serodiscordant couples in Malawi, Zimbabwe, South Africa, Botswana, Kenya, Thailand, India, Brazil and the U.S. (97% heterosexual). HIV-infected index participants had CD4 cell counts between 350 and 550 cells/mm³ at enrolment. Index participants were randomized to receive ART at enrolment (early arm) or when their CD4 cell count fell to ≤250 cells/mm³ or they developed an AIDS-defining illness (delayed arm). The primary analysis was based on genetically linked viral transmission events. When interim analysis in May 2011 demonstrated the benefits of early ART, ART was offered to all index participants in the delayed arm (N Engl J Med 2011;365:493–505); the study then continued otherwise unchanged.

Conclusions: Among highly TB screened participants with advanced HIV in RLS, empiric TB therapy did not reduce mortality at 24 weeks compared to IPT. The low mortality seen in both arms supports enhanced screening for TB prior to ART initiation and the routine use of IPT.

Results: At the end of the trial, 1171 (66%) of 1763 couples remained in follow-up (603/886 early arm; 568/877 delayed arm). Index participants were followed for 9822 person-years (py). ART was initiated by all 886 index participants in the early arm and 785 (90%) of 877 index participants in the delayed arm. Before ART was offered to all index participants, there was 1 linked infection in the early ART arm (4 total infections/1776 py) and 35 linked infections in the delayed arm (42 total infections/1757 py). After ART was offered to index participants in both study arms, there were two linked infections in the early arm (15 total infections/2537 py) and six linked infections in the delayed arm (17 total infections/2412 py). Only seven linked infections were diagnosed while the index participant was receiving ART; four infections were diagnosed shortly after the index participant started ART and three were diagnosed after ART failure. These findings demonstrate that HIV transmission is very unlikely when viral replication is suppressed.

Conclusions: The previously reported efficacy of early ART for HIV prevention was sustained for the duration of the HPTN 052 study. ART, combined with counselling and provision of condoms provides durable, highly effective protection from HIV transmission in serodiscordant couples.

http://dx.doi.org/10.7448/IAS.18.5.20482

MOAC0102
Level of viral suppression and cascade of HIV care in a South African semi-urban setting in 2012
Kevin Jean1; Adrian Puren2; Ewadle Cutler3; Beverley Singh2; Julie Bouscauillac4; Reathe Rain-Taljaard5; Dirk Taljaard6; Pascale Lissouba7; Gilles Peytavin8 and Bertran Auvert1,5,7

1INSERM, Villejuif, France. 2NIDCD-NHLS, Johannesburg, South Africa. 3Progressus, Johannesburg, South Africa. 4CHAPS, Johannesburg, South Africa. 5APHV Bichat-CI Bernard, Paris, France. 6A. Quest medical school of the University of Versailles, University of Versailles, Versailles – Saint Quentin en Yvelines, Versailles, France. 7APHV – Hospital Ambroise Pare, Boulogne, France. Presenting author email: bertran.auvert@uvsq.fr

Introduction: For antiretroviral treatment (ART) programs to have a preventive impact, the proportion of HIV-infected people being treated should be high. In 2012, seven years after the beginning of ART programs in the South-African township of Orange Farm, we measured the proportion of HIV+ who were virally suppressed, especially among age groups highly exposed to HIV (women 18–29 years and men 25–34 years).

Methods: A community-based cross-sectional representative survey conducted in 2012 among 3293 men and 3473 women. Study procedures included a face-to-face questionnaire and collection of blood samples that were tested for HIV, 10 antiretroviral drugs (ARVs) and HIV-viral load (VL).
Results: HIV prevalence was 17.0% (95% Confidence Interval: 15.7–18.3%) among men and 30.1% (28.5–31.6%) among women. Overall, 59.1% (57.4–60.8%) of men and 79.5% (78.2–80.9%) of women reported having ever been tested for HIV. When controlling for age, circumcised men were more likely to have ever been tested (66.1% vs. 53.6%; p < 0.001). Among HIV+ individuals, 21.0% (17.7–24.6%) of men and 30.5% (27.7–33.3%) of women tested positive for any ARV. The ratio of ARV+ people over those HIV+ was 0.084. Using basic calculations, we found that if ARV programs were actually treating all eligible patients since 2005, this ratio should have been 0.21–0.28, indicating an effectiveness of ART programs around 47–63%. Among ARV+ participants, 91.9% (88.7–94.3%) had viral suppression (VL < 400 cp/mL). The proportion of viral suppression among HIV+ was 27.0% (24.3–29.9%) among women and 17.5% (14.4–20.9%) among men. These proportions were lower among the highly-exposed age groups: 15.6% (12.1–19.7%) among women and 8.4% (5.0–13.1%) among men.

Conclusions: In Orange Farm, in the 2005–2012 period, ART programs were sub-optimal and, among HIV+, proportion of viral suppression was low, especially among the highly-exposed age groups. This suggests that, up to 2012, ART programs may not have substantially impacted HIV incidence. However, our study showed at community level that, when effectively taken, ARVs present a high effectiveness in suppressing VL.

http://dx.doi.org/10.7448/IAS.18.5.20338

MOAC0103
A mathematical model to determine potential costs and benefits of increasing antiretroviral therapy coverage in female sex workers: the case of Panama
Lorna Jenkins1; Jamie Nordio2; Kristzina Vasarhelyi1,3; Aurelio Nunez4; Rolando Barrios5 and Alenxander Rutherford2,6
1USF-Health and Education International Foundation, University of South Florida, Panama, Panama. 2IRMACS, Simon Fraser University, Burnaby, Canada. 3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 4National STI/HIV/AIDS Program, Ministry of Health, Panama, Panama. 5British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 6Department of Mathematics, Simon Fraser University, Burnaby, Canada.

Introduction: Panama adopted Treatment as Prevention (TasP) in February 2014 and is now seeking efficient and effective ways to expand antiretroviral therapy (ART) coverage in key populations. We developed a mathematical model to determine the ART coverage and associated costs required to meet HIV incidence reduction targets for the female sex worker (FSW) population, which has a 1.6% HIV prevalence.

Methods: The Government of Panama, British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University are collaborating to develop mathematical models for informing Panama’s TasP strategy. Quantitative and qualitative information was collected from national reports, key informant interviews and focus groups with civil society to inform a compartmental HIV transmission model incorporating disease progression and treatment. The model was calibrated and validated for 2013. Estimated FSW population size is 17,000 and according to the Global AIDS Response Progress report, current ART coverage for both FSW and the hard-to-reach client population is about 47%. Annual ART cost/individual is US$625. Simulation scenarios for meeting 50, 70 or 90% reduction in HIV incidence in FSW in 15 years assumed ART expansion either for FSW and their clients (Scenario 1) or for FSW only (Scenario 2).

Results: ART expansion for FSW costs slightly more in Scenario 1 than 2. However, overall, for both populations of FSW and clients, more infections are averted and treatment programme costs are lower for the strategy targeting FSW only (see Table 1). Furthermore, initial aggressive expansion of ART coverage leads to overall cost savings and a more effective means of averting new infections (see Figure 1). The result of no action compared to the 90% Scenario 2 strategy would be 170% more HIV infections and 50% more treatment costs over 15 years.

Conclusions: Rapid expansion of TasP for female sex workers in Panama would avert infections and treatment costs already within 15 years. Initial short-term investment to increase ART coverage would be offset by long-term savings. Since Panama adopted TasP, UNAIDS has announced the 90–90–90 targets for HIV diagnosis, treatment and suppression, which call for an even more rapid reduction in incidence. Ongoing analyses are evaluating costs and outcomes of reaching the new targets by 2020.

http://dx.doi.org/10.7448/IAS.18.5.20339

MOAC0104
Does a universal test and treat strategy impact ART adherence in rural South Africa? ANRS 12249 TasP cluster-randomized trial
Collins Iwuj3; Rosemary Dray-Spira3; Alexandra Calmy4; Joseph Larmarange1,5; Joana Orne-Gliemann2; François Dabis5; Deenan Pillay1,7 and Kholoud Porter8
1 USF-Health and Education International Foundation, University of South Florida, Panama, Panama. 2IRMACS, Simon Fraser University, Burnaby, Canada. 3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 4National STI/HIV/AIDS Program, Ministry of Health, Panama, Panama. 5British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 6Department of Mathematics, Simon Fraser University, Burnaby, Canada.

Abstract MOAC0103 - Table 1. Outcomes and costs of TasP expansion scenarios

| Population | Target incidence reduction in FSW in 15 years (%) | No ART expansion new cases in 15 years | No ART expansion US$ costs in 15 years | TasP Scenario 1 new cases in 15 years | TasP Scenario 1 US$ costs in 15 years | TasP Scenario 2 new cases in 15 years | TasP Scenario 2 US$ costs in 15 years | TasP Scenario 2 US$ costs in 15 years |
|------------|-----------------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|----------------------------------------|--------------------------------------|----------------------------------------|----------------------------------------|
| FSW        | 50                                            | 2816                                 | $1,240,560                           | 2003                                 | $911,016                               | 2000                                 | $1,025,737                             | $1,025,737                             |
| Clients    | 50                                            | 4096                                 | $3,841,072                           | 2878                                 | $3,308,139                             | 2847                                 | $3,139,332                             | $3,139,332                             |
| Both       | 50                                            | 6912                                 | $5,061,632                           | 4881                                 | $4,219,155                             | 4847                                 | $4,165,069                             | $4,165,069                             |
| FSW        | 70                                            | 2816                                 | $1,240,560                           | 1620                                 | $863,324                               | 1605                                 | $1,093,578                             | $1,093,578                             |
| Clients    | 70                                            | 4096                                 | $3,841,072                           | 2331                                 | $3,030,029                             | 2259                                 | $2,782,224                             | $2,782,224                             |
| Both       | 70                                            | 6912                                 | $5,061,632                           | 3951                                 | $3,893,353                             | 3864                                 | $3,875,802                             | $3,875,802                             |
| FSW        | 90                                            | 2816                                 | $1,240,560                           | 1118                                 | $777,438                               | 1074                                 | $1,107,593                             | $1,107,593                             |
| Clients    | 90                                            | 4096                                 | $3,841,072                           | 1615                                 | $2,818,353                             | 1480                                 | $2,260,854                             | $2,260,854                             |
| Both       | 90                                            | 6912                                 | $5,061,632                           | 2733                                 | $3,595,791                             | 2554                                 | $3,368,447                             | $3,368,447                             |
MOAC0105LB
Community-based HIV testing and linkage effectively delivers combination HIV prevention: results from a multisite randomized trial
Ruanne Barnabas1; Heidi van Rooyen2; Elioda Tumwesigye3; Justin Brantley4; Jared Baeten1; Alastair van Heerden2; Bosco Turyamureeba5; Philip Joseph4; Meaghan Krows1; James Hughes1; Connie Celum1 and Linkages1
1Department of Global Health, University of Washington, Seattle, United States. 2Human Sciences Research Council, KwaZulu-Natal, South Africa. 3Integrated Community-Based Initiatives, Kabwohe, Uganda. 4Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States. Presenting author email: rbanabas@uw.edu

Introduction: To have a population impact in generalized HIV epidemics in Africa, high coverage of combination HIV prevention strategies that reduce the susceptibility of uninfected persons and the infectiousness of infected persons is needed. Community-based HIV testing and counselling, with linkage to care and prevention, is a potential delivery platform for combination HIV prevention.

Methods: We conducted a multisite programme of community-based HIV testing and counselling, linkage to HIV care, and demand creation for voluntary medical male circumcision (VMMC) in rural communities in KwaZulu-Natal, South Africa and Sheema district, Uganda. HIV testing was done at home or through mobile units. HIV-positive persons were randomly allocated to linkage to care strategies: clinic facilitation by lay-counsellors at the initial clinic visit, lay-counsellor follow-up visits at home, or standard clinic referral. HIV-negative uncircumcised men were randomized to VMMC demand creation strategies: lay counsellor follow-up visits at home, SMS reminders, or standard VMMC promotion at the time of testing.

Results: Between June 2013 and February 2015, 15,332 persons received HIV testing and counselling. Among 1325 HIV-positive persons randomized to linkage strategies, the overall clinic linkage was high (93%). Compared to standard linkage, lay counsellor clinic facilitation increased linkage to care (RR = 1.09, 95% CI: 1.05–1.13), and home follow-up visits increased antiretroviral therapy (ART) initiation (RR = 1.23, 95% CI: 1.02–1.47). In all arms, ART initiation was limited by bottlenecks in service delivery at the clinics, although 67% of those eligible initiated ART by nine months. Overall, 82% of persons initiating ART achieved viral suppression without significant difference between study arms. Of 750 HIV-negative uncircumcised men randomized to VMMC promotion strategies, the uptake of circumcision was 41% by month 3. Compared to standard messages, VMMC uptake was significantly higher in the SMS promotion (RR = 1.72, 95% CI: 1.36–2.17) and lay counsellor follow-up arms (and RR = 1.67, 95% CI: 1.29–2.14).

Conclusions: Community-based HIV testing and linkage to care and prevention effectively deliver combination HIV prevention. Simple strategies, such as SMS reminders or lay-counsellor visits, increase linkage for ART initiation and male circumcision. Community-based strategies require integration with efficient clinical services, and

Abstract MOAC0103 Figure 1. Treatment cost for FSW population.

1Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa. 2Research Department of Infection and Population Health, University College London, London, United Kingdom. 3INSERM-UPMC Univ Paris 06, UMR_S 1136, Paris, France. 4Unite´ VIH/Sida, Hoˆpitaux Universitaires, Geneva, Switzerland. 5CEPED (UMR 196 U. Paris Descartes INED IRD), Paris, France. 6Unite´ VIH/Sida, Hoˆpitaux Universitaires, Geneva, Switzerland. 7Integrated Community-Based Initiatives, Kabwohe, Uganda. 8Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States. Presenting author email: ciwuji@yahoo.com

Introduction: HIV treatment guidelines are recommending ART at increasingly higher CD4 counts for maximizing individual and population benefits. However, the expansion of ART use may be at the expense of optimal adherence. We report on adherence and virological suppression when initiating ART at different CD4 thresholds within the Treatment as Prevention (ANRS 12249) trial of the expense of optimal adherence. We report on adherence and population benefits. However, the expansion of ART use may be increasingly higher CD4 counts for maximizing individual and population benefits. However, the expansion of ART use may be at the expense of optimal adherence. We report on adherence and population benefits. However, the expansion of ART use may be at

Figure 1. Treatment cost for FSW population.

Cost (US$ per person)

Time (years)

90% Reduction in incidence 70% Reduction in Incidence 90% Reduction in Incidence

Introduction: HIV treatment guidelines are recommending ART at increasingly higher CD4 counts for maximizing individual and population benefits. However, the expansion of ART use may be at the expense of optimal adherence. We report on adherence and virological suppression when initiating ART at different CD4 thresholds within the Treatment as Prevention (ANRS 12249) trial of universal home-based testing and immediate ART initiation in rural KwaZulu-Natal.

Methods: Using data of a cluster-randomized trial of immediate ART versus initiation according to current national guidelines (CD4 ≤ 350 cells/mm3), we compared adherence levels (≥95% vs. <95%) measured using a visual analogue scale (VAS) and pill count (PC) and virological suppression at six months (<400 c/mL) according to CD4 count at ART initiation through logistic regression models, adjusting for possible confounders (age, sex, marital status, education and employment).

Results: During March 2012—May 2014, 601 participants who were not on ART entered care in trial clinics; 382 initiated ART, 254 have completed ≥6 months on ART, 227 of whom had six months HIV RNA data and were included in analyses. One hundred sixty-nine were women; median (IQR) age and CD4 at ART initiation were 35 years (28, 46) and 313 cells/mm3 (206, 513). Adherence ≥95% at six months was high (88 and 83% by PC and VAS, respectively) with no evidence that this was associated with CD4 at initiation (aOR = 0.97 per 100 cells/mm3 higher, 95% CI: 0.83–1.12, p = 0.65 for VAS; aOR 1.13 per 100 cells/mm3 higher, 0.98–1.31, p = 0.09 for PC). Male sex was independently associated with <95% adherence (2.58, 1.24–5.35, p = 0.01; ref. females). Eighty-three percent (183/227) of those who started ART achieved HIV suppression by six months with no association with CD4 at initiation (1.13 per 100 cells/mm3 higher, 0.96–1.33, p = 0.40). Compared to those with ≥95% adherence by VAS, individuals with <95% adherence were somewhat less likely to suppress (0.44, 0.19–1.03, p = 0.06).

Conclusions: We found no evidence that, among people newly entering HIV care, higher CD4 at ART initiation was associated with reduced adherence or poorer virological suppression, at least in the short-term. In this rural South African setting, motivation to adhere to ART may be independent of the presence of symptomatic HIV disease.

http://dx.doi.org/10.7448/IAS.18.5.20340
additional strategies are needed to address clinic delays that are barriers to ART delivery.

http://dx.doi.org/10.7448/IAS.18.5.20483

MOAC0106LB
treatment as prevention: characterization of partner infections in the HIV Prevention Trials Network 052 trial
Susan H Eshleman1; Sarah E Hudelson1; San San Ou2; Andrew D Redd3; Ronald Swanstrom3; Stephen F Porcella3; Ying Q Chen4; Estelle Piwowar-Manning4; Marybeth McCauley4; Theresa Gamble5; Matthew Sievers5; Craig A Martens6; Daniel Bruno7; Li-Hua Ping8; Elena Dukhovni8; Thomas C Quinn9;10; Johnstone Kumwenda10; Madalitso Maliwichi11; Nehemiah Nhando11; Victor Akelo12; Sikhuile Moyo13; Ravindre Panchia13; Nagalingeshwaran Kumarasamy14; Nuntita Chotirosniramit15; Marineide M Rocha16; Flavio Bustorff17; Beatrix Grinsztejn18; Kenneth H Mayer19,20; James P Hughes20; Myron S Cohen23 and for the HPTN 052 Study Team
1Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, United States. 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States. 3Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, United States. 4Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States. 5Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, United States. 6Genomics Unit, Research Technologies Section, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, United States. 7FHI 360, Washington, United States. 8FHI 360, Infectious Diseases, National Institutes of Health, Baltimore, United States. 9Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, United States. 10Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 11Laboratory of AIDS and Immunology Molecular-OIC/Fiocruz, Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil. 12Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Fiocruz, Rio de Janeiro, Brazil. 13The Fenway Institute, Boston, United States. 14Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, United States. 15Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States. Presenting author email: seshlem@jhmi.edu

Introduction: In 2011, results from an interim analysis of the HPTN 052 trial demonstrated that early antiretroviral therapy (ART) was highly effective for the prevention of HIV transmission from HIV-infected adults (index participants) to their HIV-uninfected sexual partners. All index participants were offered ART after May 2011; the trial ended in May 2015. This report describes the analysis of partner infections in HPTN 052.

Methods: HIV from index-partner pairs was analyzed. Phylogenetic methods were used to compare HIV pol sequences from index-partner pairs and controls. Linkage probability was further assessed by comparing the genetic distances between pol sequences (Bayesian analysis). Selected samples were also analyzed using next generation sequencing (envy region). Three infections that occurred close to the time of index ART initiation were analyzed by BEAST and serologic methods to determine the probable timing of HIV transmission. This abstract presents provisional findings based on data available as of May 2015.

Results: Seventy-five partner infections were confirmed (64 in Africa, 6 in Asia, 5 in the Americas), including 39 described previously (JID 2011; 204:1918–1926). Linkage status was determined for 70 cases (five cases failed analysis). Of these 70 cases, 26 (37%) were classified as unlinked (the partner was most likely infected from someone other than the index participant), and 44 (63%) were classified as linked (the index was most likely the source of the partner’s HIV infection). In 7 of the 44 linked cases, the partner seroconverted while the index was receiving study ART. In four of these seven cases, the partner seroconverted shortly after the index started ART, likely before the index was virally suppressed. In the remaining three cases, the partner seroconverted when the index was not virally suppressed due to ART failure.

Conclusions: Laboratory and statistical methods were used to identify and characterize linked partner infections in HPTN 052. Seven linked infections were observed in partners after index participants started study ART: four occurred shortly after ART initiation and three occurred in the setting of ART failure. The timing of the linked transmission events supports the model that HIV transmission is very unlikely in the setting of viral suppression.

http://dx.doi.org/10.7448/IAS.18.5.20484

MOAC0201
Post prevention of mother-to-child-transmission: 30-months outcomes in the Malawian “Option B+ programme”
Andreas D Haas1; Lyson Tenthani1,2; Malango T Msukwa1; Andreas Jahn23; Dalitso Midiani1; Eustice Nhango1; Oliver Gadabu2; Kali Tal1; Adrian Spörri1; Matthias Egger2; Frank Chimbwanda3; Joep J van Oosterhout4 and Olivia Keiser1
1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2International Training and Education Centre for Health, University of Washington, Seattle, United States. 3Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi. 4Baobab Health Trust, Lilongwe, Malawi. Dignitas International, Zomba, Malawi. Presenting author email: andreas.haas@ispim.unibe.ch

Introduction: Under the Option B+ PMTCT strategy, HIV-infected pregnant and breastfeeding women initiate lifelong ART. Long-term retention after weaning is unknown. We examine treatment outcomes for up to 30-months after ART initiation.

Methods: We examined cumulative incidence of mortality, no follow-up after ART initiation, loss to follow-up after the first follow-up visit (LTF), treatment discontinuation and retention in the Malawian “Option B+ programme.” We analyzed 24-months aggregated facility-level data (65,749 patients, 654 facilities) and 30-months individual-level data (3225 patients; six large facilities) from Option B+ patients who initiated ART during 2011–2014. We excluded patients who transferred to another facility.

Results: In facility-level data, 79.9% (52,525/65,749) and 75.0% (40,509/54,029) of all patients were still in care 6 and 12 months after ART initiation. After 24 months, 70.6% (17,257/24,245) were retained, 26.8% were LTF, 1.5% had died and 0.6% stopped ART. In six large facilities with individual-level data, slightly more patients defaulted or discontinued treatment: 24 and 30 months after ART initiation retention was 67.2 and 62.6%. Most patients were lost early and many did not return after the first visit (Figure 1), but after 18 months, further LTF was low. Of those who started ART during pregnancy, 15.8% (95% confidence interval (CI): 14.4–17.4%) had no follow-up, 18.0% (95% CI: 16.0–20.0%) were LTF, 6.6% (95% CI: 5.1–8.3%) stopped ART and 0.5% (95% CI: 0.3–1.0%) died during
30 months of follow-up. Of those who initiated ART while breastfeeding, 8.5% (95% CI: 6.8–10.4%) had no follow-up, 18.6% (95% CI: 15.7–21.7%) were LTF, 1.9% (95% CI: 1.0–3.5%) stopped ART and 0.6% died (95% CI: 0.2–1.3%) (Fig. 1). Patients who collected <85% of the prescribed drugs during the first year of ART were at higher risk of LTF between 13 and 30 months compared to patients who collected > 95% of the prescribed drugs (aHR: 3.02; 95% CI: 1.99–4.59).

Conclusions: Suboptimal long-term retention in care (67–70% after two years) needs to be addressed. Attrition rates are higher in those starting ART during pregnancy versus breastfeeding. Poor early drug adherence predicts later LTF. If women stay in care throughout breastfeeding, retention after weaning is likely.

Abstract MOAC0201–Figure 1. ART outcomes for Option B+ patients.

30 months of follow-up. Of those who initiated ART while breastfeeding, 8.5% (95% CI: 6.8–10.4%) had no follow-up, 18.6% (95% CI: 15.7–21.7%) were LTF, 1.9% (95% CI: 1.0–3.5%) stopped ART and 0.6% died (95% CI: 0.2–1.3%) (Fig. 1). Patients who collected <85% of the prescribed drugs during the first year of ART were at higher risk of LTF between 13 and 30 months compared to patients who collected > 95% of the prescribed drugs (aHR: 3.02; 95% CI: 1.99–4.59).

Conclusions: Suboptimal long-term retention in care (67–70% after two years) needs to be addressed. Attrition rates are higher in those starting ART during pregnancy versus breastfeeding. Poor early drug adherence predicts later LTF. If women stay in care throughout breastfeeding, retention after weaning is likely.

http://dx.doi.org/10.7448/IAS.18.5.20341

MOAC0202

Recruiting male partners for couple HIV counselling and testing in Malawi’s Option B+ programme: a randomized controlled trial

Nora Rosenberg1,2; Tiwonge Mtande1; Friday Saidi1; Christopher Stanley1; Edward Jere1; Lusubiro Mwangomba1; Kondwani Kumwenda1; Innocent Mofolo1; Mwawi Mwale1; Annie Chauma1; William C Miller2; Irving Hoffman2 and Mina C Hosseinipour1,2

1UNC Project, Lilongwe, Malawi. 2Department of Medicine, University of North Carolina, Chapel Hill, United States. 3District Health Office, Lilongwe, Malawi.

Presenting author email: nora_rosenberg@unc.edu

Introduction: In Malawi’s antenatal programme, HIV counselling and testing (HCT) for pregnant women is nearly universal, but couple HCT (cHCT) is uncommon, even though it is included in the Option B+ guidelines. cHCT is critical for HIV-infected women: many have HIV-infected partners in need of HIV diagnosis and treatment or HIV-uninfected partners in need of HIV prevention. cHCT may also increase Option B+ retention. Two partner recruitment strategies were assessed for cHCT uptake, male HIV status, female Option B+ retention and consistent condom use.
Methods: Newly diagnosed HIV-infected pregnant women ≥ 16 years with male partners in Lilongwe were recruited from Bwaila District Hospital Antenatal Unit from March to October 2014 to participate in a randomized controlled trial. Women in the “invitation only” arm received an invitation inviting male partners to antenatal care; women in the “invitation plus tracing” arm received the same invitation but male partners were traced by phone and/or home visit if they failed to present within one week. Women were assessed one month later. Analyses were conducted using Chi-squared tests.

Results: Of 220 eligible women, 200 (90%) consented and enrolled. CHCT uptake was 52% in the invitation only arm and 74% in the invitation plus tracing arm (p = 0.001). Among the 126 men who presented for CHCT, 25% already knew they were HIV-infected; 47% learned they were HIV-infected for the first time and 25% were HIV-uninfected with no difference by arm (p = 0.8). There was a trend towards greater one-month retention among women in the invitation plus tracing arm (93%) compared to the invitation only arm (83%) (p = 0.09). Among HIV-discordant couples, unprotected sex declined from 94 to 23% (p < 0.001) following CHCT. Participation did not lead to intimate partner violence in either arm.

Conclusions: The invitation plus tracing strategy was extremely effective for recruiting male partners for CHCT and substantially more effective than the invitation only strategy. Both strategies identified many HIV-infected men and HIV-discordant couples. CHCT resulted in higher ART retention, declines in unprotected sex in HIV-discordant couples and no intimate partner violence. Scaling up an invitation plus tracing strategy within the Option B+ programme would have substantial public health benefits.

http://dx.doi.org/10.7448/IAS.18.5.20342

MOAC0203
Zimbabwe approaching virtual elimination of mother to child transmission of HIV following implementation of Option A

Raluca Buzdugan; Sandra I McCoy; Constancia Watafzua; Mi-Suk Kang Dufour; Maya Petersen; Jeffrey Dirawo; Angela Mushavi; Hilda Angela Mujuru; Agnes Mahomva; Barbara Engelsmann; Anna Hakobyan; Owen Mugurungi; Frances M Cowan; and Nancy S Padlan

School of Public Health, University of California, Berkeley, United States. Centre for Sexual Health and HIV Research Zimbabwe, Harare, Zimbabwe. Center for AIDS Prevention Studies, University of California, San Francisco, United States. Ministry of Health and Child Care, Harare, Zimbabwe. Department of Paediatrics and Child Health, University of Zimbabwe, Harare, Zimbabwe. Elizabeth Glaser Pediatric AIDS Foundation, Harare, Zimbabwe. Organization for Public Health Interventions and Development, Harare, Zimbabwe. Children’s Investment Fund Foundation, London, United Kingdom. Institute of Epidemiology & Health, University College London, London, United Kingdom.

Presenting author email: f.cowan@ucl.ac.uk

Introduction: We evaluated the impact of Option A, rolled out in August–December 2011, on HIV-free infant survival and mother-to-child transmission (MTCT) in Zimbabwe.

Methods: In 2012 and 2014, we conducted cross-sectional community-based surveys of mother-infants pairs residing in the catchment areas of 157 health facilities randomly selected from 5 of 10 provinces in Zimbabwe. Eligible infants (alive or deceased) were born 9–18 months before each survey to mothers ≥ 16 years old. We randomly selected mother-infant pairs and conducted questionnaires and verbal autopsies and collected blood samples. The impact analysis was limited to 113 catchment areas unexposed to Option A activities at baseline according to facility records; we estimated the HIV-free infant survival and MTCT rate within each catchment area and compared the 2012 and 2014 estimates using a paired t-test.

Results: We enrolled 8568 mother-infant pairs with viable maternal specimens in 2012 and 9619 in 2014, of whom 1107 (12.9%) and 1176 (12.2%) mothers respectively were HIV-infected. Among infants born to HIV-infected mothers, 90.6% (95% confidence interval [CI]: 88.8, 92.3) of infants were alive and HIV-uninfected at 9–18 months in 2012, compared to 94.7% (95% CI: 93.4, 96.0) of infants in 2014 (p = 0.001); MTCT was 9.0% (95% CI: 7.3, 10.7) in 2012 and 5.3% (95% CI: 4.0, 6.6) in 2014. In the 113 catchment areas where Option A was implemented after the infants surveyed in 2012 were born, there was a 6.5 percentage point (95% CI: 3.3, 9.7) mean increase in HIV-free infant survival (89.8 to 96.3%, p < 0.001), and 6.2 percentage point (95% CI: 3.0, 9.4) mean decrease in MTCT (9.9 to 3.7%, p < 0.001).

Conclusions: We found a substantial and statistically significant increase in HIV-free infant survival and decrease in MTCT among infants aged 9–18 months following the implementation of Option A in Zimbabwe. Our estimates capture transmissions during pregnancy, delivery and the first 9–18 months of breastfeeding. Notably, 72% of HIV-exposed infants were still breastfeeding at baseline and 78% at endpoint, so additional infections may occur. The 2014 survey also provides a baseline for evaluating Option B+, which has been recently rolled out in Zimbabwe and should further accelerate efforts to eliminate MTCT.

http://dx.doi.org/10.7448/IAS.18.5.20343

MOAC0204
Antiretroviral intensification to prevent intrapartum HIV transmission in late comers

Marc Lallemant; Billy Amzal; Saik Urien; Patumrat Sripan; Tim Cressey; Nicole Ngo-Giang-Huong; Boonsong Rawangvan; Prapan Sabiansong; Thitiporn Siriwachirachal; Tapnarong Jarupanich; Prateep Kanjanavikai; Phaibool Wanasiri; Suporn Koetsawang; Gonzague Jourdain; Sophie Le Cœur and PHPT-5 study team

1IRD174/PHTP, Chiang Mai, Thailand. 2Department of Immunology and Infectious Diseases, Harvard Chan School of Public Health, Boston, United States. 3Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. 4LASER Analytica, London, United Kingdom. 5EA 08, Sorbonne Paris Cité, Université Paris Descartes, Paris, France. 60901 INSERM, URC Paris Centre Necker Cochin, Paris, France. 7Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand. 8Nopparat Rajaneehan Hospital, Bangkok, Thailand. 9Samutprakarn Hospital, Samutprakarn, Thailand. 10Khon Kaen Hospital, Khon Kaen, Thailand. 11Banglamung Hospital, Chonburi, Thailand. 12Kasasin Hospital, Kalasin, Thailand. 13Family Health Research Center, Mahidol University, Bangkok, Thailand. 14Institut National d’Études Démographiques (INED), Paris, France.

Introduction: Infants born to HIV-infected pregnant women presenting late are at high risk of intrapartum infection. Mother/infant antiretroviral (ARV) intensification may substantially reduce this risk.

Methods: In a multicentre, phase 3, adaptive single-arm trial in Thailand, pregnant women with <8 weeks of standard ARVs (zidovudine (ZDV) + lamivudine (3TC) + lopinavir/ritonavir) and their infants received “ARV intensification” to prevent transmission at delivery: women took a single nevirapine (NVP) dose in labour and continued ARVs for four weeks; formula-fed neonates received two weeks AZT + 3TC + NVP followed by two weeks AZT + 3TC, instead of standard one-week ZDV. Infants were tested for HIV at birth, one, two, four, six months. A negative DNA PCR <48 hours, followed by a confirmed positive PCR defined intrapartum transmission.
Abstract MOAC0204 - Table 1. Women’s baseline characteristics

| Characteristics       | Historical data | Intensification |
|-----------------------|-----------------|-----------------|
| N                     | 3965            | 88              |
| Age (IQR) – years     | 25.7 (22.5–29.7)| 26.3 (22.3–33.0)|
| CD4 (IQR) – cells/mm³ | 380 (260–527)   | 368 (255–503)   |
| VL baseline (IQR) – log10 copies/mL | 4.0 (3.4–4.6) | 4.3 (3.7–4.7) |
| VL delivery (IQR) – log10 copies/mL | 3.2 (2.3–4.0) | 2.2 (1.8–2.9) |
| GA delivery (IQR) – weeks | 38.7 (37.9–39.7) | 38.6 (38.0–39.3) |
| C/section (%)         | (21%)           | (36%)           |

Data from 3965 mother/infant pairs (84 intrapartum transmissions) in three PHPT randomized perinatal HIV prevention trials (NCT00386230, NCT00398684 and NCT00409591) conducted in the same setting were used to define an historical control and build an intrapartum transmission model. Viral load (VL) during pregnancy was modelled as a function of ARVs exposure and intrapartum transmission was predicted through a logistic model with VL, maternal/infant ARVs, delivery mode and prematurity status as covariates. The Bayesian estimation of the risks of intrapartum transmission with/without intensification used all historical information and decision rules to stop for futility or superiority of ARV intensification over standard of care (risk ratio, RR < 1) were determined for three interim analyses. Prior intrapartum transmission probabilities were subsequently updated using the results of the intensification trial to derive posterior probabilities (credibility interval, CrI) as well as probability distributions of RR < 1 and RR < 0.5.

Results: At first interim analysis, the DSMB recommended stopping enrolment and reporting intensification efficacy. Overall 88 mother/infant pairs received intensification with no intrapartum transmission. The posterior probability of intrapartum transmission was 0.4% (95% CrI: 0.1–1.4%) with intensification compared to 2.0% (0.3–5.2%) without. The probability of superiority of intensification over standard of care (RR < 1) was 94.1%, and that of at least a two-fold reduction of risk (RR < 0.5) was 82.9%. ARV intensification appeared safe.

Conclusions: ARV intensification is very effective in preventing intrapartum transmission in pregnant women receiving a short course antepartum ARVs before delivery.

http://dx.doi.org/10.7448/IAS.18.5.20344

MOAC0205LB
Costs of Zimbabwe’s accelerated prevention of mother-to-child transmission of HIV programme

Ivan Ochoa-Moreno¹; Collin Mangenah²; Raluca Buzdugan³; Nancy S Padian³; Sandra I Mccoy³; Frances M Cowan³,⁴ and Sergio Bautista-Arredondo³

¹National Institute of Public Health, Cuernavaca, Mexico. ²Centre for Sexual Health and HIV/AIDS Research, Harare, Zimbabwe. ³University of California, Berkeley, United States. ⁴University College London, London, United Kingdom.

Presenting author email: f.cowan@ucl.ac.uk

Introduction: In 2010 and 2013, World Health Organization issued revised guidelines on the recommended approaches for prevention of mother-to-child transmission of HIV (PMTCT) (Options A, B, B/C). Estimating the cost of these PMTCT regimens is essential. We estimated the cost of Option A in Zimbabwe, which was rolled out in 2011. These data also represent baseline estimates to assess the cost-effectiveness of Option B/C, rolled out in Zimbabwe in late 2013.

Methods: We conducted a cross-sectional survey of 157 randomly selected health facilities offering PMTCT services in 5 of 10 provinces in Zimbabwe. In each facility, we collected data on the output and cost of PMTCT services, including staff and supplies for the whole year and for each month of 2013. We also assessed the time allocation of staff providing these services. We estimated the average cost of PMTCT services per facility and for specific services in the PMTCT cascade such as HIV testing and antiretroviral prophylaxis. We also examined the variation in costs by the type of provider.

Abstract MOAC0204 - Figure 1. Intrapartum transmission posterior probabilities.
Results: We estimated that the average cost of PMTCT services is approximately US$13,600 (median US$9074) per facility-year, which varies widely by facility size and type. On average, 80% of the overall cost corresponds to staff (US$10,900) and the remaining 20% to supplies (US$2700). The average cost per pregnant woman tested was US$75 (median US$44) and the average cost per HIV-infected pregnant woman on antiretroviral prophylaxis or treatment was US$1040 (median US$527) per year. Scale was associated with cost; 40% of the variation in the cost per pregnant woman tested can be explained by number of HIV+ women on ART/ARV, as was 50% of the variation in prophylaxis and treatment costs (see Figure).

Conclusions: These findings are the first empirical estimations of PMTCT programmes costs in Zimbabwe. Given limited resources, calls for the elimination of MTCT have challenged the international community to optimize the use of resources to increase coverage of PMTCT priority services. Information about costs is essential to the community to optimize the use of resources to increase coverage of PMTCT priority services. Information about costs is essential to the community to optimize the use of resources to increase coverage of PMTCT priority services.

Abstract MOAC0205LB—Figure 1. Facility-level variation of average cost per service in two stages of the PMTCT cascade vs. scale.

Abstract MOAC0301LB

Increasing uptake of voluntary medical male circumcision among men aged 20–34 years in Njombe and Tabora regions, Tanzania: a cluster-randomized controlled trial

Mwita Wambura1; Richard Hayes2; Jonathan Grund3; Saidi Kapiga4; Hally Maher5; Gerry Mshana1; Eudoxius Kuringe1; Marya Plotkin5; Naomi Bock3; Natasha Larke2; John Changalucha3; Helen Weiss2 and VMMC Tanzania Study Group

1NIMR, Mwanza, Tanzania, United Republic of Tanzania. 2LSHTM, London, United Kingdom. 3CDC/CGH/DGHA, Atlanta, United States. 4MITU/LSHTM, Mwanza, Tanzania, United Republic of Tanzania. 5Jhpiego/Tanzania, Dar es Salaam, Tanzania, United Republic of Tanzania. 6Jhpiego/Tanzania, Dar es Salaam, Tanzania, United Republic of Tanzania.

Presenting author email: wmwita@yahoo.com

Introduction: Tanzania introduced voluntary medical male circumcision (VMMC) in 2009 as part of its national HIV prevention strategy. Reaching men aged 20–34 years with circumcision may affect the most immediate reduction in HIV incidence. However, approximately 80% of VMMC clients in Tabora and Njombe regions are aged 10–19 years. This study evaluated the effect of a strategy to increase VMMC uptake among men aged 20–34 years in Njombe and Tabora.

Methods: A cluster-randomized controlled trial at 20 VMMC outreach sites was conducted in Njombe and Tabora, focusing on increasing VMMC uptake. The intervention, which was informed by formative research, included 1) additional demand-creation messages (non-HIV benefits of VMMC, voluntary nature of HIV testing), 2) involvement of recently circumcised men as auxiliary peer promoters, 3) separate waiting and education areas for men aged > 20 years, and 4) sessions on wound healing and post-circumcision abstinence targeting female partners. Analysis was based on cluster-level summary measures.

Results: Overall, 6251 men were enrolled in 10 intervention sites (1809 Njombe and 4442 Tabora) and 3968 men in the 10 control sites (1035 Njombe and 2933 Tabora). The proportion of clients aged 20–34 was greater in intervention sites compared to control sites (17.7% vs. 13.0%; RR = 1.4; 95% CI: 0.9–2.0; p = 0.11) and was associated with a greater number of clients in both regions (overall mean difference = 227; 95% CI: 33–420; p = 0.03). The effect of the intervention varied by region: in Njombe, there was little difference in attendance between control and intervention sites (11.3% vs. 14.7%; RR = 0.77, 95% CI: 0.4–1.6; p = 0.43), while in Tabora, there was over a twofold difference (27.5% vs. 11.5%; RR = 2.39, 95% CI: 1.7–3.4; p = 0.03). Similarly, the mean number of clients aged 20–34 was greater in intervention facilities in Tabora (mean difference = 182; 95% CI: 5–359; p = 0.05) and there was little difference in Njombe (mean difference = 12; 95% CI: −13 to 36; p = 0.31).

Conclusions: The intervention was associated with a significant increase in the proportion of VMMC clients aged 20–34 years in Tabora but not in Njombe. The lack of intervention effect in Njombe may be due to saturation, as VMMC has been available for longer. The results suggest that the intervention may be more likely to be effective in areas newly targeted for VMMC.

http://dx.doi.org/10.7448/IAS.18.5.20485

MOAC0302LB

Acceptability and feasibility of a novel approach to promote HIV testing in sexual and social networks using HIV self-tests

Harsha Thirumurthy1,2; Immaculate Akello1; Katherine Murray2; Samuel Masters5; Suzanne Maman6; Eunice Omanga7 and Kawango Agot3

Journal of the International AIDS Society 2015, 18 (Suppl 4) Oral Abstracts

Abstract: We estimated that the average cost of PMTCT services is approximately US$13,600 (median US$9074) per facility-year, which varies widely by facility size and type. On average, 80% of the overall cost corresponds to staff (US$10,900) and the remaining 20% to supplies (US$2700). The average cost per pregnant woman tested was US$75 (median US$44) and the average cost per HIV-infected pregnant woman on antiretroviral prophylaxis or treatment was US$1040 (median US$527) per year. Scale was associated with cost; 40% of the variation in the cost per pregnant woman tested can be explained by number of HIV+ women on ART/ARV, as was 50% of the variation in prophylaxis and treatment costs (see Figure).

Conclusions: These findings are the first empirical estimations of PMTCT programmes costs in Zimbabwe. Given limited resources, calls for the elimination of MTCT have challenged the international community to optimize the use of resources to increase coverage of PMTCT priority services. Information about costs is essential to the community to optimize the use of resources to increase coverage of PMTCT priority services. Information about costs is essential to the community to optimize the use of resources to increase coverage of PMTCT priority services.

Abstract MOAC0205LB—Figure 1. Facility-level variation of average cost per service in two stages of the PMTCT cascade vs. scale.

Abstract MOAC0301LB

Increasing uptake of voluntary medical male circumcision among men aged 20–34 years in Njombe and Tabora regions, Tanzania: a cluster-randomized controlled trial

Mwita Wambura1; Richard Hayes2; Jonathan Grund3; Saidi Kapiga4; Hally Maher5; Gerry Mshana1; Eudoxius Kuringe1; Marya Plotkin5; Naomi Bock3; Natasha Larke2; John Changalucha3; Helen Weiss2 and VMMC Tanzania Study Group

1NIMR, Mwanza, Tanzania, United Republic of Tanzania. 2LSHTM, London, United Kingdom. 3CDC/CGH/DGHA, Atlanta, United States. 4MITU/LSHTM, Mwanza, Tanzania, United Republic of Tanzania. 5Jhpiego/Tanzania, Dar es Salaam, Tanzania, United Republic of Tanzania. 6Jhpiego/Tanzania, Dar es Salaam, Tanzania, United Republic of Tanzania. 7Jhpiego/Tanzania, Dar es Salaam, Tanzania, United Republic of Tanzania.

Presenting author email: wmwita@yahoo.com

Introduction: Tanzania introduced voluntary medical male circumcision (VMMC) in 2009 as part of its national HIV prevention strategy. Reaching men aged 20–34 years with circumcision may affect the most immediate reduction in HIV incidence. However, approximately 80% of VMMC clients in Tabora and Njombe regions are aged 10–19 years. This study evaluated the effect of a strategy to increase VMMC uptake among men aged 20–34 years in Njombe and Tabora.

Methods: A cluster-randomized controlled trial at 20 VMMC outreach sites was conducted in Njombe and Tabora, focusing on increasing VMMC uptake. The intervention, which was informed by formative research, included 1) additional demand-creation messages (non-HIV benefits of VMMC, voluntary nature of HIV testing), 2) involvement of recently circumcised men as auxiliary peer promoters, 3) separate waiting and education areas for men aged > 20 years, and 4) sessions on wound healing and post-circumcision abstinence targeting female partners. Analysis was based on cluster-level summary measures.

Results: Overall, 6251 men were enrolled in 10 intervention sites (1809 Njombe and 4442 Tabora) and 3968 men in the 10 control sites (1035 Njombe and 2933 Tabora). The proportion of clients aged 20–34 was greater in intervention sites compared to control sites (17.7% vs. 13.0%; RR = 1.4; 95% CI: 0.9–2.0; p = 0.11) and was associated with a greater number of clients in both regions (overall mean difference = 227; 95% CI: 33–420; p = 0.03). The effect of the intervention varied by region: in Njombe, there was little difference in attendance between control and intervention sites (11.3% vs. 14.7%; RR = 0.77, 95% CI: 0.4–1.6; p = 0.43), while in Tabora, there was over a twofold difference (27.5% vs. 11.5%; RR = 2.39, 95% CI: 1.7–3.4; p = 0.03). Similarly, the mean number of clients aged 20–34 was greater in intervention facilities in Tabora (mean difference = 182; 95% CI: 5–359; p = 0.05) and there was little difference in Njombe (mean difference = 12; 95% CI: −13 to 36; p = 0.31).

Conclusions: The intervention was associated with a significant increase in the proportion of VMMC clients aged 20–34 years in Tabora but not in Njombe. The lack of intervention effect in Njombe may be due to saturation, as VMMC has been available for longer. The results suggest that the intervention may be more likely to be effective in areas newly targeted for VMMC.

http://dx.doi.org/10.7448/IAS.18.5.20486

MOAC0302LB

Acceptability and feasibility of a novel approach to promote HIV testing in sexual and social networks using HIV self-tests

Harsha Thirumurthy1,2; Immaculate Akello1; Katherine Murray2; Samuel Masters5; Suzanne Maman6; Eunice Omanga7 and Kawango Agot3
Introduction: Identifying interventions to increase men’s uptake of HIV testing in sub-Saharan Africa is essential for the success of combination prevention strategies, including treatment as prevention. HIV self-testing is an emerging approach with high acceptability, but limited evidence exists on optimal strategies for distributing self-tests and reaching men in particular. This study explored a novel approach of providing multiple self-tests to women with high HIV incidence to promote HIV testing among their sexual partners.

Methods: HIV-uninfected women aged 18–39 years were recruited at two sites in Kisumu, Kenya between January and March 2015: a drop-in centre for female sex workers (FSWs) and a health facility with antenatal and postpartum clinics. Following informed consent and instructions on using the OraQuick Rapid HIV 1/2 Test, index participants (IPs) enrolled at the health facility and drop-in centre received three and five self-tests, respectively. Structured interviews were conducted with IPs at enrolment and multiple times over three months to determine how self-tests were used. Key outcomes included the proportion of IPs reporting their primary sexual partner used a self-test.

Results: A total of 278 IPs were enrolled (101 FSWs, 61 antenatal, 116 postpartum). Follow-up interviews were completed with 262 IPs (94.2%) by May 9, 2015. Most self-tests provided at enrolment were either used by the IP or given to other persons (mean 2.7 (90%) for antenatal and postpartum IPs, 4.7 (94%) for FSWs). All but two IPs gave ≥1 self-tests to other persons, and a large majority gave a self-test to their primary sexual partner (77% FSWs, 91.8% antenatal and 86% postpartum). Ninety-eight percent of self-tests given to other persons were reported to be used. Among 367 persons who received self-tests from FSWs and used them, commercial sex clients were the largest group (211, 57%). In total, 10.6% (72/681) of those who received self-tests from IPs and used them were reported to obtain an HIV-positive result; 55% of them sought confirmatory testing.

Conclusions: Provision of multiple HIV self-tests to sub-populations of women with high HIV incidence was successful in promoting HIV testing among their sexual partners. This novel strategy warrants further consideration as countries develop self-testing policies.

http://dx.doi.org/10.7448/IAS.18.5.20487

MOAC0303LB
Community outbreak of HIV infection linked to injection drug use of oxymorphone – Indiana, 2015
Joan Duwve1,2, Karen Hoover3, Caitlin Conrad4, Romeo Galang5, Daniel Hillman6, Brooke Hoots3, Monta Patel7, Philip Peters7, Pam Pontones7, Jeremy Roseberry7, Jessica Shields7, Dorothy Waterhouse8 and Paul Weidle9

1Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, United States. 2Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, United States. 3Impact Research and Development Organization, Kisumu, Kenya. 4Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, United States. Presenting author email: hthirumu@email.unc.edu

Introduction: On 23 January 2015, the Indiana State Department of Health began investigating an outbreak of HIV infection after disease intervention specialists (DIS) reported 11 confirmed HIV cases traced to a rural community in southeastern Indiana that had reported five HIV cases between 2004 and 2013. From 2009 to 2013, the community (population 4200) had substantial unemployment (8.9%), many adults without high school diplomas (21.3%), a substantial proportion living in poverty (19%) and a limited healthcare access. A public health emergency was declared on March 26 by executive order. We report on efforts to diagnose HIV infection in this community.

Methods: For individuals newly diagnosed with HIV infection, DIS identified 491 unique individuals during contact tracing and assessed for risk and tested for HIV. Overall, 153/390 (39%) persons were diagnosed with HIV infection. There was no difference in age and sex between HIV-positive and HIV-negative tested persons (Table 1).

Conclusions: This outbreak highlights the vulnerability of rural, resource-poor populations to drug use, misuse and addiction; the importance of timely HIV surveillance activities and rapid response to interrupt disease transmission and the need for expanded mental health and substance use treatment programmes in medically underserved rural areas.

http://dx.doi.org/10.7448/IAS.18.5.20488

MOAC0304LB
HIV-1 and HCV molecular epidemiology of a large community outbreak of HIV-1 infection linked to injection drug use of oxymorphone – Indiana, 2015

Romeo R Galang1,2, Jessica Gentz3, Philip J Peters5, Sara J Blosser3, Erika L Chapman3, Caitlin Conrad7, Joan M Duwve4,5, Lilia Ganova-Raeva1,2, Walid Heneine1, Daniel Hillman1, Hongwei Jia1, Lixia Liu1, Wei Luo1, Judy Lovchik1, Silvina Masciotra1,2
S Michele Owen; Andrea Perez; Paula Peyrani; Pam Pontones; Sumathi Ramachandran; Jeremy C. Roseberry; Michelle Sandoval; Anupama Shankar; Hong Thai; Guoliang Xia; Yury Khudyakov and William M Switzer

1Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, United States. 2Epidemic Intelligence Service, CDC, Atlanta, United States. 3Indiana State Department of Health, Indianapolis, United States. 4Richard M. Fairbanks School of Public Health, Indiana University Indianapolis, United States. 5Division of Infectious Diseases, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, United States. 6Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, United States. 7University of Louisville, Louisville, United States. 8University of Louisville, Louisville, United States. 9University of Louisville, Louisville, United States. Presenting author email: ydh0@cdc.gov

Introduction: In January 2015, a cluster of HIV-1 infections was detected in a rural county in southeastern Indiana among persons who reported injection of the prescription opioid oxymorphone. As of 13 May 2015, HIV-1 infection has been diagnosed in 153 individuals. We compare molecular analyses of HIV-1 and HCV sequences among a subset of individuals in this outbreak to infer the timing of HIV transmission relative to HCV.

Methods: Serum and plasma samples were collected from November 2014 to April 2015. HIV polymerase (pol) gene sequences from persons with newly diagnosed HIV infection were phylogenetically analyzed. Phylogenetic clusters were defined when HIV-1 pol sequences were highly genetically related (>97% nucleotide identity) and statistical evidence supporting relatedness was high (Shimodaira–Hasegawa probabilities >0.99). Recency of HIV infection was determined by avidity testing using a modified Bio-Rad HIV 1/2 plus O assay (BRAI). HCV NS5B gene sequences were phylogenetically analyzed to determine the number of clusters of independent HCV strains within this population.

Results: The pol gene was sequenced for 57 HIV-1-infected persons. Two clusters of HIV-1 subtype B infection were identified (Cluster 1, n = 55; Cluster 2, n = 2; Figure, panel a). Among 49 specimens available for BRAI testing, 45 (91.8%) were recent infections. Of 36 HIV-infected specimens with HCV antibody results, 34 (94%) were HCV co-infected. The NS5B gene was sequenced for 119 HCV-infected persons. Genotype 1a (n = 82) was most common, followed by genotype 3a (n = 29), 2b (n = 5) and 1b (n = 3). Three unique clusters of HCV strains were identified (Cluster 1, n = 45; Cluster 2, n = 9; Cluster 3, n = 7; Figure, panel b). Of 118 HCV-infected specimens with HIV antibody results, 38 (32.2%) were HIV co-infected.

Conclusions: In this prescription opioid injection-associated outbreak, a single strain of HIV-1 was introduced into a population infected with multiple HCV strains. In contrast to the homogeneity of HIV strains observed in this cohort, the heterogeneity of HCV strains (clustering and non-clustering) suggests earlier introduction of HCV compared with HIV. These data demonstrate the outbreak potential with the introduction of HIV-1 into a community where HCV prevalence is high among persons who inject prescription opioids.

http://dx.doi.org/10.7448/IAS.18.5.20489

MOAC0305LB

HPTN 067/ADAPT study: a comparison of daily and intermittent pre-exposure prophylaxis dosing for HIV prevention in men who have sex with men and transgender women in New York city

Sharon Mannheimer; Yael Hirsch-Moverman; Avelino Loquere; Julie Franks; James Hughes; San-San Ou;

Abstract MOAC0304LB–Figure 1. Maximum likelihood phylogenetic tree of (a) HIV-1 pol sequences and (b) HCV NS5b sequences.
Abstract MOAC0305LB - Table 1.

| Characteristic | Study regimen daily (D), n = 59 | Study regimen time (T), n = 60 | Study regimen event (E), n = 60 | p    |
|----------------|---------------------------------|---------------------------------|---------------------------------|------|
| Number of sex events during study, excluding oral sex | 1083                           | 1311                            | 1502                            | 0.20 |
| % total sex events with complete coverage (or sex events with partial coverage % pre-sex only, % post-sex only) | 66 (24, 2)                      | 47 (30, 8)                      | 52 (29, 6)                      | 0.03 |
| Total number of required pills taken | 5370                           | 1708                            | 1063                            | <0.001 |
| Total % PrEP adherence | 65                             | 46                              | 41                              | <0.001 |
| % Participants with neurologic side effects (e.g. headache, dizzy and lightheaded) | 24                             | 20                              | 18                              | 0.64 |
| % Participants with gastrointestinal side effects (e.g. nausea, vomiting, diarrhea, bloating, gas) | 39                             | 18                              | 28                              | 0.51 |
| % Participants with detectable tenofovir (TFV) (> 0.31 ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks | 74, 61                          | 76, 56                          | 64, 50                          | 0.58 |
| Median plasma TFV concentration (ng/mL) in plasma when reporting sex in last 7 days at 10 weeks, at 30 weeks | 83, 31                          | 24, 11                          | 15, 1                           | 0.49 |
| % achieving effective plasma TFV concentration (> 5 ng/mL) when reporting sex in last 7 days at 30 weeks, at 30 weeks | 63, 56                          | 72, 50                          | 61, 39                          | 0.65 |

Results: A total of 179 participants were randomized: 176 MSM, 3 TGW; median age 30 years; 70% black, 13% white and 25% Hispanic. D arm participants had significantly higher complete coverage of sex acts (66% D, 47% T, 52% E; p = 0.03; Table 1) and highest adherence to regimen (65% D, 46% T, 41% E; p < 0.001). Significantly fewer pills were used with intermittent (T and E) PrEP (p < 0.001). Side effects were similar across arms, with gastrointestinal and neurologic symptoms most common. Participants reporting recent sex in all PrEP dosing arms achieved similar rates of detectable plasma tenofovir levels and of concentrations associated with effective PrEP dose frequency.

Conclusions: While this cohort of mostly black MSM in NYC reported higher prophylactic coverage of sex acts and higher adherence to daily PrEP, non-daily PrEP users who reported recent sex achieved comparable rates of effective tenofovir plasma concentrations. Intermittent PrEP required substantially fewer pills, although side effects were similar. This study demonstrates the feasibility of intermittent PrEP, a potentially more cost-effective alternative to daily PrEP, among U.S. black MSM.

http://dx.doi.org/10.7448/IAS.18.5.20538

MOAC0306LB

HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand

Timothy H Holtz1,2; Anupong Chittwarakorn3; Marcel E Cirlin1,2; James Hughes2; K Rivet Amico5; Craig Hendrix2; Bonnie J Dye5; Peter L Anderson5; San-San Ou5; Vanessa Elharrar10; Susan H Eshleman1; Michael Stirratt12; Robert M Grant13 and Bangkok HPTN 067/ADAPT Study Team

1HIV/STD Research Program, Thailand Ministry of Public Health – U.S. Centers for Disease Control and Prevention Collaboration, Bangkok, Thailand. 2U.S. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, United States. 3Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. 4Department of Biostatistics, University of Washington, Seattle, United States. 5Fred Hutchinson Cancer Research Center, Seattle, United States. 6Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, United States.

Introduction: Daily oral FTC/TDF (Truvada) is US FDA-approved for HIV pre-exposure prophylaxis (PrEP). HPTN 067/ADAPT, a phase II randomized, open-label PrEP trial, assessed the feasibility of intermittent FTC/TDF-based PrEP for HIV prevention among men who have sex with men (MSM) and transgender women (TGW) in New York City (NYC).

Methods: MSM and TGW were eligible if: male at birth, and reported anal intercourse and 1 other HIV risk factor in the past six months. Exclusion criteria included HIV infection, hepatitis B infection, acute HIV symptoms and abnormal renal function. Following six weeks of once/week directly observed dosing, participants were randomly assigned 1:1:1 to 24 weeks of PrEP dosed: daily (D), twice weekly plus one post-sex dose (time-driven (T)), or one pre- and one post-sex dose (event-driven (E)). Regimens were compared for prophylactic coverage (PrEP within four days pre- and 24 hours post-sex) of sex events, pills taken, side effects and plasma drug levels. Adherence and coverage were assessed using electronic monitoring adjusted by self-reported sex and pill taking behaviour collected in detailed weekly interviews.

Results: A total of 179 participants were randomized: 176 MSM, 3 TGW; median age 30 years; 70% black, 13% white and 25% Hispanic. D arm participants had significantly higher complete coverage of sex acts (66% D, 47% T, 52% E; p = 0.03; Table 1) and highest adherence to regimen (65% D, 46% T, 41% E; p < 0.001). Significantly fewer pills were used with intermittent (T and E) PrEP (p < 0.001). Side effects were similar across arms, with gastrointestinal and neurologic symptoms most common. Participants reporting recent sex in all PrEP dosing arms achieved similar rates of detectable plasma tenofovir levels and of concentrations associated with effective PrEP dose frequency.

Conclusions: While this cohort of mostly black MSM in NYC reported higher prophylactic coverage of sex acts and higher adherence to daily PrEP, non-daily PrEP users who reported recent sex achieved comparable rates of effective tenofovir plasma concentrations. Intermittent PrEP required substantially fewer pills, although side effects were similar. This study demonstrates the feasibility of intermittent PrEP, a potentially more cost-effective alternative to daily PrEP, among U.S. black MSM.

http://dx.doi.org/10.7448/IAS.18.5.20538
Abstract MOAC0306LB - Table 1. Results from Bangkok HPTN 067/ADAPT study (n = 178)

| Characteristic                                    | Daily (D) | Time-driven (T) | Event-driven (E) | Total | p value |
|--------------------------------------------------|-----------|-----------------|------------------|-------|---------|
| N                                                | 60        | 59              | 59               | 178   | –       |
| Median age                                       | 31        | 28              | 31               | 31    | –       |
| Number of sex events over full study, not including oral sex | 1485      | 1337            | 1018             | –     | 0.16    |
| % total events fully covered                      | 85        | 84              | 74               | –     | See text|
| Total required tablets actually taken             | 8047      | 3272            | 1255             | –     | <0.001  |
| Total tablets required                            | 9420      | 4121            | 1928             | –     | <0.001  |
| % total adherence                                 | 85        | 79              | 65               | –     | <0.001  |
| % detectable (≥ 9.1 fmol/million) in PBMCs when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up) | 100; 91.3 | 96.6; 94.7 | 93.3; 85.7; 96.7; 91.1 | 0.54 |
| Median drug concentration in PBMCs (fmol/million cells) when reporting sex in last 7 days (at 10 weeks of follow up; at 30 weeks of follow up) | 81.1; 102.0 | 35.3; 46.8 | 26.4; 32.9; 45.5; 60.7 | <0.001 |

Introduction: Oral FTC/TDF PrEP is effective for preventing sexual HIV acquisition when used daily. An alternate dosing (non-daily) regimen was effective in the IPERGAY trial. Daily and non-daily regimens have not been compared directly with respect to prophylactic coverage for sexual exposure.

Methods: We enrolled men who have sex with men (MSM) into a phase 2, randomized, open-label trial of oral FTC/TDF PrEP in Bangkok. We randomly assigned participants to one of three self-administered dosing regimens for 24 weeks: daily (D); time-driven twice weekly with a post-sex dose (T) or event-driven before and after sex (E). We contacted participants weekly to collect dates/times of PrEP use (monitored electronically by Wisepill™) and before and after sex (E). We contacted participants weekly to collect dates/times of PrEP use (monitored electronically by Wisepill™) and before and after sex (E). We randomized 178 MSM (median age 31 years). PrEP coverages were similar in arms D and T (85% vs. 84%, p = 0.79) and both were greater than in arm E (74%, p < 0.05). Adherence was greater in D (85%) compared with T (79%) or E (65%, p < 0.001). Compared with D, the number of doses required for full adherence was reduced by 57% in T and by 80% in E (p < 0.001). Among MSM reporting sex in the past week, PBMC tenofovir diphosphate was detectable (≥ 9.1 fmol/million cells) among 31/31 (100%) in D, 28/29 (96.6%) in T and 28/30 (93.3%) in E at week 10 on study, and in 21/23 (91.3%), 18/19 (94.7%) and 12/14 (85.7%) at week 30, respectively (p = 0.54). Median PBMC drug concentrations at week 30 were highest among men in D (102.0 vs. 46.8 vs. 32.9 fmol/million cells for D, T and E, respectively, p < 0.001). No HIV infections occurred after randomization.

Conclusions: Compared with the daily regimen, the time-driven dosing regimens offered comparably high PrEP coverage for sex acts for Thai MSM, despite slightly less adherence, while requiring fewer tablets. However, since non-daily dosing results in significantly lower PBMC drug concentrations, stricter adherence is required under these regimens to maintain prophylactic drug concentrations.

Rapid uptake and adoption of the WHO 2013 consolidated ARV guideline recommendations: paving the way to achieving the 90/90/90 global target

Introduction: Progress towards the ending the AIDS epidemic by 2030 critically depends on adoption of global guidelines that address evidenced based proven approaches to optimally treat all people living with HIV and how to best deliver interventions. With the 2013 Consolidated ARV Guidelines, WHO successfully launched new policy recommendations on the clinical, operational, programmatic and M&E aspects of HIV treatment and care.

Methods: WHO HQ with regional and country offices, held nine capacity building and dissemination consultations for >100 countries from 2013 to 2014. Through triangulation of baseline surveys, e-surveys with the country MoH HIV focal point and data compiled from the 2014 Global AIDS Response Progress Reporting, we have documented the adoption of priority HIV treatment policies within the 58 WHO focal countries. Data are presented through end 2014.

Results: Within 18 months of the launch of the 2013 consolidated antiretroviral drugs (ARVs) guidelines, 44 of 58 (76%) of focus countries adopted at least one of the major recommendations; globally another 25 countries were in the process of adopting. Sixty percent of focus countries adopted a CD4 count initiation of <500 cells/mm³, while Brazil, Thailand and Yemen offer treatment to all adults regardless of CD4 cell count. Seventy-one percent adopted a policy to treat all children with HIV <5 years; Ethiopia treats all...
More than 90% of countries adopted PMTCT Option B/B+; 59% planned to implement routine viral load monitoring. Adoption varied by WHO region (Figure 1). An update on the country implementation of these policies will be available in April 2015.

Conclusions: With the 2013 Consolidated ARV Guidelines, WHO brought together 56 new recommendations across the continuum of HIV treatment and care, and supported countries to more rapidly adopt new policies than ever before; if fully implemented, countries can achieve the 90/90/90 global target.

http://dx.doi.org/10.7448/IAS.18.5.20345

MOAD0102
Can the UNAIDS 90–90–90 target be reached? Analysis of 12 national level HIV treatment cascades
Jacob Levi1; Alice Raymond1; Anton Pozniak2; Pietro Vernazza3; Philipp Kohler4; Nathan Ford5; and Andrew Hill2
1Department of Public Health, School of Public Health, Imperial College London, London, United Kingdom. 2St. Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom. 3Cantonal Hospital, St. Gallen, Switzerland. 4Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland. 5World Health Organisation, Geneva, Switzerland.

Presenting author email: jacob.levi11@imperial.ac.uk

Introduction: UNAIDS has set the “90–90–90” target for all countries: to diagnose 90% of all HIV positive people, provide antiretrovirals for 90% of those diagnosed and achieve undetectable HIV RNA for 90% of those treated, in every country worldwide by 2020. This translates to at least 73% of all HIV positive people achieving undetectable HIV RNA in every country. We used national level HIV treatment cascades to analyze whether countries have achieved these targets.

Methods: We compared published estimates of HIV treatment cascades across 12 countries in Western and Eastern Europe, North and South America, Australia and sub-Saharan Africa. Cascades were selected based on reliable, generalizable, recently published results from large cross-sectional and longitudinal study cohorts. Data were analyzed in six stages: 1) HIV positive people, 2) Diagnosed, 3) Linked to care, 4) Retained in care, 5) On antiretroviral treatment (ART), 6) Undetectable HIV RNA. Each country level cascade was analyzed to identify whether each stage of the 90–90–90 target was met.

Results: The percentage of HIV positive people who both received ART and achieved undetectable HIV-RNA ranged from 9% (Russia) to 73% (Switzerland). None of the 12 countries met the UNAIDS target of 90% of HIV positive people diagnosed. One country (Switzerland) met the target of 90% of diagnosed people on ART. Five countries (Switzerland, Australia, UK, Denmark and The Netherlands) met the target of 90% of treated people with undetectable HIV RNA. While five Western European countries achieved ≥50% undetectable HIV-RNA, three Eastern European countries achieved under 20%. USA achieved undetectable HIV-RNA for 30% overall, the lowest amongst high-income countries, comparable to sub-Saharan Africa (29%). The largest fall between stages in the treatment cascades was between

### Abstract MOAD0102 - Table 1. Country level cascades versus 90–90–90 target

| Country                  | % Diagnosed | % On ART | % Undetectable HIV-RNA | Country                  | % Diagnosed | % On ART | % Undetectable HIV-RNA |
|--------------------------|-------------|----------|------------------------|--------------------------|-------------|----------|------------------------|
| UNAIDS 90–90–90 targets for 2020 | 90          | 82       | 73                     | Brazil (2013)            | 80          | 48       | 40                     |
| Switzerland (2012)       | 84          | 76       | 73                     | Canada (BC) (2011)       | 71          | 51       | 35                     |
| Australia (2013)         | 86          | 66       | 62                     | USA (2013)               | 82          | 40       | 30                     |
| United Kingdom (2013)    | 76          | 68       | 61                     | Sub-Saharan Africa (2013) | 45          | 39       | 29                     |
| Denmark (2010)           | 85          | 62       | 59                     | Georgia (2012)           | 52          | 26       | 20                     |
| The Netherlands (2013)   | 73          | 59       | 53                     | Estonia (2013)           | 87          | 29       | 19                     |
| France (2010)            | 81          | 60       | 52                     | Russia (2013)            | 49          | 11       | 9                      |
prevalence and diagnosis for Switzerland, UK, The Netherlands, Sub-Saharan Africa and Russia; from diagnosis to receiving ART for Australia, Brazil, USA, Georgia and Estonia, and between treatment and achieving undetectable HIV RNA for France and Canada.

**Conclusions:** Only one of the 12 countries analyzed achieved the UNAIDS 90–90–90 coverage target of 73% of HIV positive people with undetectable HIV RNA. There were disparities between countries. A standardized reporting method should be implemented to facilitate comparisons between countries to better identify gaps and inform policy.

http://dx.doi.org/10.7448/IAS.18.5.20346

**MOAD0103**

**Major outcomes of early HAART programs at CCASAnet sites: “first wave of HAART” study**

Marcelo Wolff1; Claudia P Cortes 1; Bryan E Shepherd 2; Mark Giganti 2; Catherine Mc Gowan 2 and Caribbean, Central America and South America Network (CCASAnet)

1School of Medicine, University of Chile, Santiago, Chile. 2Department of Biostatistics, Vanderbilt University, Nashville, United States.

Presenting author email: marcewolff@yahoo.com

**Introduction:** Expanded access to HAART in Latin America began slowly in the late 1990s and faster in early 2000s; many antiretrovirals used then, are now out dated and most patients presented with advanced disease stages. Characterizing these patients’ major outcomes (death, loss to follow-up (LTFU), viral suppression, CD4+ cell (CD4) count evolution and regimen changes) after a decade of HAART – not well defined at present – may provide insights into their present and future situation and provide information relevant for the management of patients who initiated HAART more recently.

**Methods:** The study included adults from six CCASAnet sites: Argentina, Brazil, Chile, Haiti, Honduras and Mexico who initiated HAART before 2004, without exclusion of non-ART-naïve. Status (active, LTFU or dead) for each patient was registered at six-month intervals for up to 10 years, as well as CD4 and viral load (VL) in active patients. The proportions of patients in first, second, third or further HAART regimen or not on HAART were also measured.

**Results:** In total, 4975 patients (66% male) met inclusion criteria. At HAART initiation, the median age was 35 years, 23% had AIDS and 45% were not ART-naïve. At 1, 3, 5, 7 and 10 years, overall rates of mortality were 4.2, 6.8, 9.0, 10.8 and 13.6% respectively. LTFU rates for the same periods were 2.4, 6.8, 10.9, 14.8 and 24.2% respectively; 62% remained in active care at 10 years (Figure 1). At the end of follow up, 85% of active patients had VL < 400 copies/mL (Haiti excluded because VL not regularly measured) and median CD4 increased from 153 to 517 cells/mm3 After 10 years, only 11% of patients remained active and on their first HAART regimen, 13% were on their second, 12% were on their third and 23% were on their fourth or more regimen. Heterogeneity in outcomes between sites was substantial.

![Abstract MOAD0103—Figure 1. Major outcomes of early HAART programs at CCASAnet.](image-url)
Conclusions: Despite advanced disease and use of mostly old antiretrovirals, a large proportion of first HAART initiators in these Latin American cohorts were alive, in active control, with substantial immune recovery and virologic suppression after 10 years. Early death was a problem as well as persistent LTFU and frequent change of therapy.

http://dx.doi.org/10.7448/IAS.18.5.20347

MOAD0104
Integrating HIV-care into primary care clinics improved access to treatment and did not compromise primary health care: province-wide trend analysis over four years during implementation in Free State, South Africa

Angeli Rawat1; K E Uebel2; David Moore3 and Annalee Yassi4
1School of Population and Public Health, University of British Columbia, Vancouver, Canada. 2Free State Department of Health, Bloemfontein, South Africa. 3British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.

Presenting author email: angelirawat@gmail.com

Introduction: The integration of HIV-care into primary health care (PHC) clinics is a strategy to expand access to antiretroviral therapy (ART). However, integration may compromise PHC service delivery within weak health systems. We designed a study to examine changes in PHC service provision (pre and post-integration) in public-sector PHC clinics in Free State, South Africa.

Methods: We analyzed administrative data on 15 PHC indicators. The data were collected monthly over a critical four year period as integration was implemented into 131 PHC clinics representing a catchment population of 1.5 million. We defined integration as the month and year the PHC clinic provided comprehensive HIV-care, from testing to treatment to follow-up. We utilized interrupted time series analysis at ±18 and ±30 months from HIV integration in each clinic to identify changes in PHC services post-integration. We conducted sensitivity analyses with linear mixed effect models to study the relationship between HIV service indicators and the PHC indicators.

Results: The number of patients receiving ART in the 131 PHC clinics studied increased from 121 (April 2009) to 57,958 (March 2013). We did not observe any changes in service indicators for 11 of the 15 PHC indicators we examined. However, we did observe decreases in population-level immunization coverage after integration by 0.98% (SE = 0.25, p < 0.001) at ±18 months and by 1.31% (SE = 0.16, p < 0.001) at ±30 months. Clinic level immunization coverage also decreased by 33 infants per 100,000 patients (SE = 8, p < 0.001) at ±30 months. None of these changes were associated with the number of HIV patients at the clinics. We also observed decreases in total clinic visits per year for adults and children under five years old.

Conclusions: Despite an extraordinary increase in patients accessing ART in PHC clinics during our study period, the vast majority of PHC indicators remained unchanged. Our findings suggest that the integration of HIV-care into public-sector PHC clinics is a viable strategy through which to expand access to ART. However, further research is needed to understand how immunization coverage is affected.

http://dx.doi.org/10.7448/IAS.18.5.20348

MOAD0105LB
Implementation scale up of the Adherence Club model of care to 30,000 stable antiretroviral therapy patients in the Cape Metro: 2011-2014

Lynne Wilkinson1; Beth Harley2; Shahida Jacobs3; Carol Cragg3; Ebrahim Kriel4; Suhair Peton5; Karen Jennings2; Michele Youngeson6 and Anna Grimsrud5
1Medecins Sans Frontieres, Cape Town, South Africa. 2City Health, Cape Town Municipality, Cape Town, South Africa. 3Department of Health, Western Cape Government, Cape Town, South Africa. 4Institute for Healthcare Improvement, Boston, United States. 5University of Cape Town, Cape Town, South Africa. 6Department of Health, Western Cape Government, Cape Town, South Africa.

Presenting author email: msfocb-khayelitsha-coord@brussels.msf.org

Introduction: The Adherence Club (AC) model of care was piloted by Médecins Sans Frontières starting in 2007. ACs are groups of approximately 30 stable antiretroviral therapy (ART) patients who met every eight weeks for group support, brief symptom screen and collection of pre-packed ART facilitated by a lay-healthcare worker. Following good pilot outcomes, from 2011 the Cape Metro health
Phylogenetically estimated HIV diversification rates reveal prevention of HIV-1 by antiretroviral therapy

Jeffrey Joy; Richard Liang; Rosemary McCloskey; Thuy Nguyen; Chanson Brumme; Guillaume Colley; Robert Hogg; Julio Montaner; P Richard Harrigan and Art Poon

BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.

Introduction: Treatment of HIV infection with antiretrovirals reduces individuals’ plasma viral loads to undetectable levels and in turn decreases the risk of transmission. Despite epidemiological evidence supporting the efficacy of “Treatment as Prevention,” quantifying this success remains a significant challenge. Phylogenetic analysis of viral sequence data can yield crucial insights into epidemic processes, including transmission dynamics. We sought to evaluate the impact of treatment on HIV transmission rates in British Columbia (BC), Canada, using phylogenetic methods.

Methods: We recovered 27,296 anonymized HIV protease and RT sequences from 7747 HIV patients in BC from the BC Centre for Excellence in HIV/AIDS database. Sequences were annotated with: sample collection date, treatment status at sample collection, date of first antiretroviral treatment and risk factor (intravenous drug use (IDU), men having sex with men (MSM) and heterosexual (HET)). Codons associated with known drug resistance were censored from the alignment prior to tree inference. We inferred a set of 1000 lineage trees using a transversion substitution model and the GTR+G+I model of nucleotide evolution. We then used the program Mesquite to calculate phylogenetic branching rates by treatment experience and risk factor. To assess the impact of treatment on onward transmission of HIV, we compared the mean HIV branching rate between treatment-experienced and treatment-naïve lineages across the BC epidemic as a whole and among risk factors.

Results: Phylogenetic branching rates were significantly lower among treatment-experienced HIV lineages relative to treatment-naive lineages (p < 0.001), implying reduced rates of HIV transmission in the former. Importantly, treatment experienced lineages had significantly lower HIV branching rates irrespective of HIV transmission risk factor (p < 0.001 for IDU, MSM and HET) or exposure to different antiretroviral drug classes (p < 0.001 NRTI, NNRTI, PI), suggesting these results are not driven by penetrance of health care into particular risk groups or therapeutic regimens.

Conclusions: Our results provide independent evidence that antiretroviral HIV treatment has limited the onward transmission of HIV to new hosts. These results are based on a lineage level measure, are measured phylogenetically rather than epidemiologically and are replicated both across different risk exposure categories and different treatment regimens.

http://dx.doi.org/10.7448/IAS.18.5.20349

TUAA0102

Phenotypic properties influencing HIV-1 transmission fitness

Katja Klein1; Annette Ratcliff2; Gabrielle Nickel2; Immaculate Nanyuka3; Mike Lobritz2; Yong Gao2; Robin Shattock2 and Eric Arts3

1Department of Microbiology and Immunology, University of Western Ontario, London, Canada. 2Department of Medicine, Case Western Reserve University, Cleveland, United States. 3Department of Infectious Diseases, Imperial College London, London, United Kingdom.

Introduction: Sexual HIV-1 infection requires penetration of the virus across the mucosal barrier and the establishment of infection in target cells. It is widely accepted that only one or a small number of HIV-1 clones is successfully transmitted from the donor to the recipient. However, little is known about the phenotypic properties of the transmitted virus and the influence the phenotype plays in the genetic bottleneck selection process. Here we evaluated possible phenotypic differences between acute and chronic HIV-1 that may effect transmission fitness.

Methods: We compared the genetic diversity of HIV-1 isolates from the female genital tract with isolates from the blood of the same donor by 454 pyrosequencing of the env region. Furthermore, we generated chimeric viruses from acute and chronic envelope genes using a yeast-based cloning strategy. The chimeric clones were then evaluated for host cell entry and receptor efficiency, sensitivity to entry inhibitors and for replication fitness in PBMCs, T cells and macrophages. Additionally we evaluated the transmission fitness across mucosal tissues by multi-virus competitions.

Results: Both acute and chronic HIV-1 clones showed similar cell entry and receptor efficiency, sensitivity to inhibitors and replication fitness. Sequence analysis revealed that primary infection in the cervix resulted in a highly genetically diverse HIV-1 population, while only one or a few HIV-1 clones are in matched blood. Analysis of mixed competitions of acute and chronic HIV-1 env-clones in ex vivo tissue models revealed higher transmission fitness of acute isolates than chronic. We observed that higher transmission fitness was related to a reduced number of conserved N-linked glycans on the envelope of acute viruses.

Conclusions: Chronic HIV-1 isolates appear to stay and replicate in the mucosal tissue, while acute isolates are preferentially bound by tissue residing dendritic cells/langerhans cells (DCs/LCs) and are subsequently transmitted to T cells. High levels of mannose binding proteins in tissue and lectins on epithelial cells may be responsible...
for a passive selection process of HIV-1 with fewer glycans for transmission due to reduced lectin binding.

http://dx.doi.org/10.7448/IAS.18.5.20350

TUAA0103
Population-level spread of immune-driven mutations in HIV-1 polymerase during the North American epidemic
Natalie Nicole Kinloch1; Daniel R Macmillan5; Anh Q Le1; Laura A Cotton2; Rosemary Mccluskey2; David R Bangsberg4; Susan Buchbinder3; Mary Carrington7; Jonathan Fuchs6,5; P Richard Harrigan3; Beryl Kolbin1; Martin Markowitz3; Kenneth Mayer1,2,10; M J Millroy2; Martin T Schechter11; Theresa Wagner1; Bruce D Walker3; Jonathan M Carlson1,2; Art F Y Poon1,2,11 and Zabrina L Brumme1,2

1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 2British Columbia Centre for Excellence, Vancouver, Canada. 3Ragon Institute of MGH, MIT, and Harvard, Cambridge, United States. 4San Francisco Department of Public Health, San Francisco, United States. 5Laboratory of Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, United States. 6University of California, San Francisco, United States. 7New York Blood Center, New York, United States. 8Aaron Diamond AIDS Research Center, New York, United States. 9Fenway Community Health, Boston, United States. 10Harvard Medical School, Cambridge, United States. 11Faculty of Medicine, University of British Columbia, Vancouver, Canada. 12Microsoft Research, Seattle, United States.

Presenting author email: nkinloch@sfu.ca

Introduction: HLA-driven HIV-1 immune escape mutations that persist following transmission could gradually spread in the viral population, compromising host antiviral immunity over time. We investigate the extent and correlates of escape mutation accumulation in HIV-1 Polymerase (Pol) sequences in North America from 1979 to present.

Methods: HIV-1 RNA Pol and HLA class I genotyping was performed on 338 Historic (1979–1989) and 278 Modern (2001–2011) specimens from Boston, New York, San Francisco and Vancouver. HLA-associated polymorphisms were defined according to published lists. Historic and modern datasets were also investigated for the presence for novel HLA-associated mutations using phylogenetically-informed methods. Ancestral reconstruction of the HIV-1 epidemic founder sequence was performed using bayesian evolutionary analysis by sampling trees (BEAST) and Hypothesis testing using Phylogenies (HyPhy).

Results: The estimated HIV-1 epidemic founder sequence dated to ~1969 and was near-identical to the modern subtype B consensus, suggesting no historic selective sweeps have occurred to shift the population consensus. No HLA-associated polymorphisms unique to the historic dataset were identified. Nevertheless, pairwise sequence diversity of modern HIV-1 sequences was approximately two-fold greater than historic sequences, with diversification predominating at HLA-associated sites (p < 0.0002). N = 20 published HLA-associated polymorphisms were investigated for spread over time. Overall, their median background frequencies (in individuals lacking the restricting HLA) were 6.6% vs. 16.8% in historic and modern eras respectively (p = 0.0004); polymorphism frequencies in reconstructed pre-1979 ancestral sequences were also consistent with gradual spread (p < 0.01). No correlation was observed between HLA allele frequency and relative spread of its associated polymorphisms (r = −0.13, p = 0.8); rather, polymorphisms restricted by protective HLA alleles exhibited greater relative spread than those restricted by non-protective alleles (r = 0.83, p = 0.0047). Despite these overall increases, the frequency of many polymorphisms (e.g. B*51-associated RT-113ST) remained consistent throughout the eras. Moreover, at the whole-sequence level, the median extent of adaptation of the typical circulating modern HIV-1 Pol sequence to the average North American host remains 0%, indicating a low overall risk of acquiring HIV-1 harbouring adaptations to one’s HLA profile.

Conclusions: Immune escape mutations in HIV-1 Pol have spread significantly in the population since the genesis of the North American epidemic; however, these changes are unlikely to herald immediate consequences for host antiviral immunity on this continent.

http://dx.doi.org/10.7448/IAS.18.5.20351

TUAA0104
Primary resistance against dolutegravir decreases HIV integration
Thibault Mesple`de; Kaitlin Anstett; Nathan Osman; Said Hassounah; Jaming Liang; Yingshan Han and Mark Wainberg

Presenting author email: tibo_mes@hotmail.com

Introduction: Dolutegravir is an integrase inhibitor that has shown a high genetic barrier against the emergence of resistant strains. No resistance substitution has been observed in treatment-naı ¨ve individuals treated with this drug. In tissue culture experiments, we have identified the R263K resistance substitution as a signature substitution for HIV resistance against dolutegravir, an observation that was later confirmed in highly treatment-experienced individuals. Given the importance of DNA integration in the establishment of HIV persistence, we tested the ability of dolutegravir-resistant HIV strains to integrate within human DNA.

Methods: We used an Alu-mediated quantitative PCR to measure levels of integration of dolutegravir-resistant variants in primary human PBMCs. Levels of integration were normalized using the b-actin gene. These experiments were performed using subtype B and C viruses.

Results: Our results show that dolutegravir-resistant variants are impaired in their ability to integrate within human DNA. The integration levels of subtype B and C R263K variants were decreased by 30% and 40% compared to WT viruses, respectively. More important, the addition of several secondary substitutions failed to restore integration to a level comparable to WT and, in some cases, further lowered integration to only 20% of WT.

Conclusions: The relative inability of dolutegravir-resistant variants to integrate within human DNA may contribute to a progressive decrease in the viral reservoir of individuals who develop these substitutions.

http://dx.doi.org/10.7448/IAS.18.5.20352

TUAA0105
HIV-1 integrase variants retarget proviral integration and are associated with disease progression
Jonas Demeulemeester1; Sofie Vets1; Rik Schrijvers1; Paradise Madlala1,2; Marc De Maeyer3; Jan De Rijck1; Thumbi Ndung’u2; Zeger Debryse1 and Rik Gijbbers3

1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven University, Leuven, Belgium. 2HIV Pathogenesis Program, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 3Faculty of Veterinary Medicine, University of Veterinary Medicine, Leuven, Belgium.

Presenting author email: rik.gijbbers@med.kuleuven.be

Introduction: Distinct integration patterns of different retroviruses, including HIV-1, have puzzled virologists for over 20 years. A tetramer of the viral integrase (IN) assembles on the two viral cDNA ends, docks onto the target DNA (tdNA) to form the target capture
HIV IN 119 and IN 231 affect both local and global rapid disease progression in a chronic HIV-1 subtype C infection cohort.

Results: We identified retroviral IN amino acids affecting molecular recognition in the TCC and resulting in distinct local TDA nucleotide biases. These residues also determine the propensity of the virus to integrate into flexible TDA sequences. Remarkably, natural polymorphisms IN119 and IN231 retard viral integration away from gene dense regions. Precisely these variants were associated with rapid disease progression in a chronic HIV-1 subtype C infection cohort.

Conclusions: Our findings reveal how polymorphisms at positions corresponding to HIV IN119 and IN231 affect both local and global integration site targeting. Intriguingly, these findings link integration site selection to virulence and viral evolution but also to the host immune response and antiretroviral therapy, since HIV-1 IN119 is under selection by HLA alleles and integrase inhibitors.

http://dx.doi.org/10.7448/IAS.18.5.20353

TUA0106LB

HIV-1-specific IgG antibody levels correlate with the presence of a specific HLA class II allele to impact acquisition and vaccine efficacy

Heather Prentice1; Georgia Tomaras2; Daniel Geragthy3; Richard App5; Yooyi Fong3; Philip Ehrenberg3; Morgane Rolland5; Gustavo Kijak5; Wyatt Nelson3; Allan Decamp3; Xiaoying Shen2; Nicole Yates2; Susan Zolla-Pazner5; Sorachai Nityaphan5; Supachai Rerk-Ngarm5; Funnee Pittisutthithum5; Guido Ferrari2; David Montefiori2; Juliana McElrath3; Robert Bailer9; Richard Koup9; Hans-Peter Kiem1,4

1US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States. 2Duke University School of Medicine, Durham, United States. 3Fred Hutchinson Cancer Research Center, Seattle, United States. 4Frederick National Laboratory for Cancer Research, Leidos Inc., Frederick, United States. 5New York University School of Medicine, New York, United States. 6New York University School of Medicine, New York, United States. 7AFRIMS, Bangkok, Thailand. 8Ministry of Public Health, Nonthaburi, Thailand. 9Mahidol University, Bangkok, Thailand. 10Vaccine Research Center, NIH, Bethesda, United States.

Presenting author email: rthomas@hivresearch.org

Introduction: The RV144 trial had a vaccine efficacy of 31%, and IgG antibodies to HIV-1 Envelope (Env) amino acid positions 120–204 were identified as a predictor of decreased risk of infection. The IgG responses were binding to scaffolded Env antigen comprising the variable loops 1 and 2, flanked by partial regions of the first and second conserved domains. Since HLA class II molecules are expressed on antigen-presenting cells and modulate CD4 T-cell stimulation of antibody production by B cells, we tested whether HLA allotypes influenced vaccine response and efficacy.

Methods: HLA-DRB1, DQB1 and DPB1 were genotyped in 760 individuals. Direct associations of 31 HLA class II alleles on Env (120–204)-specific IgG were compared using linear regression models. Interaction of HLA with IgG response to Env (120–204) was tested for an effect on acquisition by logistic regression.

Results: Higher levels of Env (120–204) IgG antibody directly correlated with the presence of DPB1*13 (p = 0.002, q = 0.05). Env (120–204)-specific IgG antibody levels also associated with decreased risk of HIV-1 infection only with the presence of DPB1*13 [OR = 0.29 per 1-SD increase, p = 0.006]. Both of these findings were replicated with Env antigens across multiple viral subtypes. Vaccine efficacy increased to 71% among individuals that were DPB1*13+ and had higher levels of Env (120–204)-specific IgG levels relative to the placebo. To delineate the anti-Env antibody responses in DPB1*13+ individuals, we screened overlapping peptides to Env (120–204). Frequency and magnitude of IgG response specifically to Env peptide positions 119–133, which are involved in Env binding to CD4, associated with both presence of DPB1*13 and protection from HIV-1 acquisition among individuals with a DPB1*13 allele. Further evidence that immune responses induced by vaccination in individuals carrying DPB1*13 are different from those without DPB1*13 was apparent in significant viral sequence differences specifically in infected vaccine recipients with DPB1*13.

Conclusions: DPB1*13-associated immune responses to vaccination is associated with decreased risk of HIV-1 acquisition. The specific differences in vaccine-induced responses elicited by individuals with HLA-DPB1*13 should be examined to determine the mechanism of protection of the vaccine. Understanding this HLA class II restricted mechanism will enable improved HIV vaccine design.

http://dx.doi.org/10.7448/IAS.18.5.20541

TUA0202

Zinc finger nuclease gene editing for functional cure in a non-human primate model of HIV/AIDS

Christopher Petersen1; Jianbin Wang2; Patricia Polacin2; Michael Holmes2; Shiu-Lok Hu2; Philip Gregory2 and Hans-Peter Kiem1,4

1Fred Hutchinson Cancer Research Center, Seattle, United States. 2Sanago Biosciences, Richmond, United States. 3Washington National Primate Research Center, University of Washington, Seattle, United States. 4Presenting author email: cwpeters@fhcrc.org

Introduction: Nuclease-mediated gene editing in hematopoietic stem cells (HSCs) holds great promise in the cure of HIV infection, but little information is available regarding the feasibility of this approach in large animal models. To better evaluate the function of HSCs following gene editing, we have engineered cells with disrupted CCR5 alleles and assessed engraftment following autologous transplant in the pigtailed macaque, M. nemestrina. Disrupted CCR5 alleles in this model should directly protect against infection with simian/human immunodeficiency virus (SHIV). We are evaluating the extent to which CCR5-disrupted cell progeny engraft in macaques and testing whether these cells impede infection by SHIV.

Methods: Zinc finger nucleases (ZFNs) are used to target the CCR5 locus in macaque HSCs. Engraftment and persistence of these autologous stem cells and stem cell-derived lymphoid and myeloid cells are measured ex vivo and in vivo. Animals are challenged with SHIV virus containing an HIV envelope; to approximate the status of an HIV+ patient, three-drug combination antiretroviral therapy (cART) is initiated following viral set point. Animals reach undetectable levels of plasma viremia prior to autologous transplant with gene-edited cells.

Results: CCR5 targeting experiments yield up to 60% gene disruption in CD34+ cells ex vivo, translating to approximately 5% steady state bulk disruption in vivo. Gene-disrupted cells demonstrate long-term, multilineage engraftment in macaques, including comparable levels of disruption in CD3+, CD20+, CD14+ and granulocyte subsets. We also observe biallelic disruption of CCR5 in colony forming assays. Importantly, this approach is equally feasible in SHIV-naive and in SHIV-infected, cART-suppressed animals. During robust SHIV replication, our preliminary data suggest that CCR5-deleted cells undergo positive selection in vivo.
**Conclusions:** This is the first demonstration of successful long-term multilineage engraftment of ZFN-edited, CCR5-deleted HSCs in a non-human primate (NHP) transplantation model. Our strategy results in robust levels of target gene disruption in vivo, yet does not impair HSC engraftment or differentiation. CCR5-deleted cells can undergo positive selection following challenge with SHIV. Our model enables the evaluation of novel therapeutic approaches not only in the context of acute HIV exposure, but also in the clinically relevant setting of pre-existing latent HIV infection.

http://dx.doi.org/10.7448/IAS.18.5.20354

**TUA0203**

**Crispr/Cas9 gene editing eradicates latent and protects cells against new HIV-1 infection**

Rafal Kaminski 1; Wenhui Hu 1; Yonggang Zhang 1; Jonathan Karn 2 and Kamel Khalili 1

1Department of Neuroscience, Temple University, Philadelphia, United States. 2Case Western Reserve, Cleveland, United States.

Presenting author email: kkhalili@temple.edu

**Introduction:** A sterilizing cure for HIV-1/AIDS requires a strategy that eliminates all or at least some critical regions of the HIV-1 genome including the promoter positioned within the 5’ LTR of the viral genome from cells serving as a stable reservoir for HIV-1, that is, resting CD4+ T-lymphocytes, macrophages and brain microglia, with no adverse impact on the host cells.

**Methods:** We have tailored CRISPR/Cas9 gene editing by bioinformatic screening, surveyor assay, and whole genome sequencing and have successfully developed a series of guide RNAs (gRNAs) that, in complex with Cas9 nuclease, effectively and safely eliminate integrated copies of HIV-1 proviral DNA in several human cell culture models. We assessed the impact of our gene editing strategy on viral transcription and replication by measuring the level of a GFP reporter and viral p24, upon reactivation of virus from the latent stage by treatment with phorbol myristate acetate (PMA) and trichostatin A (TSA).

**Results:** We demonstrated inactivation of HIV-1 gene expression and replication in latently infected T-lymphocytes and promonocytic lines as well as microglial cells upon excising the proviral DNA fragment corresponding to the entire coding sequence of HIV-1 spanning the 5’ to 3’ LTRs from the host chromosome by the CRISPR/Cas9 approach. Further, we demonstrate that the presence of LTR-specific multiplex of guide RNAs in cells expressing Cas9 acts as an efficient inhibitor blocking new HIV-1 infection.

**Conclusions:** Our findings suggest that the strategy involving the newly developed CRISPR/Cas9 serves as a promising platform that can be advanced for eradication of HIV-1 and a cure for AIDS.

http://dx.doi.org/10.7448/IAS.18.5.20355

**TUA0204LB**

**Investigating the role of the immune checkpoint receptor TIGIT in T cells during HIV disease progression and as a target for immune restoration**

Glen Chew 1; Tsuyoshi Fujita 2; Kiera Clayton 3; Naoto Ishii 2; Mohamed Abdel-Mohsen 2; Teri Liegler 2; Fredrick Hecht 3; Mario Ostrowski 2; Cecilia Shikuma 3; Mark Maurer 4; Alan Korman 4; Steven Deeks 4 and Lishomwa Ndhlovu 1

1Department of Tropical Medicine, Medical Microbiology, and Pharmacology, University of Hawaii, Manoa, Honolulu, United States. 2Department of Microbiology and Immunology, Tohoku University, Sendai, Japan. 3Department of Immunology, University of Toronto, Toronto, Canada. 4Department of Medicine, University of California, San Francisco, United States. 5Hawaii Center for HIV/AIDS, University of Hawaii, Manoa, Honolulu, United States. 6Biologics Discovery California, Bristol-Myers Squibb, Redwood City, United States.

Presenting author email: glenchew@hawaii.edu

**Introduction:** HIV infection induces a series of phenotypic and functional changes to T cells that eventually results in a state of T-cell exhaustion and failure to control viral replication. T-cell-Ig-and-ITIM-domain (TIGIT) is a recently described negative checkpoint receptor expanded on CD8+ T cells during LCMV infection in mice and inhibits anti-viral effector CD8+ T-cell activity. We hypothesized that during progressive HIV infection, TIGIT surface expression will mark an expanded population of dysfunctional T cells, and that novel monoclonal antibodies (mAb) targeting TIGIT would restore anti-HIV-specific T-cell responses.

Abstract TUA0203: Figure 1. Eradication of HIV-1 DNA in latently infected cells. A. Treatment of latently infected T-lymphocytes with PMA and TSA activates viral gene expression and expression of GFP reporter in more than 93% of the cells. The presence of gRNAs (LTR A/B) and Cas9 dramatically prevented viral replication. B. Examination of DNA by PCR and direct sequencing verifies removal of integrated proviral DNA from chromosome 16.
**Methods:** Surface expression of TIGIT and PD-1 on T cells was measured by flow cytometry from 103 HIV-infected participants (non-controllers (n = 20), elite controllers (n = 20), antiretroviral (ART) suppressed (n = 39), acutely infected (n = 24)) and 20 age- and gender-matched HIV-uninfected controls. Quantified cell associated HIV (CA-HIV) DNA and RNA from purified CD8+ T cells. Functional characterization of TIGIT + T cells was performed, and ex vivo HIV-specific cytolytic and proliferative responses were assessed in the presence of mAb targeting TIGIT and/or PD-1 pathways (anti-TIGIT mAb and anti-PD-L1 mAb).

**Results:** In controls, a median of 28.05% of CD8+ T cells was TIGIT+ (IQR 24.43, 39.15). In comparison, we found a significant expansion of TIGIT+ CD8+ T cells during chronic (median 57.1%, IQR 42.6, 63.45; p < 0.0001) and a non-significant trend in acute HIV infection (40.40%, IQR 28.3, 47.8; p = 0.08). TIGIT expression remained elevated despite viral suppression and associated with CD4+ CA-HIV DNA. TIGIT+ and TIGIT+PD-1+ CD8+ T cells inversely correlated with CD4 count (p = 0.0016, r = −0.658; p = 0.0024, r = −0.385, respectively). TIGIT was expressed on >50% HIV-specific CD8+ T cells; however, TIGIT+ T cells failed to produce cytokines in response to HIV antigens. Single blockade of TIGIT led to a significant increase of interferon gamma response to HIV Gag compared to no blockade (p = 0.027). Co-blockade of TIGIT and PD-1 led to greater restoration of HIV-specific CD8+ T-cell proliferative responses (4.10%, IQR 1.46, 22.28) than single blockade of TIGIT (3.47%, IQR 1.11, 10.08; p = 0.0078) or PD-L1 (3.945%, IQR 1.15, 17.53; p = 0.039).

**Conclusions:** These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells and suggest TIGIT along with other checkpoint receptors may be novel curative HIV targets.

http://dx.doi.org/10.7448/IAS.18.5.20542

**TUA0205LB**

**Oestrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs**

Jonathan Karn1; Biswajit Das2; Curtis Dobrowolski2; Eileen Scully2,3; Steven Deeks3; Monica Gandhi4 and Rowena Johnston5

1Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, United States. 2Brigham and Women’s, Boston, United States. 3Massachusetts General Hospital, Boston, United States. 4UCSF School of Medicine, San Francisco, United States. 5amfAR, The Foundation for AIDS Research, New York, United States.

**Introduction:** Unbiased shRNA library screens have been used to identify novel genes and pathways that are required to maintain HIV latency and/or play an essential role in HIV transcription. One of the most prominent and robust “hits” was the oestrogen receptor type 1 (ESR-1).

**Methods:** The activities of ESR-1 agonists, antagonists and oestrogen on proviral reactivation were studied in transformed and primary cell models of latency and in patient cells.

**Results:** Specific antagonists of ESR-1, such as Tamoxifen and Fulvestrant, are weak proviral activators but sensitize latently infected cells to very low doses of the proviral activators TNF-α and SAHA (HDAC inhibitor). By contrast, a selective ESR-1 agonist stilbestrol strongly suppress both TNF-α and SAHA reactivation. In contrast to the ESR-1 antagonists, ESR-2 antagonists were not effective inducers of HIV expression in cell models. Co-activator 3 (SRC-3) is an upstream modulator of ESR-1, which was also identified as a hit in the shRNA screen. Blocking of SRC-3 by its inhibitor Gossypol also induces latent proviruses. Consistent with these results, specific knock-down of ESR-1 in Jurkat 2010 cells with shRNA constitutively re-activates the latent provirus. In the HAART-treated patient samples, there was a modest increase of spliced HIV env mRNA when resting memory cells were treated with the ESR antagonists Fulvestrant or Tamoxifen alone. Proviral reactivation by ESR antagonists was synergistically increased by SAHA. By contrast, β-estradiol at concentrations in the physiological range led to dramatic reductions in proviral reactivation efficiencies. This is consistent with earlier observations that high levels of β-estradiol can block HIV replication.

**Conclusions:** ESR-1 is a pharmacologically attractive target that can be exploited in the design of therapeutic strategies aimed at eradication of the latent reservoir. Our results show that drugs targeting ESR-1 can be used to either promote the re-activation of latent proviruses (agonists) or limit their responses (agonists). The profound effects of β-estradiol on HIV reservoir reactivation suggest that there may be gender-specific differences in HIV reservoirs and highlight the need to tailor latency reactivation strategies for both men and women.

http://dx.doi.org/10.7448/IAS.18.5.20543
Treatment groups were regarded as non-inferior if the lower limit of the 95% confidence interval (95% CI) for the difference in VF was above −10% in an intention-to-treat (ITT) analysis at 48 weeks.

**Results:** A total of 559 patients were randomized (ATV200; N = 279 vs. ATV300; N = 280). At baseline, 85% used lopinavir/ritonavir, mean age was 42 years, body weight was 59 kg, CD4 was 539 cells/mm³ and total bilirubin was 0.85 mg/dL. At week 48, by ITT, the proportion of patients in ATV200 vs. ATV300 with pVL <200 copies/mL (difference, 95% CI) was 97.1% vs. 96.4% (0.68, −2.29 to 3.65), the proportions with pVL <50 copies/mL were 93.4% vs. 91.7% (1.71, −2.67 to 6.09). In per-protocol analyses, the proportions with pVL <200 copies/mL were 98.5% vs. 99.2% (−0.72, −2.6 to 1.16). Only one ATV200 recipient developed major resistance (ISO I) to ATV.

Discontinuation from randomized therapy was 8 (2.9%) in ATV200 [1 death, 2 VF, 1 jaundice, 2 rash, 2 others] and 21 (7.5%) in ATV300 (2 deaths, 7 jaundice, 7 rash, 5 others) (p = 0.01). At week 48, there was no difference between treatment arms in CD4, total cholesterol, triglyceride and Crcl (all p > 0.1). Comparing ATV200 vs. ATV300, the number (%) of patients with total bilirubin >3.2 mg/dL was 27 (10%) vs. 46 (17%) respectively (p = 0.017).

**Conclusions:** A lower dose of ATV/r-based regimens in Thais is non-inferior compared to standard dose ATV/r. Higher dose ATP was associated with higher rates of treatment discontinuation. ATV/r 200/100 mg can be recommended as part of routine care for Asian adults who have well-controlled HIV infection on a PI-based regimen.

http://dx.doi.org/10.7448/IAS.18.5.20356

**TUAB0102**

Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment

Tony Mills; Jamie Andrade; Giovanni Diperri; Jan Van Lunzen; Ellen Koening; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; Calvin Cohen; Andrew Plummer; YoPei Liu and Scott McCallister

1 Anthony Mills MD, Inc., Los Angeles, United States. 2 Hospital Civil de Guadalajara, Guadalajara, Mexico. 3 University Hospital Amedeo De Soto, Turin, Italy. 4 University of New England, Boston, United States. 5 Instituto Dominicano de Estudios Virologicos IDEZ, Santo Domingo, Dominican Republic. 6 Whitman-Walker Health, Washington, United States. 7 Centre Hospitalier Universitaire Valdois, Lausanne, Switzerland. 8 Centro de Referencia e Treinamento Em DST/AIDS, Sao Paolo, Brazil. 9 Maple Leaf Research, Toronto, Canada. 10 La Playa Medical Group, San Diego, United States. 11 Orlando Immunology Center, Orlando, United States. 12 Community Research Initiative of New England, Boston, United States. 13 Gilead Sciences, Foster City, United States.

Presenting author email: tmills@tonymillsmd.com

**Introduction:** Despite a favourable efficacy and safety profile, TDF-based regimens may be associated with renal toxicity and reduced bone mineral density (BMD). TAF is a novel tenofovir prodrug in which TFV plasma levels are 90% lower than seen with TDF, thereby reducing off-target side effects. Week 48 data in patients switching to a once-daily fixed dose combination regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/CF/TAF) are described.

**Methods:** Virologically suppressed adults (HIV-1 RNA <50 copies/mL) with normal renal function taking one of four different TDF-based regimens for at least 48 weeks were randomized 2:1 to receive E/CF/TAF or to retain their prior TDF-based regimen. Following randomization, all treatments were open-label.

**Results:** Of 1196 patients completing at least 48 weeks of treatment, 799 received E/CF/TAF and 397 received their prior TDF regimen: E/CF/TDF, 31.9%; EFV/FTC/TDF, 26.1%; ATV/RTV + FTC/TDF, 26.8%; ATV/COBI + FTC/TDF, 15.0%. Virologic success <50 copies/mL occurred in 95.6% on E/CF/TAF and 92.9% on FTC/TDF + 3rd Agent (weighted difference: 2.7%; 95% CI: −0.3% to +5.6%), with virologic failure in 1.1% and 1.3% of patients, respectively. General safety was similar between the arms. The mean percent change (SD) in hip BMD: +1.95% (3.0) for E/CF/TAF and −0.14% (3.0) for FTC/TDF + 3rd Agent (p < 0.001); the mean percent change (SD) in spine BMD: +1.86% (3.1) for E/CF/TAF and −0.11% (3.7) for FTC/TDF + 3rd Agent (p < 0.001). There were no cases of Fanconi Syndrome on E/CF/TAF and one case on FTC/TDF + 3rd Agent. For patients on either a COBI or RTV boosted regimen prior to randomization, the estimated GFR increased 1.8 mL/min for E/CF/TAF and decreased 3.7 mL/min for FTC/TDF + 3rd Agent (p < 0.001). As shown in the table, multiple measures of quantitative proteinuria, including tubular proteinuria, had statistically significant improvements for patients switching to E/CF/TAF as compared with those retaining their prior TDF-based regimen.

**Conclusions:** These 48 week data demonstrate that patients who switch from a TDF-based regimen to E/CF/TAF maintain high efficacy, have statistically significant increases in BMD and have statistically significant improvements in multiple tests of renal function, as compared with patients remaining on their prior TDF-based regimen.

http://dx.doi.org/10.7448/IAS.18.5.20357

**TUAB0103**

Subjects with renal impairment switching from tenofovir disoproxil fumarate to tenofovir alafenamide have improved renal and bone safety through 48 weeks

Samir Gupta; Anton Pozniak; Josa Arribas; Frank Post; Mark Bloch; Joseph Gathe; Paul Benson; Joseph Custodio; Michael Abram; Xuelian Wei; Andrew Cheng; Scott McCallister and Marshall Fordyce

1 Indiana University, Indianapolis, United States. 2 Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom. 3 Kings College Hospital NHS Foundation Trust, London, United Kingdom. 4 Holdsworth House Medical Practice, Sydney, Australia. 5 Baylor College of Medicine, Houston, United States. 6 Be Well Medical Center, Berkley, United States. 7 Gilead Sciences Inc., Foster City, United States.

Presenting author email: sgupta1@iu.edu

**Abstract**

**TUAB0102**  **Table 1. Changes in proteinuria and tubular proteinuria**

|                        | Median % change baseline to Week 48 | E/C/F/TAF | FTC/TDF + 3rd Agent | Significance |
|------------------------|------------------------------------|-----------|---------------------|-------------|
| Urine protein: creatinine (UPCR) | −18.5%                            | +9.4%     | p < 0.001           |             |
| Urine albumin: creatinine (UACR) | −18.4%                            | +5.3%     | p < 0.001           |             |
| Retinol binding protein: creatinine (RBP: CR) | −32.9%                            | +15.7%    | p < 0.001           |             |
| Beta-2-microglobulin: creatinine (B2MG: CR) | −49.2%                            | +14.4%    | p < 0.001           |             |

**http://dx.doi.org/10.7448/IAS.18.5.20356**
**Introduction:** Tenofovir (TFV) is renally eliminated, and the prodrug, tenofovir disoproxil fumarate (TDF), has been associated with renal toxicity and reduced bone mineral density (BMD). Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that results in 90% lower plasma TFV levels as compared to TDF. The safety and efficacy of a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and TAF (E/C/TAF) was assessed in HIV-1 infected patients with mild to moderate renal impairment.

**Methods:** Virologically suppressed adults with stable renal impairment (eGFR$_{C2}$ 30–69 mL/min) had their treatment switched from both TDF- and non-TDF-containing regimens to open-label E/C/TAF. Week 48 safety data by pre-switch TDF use are presented. **Results:** Of 242 subjects switched to E/C/TAF (mean age 58 years (range: 24–82), 18% Black, 39% HTN and 14% DM) 158 subjects (65%) were taking TDF-containing regimens prior to switch. At Week 48, the median (Q1, Q3) change from baseline for eGFR$_{C2}$ was $+0.2 (-5.8, 6.3)$ mL/min ($p = 0.81$) and for eGFR-cystatin C was $+2.7 (-6.2, 14.1)$ mL/min/1.73 m$^2$ ($p = 0.003$). The following measures of renal tubular function improved significantly ($p < 0.001$ for all) for subjects switching from TDF-containing regimens to E/C/TAF: quantified proteinuria (UPCR, median (Q1, Q3) % change; $-55 (-70, -28)$, albuminuria (UAOR, median (Q1, Q3) % change; $-61 (-81, -27)$), retinal binding protein (RBP4, median (Q1, Q3) % change; $-82 (-95, -55)$) and beta-2-microglobulin (B-2-MgCr, median (Q1, Q3) % change; $-89 (-97, -61)$). The prevalence of clinically significant proteinuria (UPCR > 200 mg/g) and albuminuria (UAOR > 30 mg/g) decreased from 48% to 13% and from 56 to 22%, respectively. Significant increases in mean change in hip (+1.29%) and spine (+2.60%) BMD were observed at 48 weeks ($p < 0.001$ for both). Subjects taking non-TDF based regimens pre-switch (n = 84) had no significant changes from baseline measures of renal function or BMD.

**Conclusions:** Subjects with mild and moderate renal impairment (eGFR 30 to 69 mL/min) who switched from TDF-containing regimens to once daily single-tablet E/C/TAF experienced improvements in multiple assessments of renal and bone safety through 48 weeks. This data support the safety of E/C/TAF in patients with impaired renal function.

http://dx.doi.org/10.7448/IAS.18.5.20358

**TUAB0104**

**Efficacy and safety of doravirine 100 mg QD vs. efavirenz 600 mg QD with TDF/FTC in ART-naive HIV-infected patients: week 24 results**

Jose Gatell$^1$; Francois Raffi$^2$; Andreas Plettenberg$^3$; Don Smith$^4$; Joaquin Portilla$^5$; Christian Hoffmann$^6$; Keikawus Arasteh$^7$; Melanie Thompson$^8$; Debbie Hagins$^9$; Javier Morales-Ramirez$^{10}$; Xia Xu$^{11}$; and Hedy Teppler$^{11}$

**Abstract TUAB0104**

**Table 1. Week 24 Efficacy, including subgroup responses by screening RNA ≤ or > 100,000 c/mL**

| Endpoint                                | DOR$^1$ (N = 108) | EFV$^1$ (N = 108) | Difference |
|-----------------------------------------|-------------------|------------------|------------|
| HIV RNA < 40c/mL$^1$                    | 72.2%             | 73.1%            | -1.2 (-13.0, 10.5) |
| screening RNA ≤ 100K$^6$ (n = 66, 63)   | 83.3%             | 85.7%            | -2.4 (-15.3, 10.6) |
| screening > 100K$^6$ (n = 38, 38)       | 60.5%             | 65.8%            | -5.3 (-26.4, 16.4) |
| HIV RNA < 200c/mL$^1$                   | 88.9%             | 87.0%            | 1.9 (-7.0, 11.0) |
| screening RNA ≤ 100K$^6$ (n = 66, 63)   | 92.4%             | 92.1%            | 0.4 (-9.8, 10.8) |
| screening > 100K$^6$ (n = 38, 38)       | 92.1%             | 94.7%            | -2.6 (16.5, 10.7) |
| Mean change in CD4 count$^2$            | 154/mm$^3$        | 146/mm$^3$       | 8 (-37, 52) |

$^1$with TDF/FTC.

$^2$Non-completer = Failure (NC = F) approach to missing data.

$^3$Observed Failure (OF) approach to missing data.

$^1$University of Barcelona, Barcelona, Spain. $^2$Department of Infectious Diseases, Hotel-Dieu University Hospital, Nantes, France. $^3$IfI Institute for Infections, Hamburg, Germany. $^4$Albion Centre, Sydney, Australia. $^5$University Miguel Hernandez, Alicante, Spain. $^6$ICH Study Center, Hamburg, Germany. $^7$EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany. $^8$AIDS Research Consortium of Atlanta, Atlanta, United States. $^9$Chatham County Health Department, Savannah, United States. $^{10}$Clinical Research Puerto Rico, San Juan, Puerto Rico. $^{11}$Merck & Co., Inc., Kenilworth, United States.

Presenting author email: gatell@fundusoriano.es

**Introduction:** Doravirine (DOR), an investigational NNRTI with a novel resistance profile, was compared with efavirenz (EFV) in a double-blind, randomized, 2-part study in ART-naive HIV-infected patients who also received tenofovir/emtricitabine (TDF/FTC). In Part 1 (dose selection), DOR at 25, 50, 100 and 200 mg QD showed rates of virologic suppression similar to EFV 600 mg QD; DOR 100 mg was selected for ongoing evaluation. Part 2 enrolled additional patients to receive DOR 100 mg or EFV. Using data from Parts 1 + 2 combined, DOR 100 mg showed significantly fewer CNS AEs than EFV at week 8.

**Methods:** Week 24 efficacy and safety results were analyzed for all patients who received DOR 100 mg or EFV in Part 1 (n = 42 per group) and Part 2 (n = 66 per group) combined. Patients were stratified at randomization by screening RNA ≤ or > 100,000 copies/mL. Primary endpoints were the proportion of patients with HIV RNA ≤ 40 c/mL (efficacy) and the proportion of patients with pre-specified CNS events (safety).

**Results:** Of the 108 patients randomized and treated per group, mean baseline RNA was 4.6 log$_{10}$ c/mL in both the DOR and EFV groups, and mean CD4 counts were 432 and 448 cells/mm$^3$, respectively. Discontinuations in the DOR and EFV groups, respectively, were 4.6 and 12.0%. The most common drug-related clinical AEs in the DOR and EFV groups, respectively, were nausea (7.4%; 5.6%), dizziness (6.5%; 25.0%), abnormal dreams (5.6%; 14.8%), nightmares (4.6%; 8.3%) and sleep disorder (3.7%; 6.5%). Drug-related AEs leading to discontinuation were hallucination for DOR (n = 1) and dysesthesia, hallucination, drug eruption, dizziness and disturbance in attention in patients taking EFV (n = 5). The most common CNS AEs (all causality) were dizziness (DOR 9.3%; EFV 27.8%), insomnia (7.4%; 2.8%), abnormal dreams (6.5%; 17.6%) and nightmares (6.5%; 8.3%). Lab abnormalities of Grade 2 or greater were uncommon in both groups.

**Conclusions:** DOR 100 mg qd demonstrated antiretroviral activity and immunological effect similar to EFV (each with TDF/FTC) and was generally safe and well tolerated during 24 weeks of treatment in ART-naive, HIV-1 infected patients. Treatment-emergent CNS AEs
Abstract TUAB0104: Table 2. Week 24 Clinical Adverse Event (AE) Summary & Primary Safety Analysis (CNS AEs)

| Proportion of patients with: | DOR\(^1\) (N = 108) | EFV\(^1\) (N = 108) | Difference [DOR-EFV] (95% CI) |
|-----------------------------|---------------------|---------------------|-------------------------------|
| One or more AEs             | 75.9%               | 84.3%               | −83 (−19.1, 2.4)              |
| Drug-related AEs            | 27.8%               | 55.6%               | −27.8 (−39.9, 14.8)           |
| Serious AE                  | 0.9%                | 4.6%                | −3.7 (−9.6, 0.9)              |
| Serious drug-related AEs    | 0%                  | 0.9%                | −0.9 (−5.1, 2.5)              |
| Discontinued due to AEs     | 0.9%                | 5.6%                | −4.6 (−10.8, 0.1)             |
| One or more CNS AEs         | 26.9%               | 46.3%               | −19.4 (−31.7, 6.6)*           |

\(^1\)with TDF/FTC.

*Pre-specified safety hypothesis, p < 0.001.

through week 24 were significantly less common in the DOR group than in the EFV group.

http://dx.doi.org/10.7448/IAS.18.5.20359

TUAB0105

Raltegravir for prevention of mother-to-child transmission of HIV

Marie-Julie Tranah\(^1\); Valérie Lamarre\(^{1,2,3}\); Marie-Elaine Metras\(^6\); Normand Lapointe\(^4,5\) and Fatima Kakkar\(^1,2,3\)

\(^1\)Université de Montréal, Faculté de Médecine, Montreal, Canada.
\(^2\)CHU Ste-Justine, Département de Maladies Infectieuses, Montreal, Canada.
\(^3\)Centre Maternel et Enfantile sur le Sida, Montreal, Canada.
\(^4\)CHU Ste-Justine, Département de Pharmacie, Montreal, Canada.
\(^5\)CHU Ste-Justine, Département d’Immunologie, Montreal, Canada.

Presenting author email: fatima.kakkar@umontreal.ca

Introduction: Raltegravir (RAL), though currently category C in pregnancy and not recommended for use in newborns, has been used in exceptional cases for prevention of mother-to-child-transmission (PMTCT). We report on the outcomes of 14 infants exposed in utero to RAL and the first newborn to be treated with RAL for six weeks for PMTCT.

Methods: Infants born to mothers treated with RAL during pregnancy from the Centre Maternel et Enfantile sur le Sida (CMIS) mother-child cohort between 2010 and 2014 were included in the study. RAL levels were tested on the first available stored plasma sample after birth, and in the treated newborn, therapeutic drug monitoring was done at weekly intervals.

Results: In RAL-exposed infants, RAL was given to mothers at standard doses of 400 mg BID, started at a mean GA of 30 weeks (range pre-conception-37.5 weeks). Indications for RAL included drug resistance and/or detectable viral load in the third trimester. Mean GA was 38.5 weeks (±1.76), and mean birthweight was 3200 g (±540). There were no clinical adverse events noted among RAL-exposed infants (mean follow-up time 119 weeks, range 48–144), and all were confirmed HIV negative. RAL levels tested in two exposed newborns at 16 and 30 hours of life were detectable at 0.9345 mg/L and 0.0381 mg/L, respectively, and undetectable in six other infants tested at days 4–14. RAL granules for suspension (Merck, special access) were obtained for prophylaxis of a term newborn (39 weeks GA) from a mother with multidrug-resistant virus and started at 1.5 mg/kg BID, along with zidovudine and lamivudine at standard doses. RAL levels were consistently above the targeted trough for treatment (0.02 mg/L) (Table 1) for the duration of therapy. RAL was well tolerated and at follow-up, the infant was confirmed HIV negative.

Conclusions: RAL in late pregnancy had no adverse effects on infants exposed in utero. RAL treatment in the newborn at doses of 1.3–1.6 mg/kg BID was well tolerated and resulted in therapeutic drug levels. Given detectable levels of RAL in the first 30 hours of life in exposed infants, the timing and role of RAL in PMTCT should further be considered.

http://dx.doi.org/10.7448/IAS.18.5.20360

TUAB0106LB

Second-generation HIV-1 maturation inhibitor BMS-955176: antiviral activity and safety with atazanavir ± ritonavir

Carey Hwang\(^1\); Dirk Schürmann\(^2\); Christian Sobotha\(^2\); Marta Boffito\(^3\); Heather Sevinsky\(^4\); Neelanjana Ray\(^1\); Palanikumar Ravindran\(^1\); Hong Xiao\(^1\); Mark Krystal\(^4\); Ira Dicker\(^4\); Dennis Grasela\(^4\); Max Lataillade\(^5\) and for the BMS HIV Global Development Team

\(^1\)Bristol-Myers Squibb, Research and Development, Princeton, United States. \(^2\)Charité Research Organisation GmbH, Berlin, Germany. \(^3\)St. Stephen’s Centre, Chelsea and Westminster Hospital, London, United Kingdom. \(^4\)Research and Development, Bristol-Myers Squibb, Wallingford, United States. \(^5\)Presenting author email: carey.hwang@bms.com

Introduction: BMS-955176 is a second-generation HIV-1 maturation inhibitor that targets the HIV-1 Gag polyprotein, inhibiting the last protease cleavage event between capsid protein p24 and spacer peptide 1, resulting in the release of immature, non-infectious virions. Ten days of BMS-955176 monotherapy resulted in maximum median declines in HIV-1 RNA that plateaued at 1.64 log\(_{10}\) c/mL. Using this model, we compared antiviral activity and safety of atazanavir ± ritonavir plus BMS-955176 (BMS) vs. atazanavir ± ritonavir (ATR) and efavirenz (EFV) with ATR. Clinical trial registration number: NCT01838228.

Abstract TUAB0105S Table 1. Raltegravir levels in a treated newborn

| Day of life | Weight (kg) | Dose | mg/kg/dose | Trough (hours) | Trough level | Peak (hours) | Peak level | Adjusted |
|-------------|-------------|------|------------|---------------|--------------|--------------|------------|----------|
| 6           | 3.115       | 5 mg BID | 1.61 | 11.67 | 0.36 | 1.97 | 0.87 | No |
| 9           | 3.220       | 5 mg BID | 1.55 | 11.25 | 0.75 | 1.25 | 0.15 | No |
| 20          | 3.565       | 5 mg BID | 1.40 | 12   | 0.07 | 1.17 | 0.33 | No |
| 27          | 3.835       | 5 mg BID | 1.30 | 11   | 0.06 | 1.15 | 0.02 | Increased to 6 mg BID |
| 40          | 4.275       | 6 mg BID | 1.40 | N/A | N/A | N/A | N/A | Stopped |
doses between 40 mg and 120 mg once daily (QD). Two drug combination studies in vitro demonstrated that BMS-955176/ atazanavir (ATV) had an additive effect. Due to the proximity of their sites of inhibition in the virus life cycle and the potential for synergy, we assessed the antiviral activity and safety of BMS-955176 with ATV/ritonavir (RTV) for 28 days in HIV-1-infected subjects. In addition, this combination is being further evaluated to potentially serve as part of a booster-sparing and nucleos(t)ide-sparing strategy.

**Methods:** AI468002 (NCT01803074) was a Phase 2a, randomized, multipart trial. In Part B, 28 HIV-1 subtype B-infected subjects (HIV-1 RNA >5000 c/mL, CD4+ T-cell counts >200 cells/μL) were randomized 2:2:2:1 to four treatment groups (all QD): BMS-955176 40 mg/QD + ATV 400 mg/QD; BMS-955176 40 mg/QD + ATV 300 mg/QD + RTV 100 mg/QD; BMS-955176 80 mg/QD + ATV 400 mg/QD; and a standard-of-care (SOC) control of tenofovir disoproxil fumarate 300 mg/QD + emtricitabine 200 mg (fixed-dose combination) + ATV 300 mg/QD + RTV 100 mg/QD.

**Results:** Median change in HIV-1 RNA at Day 29 was -1.66 (-1.19, -2.04) for BMS-955176 40 mg/QD + ATV 400 mg/QD; -1.99 (-1.04, -3.32) for BMS-955176 40 mg/QD + ATV 300 mg/QD + RTV 100 mg/QD; -2.18 (-1.53, -2.68) for BMS-955176 80 mg/QD + ATV 400 mg/QD; and -2.22 (-1.83, -2.84) for the SOC control, respectively (Table 1 and Figure 1). There were no deaths, serious adverse events (SAEs), or AEs leading to discontinuation. Furthermore, the median bilirubin level was below the upper limit of normal for subjects receiving unboosted ATV with BMS-955176, in contrast to the level observed for subjects receiving BMS-955176 40 mg + ATV + RTV or SOC.

**Conclusions:** In this study, BMS-955176 80 mg + ATV and 40 mg + ATV + RTV had similar maximum median declines in HIV-1 RNA compared with the SOC control. BMS-955176 with ATV + RTV was generally well tolerated. A Phase 2b study investigating BMS-955176 in a booster-sparing and nucleos(t)ide-sparing regimen in treatment-experienced patients will begin in Q2 2015.

http://dx.doi.org/10.7448/IAS.18.5.20544

**TUAB0201**

A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study

Laurence Brunet¹; Erica EM Moodie²; James Young³; Sharon_Walmsley²; Mark Hull⁴; Curtis Cooper⁵; Marina B Klein⁶,⁷ and Canadian Co-Infection Cohort Study Investigators
Abstract TUAB0202- Table 1. SVR12 by HIV regimen and overall

| Virologic response | TDF + FTC + EFV (N = 160) | TDF + FTC + RAL (N = 146) | TDF + FTC + RPV (N = 29) | Overall (N = 335) |
|-------------------|-----------------------------|-----------------------------|--------------------------|------------------|
| SVR12, n (%)      | 151 (94)                    | 141 (97)                    | 28 (97)                  | 320 (96)         |
| On-Treatment Failure, n (%) | 1 (<1)                    | 0                           | 1 (3)                    | 2 (<1)           |
| Relapse, n (%)    | 8 (5)                       | 2 (1)                       | 0                        | 10 (3)           |
| Other, n (%)      | 0                           | 3 (2)                       | 0                        | 3 (<1)           |

TDF: Tenofovir; FTC: Emtricitabine; EFV: Efavirenz; RAL: Raltegravir; RPV: Rilpivirine

Introduction: Historically HIV co-infection was considered a negative predictor of HCV response to treatment with interferon/ribavirin (IFN/RBV). For sofosbuvir-based regimens, HIV/HCV patients have achieved similar sustained virologic response (SVR) rates as HCV mono-infected patients. We evaluated the safety and efficacy of the IFN-free, RBV-free, single tablet regimen of ledipasvir/sofosbuvir (LDV/SOF) in HCV genotype 1 or 4 patients co-infected with HIV-1 in the Phase 3 ION-4 study.

Methods: HCV treatment naïve and experienced HIV co-infected patients on stable, approved antiretroviral (ARV) regimens were enrolled and received LDV/SOF (90 mg/400 mg) once daily for 12 weeks. Patients with compensated cirrhosis were eligible. Permitted concomitant ARVs included tenofovir and emtricitabine (TDF + FTC) with raltegravir (RAL), efavirenz (EFV) or rilpivirine (RPV). Safety evaluations included adverse event (AE) and standard laboratory parameter monitoring in addition to enhanced renal toxicity monitoring, CD4 count and HIV-1 RNA levels. The primary efficacy endpoint was SVR12.

Results: A total of 335 patients with GT1a (75%), GT1b (23%) and GT4 (2%) were enrolled; 82% were male, 61% were white, mean age was 52 (range 26–72), mean baseline HCV RNA was 6.7 log10 IU/mL using PI-based regimens, although we could not account for all patient characteristics influencing the choice of an anchor agent.

http://dx.doi.org/10.7448/IAS.18.5.20361
(range 4.1–7.8), median baseline CD4 count was 662 cells/μL (Q1, Q3 = 469, 823), 20% had cirrhosis, 24% were IL28B CC genotype and 55% had not responded to prior HCV treatment. Patients were taking EFV (48%) or RAL (44%) or RPV (9%). The table shows SVR12 by ARV regimen. Overall, the SVR12 rate was 96% (320/335); two patients had on-treatment virologic failure likely due to non-compliance and 10 had virologic relapse after discontinuing treatment. SVR12 was similar among non-cirrhotic (96%) and cirrhotic (94%) patients and also among treatment naive (94%) and treatment experienced (97%) patients. No patient had confirmed HIV virologic rebound (HIV-1 RNA ≥ 400 copies/mL). No patients discontinued study drug due to an AE. AEs occurring in ≥10% of patients were headache (25%), fatigue (21%) and diarhoea (11%). No significant lab abnormalities were observed.

**Conclusions:** The IFN-free, RBV-free, single tablet regimen of LDV/SOF administered once daily for 12 weeks is highly effective and well tolerated in treatment-naïve and experienced, genotype 1 or 4 HCV-infected patients with HIV-1 co-infection, including those with cirrhosis.

http://dx.doi.org/10.7448/IAS.18.5.20362

**TUAB0203**

**High SVR rates in HCV/HIV-1 co-infected patients regardless of baseline characteristics**

David Wyles1; Joseph J Erno2; Jay Lalezari3; Chia Wang4; Peter J Ruane5; Gary Blick6; Laveeza Bhatti7; Yiran B Hu8; Melannie Co8; Krystal Gibbons9; Roger Trinh10 and Mark S Sulkowski11

1 Department of Medicine, University of California San Diego, San Diego, United States. 2 Department of Medicine, University of North Carolina, Chapel Hill, United States. 3 Quest Clinical Research, San Francisco, United States. 4 Virginia Mason Medical Center, Seattle, United States. 5 Ruane Medical and Liver Health Institute, Los Angeles, United States. 6 CIRCLE CARE CENTER, Norwalk, United States. 7 AIDS Healthcare Foundation, Beverly Hills, United States. 8 AbbVie Inc., Chicago, United States. 9 Infectious Disease Center for Viral Hepatitis, Johns Hopkins University, Baltimore, United States.

**Abstract TUAB0203 - Table 1.** SVR12 rates by baseline characteristic, n/N (%)

| Characteristic | 12-week OBV/PTV/DSV | 24-week OBV/PTV/DSV |
|---------------|---------------------|----------------------|
| Overall       | 29/31 (94)          | 29/32 (91)           |
| Black race    | 7/7 (100)           | 7/8 (88)             |
| Hispanic or Latin ethnicity | 7/8 (88) | 7/8 (88) |
| Age, ≥55 years | 7/8 (88)         | 12/12 (100)          |
| BMI ≥30       | 3/3 (100)           | 7/7 (100)            |
| IL28B genotype | CT 16/16 (100)     | 19/20 (95)           |
|               | TT 8/10 (80)         | 4/5 (80)             |
| Prior pegIFN/RBV treatment experience | | |
| Naïve         | 19/20 (95)          | 20/22 (91)           |
| Relapser      | 1/1 (100)           | 3/3 (100)            |
| Partial response | 5/5 (100)       | 2/2 (100)            |
| Null response  | 4/5 (80)            | 4/5 (80)             |
| Baseline HCV RNA ≥800,000 IU/mL | | |
| Baseline CD4+T-cells/mm³ | 2/2 (100) | 5/5 (100) |
| <350          | 8/8 (100)           | 7/8 (88)             |
| 350 – <500    | 1/1 (100)           | 5/5 (100)            |
| Baseline fibrosis stage | | |
| F2            | 5/5 (100)           | 5/5 (100)            |
| F3            | 3/4 (75)            | 1/1 (100)            |
| F4            | 5/6 (83)            | 5/6 (83)             |

SVR12, sustained virologic response at post-treatment week 12; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; RBV, ribavirin.

T-cell counts did not negatively affect SVR12 rates. The regimen was well tolerated with no discontinuation due to adverse event or serious adverse event.

**Conclusions:** In HCV genotype 1 patients co-infected with HIV-1, OBV/PTV/DSV + RBV achieved high rates of SVR12 regardless of baseline host, viral and disease characteristics whether treated with 12 or 24 weeks of therapy.

http://dx.doi.org/10.7448/IAS.18.5.20363

**TUAB0204**

**Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver-related complications and hospital admissions in HIV/HCV co-infected patients with cirrhosis**

Jose Luis Casado; Sara Baion; Carmen Quereda; Ana Moreno; Maria J Perez Elias and Santiago Moreno

Infectious Diseases, Ramon y Cajal Hospital, Madrid, Spain.

Presenting author email: smoreno.hrc@salud.madrid.org
**Abstract TUAB0205**

- **Table 1.**

| SVR (42) | No SVR (91) |
|---------|-------------|
| FR (23, 55%) | No FR (19, 45%) | p | FR (14, 15%) | No FR (77, 85%) | p |
| TE (Kpa) | 7.1 (6.3–8.8) | 17.5 (13.8–26.3) | <0.01 | 11.6 (6.3–11.2) | 21.3 (17.2–45.4) | <0.01 |
| Death (n, %) IR | 4 (17%) 2.45 | 6 (32%) 5.36 | 0.01 | 2 (14%) 1.3 | 37 (48%) 7.6 | <0.01 |
| Liver-related death (n, %), IR | 1 (4%) 0.61 | 3 (16%) 2.68 | 0.01 | 1 (7%) 3.65 | 29 (38%) 5.9 | <0.01 |
| Liver-related complications (n, %) IR | 1 (4%) 1.22 | 2 (11%) 1.78 | 0.2 0.15 | 5 (36%) 3.25 | 33 (43%) 6.81 | 0.01 <0.01 |
| Hospital admissions (n, %) IR | 2 (9%) 1.22 | 3 (16%) 2.68 | 0.7 0.13 | 4 (29%) 2.6 | 27 (30%) 5.6 | 0.2 0.04 |

**Introduction:** There are few data about the clinical outcome of hepatitis C (HCV)/HIV co-infected patients with liver cirrhosis after therapy, considering the possibility of fibrosis regression (FR).

**Methods:** We compared the incidence rate (IR), and the time to develop a liver complication and death, in 139 cirrhotic patients according to sustained virological response (SVR) or and FR, as established by a confirmed 1-point decrease in Metavir score by transient elastography (TE).

**Results:** Overall, 42 patients reached SVR, and 23 of them (55%) had FR, in comparison with only 14 of the 91 (15%) without SVR. During a median follow up of 6.8 years (916.8 person-years), the IR of death, liver-related death, liver-related complications and hospital admissions were significantly lower in patients with SVR/FR (Table). SVR patients without FR had a worse IR of death (5.36) and liver-related death (2.68) than non-SVR patients with FR (1.3 and 0.65, respectively; p < 0.01). In Cox multivariate analysis, only FR was associated with a lower risk of death (adjusted hazard ratio; HR, 0.36; 95% CI 0.15–0.86), and liver-related death (HR 0.15; 95% CI 0.03–0.65), whereas both FR (HR 0.09; 95% CI 0.03–0.3, p < 0.01) and SVR (HR 0.24; 95% CI 0.07–0.87) decreased the risk of liver-related complications.

**Conclusions:** FR is frequent after anti-HCV therapy in HIV/HCV co-infected patients with compensated cirrhosis who achieve SVR, and it is associated with the highest reduction of death of any cause, liver-related mortality, liver-related complications and hospital admissions.

http://dx.doi.org/10.7448/IAS.18.5.20364

**TUAB0205**

How generalizable are direct antiviral agents (DAAs) trials for real world people co-infected with HIV/hepatitis C?

Sahar Saeed1; Kathleen Rollet-Kurhajec2; Erin C Strumpf2; Marina B Klein3 and The Canadian Co-Infection Cohort (CTN22)

**Abstract TUAB0205**

Table 1. Inclusion/exclusion criteria

| Exclusion criteria (exclusive) | No (%) among genotype 1 (n = 699) | No (%) among genotypes 1, 2 and 3 (n = 887) |
|-------------------------------|-----------------------------------|---------------------------------------------|
| Specific cART regimens*        | 380 (54)                          | 484 (55)                                    |
| Active drug abuse within 12 months (excluding marijuana use) | 320 (46)                          | 402 (45)                                    |
| HIV VL > 50 copies/mL          | 175 (25)                          | 225 (25)                                    |
| HbA1c > 10% (used HOMA IR > 2 as surrogate) | 171 (24)                          | 217 (24)                                    |
| APRI* of <1 or ≥ 2             | 129 (18)                          | 171 (19)                                    |
| CD4 T-cell count < 200 cells/mm³ | 106 (15)                          | 136 (15)                                    |
| Decompensated liver disease    | 23 (3)                            | 27 (3)                                      |

*Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada. 2Department of Medicine, Division of Infectious Diseases/Chronic Viral Illness Service, Royal Victoria Hospital, McGill University Health Centre, Montreal, Canada. 3CIHR Canadian HIV Trials Network, Vancouver, Canada. Presenting author email: sahar.saeed@mail.mcgill.ca

**Introduction:** Worldwide, approximately seven million people are co-infected with HIV-Hepatitis C (HCV). The most common risk factor for co-infection is injection drug use. HCV treatments have evolved at an unprecedented speed; Simpeprevir (SIM) and Sofosbuvir (SOF) are among the latest DAAs approved for use. However clinical trials conducted with these agents have enrolled a small number of individuals, in ideal circumstances with strict inclusion/exclusion criteria. This provokes the question: how generalizable are their results?

**Methods:** We examined the study population characteristics (based on published inclusion/exclusion criteria) from the only two efficacy trials evaluating SIM (NCT01479868) and SOF (NCT01667731: PHOTON-1) for HIV-HCV co-infected patients and compared them to participants in the Canadian Co-Infection Cohort (CCC), a prospective cohort following 1383 co-infected people from across Canada (representing ~23 co-infected population in care).

**Results:** Due to eligibility criteria, 30% (49/160) of screened subjects from 32 international study locations and 29% (96/330) of screened subjects from 27 American sites were excluded from the SIM and SOF trials, respectively. Of 1383 CCC participants, 1054 (76%) had evidence of chronic HCV (RNA+) at last visit; 699 (66%) infected with HCV genotype 1 and 887 (84%) infected with genotype 1, 2 or 3 and therefore could have been eligible for these trials. After applying all the available trial inclusion/exclusion criteria, only 8.6% of genotype 1 (60/699) and similarly 8.6% (76/887) overall would have been eligible to participate. Active drug use within 12 months accounted for 46% of reasons for non-eligibility, restriction to specific...
antiretroviral therapies and liver fibrosis staging were also highly exclusive as described in Table 1. **Conclusions:** Limited population level data makes it difficult to examine external validity of clinical trials. However using data from the CCC, we have illustrated that results obtained from clinical trials are not generalizable to the HIV-HCV patients in Canada and caution should be used when translating trial results in the real world.

http://dx.doi.org/10.7448/IAS.18.5.20365

TUAB0206LB
High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study

Jürgen K Rockstroh1; Mark Nelson2; Christine Katlama3; Jay Lalezari4; Josep Mallolas5; Mark Bloch6; Gail Matthews7; Michael S Saag8; Philippe Zamar9; Chloé Orkin10; Jacqueline Gress11; Melissa Shaughnessy11; Stephanie Klopfer11; Heather L Platt11; Michael Robertson11 and Mark Sulkowski12

1Bonn University Hospital, Bonn, Germany. 2Chelsea and Westminster Hospital, London, United Kingdom. 3Paris VI and Hôpital Pitie-Salpetrière, Université Pierre et Marie Curie, Paris, France. 4Quest Clinical Research, San Francisco, United States. 5Hospital Clinic, University of Barcelona, Barcelona, Spain. 6Holdsworth House Medical Practice, Darlinghurst, Australia. 7St. Vincent’s Hospital, Sydney, Australia. 8University of Alabama at Birmingham, Birmingham, United States. 9Carolina's Medical Center, Charlotte, United States. 10Royal London Hospital, Bart’s Health NHS Trust, London, United Kingdom. 11Merck & Co. Inc., Kenilworth, United States. 12School of Medicine, Johns Hopkins University, Baltimore, United States.

Presenting author email: juergen.rockstroh@ukb.uni-bonn.de

**Introduction:** The fixed-dose combination of grazoprevir (GZR, MK-5172, 100 mg, an NS3/4 protease inhibitor)/elbasvir (EBR, MK-8742, 50 mg, an NSSA inhibitor), an interferon-free, ribavirin-free, once-daily tablet has shown robust efficacy and safety in diverse populations. C-EDGE co-infection is an on-going phase-III study evaluating GZR/EBR tablet has shown robust efficacy and safety in diverse populations. C-50 mg, an NS5A inhibitor), an interferon-free, ribavirin-free, once-daily tablet has shown robust efficacy and safety in diverse populations. C-EDGE co-infection is an on-going phase-III study evaluating GZR/EBR.
Abstract TUA0207LB  Table 1. Efficacy of DCV + SOF + RBV regimens in HIV/HCV co-infection

| Treatment duration | Genotype status |
|--------------------|----------------|
|                    | GT1 (all)       | GT1 cirrhotic | GT3 (all) | GT3 cirrhotic | GT4 (all) | GT4 cirrhotic |
| 12 weeks           | 104/116        | (89.7%)      | 13/15     | 12/13        | 26/28      | 16/17        |
| N = 164            | (93.0%)        |              |           |              |           |              |
| 24 weeks           | 107/115        | (93.0%)      |           |              |           |              |
| N = 98             | (95.5%)        |              |           |              |           |              |

Overall, SVR4 was obtained in 90.2% (148/164) and SVR12 in 95.9% (94/98) of the cases.

Among patients treated with DCV + SOF for 12 or 24 weeks, 96.0% (24/25) and 95.1% (58/61) achieved an SVR12, respectively, compared to 100% (6/6) and 100% (6/6) for patients receiving DCV + SOF + RBV. Neither duration of treatment nor cirrhosis status and genotype influenced the rate of SVR12 (Table 1).

Treatment discontinuations occurred in 17 patients (3%) and were related to an adverse event (n = 5), death (n = 4, not related to treatment), patient decision (n = 3), contraindication (n = 3), unknown reason (n = 1) and patient lost to follow-up (n = 1).

Conclusions: DCV + SOF + RBV regimen was well tolerated and demonstrated high SVR12 rate in HIV-HCV co-infected patients with advanced liver disease.

http://dx.doi.org/10.7448/IAS.18.5.20546

TUAC0101LB

Impact of conditional cash incentives on HSV-2 and HIV prevention in rural South African high school students: results of the CAPRISA 007 cluster randomized controlled trial

Quarraisha Abdool Karim1,2; Kerry Leask3; Ayessa Kharsany; Hilton Humphries; Fanele Ntombe1; Natasha Samsunder2; Cheryl Baxter; Janet Frohlich; Lynn van der Elst3 and Salim Abdool Karim1,2

1CAPRISA, Durban, South Africa. 2Department of Epidemiology, Columbia University, New York, United States. 3MIET Africa, Durban, South Africa.

Presenting author email: quarraisha.abdoolkarim@caprisa.org

Introduction: Young women in southern Africa have high rates of sexually transmitted infections, including herpes simplex virus type-2 (HSV-2) and HIV. We investigated whether conditional cash incentives (CCIs) reduced the incidence of HSV-2 and HIV in rural high school students in South Africa.

Methods: An open-label, matched-pair, cluster randomized controlled trial (CAPRISA 007) was undertaken in 3217 consenting male grade 9 and 10 students. A locally developed HIV prevention programme, My Life! My Future!, was actively implemented in all 14 schools. Seven schools (n = 1592 students) were randomly assigned to receive; in addition, cash incentives (maximum of $175 over two years) for fulfilling any combination of four conditions: annual HIV testing, performance in school tests, participation in My Life! My Future!, and a written report on their community involvement project. HSV-2 and HIV serology was undertaken at baseline, 12 months and 24 months. In the intent-to-treat analysis, incidence rate ratios (IRRs) and p-values were adjusted for the matched-pair cluster design.

Results: HSV-2 prevalence at baseline was 9.0% in CCI schools and 7.3% in control schools. During follow-up, there were 319 new HSV-2 infections, with an incidence rate of 6.2 per 100 person-years in CCI schools.
schools compared to 8.7 per 100 person-years in control schools (IRR = 0.70, 95% CI: 0.57–0.86; p = 0.007). HSV-2 incidence was 7.1 per 100 person-years in the 760 students who received <$65, 6.3 per 100 person-years in the 304 students who received $65–$95, and 4.2 per 100 person-years in the 265 students who received >$95 (Trend test, p = 0.12). The lower-than-anticipated overall HSV incidence rate of 1.6 per 100 person-years was similar in both groups of schools (IRR = 1.26, 95% CI: 0.66–2.39; p = 0.419). A fourfold larger study would be required for 80% power to observe a 30% HSV incidence reduction.

**Conclusions:** CCI schools had 30% lower HSV-2 incidence. Students who received larger cash incentives had lower HSV-2 incidence rates. The impact of CCI on HIV could not be adequately assessed as incidence was lower than expected, likely due to HIV lowering effects of both study-initiated and background community HIV interventions.

http://dx.doi.org/10.7448/IAS.18.5.20547

**TUAC0102**

The effect of conditional economic compensation and lottery-based rewards on uptake of medical male circumcision in Kenya: a randomized trial

Harsha Thirumurthy1,2; Samuel Masters1; Samwel Rao3; Katherine Murray4; Eunice Omanga5 and Kawango Agot5

1Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, United States. 2Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, United States. 3Impact Research and Development Organization, Kisumu, Kenya.

**Introduction:** Low uptake of male circumcision has been a major challenge to scaling-up and maximizing the HIV prevention impact of voluntary medical male circumcision (VMMC) services in eastern and southern Africa. There is limited evidence on effective demand creation strategies for VMMC that address reported barriers to male circumcision. Building on insights from behavioural economics, we assessed whether providing compensation for opportunity costs of time or lottery-based rewards can increase VMMC uptake among men in Nyanza Province, Kenya.

**Methods:** Uncircumcised men aged 21–39 years were provided information on VMMC services and randomized in 1:1:1 ratio to two intervention groups or a control group. One intervention group was offered compensation of US$12.50 conditional on VMMC uptake. Compensation was provided in the form of food vouchers valid at shops in the study region. A second intervention group was offered the opportunity to participate in a lottery with high-value prizes upon undergoing circumcision. The primary outcome was VMMC uptake within three months.

**Results:** Among 903 participants enrolled, those randomized to receive compensation of US$12.50 had the highest VMMC uptake (8.4%, 26/308), followed by those receiving lottery-based rewards (3.3%, 10/302) and those in the control group (1.3%, 4/299). Logistic regression analysis showed that compared to the control group, the US$12.50 group had significantly higher VMMC uptake (Adjusted odds ratio (AOR) 7.1; 95% CI 2.4–20.8). Participants in the lottery-based rewards group were not significantly more likely to become circumcised than participants in the control group (AOR 2.5; 95% CI 0.8–8.1). The effect of providing compensation of US$12.50 was largest among participants who were contemplating circumcision at the time of enrolment.

**Conclusions:** Providing conditional economic compensation was effective in increasing circumcision uptake among men in a short time period. The results are consistent with studies showing that small incentives can modify health behaviours by addressing barriers such as opportunity costs of time and present-biased decision-making. Contrary to findings from studies in high-income countries, lottery-based rewards did not significantly increase circumcision uptake. Testing economic interventions in other settings and applying them to different HIV behaviours can be useful for assessing the generalizability of the findings.

http://dx.doi.org/10.7448/IAS.18.5.20366

**TUAC0103**

Estimating the population-level effect of homelessness on HIV viral suppression among people who use drugs: an observational study

Brandon D L Marshall1; Beth Elston1; Sabina Dobrer2; Julio Montaner2,3; Thomas Kerr2,3; Evan Wood2,3 and M-J Milloy2,3

1Department of Epidemiology, Brown University, Providence, United States. 2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 3Department of Medicine, University of British Columbia, Vancouver, Canada.

**Presenting author email:** brandon_marshall@brown.edu

**Introduction:** Homelessness has been identified as an important structural barrier to effective antiretroviral therapy (ART) utilization among HIV-infected people who use drugs (PWUD). However, the potential effect of reducing homelessness on viral suppression rates at the community level is unknown. We used an imputation-based marginal modelling approach to estimate change in the prevalence of viral suppression among HIV-infected PWUD, if homelessness were eliminated from the population.

**Methods:** We used data from a cohort study of community-recruited PWUD in Vancouver, Canada. Of note, HIV/AIDS treatment and care is provided free of charge in this setting. Persons were eligible to participate if they were HIV-infected and used an illicit drug in the month prior to enrolment. We assessed self-reported baseline housing status in the past six months. Viral suppression was defined as HIV RNA viral load <50 copies per mm³ at first study visit. We estimated the effect of homelessness on viral suppression using modified-Poisson regression, adjusting for demographics, socioeconomic characteristics, trauma history, depression, addiction treatment and other confounders. Then, a marginal modelling approach was applied. First, we imputed the outcome probability for each individual while manipulating the exposure (homelessness) to never exposed, and then averaged these probabilities across the population. Bootstrapping was conducted to calculate 95% confidence limits.

**Results:** Of 718 eligible individuals enrolled between January 2005 and December 2013, the majority was male (66%), white race/ethnicity (55%) and had a history of injection drug use (94%). At baseline, 230 (32%) reported homelessness. The prevalence of viral suppression was 35% (95% CI: 31–38%). Adjusted marginal models estimated a 14% relative increase (95% CI: 10–24%) in viral suppression prevalence in the entire sample – to 40% (95% CI: 36–45%) – if all homeless individuals were housed. Among those homeless at baseline, adjusted marginal models estimated that eliminating this exposure would increase viral suppression from 19% (95% CI: 14–24%) to 37% (95% CI: 33–42%).

**Conclusions:** Reducing homelessness among HIV-infected PWUD could have significant population-level benefits on outcomes in the HIV care continuum. Low threshold shelter and housing support programs should be considered as key components in comprehensive strategies to increase population-level viral suppression for PWUD.

http://dx.doi.org/10.7448/IAS.18.5.20367
TUAC0104

Applying principles of behavioural economics to ART adherence: discount rate, future expectations and intrinsic motivation for adherence among ART initiates in Shinyanga region, Tanzania

Nancy Czaicki1; Prosper Njau2; Sergio Bautista-Arredondo3; Otieno Simba4; Nancy Padian1 and Sandra McCoy5

1Epidemiology, University of California Berkeley, Berkeley, United States. 2Department of Global Health and Population, University of the Witwatersrand, Johannesburg, South Africa. 3Department of Global Health and Population, Harvard School of Public Health, Boston, United States. 4Health Systems and Impact Evaluation, Wellcome Trust Africa Centre for Health and Population Studies, Mtubatuba, South Africa. Presenting author email: nhaber@mail.harvard.edu

Introduction: Behavioural economic theory suggests that understanding motivations and future preferences of people living with HIV infection (PLHIV) can inform the development of interventions supporting adherence to treatment and care. For example, PLHIV with high levels of intrinsic motivation to adhere to ART may require less external motivation, such as cash incentives. In addition, PLHIV who disproportionally value the present and heavily discount the future may be less likely to adhere to ART, a behaviour with future benefits and present costs. We measured these constructs among antiretroviral therapy (ART) initiates at four HIV care and treatment clinics in Shinyanga Region, Tanzania.

Methods: We analyzed data collected from in-person interviews between December 2013 and December 2014 with food-insecure, HIV-infected adults who initiated ART in the past 90 days. Temporal discount rate, the rate at which individuals discount future costs and benefits, was measured using a bidding process to assess the acceptable percent increase of a hypothetical monetary offer they would receive in three months compared to a smaller amount received today. Future health expectations were assessed for one year from now, and intrinsic motivation for ART adherence was measured as the mean score (range: 0–3) on a Likert-scale using questions in the Treatment Self-Regulation Questionnaire.

Results: Overall, 511 food-insecure recent ART initiates were interviewed (mean age: 37, 64% female). Nearly all (99%) expected their health to be somewhat (55%) or much better (44%) one year after interview (mean age: 37, 64% female). Nearly all (99%) expected their health to be somewhat (55%) or much better (44%) one year from now. Excluding those who initiated treatment on the same day of the interview, mean internal motivation was 2.75 (standard deviation 0.36; n = 423). Temporal discount rates (n = 489) fell into four ranges: <50% (8%), 50–100% (37%), 101–200% (54%) and >200% (2%).

Conclusions: These data indicate high levels of both intrinsic motivation for ART adherence and optimism towards future health among food-insecure ART initiates in Tanzania, suggesting that interventions designed to strengthen and sustain intrinsic motivation may be appropriate. The high discount rates indicate a greater focus on the present; thus, interventions aiming to overcome the short-term cost barriers to adherence and care (e.g., time, transport and competing needs) in order to achieve future gains may be highly effective among this population.

http://dx.doi.org/10.7448/IAS.18.5.20368

TUAC0105

Negative impact of South Africa’s disability grants on HIV/AIDS recovery

Noah Haber1; Frank Tanser2; Kobus Herbst3; Deenan Pillay2; Till Bärnighausen2,7 and Wellcome Trust Africa Centre for Health and Population Studies

1Department of Global Health and Population, Harvard School of Public Health, Boston, United States. 2Health Systems and Impact Evaluation, Wellcome Trust Africa Centre for Health and Population Studies, Mtubatuba, South Africa. Presenting author email: nhaber@mail.harvard.edu

Introduction: The South African disability grant (DG) has been theorized to incentivize poor recovery by tying grant receipt to AIDS sickness. Prior to 2008, many official guidelines defined qualifying AIDS disability as a CD4 count below 200 mmHg, and this recommendation persists unofficially. We make two predictions:
1) The population distribution of CD4 counts will have an observable discontinuity with excess mass just below the CD4 qualification threshold of 200 mmHg, and
2) individuals receiving the grant will recover more slowly around this threshold than those who do not, due to threat of grant loss.

Methods: The analysis utilizes a two-stage panel regression methodology to absorb individual trends and identify differential recovery rates around the CD4 threshold of 200 mmHg. The dataset for this analysis utilizes the Africa Centre Demographic Information System (ACDIS), an open cohort health and demographic monitoring programme consisting of annual surveys, individually matched with an HIV-focused clinical informatics system in rural KwaZulu-Natal, South Africa. Data are restricted to HIV+ individuals from 2004 to 2011, who have at least four observed CD4 counts, with at least one observed CD4 count above and below 200 mmHg.

Results: The cohort for this analysis consists of 11,160 observations from 1450 individuals. The distribution of CD4 counts shows clear excess mass just below a CD4 count of 200 mmHg, with more pronounced for CD4 counts occurring in 2008 or earlier. Among observations around the threshold, the rate of recovery of those receiving DGs is 0.23 mmHg/year lower (p = 0.020) than that of those not receiving DGs, controlling for individual recovery trends, age, education, time, household assets and employment. Stratifying on gender, the effect is seen much stronger among women with a differential recovery rate of 58 mmHg/year (p = 0.018). The effect is significantly larger for observations in 2008 or earlier.

Conclusions: This study finds that the South African DG system resulted in a modest but significant manipulation of CD4 counts in order to qualify for the grant. While policy changes have likely reduced the severity of the effect, policy makers should ensure that incentives from grants are aligned with health incentives to reduce poor outcomes, infectivity and drug resistance.

http://dx.doi.org/10.7448/IAS.18.5.20369

TUAC0106LB

HPTN 068 conditional cash transfer to prevent HIV infection among young women in South Africa: results of a randomized controlled trial

Audrey Pettifor1,2; Catherine MacPhail3; Amanda Selin4; Xavier Gomez-Oliva5; James Hughes6; Ryan Wagner7; Wonderful Mabuza5; Immitrude Mokoena5; Susan Eshleman3; Estelle Piwowar-Manning8; Rhian Twine5; Aimée Julien4; Cheryl Marcus9; Philip Andrew7; Jing Wang9; Yi Xiong9; Laura McKinstry5; Erica Hamilton9; Yaw Agyei10; Susannah Allison10; Paul Sato11; Ellen Towner11; Stephen Tollman11; Kathleen Kahn11 and HPTN 068 Study Team

1Department of Global Health and Population, University of the Witwatersrand, Johannesburg, South Africa. 2University of New England, Armidale, Australia. 3Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, United States. 4School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. 5University of New England, Armidale, Australia. 6Carolina Population Center, University of North Carolina, Chapel Hill, United States. 7MRC/Wits Rural Public Health and Health Transitions Unit, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Introduction: Young women in South Africa face a particularly high risk of HIV infection. Structural factors such as schooling, socio-economic status (SES) and financial dependence on partners contribute to this risk. Cash transfers have shown promise in reducing HIV risk in young women by addressing these factors. HPTN 068 is the first randomized trial to examine the impact of conditional cash transfers on HIV incidence among young women.

Methods: HPTN 068 is a phase III individually randomized trial to assess the impact of a conditional cash transfer on the acquisition of HIV among South Africa young women. Young women and their parent/guardian in the intervention arm received a monthly cash transfer conditional on 80% school attendance, which was verified using school attendance rosters. The intervention ran from April 2011 to March 2015. Participants enrolled in the study were aged 13–20, in high school, not married or pregnant and resident in the Agincourt Health and Demographic Surveillance System (AHDSS) site in rural Mpumalanga Province. Participants were seen at baseline, then annually for up to three follow-up visits, where HIV and HSV-2 testing was conducted and an interview was completed using Audio Computer-Assisted Self Interviewing (ACASI). The interview assessed sexual behaviour including partner-specific details, schooling, mental health, SES and gender power dynamics. Participants were tested for HIV infection using two HIV rapid tests with Western blot confirmation. Stored samples from all participants at all visits were also tested at the HPTN Laboratory Center using assays that included an HIV antigen/antibody test and a qualitative HIV RNA test. To compare treatment arms, time to first HIV detection was analysed using a Cox proportional hazards model.

Results: We will present the impact of the conditional cash transfer on HIV incidence, unprotected sex, pregnancy, age difference with partners, number of sex partners, transactional sex, age of sexual debut and school attendance.

Conclusions: Cash transfers are increasingly being included as part of the package of prevention services that should be offered to young women to reduce HIV risk in sub-Saharan Africa. The evidence from this RCT will have important implications for HIV prevention policy and practice.

http://dx.doi.org/10.7448/IAS.18.5.20548
TUAC0203

Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana

Faith Henderson1; Allan Taylor1; Lovemore Chimwanda2; Tiffany Williams2,3; Craig Borkowf1; Michael Kasonde4; Rodney Mutanhaurwa5; Onkabetse Matlhaba6; Kathy Hageman1 and Paula Casillas1

Abstract TUAC0202 - Figure 1. Adherence, Risk Behavior and STI incidence Over Time in the Demo Project.

(MSM) and transgender women (TGW). Little is known about adherence, sexual behaviour and HIV/STI incidence among those who elect to take PrEP in real-world settings.

Methods: The Demo Project is the first US multi-site open-label study assessing PrEP delivery in municipal STD (San Francisco, Miami) and community-health (Washington, DC) clinics. HIV-uninfected MSM/TGW were offered 48 weeks of PrEP. Tenofovir-diphosphates levels were measured in dried blood spots (DBS) in a random sample of participants (pts). Correlates of adherence were assessed using multivariable logistic regression. Sexual behaviours, PrEP discontinuations and HIV/STI incidence are described.

Results: From 9/2012 to 1/2014, 557 pts enrolled, with 83% retained for the final visit (468.8 person-years (py)). Longitudinal drug levels, sexual behaviour and STI incidence are shown (Figure). Among 147 pts with DBS testing, 65% had drug levels consistent with taking ≥4 doses/week at all visits, 3% always had DBS levels <2 doses/week, and 32% had an inconsistent pattern. Black pts, being self-referred to the PrEP programme and having a greater number of condomless anal sex (AS) partners were independently associated with DBS ≥4 doses/week (all p < 0.05). Median AS partners in the past three months declined from baseline to week 48 (5 to 4, p < 0.0008). Two-thirds reported condomless receptive AS (CRAS) at baseline, which remained stable during follow-up (p = 0.96). Twenty pts chose to stop PrEP due to low self-perceived HIV risk, however 65% of these pts reported CRAS in the prior three to six months. Three participants were acutely infected at enrolment, and one seroconverted during follow-up (HIV incidence 0.21/100 py). This subject had DBS <2 doses/week at all prior visits. Overall, 27.5% had early syphilis, GC or CT at screening, and 38% had ≥1 STI during follow-up; STI incidence was high (47.9, 42.8 and 12.6/100 py for CT, GC and syphilis) but did not increase over time (p = 0.87).

Conclusions: PrEP adherence was high and HIV incidence was low in this cohort at ongoing high sexual risk for HIV. STIs were common during PrEP use, highlighting the importance of screening and treatment. Strategies for counselling on appropriate PrEP discontinuation are warranted.

http://dx.doi.org/10.7448/IAS.18.5.20371
TUAC0204LB
An HIV pre-exposure prophylaxis demonstration project and safety study for young men who have sex with men in the United States (ATN 110)
Sybil Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Sierry; Nancy Liu; Brandy Rutledge; Jennifer Brothers; Jim Rooney; Craig M Wilson and Adolescent Medicine Trials Network for HIV/AIDS Interventions (AT)
1Psychiatry, Stroger Hospital of Cook County, Chicago, United States. 2New York University Medical Center, New York, United States. 3University of California Los Angeles, Los Angeles, United States. 4NICHD/MPIDB, Bethesda, United States. 5Westat, Rockville, United States. 6Gilead Sciences, Foster City, United States. 7University of Alabama at Birmingham, Birmingham, United States. Presenting author email: shosek@cookcountyhhs.org

Introduction: Young men who have sex with men (YMSM), particularly racial/ethnic minority YMSM, are a key population for implementation of domestic pre-exposure prophylaxis (PrEP) interventions. This open-label PrEP study examined uptake and adherence to PrEP and assessed sexual risk behaviour among a diverse sample of YMSM in 12 U.S. cities.

Methods: ATN110 combined PrEP with evidence-based behavioural risk reduction interventions along with frequent sexual health and adherence promotion counselling. Eligible participants were 18- to 22-year-old HIV-uninfected MSM who reported HIV transmission risk behaviour in the past six months. Participants were recruited and screened for preliminary eligibility through venue-based outreach, community presentations and online advertising. Laboratory screening determined final eligibility. Study visits occurred at baseline, monthly through week 12, then quarterly through week 48. Dried blood spots were serially collected for the quantification of tenofovir diphosphate (TFV-DP) blood levels.

Results: Between March and September 2013, 2186 individuals were approached, 277 (13%) were preliminarily eligible and 200 were enrolled (mean age = 20.2; 54.5% Black, 26.5% Latino). Eleven (4%) had undiagnosed HIV infection at screening and two acute HIV infections were diagnosed at baseline. Diagnosis of STIs at baseline was high (22%) and remained high across visits. Most participants (98%) chose to take PrEP. Figure 1 shows TFV-DP levels. At week 4, 56% of participants had TFV-DP levels consistent with ≥4 pills/week. By week 48, 34% of participants had TFV-DP levels consistent with ≥4 pills/week, with a noticeable drop-off occurring at Week 24. Four HIV seroconversions occurred on study (3.29/100 person-years); all had TFV-DP BLQ at diagnosis. Condomless sex was reported by >80% of participants throughout the study and condomless anal sex with last partner was associated with higher TFV-DP levels.

Conclusions: ATN110 enrolled a diverse sample of YMSM vulnerable to HIV. PrEP uptake was high with the majority achieving protective drug levels during initial monthly visits. As visits decreased in frequency, so did adherence, while reported sexual risk behaviour remained constant. Given the frequency of STI diagnoses, HIV infections may have been higher without PrEP. YMSM in the U.S. may need access to PrEP in youth-friendly settings with tailored adherence support and potentially augmented visit schedules.

http://dx.doi.org/10.7448/IAS.18.5.20549

TUAC0205LB
Pre-exposure prophylaxis uptake and associated factors among MSM and TGW in the PrEP Brasil demonstration project
Brenda Hoagland; Valdilea G Veloso; Raquel B De Boni; José Valdez Madruga; Esper G Kallas; Nilo Martinez Fernandes; Ronaldo I Moreira; Albert Y Liu; Beatriz Grinsztejn and PrEP Brasil Study Team
1IPEC, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 2Fiocruz, Rio de Janeiro, Brazil. 3CRT, São Paulo, Brazil. 4USP, São Paulo, Brazil. 5Bridge HIV, San Francisco Department of Public Health, San Francisco, United States. Presenting author email: beatriz.grinsztejn@gmail.com

Introduction: In Brazil, men who have sex with men (MSM) and transgender women (TGW) are the populations most heavily affected by the AIDS epidemic. Although the WHO recommends pre-exposure prophylaxis (PrEP) for these populations, the feasibility and interest...
Abstract TUAC0205LB  Table 1. Study population characteristics and PrEP uptake

|                              | Approached (1) | Potentially Eligible (2) | Included (3) | Declined (4) | Percent of PrEP uptake* p-value** |
|------------------------------|----------------|-------------------------|--------------|--------------|----------------------------------|
| Overall                      | 986            | 798                     | 409          | 365          | 51.25                            |
| Site location (5)            |                |                         |              |              |                                  |
| FIOCRUZ                      | 622            | 455                     | 175          | 282          | 57.22                            |
| CRT-SP                       | 225            | 216                     | 135          | 57           | 62.5                             |
| USP-SP                       | 139            | 127                     | 99           | 26           | 77.95                            |
| Age years                    |                |                         |              |              |                                  |
| 18–25                        | 335            | 266                     | 127          | 128          | 47.74                            |
| 26–35                        | 435            | 358                     | 189          | 165          | 52.79                            |
| >45                          | 56             | 50                      | 31           | 15           | 62                              |
| Sexual identity              |                |                         |              |              |                                  |
| Homosexual                   | 823            | 658                     | 343          | 293          | 52.13                            |
| Bisexual                     | 99             | 87                      | 36           | 47           | 41.38                            |
| Tranagender woman            | 44             | 36                      | 24           | 14           | 66.67                            |
| Other                        | 19             | 16                      | 6            | 10           | 37.5                             |
| Color/Race                   |                |                         |              |              |                                  |
| White                        | 455            | 399                     | 219          | 161          | 54.89                            |
| Non-white                    | 531            | 399                     | 190          | 204          | 47.62                            |
| Schooling years              |                |                         |              |              |                                  |
| <12                          | 89             | 66                      | 26           | 42           | 39.39                            |
| >12                          | 897            | 732                     | 383          | 323          | 52.32                            |
| Steady partner               |                |                         |              |              |                                  |
| Yes                          | 472            | 385                     | 223          | 149          | 57.92                            |
| No                           | 514            | 413                     | 186          | 216          | 45.04                            |
| Perceived likelihood of getting HIV in the next year |                |                         |              |              |                                  |
| 0–25%                        | 569            | 437                     | 189          | 237          | 43.25                            |
| 50–100%                      | 417            | 361                     | 220          | 128          | 60.94                            |
| Previous HIV test (last 12 months) |            |                         |              |              |                                  |
| Yes                          | 657            | 575                     | 334          | 219          | 58.09                            |
| No                           | 329            | 223                     | 75           | 146          | 33.63                            |
| Prior PrEP awareness         |                |                         |              |              |                                  |
| Yes                          | 594            | 498                     | 296          | 183          | 59.44                            |
| No                           | 389            | 297                     | 112          | 180          | 37.71                            |
| # Male condomless anal sex partners (last 12 months) |            |                         |              |              |                                  |
| <2                           | 512            | 370                     | 143          | 222          | 38.65                            |
| 2 or more                    | 474            | 428                     | 266          | 143          | 62.15                            |
| Anal sex with HIV-positive partners (12 months) |            |                         |              |              |                                  |
| Yes                          | 346            | 324                     | 208          | 104          | 64.2                             |
| No                           | 211            | 87                      | 41           | 44           | 47.13                            |
| I do not know                | 429            | 387                     | 160          | 217          | 41.34                            |
| STD diagnosis (12 months)    |                |                         |              |              |                                  |
| Yes                          | 138            | 128                     | 79           | 39           | 61.72                            |
| No                           | 848            | 670                     | 330          | 326          | 49.25                            |

(1) All individuals approached for pre-screening who were age 18 or older, male at birth, lived in the State, self-reported HIV negative status and reported having at least one male sexual partner in last 12 months.

(2) Includes all individuals approached at pre-screening (1) who: a) reported 2 or more male condomless anal sex partners OR anal sex with HIV positive partner OR STD diagnosis in last 12 months; and b) had a negative HIV test results.

(3) Individuals who enrolled the study.

(4) Decline represents the sum of refusals in all steps. Individuals who agreed to participate but did not show up at the screen or enrollment visit were considered as declining.

(5) FIOCRUZ-RJ: Fundação Oswaldo Cruz, located in Rio de Janeiro; CRT-SP: Centro de Referência e Treinamento em DST e AIDS, located in São Paulo; USP-SP: Universidade de São Paulo.

*% uptake- # Included/# Potentially eligible at pre-screening.

**chi-square for bivariate analyses.
in this prevention strategy in real-world settings in low- and middle-income countries are unknown. This study aims to describe PrEP uptake and associated factors in Brazil.

**Methods:** PrEP Brasil is a demonstration project to assess the feasibility of implementing PrEP provided at no cost to high risk MSM and TGW within the Brazilian public health system. The project was advertised through social and other media. Participants were assessed for PrEP eligibility at FIOCRUZ, CRT-Sp and USP. At USP, 100% participants were self-referred, while at FIOCRUZ and CRT, they were either self-referred or assessed for participation during HIV-testing or post-exposure prophylaxis provision. Predictors of PrEP uptake were assessed using a Poisson regression model.

**Results:** Of 986 MSM/TGW approached between April 2014 and April 2015, 798 were potentially eligible and 409 were enrolled. PrEP uptake was 51.25%. Median age at enrolment was 29 years (IQR 25–35); 93.5% had ≥12 years of education; 83.9%, 8.8% and 5.9% identified themselves as homosexual, bisexual or TGW, respectively (Table); syphilis prevalence, rectal Chlamydia and Gonorrhoea detection were 21.3%, 8.2% and 4.7%, respectively. In multivariate analysis, factors associated with PrEP uptake were: recruitment at CRT-Sp (aRR 1.27; 95% CI 0.99 – 1.62) or USP-Sp (aRR 1.72; 95% CI 1.33 – 2.24) versus FIOCRUZ; having a steady partner (aRR 1.45, 95% CI 1.18 – 1.78); having an HIV-test within the last 12 months (aRR 1.33, 95% CI 1.01 – 1.74); prior PrEP awareness (aRR 1.27, 95% CI 1.0 – 1.59) and having ≥ 2 male condomless sex partners within the last 12 months (aRR 1.65, 95% CI 1.32 – 2.05).

**Conclusions:** This is the first PrEP demonstration project for MSM and TGW in a middle-income country. Overall, PrEP uptake was high. The higher uptake among those at higher risk and with an existing awareness of PrEP emphasizes the importance of establishing strategies to improve HIV risk perception and PrEP awareness in the MSM and TGW communities in Brazil.

http://dx.doi.org/10.7448/IAS.18.5.20550

**TUAC0206LB**

**Pharmacokinetics and pharmacodynamics of tenofovir reduced-glycerin 1% gel in the rectal and vaginal compartments in women: a cross-sectional study with directly observed dosing**

Gonasagrie Nair1; Jessica E Justman2; Jeanna Piper3; Mark Marzinke4; Craig Hendrix4; James Dai5; Jason Pan5; Beth Galaska6; Lisa Levy7; Jill Shwartz8; Ian McGowan9 and Charlene Dezutti6

1Centre for AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa. 2ICAP at Columbia University, Columbia University, New York, United States. 3NIAID/DAIDS, Bethesda, United States. 4Johns Hopkins University, Baltimore, United States. 5HCRU-C-SHARP, Seattle, United States. 6Microbicides Trial Network, Pittsburgh, United States. 7FHI 360, Washington, United States. 8CONRAD, Arlington, United States. 9Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, United States.

Presenting author email: jj2158@columbia.edu

**Introduction:** Tenofovir (TFV) gel, when used consistently as a vaginal microbicide, prevents HIV infection. As unprotected anal intercourse is prevalent amongst heterosexual women, data on TFV concentrations and anti-HIV activity in the rectal compartment following vaginal application, and vice versa, are needed.

**Methods:** MTN-014 is a phase 1 cross-over, randomized trial comparing the pharmacokinetics of TFV reduced-glycerin (RG) 1% gel following 14 days each of daily rectal versus vaginal directly observed dosing (DOD), with a six-week washout period in between each phase. Vaginal and rectal tissue and fluid and blood samples were collected 24 hours after the end of each phase and analyzed for TFV and TFV-diphosphate (TFV-DP) concentrations. Vaginal and rectal fluids were tested for HIV inhibition using a TZM-bl assay.

**Results:** Fourteen HIV-uninfected women, mean age 34 years, were enrolled at the Bronx Prevention Center in New York City and 13 completed all study procedures. Of the 392 expected doses, 91% were DOD, two (0.5%) were missed and the remaining doses were reported as used. Mean plasma TFV concentrations were similar after 14 days of either dosing route (Table). Rectal concentrations of TFV and TFV-DP were detectable after vaginal dosing in only 1 of 13 and 2 of 13 tissue samples, respectively, while vaginal concentrations of TFV and TFV-DP were detectable after rectal dosing in 6 of 14 and 3 of 14 samples, respectively. Rectal and vaginal dosing phases each resulted in markedly lower levels of tissue TFV and TFV-DP concentrations in the opposite compartment, with at least 1.7 log 10 differences between mean concentrations in the two compartments.

After vaginal dosing, inhibition of HIV increased by 42% in vaginal fluid, but no change was found in rectal fluid. No change in HIV inhibition in vaginal or rectal fluid was noted after rectal dosing.

**Conclusions:** Cross-compartmental concentrations of TFV and TFV-DP were low in this study comparing rectal and vaginal DOD TFV RG 1% gel, and pharmacodynamics activity was noted only in the vaginal fluid compartment. Whether these low tissue concentrations are protective remains to be determined.

http://dx.doi.org/10.7448/IAS.18.5.20551

**Abstract TUAC0206LB**

**Table 1. Compartmental pharmacokinetics of tenofovir gel**

| Compartment | Vaginal use phase | Rectal use phase |
|-------------|------------------|-----------------|
|             | Mean (standard deviation) | number of samples with detectable drug | Median, IQR | Mean (standard deviation) | number of samples with detectable drug | Median, IQR |
| TFV (ng/mL) | 0.99 (1.27)       | 10/14 (71%)     | 0.58 (0, 1.31) | 1.19 (1.74)       | 10/14 (71%)     | 0.82 (0, 1.22) |
| Vaginal tissue | 45.8 (72.6)       | 12/13 (92%)     | 8.5 (1.0, 44.8) | 0.09 (0.12)       | 6/14 (43%)      | 0 (0, 0.16)   |
| TFV-DP (fmol/mg) | 1945 (4105)      | 12/13 (92%)     | 166 (37, 2377) | 13 (30)          | 3/14 (21%)      | 0 (0, 0)      |
| Rectal tissue | 0.02 (0.06)       | 1/13 (8%)       | 0 (0, 0)       | 12.2 (27.1)       | 12/14 (86%)     | 3.0 (0.7, 10.9) |
| TFV (ng/mL) | 10.48 (25.81)     | 2/13 (15%)      | 0 (0, 0)       | 710 (1306)        | 10/14 (71%)     | 196 (0, 550)  |
| TFV-DP (fmol/mg) | 10.48 (25.81)     | 2/13 (15%)      | 0 (0, 0)       | 710 (1306)        | 10/14 (71%)     | 196 (0, 550)  |
Results

The First affiliated hospital of China Medical University. Simplex virus-2 (HSV-2) were also tested. The study process and established HIV infections were determined by Western Blot and BED HIV-1 capture enzyme immunoassay. Syphilis and herpes

Methods

This progressive epidemic of new infections called for a multi-centric, national-level information regarding the burden and predictors of recent upsurge of new HIV infections among men who have sex with men (MSM) is a major concern in China. Paucity of interventions specifically targeting high-risk MSM especially

Introduction

Worsen epidemic of early HIV infection among men who have sex with men in China: implication for real time action

Methods

Mixed methods were used to recruit MSM (engaged in sex with men (oral and/or anal) within the last one year, aged 18 years or older and agreed to provide written informed consent) from seven cities (Shanghai, Nanjing, Changsha, Zhengzhou, Jinan, Shenyang and Kunming) in different regions of China between 2012 and 2013. Early and established HIV infections were determined by Western Blot and BED HIV-1 capture enzyme immunosassay. Syphilis and herpes simplex virus-2 (HSV-2) were also tested. The study process and content were approved (No. 2011[36]) by the Ethics Committee of The First affiliated hospital of China Medical University.

Results

A total of 4496 eligible MSM were recruited. The majority was aged ≤35 years (77.5%), migrants (60.3%), never married (69.8%) and played receptive role in anal sex (70.5%). The HIV prevalence was 9.9% and 41.9% were recently infected, with HIV incidence of 8.9/100 person-years. The prevalence of HSV-2 and syphilis were 12.5 and 8.5%, respectively. Early HIV infection was associated with having multiple male partners (aOR = 1.4, 95% CI 1.1–1.9), recreational drug use (aOR = 2.2, 95% CI 1.6–3.0), anal bleeding (aOR = 2.1, 95% CI 1.4–3.0), circumcision experience (aOR = 2.0, 95% CI 1.3–3.1), syphilis infection (aOR = 2.8, 95% CI 1.9–4.3) and HSV-2 infection (aOR = 2.3, 95% CI 1.5–3.3).

Conclusions: HIV epidemic among Chinese MSM was worsening with an alarming number of recently infected HIV patients along with high burden of STIs. High rate of early HIV infection is potentially resulting in progressive deterioration of the overall HIV epidemic among MSM in China. Interventions specifically targeting high-risk MSM especially those having high-risk behaviours (especially multiple partners and recreational drug use), syphilis or HSV-2 infection and anal bleeding were urgently required for efficient control of HIV among MSM in China.

http://dx.doi.org/10.7448/IAS.18.5.20373

TUAC0303

Dramatic declines in lifetime HIV risk and persistence of racial disparities among men who have sex with men in King County, Washington, USA

Galant Chan1; Amy Bennett2; Susan Buskin2,3; Julia Dombrowski1,2 and Matthew Golden1,2

Introduction: In the United States, HIV disproportionately affects men who have sex with men (MSM), who account for >60% of new cases. Although recent data suggest HIV incidence is declining nationally, rates in MSM are stable, and the proportion of cases occurring in black MSM is increasing. Because sexual mixing is largely age-assortative, using life tables to estimate risk within birth cohorts may be useful in assessing and anticipating trends in the population’s risk.
Methods: We constructed life tables for the period 1982–2012 to estimate the cumulative risk of HIV diagnosis among MSM born 1940–1994 in King County. We used U.S. Census data to define the size of the white and black male populations of King County, Washington, national and local survey data to estimate the proportion of men who are MSM, and local surveillance data to define the number of HIV diagnoses in MSM each year.

Results: We estimated that 6% of the local male population was MSM. Age-specific risk of HIV diagnosis increased in birth cohorts from the 1940s until the mid-1960s and thereafter declined, plateauing among cohorts born after the mid-1970s (Figure 1). This trend occurred in both white and black MSM. In the peak risk cohort, among MSM born 1960–64, >40% of white and >60% of black MSM had been diagnosed with HIV by age 50. A dramatic decline in this risk was evident when comparing the percentage of MSM diagnosed with HIV in different birth cohorts. Among white and black MSM born 1960–1964, the cumulative risk of HIV diagnosis by age 35 was 29 and 42%, respectively, while among MSM born 1975–1979, this risk decreased to 9 and 15%, respectively. However, as absolute risk of HIV diagnosis decreased overall in younger cohorts, relative differences between white and black MSM appeared to increase. Throughout the period and across birth cohorts, cumulative HIV risk was 18 to 84% higher among black versus white MSM.

Conclusions: Comparing birth cohorts, cumulative HIV risk among MSM in King County has declined approximately 65% in those born after the mid-1960s, although racial disparities persist. Our findings highlight the importance of evaluating HIV risk within birth cohorts and demonstrate remarkable local progress in HIV prevention.

http://dx.doi.org/10.7448/IAS.18.5.20375

TUAC0304

Ethical considerations for inclusion of men who have sex with men under the age of 18 in epidemiological research: evidence from six sub-Saharan African countries

Ashley Grosso1; Shauna Stahlman1; Tampose Mothopeng2; Noah Taruberekera3; Gautier Ouedraogo4; Odette Ky-Zerbo5;
Abstract TUAC0304  

Table 1. Proportion of MSM sampled who had anal sex <18 yr

| Country                  | Percentage (n/N) of MSM study participants who first had anal sex with a man when they were under the age of 18 | Percentage of study participants under 18 years old |
|--------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Bobo-Dioulasso, Burkina Faso | 51.21% (169/330)                                                                                   | N/A                                               |
| Ouagadougou, Burkina Faso | 51.31% (176/343)                                                                                   | N/A                                               |
| Kara, Togo                | 41.95% (138/329)                                                                                   | N/A                                               |
| Lome, Togo                | 63.84% (226/354)                                                                                   | N/A                                               |
| Gambia                   | 43.69% (90/206)                                                                                     | 12.14% (25/206)                                   |
| Maputsoe, Lesotho         | 40.95% (129/315)                                                                                   | N/A                                               |
| Maseru, Lesotho           | 35.85% (76/212)                                                                                     | N/A                                               |
| Malawi                   | 16.32% (55/337)                                                                                     | N/A                                               |
| Swaziland                | 14.46% (47/325)                                                                                     | N/A                                               |

Vincent Pitche6; Simplice Anato7; Bhekie Sithole8; Xollie Mabuza5; Nuha Ceesay25; Daouda Diouf11; Gift Trapence12; Eric Umar13 and Stefan Baral1

1Center for Public Health and Human Rights, Johns Hopkins University, Baltimore, United States. 2Matrix Support Group, Maseru, Lesotho. 3Population Services International, Johannesburg, South Africa. 4Instituto de Recherche en Sciences de la Sante, Ouagadougou, Burkina Faso. 5Programme d'Appui au Monde Associatif et Communautaire, Ouagadougou, Burkina Faso. 6Conseil National de lutte contre le SIDA du Togo, Lomé, Togo. 7Arc en Ciel, Lomé, Togo. 8Department of Health Sciences, University of Stellenbosch, Stellenbosch, South Africa. 9Rock of Hope, Manzini, Swaziland. 10UNAIDS, Banjul, Gambia. 11Enda Sante, Dakar, Senegal. 12Center for the Development of People, Blantyre, Malawi. 13Malawi College of Medicine, Blantyre, Malawi.

Presenting author email: grossoas@gmail.com

Introduction: In many settings, laws or institutional review board policies require parental permission for youth <18 years to participate in research. Individual and social risk factors for HIV acquisition often occur before age 18. Youth may be unwilling to participate in HIV epidemiological research requiring parental consent due to the sensitive nature of risk factors such as sexual behaviours and experiences of violence. Young men who have sex with men (MSM) are at especially high risk for HIV acquisition and are often unwilling or unable to disclose their sexual orientation or practices to their parents. In sub-Saharan Africa, where HIV prevalence among MSM is high and sex between men is criminalized or highly stigmatized in many countries, epidemiologic research on this vulnerable population of young MSM is particularly relevant and sparse. One strategy for assessing the potential size of the population of young (i.e. <18) MSM is to ask adult MSM retrospective questions about the age at which they first had anal sex with a man.

Methods: MSM aged 18 or older were recruited using respondent-driven sampling in Burkina Faso, Togo, Lesotho, Malawi and Swaziland. MSM aged 15 and above were recruited using snowball sampling in Togo. Participants completed a survey that included a question asking how old they were when they first had anal sex with another man. This variable was dichotomized and tabulated to assess the prevalence of anal sex under the age of 18.

Results: Across settings, 40.20% (1105/2751) of MSM had anal sex with a man before the age of 18. The highest percentage was in Lomé, Togo (63.84%), while the smallest percentage was in Swaziland (14.46%). MSM under the age of 18 represented 12.14% of the study sample in The Gambia.

Conclusions: A substantial proportion of MSM participants had anal sex with a man under the age of 18. Further research on this group, including a waiver of requirements for parental consent for participation, is warranted. Given the relatively small proportion of study participants under the age of 18 in a setting where this was feasible, additional outreach strategies such as web-based recruitment may be necessary.

http://dx.doi.org/10.7448/IAS.18.5.20376

TUAC0305

Nuanced seroadaptive behaviours among Seattle men who have sex with men: sexual decision-making based on ART use/viral load and recency of partner HIV testing

Christine M Khosropour2; David A Katz2,3; Julia C Dombrowski2,3 and Matthew R Golden2,3

1Department of Epidemiology, University of Washington, Seattle, United States. 2Department of Medicine, University of Washington, Seattle, United States. 3HIV/STD Program, Public Health – Seattle & King County, Seattle, United States.

Presenting author email: ckhosro@uw.edu

Introduction: Seroadaptive behaviours among men who have sex with men (MSM) may protect against HIV. Anecdotally, some MSM incorporate partners’ antiretroviral therapy (ART)/viral load (VL) or HIV testing frequency into sexual decision-making. The frequency and effect of these strategies is unknown.

Methods: HIV-negative MSM attending an STD clinic in Seattle, WA from March–December 2014 were enrolled in a study of seroadaptive behaviours. Men completed a computer-based survey on behaviours in the past 12 months. HIV testing was performed per clinic protocol. Among HIV-negative men with HIV-negative partners, we examined if the timing of the partner’s last HIV test was associated with condomless anal intercourse (CAI). Of those with HIV-positive partners, we asked (in aggregate) if respondents’ decision to have sex or use condoms was based on partner ART use or VL (i.e. ART/VL serosorting). We compared proportions with chi-square tests.

Results: We enrolled 988 (58%) of 1718 eligible HIV-negative MSM. The mean age was 33 and 62% were white, non-Hispanic. Most (69%) had CAI with HIV-negative partners, 18% had CAI with HIV-positive partners and 22% reported no CAI. The majority (86%) asked HIV-negative partners when the partner last tested negative. CAI was more common among men whose most recent partner tested ≤3 months ago compared to men whose partner tested >3 months ago.
or the partner did not know when he last tested (48% vs. 40%, \( p = 0.02 \)). Of 222 men with HIV-positive partners, 60 and 64% decided whether to have sex/use condoms based on their partners’ ART use or VL, respectively. CAI with an HIV-positive partner was more common among men who reported ART/VL serosorting compared to those who did not (79% vs. 57%, \( p = 0.03 \)), but testing newly positive for HIV was less common among men who reported ART/VL serosorting compared to men who did not (1/120 (1%) vs. 2/23 (9%).

**Conclusions:** Among Seattle MSM, nuanced seroadaptive behaviours such as ART/VL serosorting and using the recency of a partner’s HIV test to inform sexual decision-making are common. The high prevalence of these behaviours suggests they could impact HIV incidence rates, but the individual- and population-level effects of these behaviours are uncertain.

http://dx.doi.org/10.7448/IAS.18.5.20377

**TUAC0306**

**Viral load awareness and risk behaviour in male serodiscordant couples in Australia, Brazil and Thailand**

**Benjamin Robert Bavinton** 1; **Fengyi Jin** 3; **Garrett Prestage** 2, 3; **Iryna Zablotska** 3; **Beatriz Grinsztejn** 4; **Nittaya Phanuphak** 4; **Ruth Khallil Friedman** 5; **Andrew Edwin Grulich** 1 and **Opposites Attract Study Group**

1The Kirby Institute, University of New South Wales, Kensington, Australia. 2Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia. 3Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 4Thai Red Cross AIDS Research Centre, Bangkok, Thailand.

**Introduction:** There are very limited data from homosexual male serodiscordant couples (HM-SDC) on the impact of antiretroviral therapy (ART) and viral load (VL) on HIV transmission risk and on risk behaviours within such couples. To date, no studies have investigated the issue in middle income countries.

**Methods:** Opposites Attract is an ongoing multisite cohort study of HM-SDC in Australia, Brazil and Thailand. HIV-positive partners (HPP) had VL tested; HIV-negative partners (HNP) had HIV antibody tests and reported sexual behaviour and perception of the HPP’s most recent VL test. Undetectable VL (UVL) was defined as <200 copies/mL. We compared couples from the three countries; baseline differences were examined with bivariate logistic regression.

**Results:** By January 2015, 242 couples were enrolled (Australia = 137, Brazil = 53, Thailand = 52). The majority of HPP were taking ART (80.2%); this was lower in Thailand than in Australia and Brazil (p < 0.001), accompanied by higher proportions with UVL in Australia (88.2%) and Brazil (85.0%) than in Thailand (69.2%, \( p = 0.008 \)). Overall, 61.2% of HNP perceived their HPP’s VL test result to be undetectable. Brazilian and Thai HNP were more likely not to know the result (17.0 and 38.5%) compared to Australians (5.1%, \( p < 0.001 \)). Australian HNP reported more sex with other partners than Brazilian (p = 0.013) but not Thai HNP (p = 0.183). Australian HNP reported more condomless anal intercourse (CAI) with outside partners compared to both Brazilians (p = 0.002) and Thais (p = 0.012). 54.6% of HNP reported CAI with study partner in the last three months. Compared to Australia (67.9%), this was lower in Brazil (45.3%, p = 0.005) and Thailand (28.9%, p < 0.001). Overall, 63.5% of HNP who perceived the HPP’s VL to be undetectable reported CAI in the last three months, compared to only 40.4% of HNP in which the HPP’s VL was perceived to be detectable/unknown (OR = 0.39, 95% CI = 0.23–0.66, \( p = 0.001 \)). While this was strongly associated amongst Australian couples (p = 0.002), there was no such association in Brazil or Thailand.

**Conclusions:** Australian HNP were more aware of their partner’s VL results. Australian HM-SDC with perceived UVL practiced more CAI, suggesting they may be acting upon beliefs that treatment-as-prevention is effective. This pattern was not seen in Brazil and Thailand.

http://dx.doi.org/10.7448/IAS.18.5.20378

**TUAC0401**

**Estimating the number of people who inject drugs in two urban areas in Mozambique using four different methods, 2014**

**Isabel Sathane** 1; **Roberta Horth** 2; **Makini Boothe** 3; **Cynthia Sema Baltazar** 4; **Peter Young** 4; **Henry Fisher** 4; **Eugenia Teodoro** 5; **Maria Lidia Gouveia** 5; **Tim Lane** 4 and **Willi Mfiearland** 2

1MARPS, I-TECH Mozambique, Maputo, Mozambique. 2Department of Public Health (SFDPH), Surveillance Prevention & Public Health Group, University of California, San Francisco, United States. 3National Institute of Health, Ministry of Health, Maputo, Mozambique. 4Centers for Disease Control and Prevention, Maputo, Mozambique. 5Department of Mental Health, Ministry of Health, Maputo, Mozambique.

**Introduction:** There are few [VR1] data on HIV prevalence and the number of people who inject drugs (PWID) in Mozambique. As part of the Integrated Biological and Behavioral Surveillance (IBBS) Survey implemented in 2014, we conducted the first population size estimation among PWID in two urban areas, Maputo (n = 353) and Nampula (n = 139).

**Methods:** Given the lack of a gold standard, we synthesized four independent methods to estimate the number of PWID: unique object multiplier, wisdom of the crowd, sequential sampling and literature review. The unique object estimate is calculated as the number of objects distributed to PWID pre-survey, divided by the proportion of survey participants who reported receiving the objects. The wisdom

|                                | Total (n = 242) | Australia (n = 137) | Brazil (n = 53) | Thailand (n = 52) |
|--------------------------------|-----------------|---------------------|-----------------|-------------------|
| HPP: taking ART                | 194 (80.2)      | 124 (90.5)          | 45 (84.9)       | 25 (48.1)         |
| HPP: viral load <200 copies/mL (available for 227 HPP) | 189 (83.3) | 119 (88.2) | 34 (85.0) | 36 (69.2) |
| HPP: Adherence to ART >90% (of those taking ART) | 170 (91.9) | 107 (92.2) | 40 (88.9) | 23 (95.8) |
| HNP: perceived VL of HPP      |                 |                     |                 |                   |
| Undetectable VL               | 148 (61.2)      | 107 (78.1)          | 34 (64.2)       | 7 (13.5)          |
| Detectable VL                 | 58 (24.0)       | 23 (16.8)           | 10 (18.9)       | 25 (48.1)         |
| Don’t know VL                 | 36 (14.9)       | 7 (5.1)             | 9 (17.0)        | 20 (38.5)         |
| HNP: any CAI with outside partners, last three months | 45 (18.6) | 38 (27.7) | 2 (3.8) | 5 (9.6) |
| HNP: any CAI with study partner, last three months | 132 (54.6) | 93 (67.9) | 24 (45.3) | 15 (28.9) |
of the crowd method polls the participants on how many people they believe inject drugs in each city (responses equal to the personal network size were excluded). The sequential sampling method applies a Bayesian approach to the self-reported PWID network size of each participant to infer the size of the hidden population. In the literature review, estimates were based on proportions of adults who are PWID from other African locations applied to the 2014 census projections for Maputo and Nampula. A consensus meeting among stakeholders agreed that the median of all four methods was the best estimate of population size of PWID in each city and also agreed to the lowest and highest estimates as “acceptable bounds.”

Results: HIV prevalence was 50.3% (95% confidence interval (CI): 40.7–58.9) and 36.8% (CI: 24.3–49.3) in Maputo and Nampula, respectively. The numbers of PWID were estimated at 1445 (0.19% of adults) (acceptable bounds: 1281 (0.17%) to 3524 (0.46%)) and 465 (0.14%) (acceptable bounds: 354 (0.10%) to 3921 (1.16%)). Using these population size estimates, there are 727 and 171 PWID infected with HIV and in need of care and/or treatment services in Maputo and Nampula, respectively.

Conclusions: Our results highlight the feasibility of using the median of multiple methods to estimate the size of PWID in two urban areas in Mozambique. Given the limited population size and high rates of infection, harm-reduction, prevention interventions and HIV care and treatment services should be practical and affordable in this population.

http://dx.doi.org/10.7448/IAS.18.5.20379

Efficacy of a network intervention in reducing HIV incidence among people who inject drugs in Ukraine: preliminary results from a clustered randomized trial

Robert Booth1; Jonathan Davis1; Sergiy Dvoryak2; John Brewster3; Steffanie Strathdee3 and Carl Latkin4

Abstract TUAC0401 – Figure 1. (a) Population size estimation using four independent methods, Maputo City. (b) Population size estimation using four independent methods, Nampula.
TUAC0403
Factors associated with initiation of antiretroviral therapy among HIV-infected people who use illicit drugs

Brenden Joseph1 and M. J Millroy1,2

1British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2Faculty of Medicine, University of British Columbia, Vancouver, Canada.

Introduction: Treatment-as-prevention-based efforts to reduce HIV/AIDS-associated morbidity, mortality and HIV viral transmission among people who use illicit drugs (PWUD) rely on prompt engagement in antiretroviral therapy (ART). However, the longitudinal factors that promote or block initiation of ART among PWUD are not well described. Thus, we sought to identify factors associated with time from seroconversion to ART initiation among PWUD.

Methods: Using data from two observational prospective cohorts of illicit drug users linked to comprehensive ART dispensation records, we included HIV-seronegative individuals at baseline who seroconverted during follow-up. We fit multivariable Cox proportional hazards models adjusted for a time-updated measure of clinical eligibility for ART to identify factors independently associated with time to treatment initiation following seroconversion.

Results: We included 133 individuals of whom 98 (73.7%) initiated ART during follow-up at a rate of 17.6 per 100 person-years. In a multivariable model adjusted for clinical eligibility, living in the HIV epicentre (adjusted hazard ratio (AHR) = 1.62, 95% confidence interval (95% CI) = 1.01–2.58), methadone maintenance therapy (MMT) (AHR = 2.37, 95% CI = 1.56–3.60) and a later year of interview (AHR = 1.07, 95% CI = 1.02–1.13) were associated with shorter time to ART initiation. Barriers to ART initiation were illicit income generation (AHR = 0.51, 95% CI = 0.32–0.79) and incarceration (AHR = 0.52, 95% CI = 0.28–0.97).

Conclusions: In this sample of community-recruited HIV-positive PWUD with well-defined dates of seroconversion, we found that illicit income generation and incarceration were barriers to ART initiation while MMT and living in the HIV epicentre promoted ART initiation independent of clinical eligibility. Current efforts to scale-up HIV treatment among PWUD should consider these factors in order to reduce HIV/AIDS-associated morbidity, mortality and HIV viral transmission.

http://dx.doi.org/10.10448/IAS.18.5.20380

TUAC0404
Periodic HIV testing and immediate antiretroviral therapy among people who inject drugs in Vietnam

Huu Hai Nguyen1; Duc Duong Bui2; Thi Thanh Thu Dinh2; Minh Sang Nguyen3; Hong Tran Tran3; Le Hai Nguyen3; Thi Thuy Van Nguyen3; Quoc Dat Vu3; Ba Nhan Do3; Al Kim Anh Le3; Ba Can Nguyen3; Amithib Suthar3; Ying-Ru Lo4; Hong Thang Pham3; Minh Giang Le4; Hoang Long Nguyen4 and Masaya Kato1

1Department of Psychiatry, University of Colorado Denver, Denver, United States. 2Ukrainian Institute on Public Policy, Kiev, Ukraine. 3University of California San Diego, San Diego, United States. 4Johns Hopkins University, Baltimore, United States. Presenting author email: robert.boothe@ucdenver.edu

Introduction: HIV incidence among people who inject drugs (PWID) in Ukraine is among the highest in the world. We assessed the efficacy of two interventions, a network-based peer intervention combined with HIV testing and counselling (T/C combined; experimental condition, N = 614) versus HIV testing and counselling alone (T/C alone; control condition, N = 592), in reducing HIV incidence among PWID.

Methods: Between 2010 and 2014, 1205 HIV-seronegative PWID were recruited from street settings in Odessa, Donetsk and Nikolaev. We used a clustered randomized design that consisted of 611 networks and included: peer-leaders; first wave network members; and second wave network members. Participants were randomly assigned to interventions in groups of 16 and interviewed at baseline, 6 and 12 months. Interviewers and HIV tester/counsellors were not blinded to intervention. Cox regression was used to compare HIV incidence between groups, incorporating GEE to account for clustering.

Results: Preliminary results suggest that mean age and duration of injection was 31.8 and 11.7 years, respectively; 75% were male. In the past 30 days, 43% injected daily, 46% injected always with others, 78% had ≥1 sex partner. HIV incidence was 19.0 per 100 person-years (py) in the experimental condition compared to 31.8 per 100 py in the control condition (p < 0.001). PWID in the experimental condition had a 39% reduced hazard for HIV seroconversion versus the control group (p < 0.001). With each year increase in age, the hazard increased by 5% (p < 0.001), and with each injection episode in the past 30 days, the hazard increased by 0.6% (p = 0.02). Those who were sexually active in the last 30 days had a 26% reduced hazard (p = 0.03).

Conclusions: The combined network-based peer intervention and was more efficacious in reducing HIV incidence among PWID in Ukraine than T/C alone.

TUAC0404
Periodic HIV testing and immediate antiretroviral therapy among people who inject drugs in Vietnam

Huu Hai Nguyen1; Duc Duong Bui2; Thi Thanh Thu Dinh2; Minh Sang Nguyen3; Hong Tran Tran3; Le Hai Nguyen3; Thi Thuy Van Nguyen3; Quoc Dat Vu3; Ba Nhan Do3; Al Kim Anh Le3; Ba Can Nguyen3; Amithib Suthar3; Ying-Ru Lo4; Hong Thang Pham3; Minh Giang Le4; Hoang Long Nguyen4 and Masaya Kato1

1Department of Psychiatry, University of Colorado Denver, Denver, United States. 2Ukrainian Institute on Public Policy, Kiev, Ukraine. 3University of California San Diego, San Diego, United States. 4Johns Hopkins University, Baltimore, United States. Presenting author email: robert.boothe@ucdenver.edu

Introduction: HIV incidence among people who inject drugs (PWID) in Ukraine is among the highest in the world. We assessed the efficacy of two interventions, a network-based peer intervention combined with HIV testing and counselling (T/C combined; experimental condition, N = 614) versus HIV testing and counselling alone (T/C alone; control condition, N = 592), in reducing HIV incidence among PWID.

Methods: Between 2010 and 2014, 1205 HIV-seronegative PWID were recruited from street settings in Odessa, Donetsk and Nikolaev. We used a clustered randomized design that consisted of 611 networks and included: peer-leaders; first wave network members; and second wave network members. Participants were randomly assigned to interventions in groups of 16 and interviewed at baseline, 6 and 12 months. Interviewers and HIV tester/counsellors were not blinded to intervention. Cox regression was used to compare HIV incidence between groups, incorporating GEE to account for clustering.

Results: Preliminary results suggest that mean age and duration of injection was 31.8 and 11.7 years, respectively; 75% were male. In the past 30 days, 43% injected daily, 46% injected always with others, 78% had ≥1 sex partner. HIV incidence was 19.0 per 100 person-years (py) in the experimental condition compared to 31.8 per 100 py in the control condition (p < 0.001). PWID in the experimental condition had a 39% reduced hazard for HIV seroconversion versus the control group (p < 0.001). With each year increase in age, the hazard increased by 5% (p < 0.001), and with each injection episode in the past 30 days, the hazard increased by 0.6% (p = 0.02). Those who were sexually active in the last 30 days had a 26% reduced hazard (p = 0.03).

Conclusions: The combined network-based peer intervention and was more efficacious in reducing HIV incidence among PWID in Ukraine than T/C alone.

http://dx.doi.org/10.7448/IAS.18.5.20380
informing the revision of the national guidelines to include immediate ART in key populations.

http://dx.doi.org/10.7448/IAS.18.5.20382

TUAC0405
Social and socio-economic benefits of antiretroviral therapy adherence among HIV-infected people who use illicit drugs in Vancouver, Canada
Lindsey Richardson 1,2; Thomas Kerr 1,3; Bob Hogg 1,4; Silvia Guillemi 1; Julio Montaner 1,3; Evan Wood 1,3 and M-J Milloy 1,3
1B.C. Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2Department of Sociology, University of British Columbia, Vancouver, Canada. 3Division of AIDS, University of British Columbia, Faculty of Medicine, Vancouver, Canada. 4Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Presenting author email: lrichardson@cfenet.ubc.ca

Introduction: There is extensive documentation of the direct clinical benefits of antiretroviral therapy (ART) adherence leading to plasma HIV RNA-1 viral load suppression. However, very little is known about the social, socio-economic and ancillary clinical benefits of ART adherence, particularly among people who use illicit drugs (PWUD).

Methods: We used longitudinal data from a prospective cohort of community-recruited HIV-positive PWUD in Vancouver, Canada, a setting of free and universal access to HIV care. Participant data were linked to comprehensive HIV clinical monitoring and ART dispensation records. We developed a series of generalized linear mixed effects models, adjusting for potential confounders. Models examine whether, among ART-exposed individuals, becoming optimally adherent to ART medication (i.e. ≥95% using a validated measure of pharmacy dispensation) resulted in associated social, socio-economic and ancillary clinical benefits, such as relationship initiation, transitioning out of homelessness, entering employment, ceasing involvement in illegal or prohibited income generation activity (e.g. street-based income generation, sex work, drug dealing or other illegal activities) and enrolling in addiction treatment.

Results: Between December 2005 and November 2013, of the 724 eligible study participants, 241 (33.3%) self-reported as women and 404 (55.8%) as Caucasian, with 463 (64.0%) individuals becoming ≥95% adherent to ART at least once during the study period. In final multivariate models, becoming adherent to ART was positively and significantly associated with ceasing prohibited or illegal income generation activities (adjusted odds ratio (AOR): 1.52; 95% confidence interval (CI): 1.20–1.94) and transitioning out of homelessness (AOR: 1.38; 95% CI: 1.12–1.71), while ART adherence was marginally associated with initiating a romantic relationship (AOR: 1.31, 95% CI: 0.96–1.81).

Conclusions: These findings suggest that becoming adherent to ART results not only in virologic suppression among HIV infected PWUD, but also increases the likelihood of reducing key drivers of social and socio-economic vulnerability. These secondary benefits of ART adherence hold the potential to reinforce ongoing engagement in HIV care and support significant improvements in quality of life and individual health among this marginalized population. Findings reinforce the clinical and non-clinical importance of promoting access and adherence to ART among HIV-positive individuals who use illicit drugs.

http://dx.doi.org/10.7448/IAS.18.5.20383

TUAC0406LB
Modelling the impact of improvements in the cascade of care for chronic hepatitis C among people who inject drugs (PWID) in Montréal, Canada
Anthony Cousien 1,2,3; Pascale Leclerc 3; Carole Morissette 3; Julie Bruneau 4; Elise Roy 5; Yazdan Yazdanpanah 1,2,6 and Joseph Cox 3,7
1INSERM, IAME, UMR 1137, Paris, France. 2IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France. 3Direction de santé publique du Centre intégré universitaire de santé et de services sociaux du Centre-Est-de-l’île-de-Montréal, Montréal, Canada. 4Centre de recherche, Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada. 5Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Campus Longueuil, Longueuil, Canada. 6Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, Paris, France. 7Chronic Viral Illness Service, McGill University Health Centre, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada.
Presenting author email: anthony.cousien@insERM.fr

Introduction: Since 2010, HCV incidence among active (i.e. injection past six months) PWID in Montréal remains greater than 15 of 100 person-years (p-y). The arrival of new direct-acting antivirals (DAA) with high sustained virological response rates and improved
Abstract TUAC0406LB – Table 1.

| Scenario                          | Average time before linkage to care (years) | Prevalence after 10 years (%) mean (95% CI) | Incidence after 10 years (/100 persons-years) mean (95% CI) | % of complication avoided compared to Scenario 1 over 40 years mean (95% CI) |
|----------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------|
| Scenario 1 (Reference)           |                                             |                                             |                                                             |                                                                          |
| New DAAs under the current cascade of care: |                                             |                                             |                                                             |                                                                          |
| 10 years (%) average time from chronic infection to diagnosis | 54.6 (54.4;54.8) | 9.4 (9.1;9.6) | / | / |
| δ = 0.2 years; annual lost to follow-up probability ψ = 14%; initiation of treatment if linked to care σ = 5%/year; SVR rate with current adherence to treatment (SVR) = 81.3% | 57.7 (57.5;57.8) | 10.1 (9.8;10.4) | / | / |
| Scenario 2                        |                                             |                                             |                                                             |                                                                          |
| Decrease time from chronic infection to diagnosis: |                                             |                                             |                                                             |                                                                          |
| 10 years (%) δ = 0.5 years         | 56.8 (56.7;56.7) | 9.9 (9.6;10.1) | 1.7 (0.8;2.6) | 10.3 (10;10.6) | / |
| Scenario 3                        |                                             |                                             |                                                             |                                                                          |
| Improve adherence to treatment:    | 56.6 (56.5;56.6) | 9.6 (9.4;9.9) | 3.2 (2.2;4.2) | / |
| 10 years (%) SVR rate likewise in clinical trials (SVR = 90%) | 58.5 (58.3;58.7) | 9.8 (9.5;10.1) | 3.4 (2.6;4.3) | / |
| Scenario 4                        |                                             |                                             |                                                             |                                                                          |
| Improve treatment rate:           | 45.6 (45.4;45.8) | 7.8 (7.6;8.0) | 15.5 (14.7;16.3) | / |
| 10 years (%) σ = 10%/year          | 53.5 (53.3;53.7) | 9.1 (8.9;9.4) | 0.9 (-0.2;2.0) | / |
| Scenario 5                        |                                             |                                             |                                                             |                                                                          |
| Improve treatment rate:           | 41.4 (41.2;41.6) | 7.3 (7.1;7.5) | 27.2 (26.3;28.0) | / |
| 10 years (%) σ = 20%/year          | 45.7 (45.5;45.9) | 7.8 (7.6;8.1) | 24.3 (23.6;25.1) | / |
| Scenario 6                        |                                             |                                             |                                                             |                                                                          |
| Combined scenario                 |                                             |                                             |                                                             |                                                                          |
| 10 years (%)                         | 26.9 (26.7;27.0) | 4.9 (4.8;5.1) | 39.3 (38.8;39.8) | / |
| Combined scenario                  |                                             |                                             |                                                             |                                                                          |
| 10 years (%) δ = 2.0 years; annual lost to follow-up probability ψ = 14%; initiation of treatment if linked to care σ = 5%/year; SVR rate with current adherence to treatment (SVR) = 81.3% | 59.5 (59.4;59.7) | 10.3 (10;10.6) | / | / |

Ci: confidence interval
SVR: Sustained virological response

tolerability raises the question of whether treatment could be used to prevent HCV transmission. Our objective was to assess how improvements in the cascade of care can impact future HCV incidence, prevalence and complications among PWID in Montréal. **Methods**: We used a dynamic model to simulate HCV transmission and natural history among active PWID in Montréal from 2015. The reference scenario (scenario 1) was the current cascade of care including new DAA as standard treatment (see Table 1). HCV prevalence and incidence after 10 years and the number of liver complications avoided after 40 years were estimated under different conditions: decreased time from chronic infection to diagnosis (scenario 2), greater adherence to treatment (scenario 3), improved treatment rate (scenarios 4 and 5) and a combination of these interventions (scenario 6). Due to a lack of data on time to linkage to care (time between diagnosis and first consultation related to hepatitis C), simulations considered three such intervals: one, three and five years. A thousand simulations were performed per scenario. **Results**: Scenarios 2 and 3 showed similar results for HCV prevalence (53.3%–59.5%) and incidence (9.1–10.3/100 p-y) after 10 years, and less than a 3.4% difference in the number of liver complications after 40 years relative to the reference scenario. Improving access to treatment (scenarios 4 and 5) demonstrated a great decrease in all outcomes. When combining all interventions (scenario 6), prevalence and incidence decreased until 26.9% and 4.9/100 p-y, respectively, and the number of liver complications until 39.3%, depending on the time to linkage to care.

**Conclusions**: Our results suggest that decreasing time to diagnosis or improving treatment adherence is not sufficient to impact HCV prevalence, incidence and complications among PWID in Montréal. The current level of treatment access in the cascade of care is limiting a massive decrease in disease burden and transmission. A substantial treatment scale-up is necessary in this population.

http://dx.doi.org/10.7448/IAS.18.5.20552

**TUAD0101**

**Where to strengthen care: model-based triangulation of trends in the HIV care cascade**

Anna Bershteyn; Daniel Klein; Kevin Oishi and Philip Eckhoff

Institute for Disease Modeling, Bellevue, United States.

Presenting author email: abershteyn@intven.com

**Introduction**: The HIV “cascade of care” provides a framework for identifying priority areas for improvement of HIV services. In sub-Saharan Africa, the cascade has yet to be characterized nationally due to challenges such as distinguishing first initiation of care from re-initiation absent unique patient identifiers. Lacking direct data characterizing the cascade, we hypothesize that national-level temporal trends in care can be triangulated based on epidemiological, actuarial and programmatic information fed into a quantitative model. **Methods**: We simulated the HIV care cascade in South Africa using an epidemiological model calibrated to age- and gender-specific HIV
prevalence and mortality, national population dynamics and monitoring data from the public-sector HIV treatment programme. Data were available up to 2012, beyond which we assumed continuation of current trends in scale-up. HIV-associated mortality in the model was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.

Results: Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality, predicted to decline from 47% of HIV-associated deaths in 2015 to 37% in 2020. Late initiation was the second-largest and declined more slowly because increasing CD4 counts at initiation were partially offset by growing numbers of patients initiating care. LTFU was the third-largest but the most rapidly-growing category of HIV mortality. Programmatic data about re-initiation of care is lacking, but under the assumption that half of patients LTFU will re-initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV-associated deaths, mostly among those receiving treatment rather than in pre-ART care. This proportion remained constant over time because the growing population on treatment rather than in pre-ART care. This proportion was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.

Conclusions: Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality. Programmatic data about re-initiation of care is lacking, but under the assumption that half of patients LTFU will re-initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV-associated deaths, mostly among those receiving treatment rather than in pre-ART care. This proportion remained constant over time because the growing population on treatment rather than in pre-ART care. This proportion was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.

Conclusions: Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality. Programmatic data about re-initiation of care is lacking, but under the assumption that half of patients LTFU will re-initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV-associated deaths, mostly among those receiving treatment rather than in pre-ART care. This proportion remained constant over time because the growing population on treatment rather than in pre-ART care. This proportion was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.

Conclusions: Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality. Programmatic data about re-initiation of care is lacking, but under the assumption that half of patients LTFU will re-initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV-associated deaths, mostly among those receiving treatment rather than in pre-ART care. This proportion remained constant over time because the growing population on treatment rather than in pre-ART care. This proportion was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.

Conclusions: Failure to initiate care constituted the largest but most rapidly declining category of HIV mortality. Programmatic data about re-initiation of care is lacking, but under the assumption that half of patients LTFU will re-initiate care, deaths LTFU were not expected to surpass deaths due to late initiation by 2020. Those receiving care constituted 3% of HIV-associated deaths, mostly among those receiving treatment rather than in pre-ART care. This proportion remained constant over time because the growing population on treatment rather than in pre-ART care. This proportion was classified into those dying without initiating care, having initiated late (CD4 < 200), lost to follow-up (LTFU) after previous initiation or currently in care.
lines and could be used to identify people at risk of poor ART outcomes.

http://dx.doi.org/10.7448/IAS.18.5.20385

TUAD0103
Estimating national coverage of antiretroviral therapy among HIV-infected persons using multiple methods, Kenya 2012
Andrea Kim1; Lucy Nganga1; Irene Mukui1; Joyce Wamicwe1; Sofie Mwanyumba2; Nancy Bowen3; Lubbe Wiesner4; Kevin De Cock1 and KAIS Study Group
1Division of Global HIV/AIDS, US Centers for Disease Control and Prevention, Nairobi, Kenya. 2National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya. 3National Public Health Laboratory Services, Ministry of Health, Nairobi, Kenya. 4Division of Pharmacology, University of Cape Town, Cape Town, South Africa.
Presenting author email: aakim@cdc.gov

Introduction: Accurate estimates of antiretroviral therapy (ART) coverage are needed to track progress towards global targets from the Joint United Nations Programme on HIV/AIDS (UNAIDS) which aim for 90% of HIV+ persons on ART by 2020. ART coverage is reported annually to UNAIDS using mathematically-modelled estimates of the number of HIV+ persons eligible for ART based on an assumed distribution of CD4 counts in the HIV+ population and the number of persons receiving ART in health facilities. We compared ART coverage reported to UNAIDS with coverage estimated from a nationally representative survey in Kenya using two independent methods.

Methods: The 2012 Kenya AIDS Indicator Survey was a population-based household survey of persons aged 18 months-64 years conducted from 10/2012 to 2/2013. Interviews collected data on ART use for persons reporting HIV+ status. Blood samples were tested for HIV, and HIV+ samples tested for ART by High Performance Liquid Chromatography coupled to Tandem Mass Spectrometry. We estimated and compared ART coverage among HIV+ persons aged 15–64 years based on: 1) routine programme monitoring data; 2) self-report; and 3) biological confirmation of ART. ART eligibility in the survey was defined as: CD4 count < 350 cells/mm³ or having active tuberculosis. Estimates were weighted to adjust for survey design and non-response.

Results: According to ART programme monitoring data, 549,000 adults were receiving ART in 2012, covering 39.6% (confidence interval (CI) 36.8–43.0) of HIV+ persons and 78.3% (CI 74.8–82.8) of those ART-eligible. Of 11,626 survey respondents, 648 (5.6%) were HIV+ and 559 (86.3%) had samples available for ART testing. Among those, 42.5% (CI 0.4–47.7) tested positive for ART while 34.2% (CI 29.1–39.3) reported receiving ART. Based on biological confirmation of ART, coverage among ART-eligible persons was 71.0% (CI 63.2–78.9) or 444,000 persons while coverage based on self-report was 63.4% (CI 53.2–73.6) or 374,000 persons.

Conclusions: Self-report underestimated ART coverage by 70,000 persons while programme data may overestimate coverage by up to 105,000 persons. Until monitoring systems for the national ART programme are strengthened and mathematical models are updated to reflect actual need for ART, surveys that provide biological confirmation of ART may be required to accurately track national estimates of ART coverage.

http://dx.doi.org/10.7448/IAS.18.5.20386

TUAD0104
Crowdsourcing to spur first-time HIV testing among men who have sex with men and transgender individuals in China: a non-inferiority pragmatic randomized controlled trial
Larry Han1; Weiming Tang2; John Best3; Ye Zhang2; Julie Kim2; Fengyi Liu2; Katie Mollan2; Michael Hudgens2; Barry Bayus3; Fern Terris-Prestholt3; Samuel Galler3; Ligang Yang2; Rosanna Peeling3; Paul Volberding3; Baoli Ma4; Bin Yang2; Shujie Huang2; Kevin Fenton2; Chongyi Wei5; and Joseph Tucker10
1Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, United States. 2Guangdong Provincial STD Control Center, Guangzhou, China. 3Medicine, University of California San Francisco, San Francisco, United States. 4Kenan-Flagler Business School, University of North Carolina at Chapel Hill, Chapel Hill, United States. 5London School of Hygiene & Tropical Medicine, London, United Kingdom. 6Department of International Development, Oxford University, Oxford, United Kingdom. 7Blue City, Beijing, China. 8Public Health England, London, United Kingdom. 9Epidemiology and Biostatistics, University of California – San Francisco, San Francisco, United States. 10University of North Carolina Project – China, Guangzhou, China.

Presenting author email: jdtucker@med.unc.edu

Introduction: Improving first-time HIV testing among key populations, especially young MSM and transgender (TG) individuals, is a global health priority. However, most HIV testing campaigns do not reach untested populations and have minimal impact from key populations. Crowdsourcing, the process of taking a task performed by an individual and opening it to a large group in the form of a contest, may enhance HIV testing interventions. We organized a non-inferiority, pragmatic randomized controlled trial to compare first-time HIV testing rates among MSM and TG individuals who received either a crowdsourced HIV test promotion intervention or a health marketing intervention.

Methods: Participants were recruited through three large MSM web portals in China. We randomly assigned 721 MSM and TG individuals (≥16 years old, never before tested for HIV) to one of two video interventions. The crowdsourced video was developed using an open contest and formal transparent judging while the evidence-based health marketing video was designed by experts. We followed up four weeks post-intervention via text message to assess HIV test uptake. Descriptive statistics and sensitivity analyses for missing data were carried out to assess test uptake. Cost-minimization analysis was used to evaluate economic and financial costs of the two interventions. The trial was registered (NCT02248558).

Results: Overall, 624/721 (86.5%) MSM and TG individuals responded to the text message. HIV test uptake was similar between the crowdsourced arm (37.1%, 114/307) and the health marketing arm (35.0%, 111/317). Sensitivity analysis using imputation sup-
plemented the similarity of the two approaches. Within the crowdsourced arm (37.1%, 114/307) and the health marketing
interventions. The trial was registered (NCT02248558).

Conclusions: We provide proof of principle for using crowdsourcing as a tool to enhance community engagement and improve HIV testing services. Crowdsourcing may be a cost-effective method to optimize HIV interventions, especially interventions targeting young key populations.

http://dx.doi.org/10.7448/IAS.18.5.20387

TUAD0105LB

The effect of a population-based health department Data-to-Care intervention to increase HIV care engagement and antiretroviral use: a controlled evaluation

Julia C Dombrowski1,2; James P Hughes3,5; Susan E Buskin2,4; Jane M Simoni1; David Katz1,2; Mark Fleming2; Angela Nunez2 and Matthew R Golden1,2,4
1Medicine, University of Washington, Seattle, United States. 2HIV/STD Program, Public Health – Seattle & King County, Seattle, United States. 3Biostatistics, University of Washington, Seattle, United States. 4Epidemiology, University of Washington, Seattle, United States. 5Psychology, University of Washington, Seattle, United States.

Presenting author email: jdombrow@uw.edu

Introduction: The US CDC promotes the use of HIV surveillance data to identify out-of-care persons and return them to care (“Data-to-Care”).

Methods: We used stepped wedge cluster randomization to institute a Data-to-Care programme in Seattle-King County, Washington, DC, USA. We attempted to provide the intervention to all eligible persons in the county, initiated in a randomly assigned order based on cases’ medical provider (the cluster). Eligible persons had 1) no CD4 or viral load (VL) reported for ≥12 months or 2) VL > 500 and CD4 < 350 at last report. Programme staff contacted patients to offer assistance relinking to HIV care and treatment. The primary study outcome was time to viral suppression (first VL < 200 reported to surveillance), starting from the programme implementation date. The secondary outcome was care relinkage (first VL or CD4 reported). We used Cox Proportional Hazards to compare outcomes during control periods (before initiation of each case’s provider cluster) to intervention periods (after initiation of the cluster). We censored cases at the time of ascertainment of relocation or death, or end of the observation period. The intention-to-treat (ITT) analysis included all eligible cases; the modified ITT (mITT) analysis excluded cases found to have died or moved.

Results: The ITT and mITT analyses included 1008 and 824 persons, respectively (Figure). Study staff provided the individual intervention to 165 persons, of whom 73% relinked to care within one month and 70% achieved viral suppression within six months. The incidence rate testing ($131/person vs. $238) and detecting new HIV diagnoses ($415/person vs. $799).

Conclusions: We provide proof of principle for using crowdsourcing as a tool to enhance community engagement and improve HIV testing services. Crowdsourcing may be a cost-effective method to optimize HIV interventions, especially interventions targeting young key populations.

http://dx.doi.org/10.7448/IAS.18.5.20387

Abstract TUAD0104 - Table 1. Pre-specified sub-analyses among MSM in China

| Test | Crowdsourced | Health marketing |
|------|--------------|------------------|
| Tested/total (%) | RR | 95% CI | p | Tested/total (%) | RR | 95% CI | p |
| Multi-time video watching | 66/126 (52.4%) | 1.97 | 1.47–2.65 | <0.001 | 67/151 (44.4%) | 1.67 | 1.23–2.28 | 0.001 |
| First-time video watching | 48/181 (26.5%) | Ref | | | 44/166 (26.5%) | Ref | | |
| Northern web portal | 106/316 (33.5%) | 1.27 | 0.70–2.33 | 0.42 | 90/266 (26.6%) | 0.82 | 0.57–1.88 | 0.30 |
| Other web portals | 8/36 (22.2%) | Ref | | | 21/51 (41.2%) | Ref | | |
| Yes – condomless sex | 28/71 (39.4%) | 1.21 | 0.84–1.74 | 0.62 | 26/62 (41.9%) | 1.30 | 0.90–1.88 | 0.16 |
| No – condomless sex | 50/153 (32.7%) | Ref | | | 52/161 (32.3%) | Ref | | |
| Overall | 114/307 (37.1%) | | | | 111/317 (35.0%) | | | |
of viral suppression was higher during the intervention versus control periods, but the difference was not statistically significant (Table). The HR associated with the intervention was higher among persons with last VL/CD4 <500 in the past year than persons with no labs in the past year.

**Conclusions:** Data-to-Care programmes can relink some persons to HIV care, but the effect of these programmes may be limited by the large numbers of persons who have moved, died or cannot be reached, and the rate of relinkage to care in the absence of the intervention. Focusing on persons with recently reported unsuppressed VLs rather than a gap in lab reports may be more effective and efficient.

**Abstract TUAD0105LB**

**Figure 1. Flowchart of programme implementation.**

**Table 1. Summary of intention-to-treat (ITT) and modified ITT results.**

| Population, outcome | % Achieved by end of observation period | Hazard ratio (95% CI) of incidence rates in intervention versus control period |
|---------------------|----------------------------------------|--------------------------------------------------------------------------------|
| Total population, viral suppression | 30 | 1.27 (0.89–1.80) |
| ITT analysis (N = 1008) | 37 | 1.18 (0.83–1.68) |
| No labs for 12 months, relinkage | 47 | 0.99 (0.74–1.34) |
| mITT analysis (N = 276) | 28 | 0.79 (0.40–1.55) |
| Last VL > 500 in past year, viral suppression | 41 | 1.4 (0.96–2.19) |

**Retaining mother-baby-pairs in care and treatment: the mothers2mothers Mentor Mother Model**

**Kathrin Schmitz**, **Esca Scheepers**, **Emeka Okonji** and **Vicent Kawooya**

Department of Programmes and Technical Support, mothers2mothers, Cape Town, South Africa. 
Research and Strategic Information, mothers2mothers, Cape Town, South Africa. 
mothers2mothers Uganda, Jinja, Uganda.

**Introduction:** Retaining HIV-positive mothers and their babies in prevention of mother-to-child HIV transmission (PMTCT) care is critical for the elimination of mother-to-child-transmission. mothers2mothers is a peer education and psychosocial support programme operating in six Option B+ countries in Africa. m2m Mentor Mothers are women living with HIV who have recently experienced PMTCT. They are trained and employed to support other mothers and their families through the same process. In 2014, the m2m Mentor Mother Model implemented under the STAR-EC Programme in Uganda was evaluated externally in order to investigate whether maternal and infant PMTCT outcomes and maternal psychosocial well-being outcomes were associated with exposure to m2m Mentor Mothers.

**Methods:** A quasi-experimental matched area comparison design was used. PMTCT outcomes were measured retrospectively among 2282 mother-baby-pairs who accessed PMTCT services between January 2011 and March 2014 in 31 intervention facilities (where...
Abstract TUAD0201  Table 1. Comparison of PMTCT outcomes

| Outcome indicator                                                                 | Average effects among matched exposed subjects in m2m sites (%) | Average effects among matched unexposed subjects in control sites (%) | PSM net effect (percentage points) | p    |
|-----------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------|------|
| Receipt of ARVs/ART for PMTCT among HIV-positive pregnant women                   | 91.8                                                         | 95.1                                                                | −3.3                              | <0.001|
| ANC attendance at least four times during pregnancy among HIV-positive women       | 49.30                                                        | 39.70                                                                | 9.6                               | <0.001|
| Delivery by skilled health personnel in past 12 months among HIV-positive women    | 87.10                                                        | 75.80                                                                | 11.3                              | <0.001|
| Retention in care among HIV-positive women 12 months after ART initiation         | 90.90                                                        | 63.60                                                                | 27.3                              | <0.001|
| Receipt of Nevirapine suspension at birth by HIV-exposed babies (ART prophylaxis for PMTCT) | 86.00                                                        | 59.00                                                                | 27                                | <0.001|
| Percentage of HIV-exposed children who were given a PCR test at six weeks after birth | 71.50                                                        | 45.80                                                                | 25.8                              | <0.001|
| Percentage of HIV-exposed children who were given an HIV test six weeks after cessation of breast feeding | 60.50                                                        | 31.40                                                                | 29.4                              | <0.001|
| Percentage of HIV-exposed children who were given an HIV test 18 months after delivery | 60.20                                                        | 18.10                                                                | 42.1                              | <0.001|
| Linkage of HIV-positive babies to paediatric ART                                    | 60.90                                                        | 27.80                                                                | 33                                | <0.001|

m2m Mentor Mothers provided peer education and psychosocial support and 31 matched control facilities (where no peer education and psychosocial support were provided). Furthermore, 796 pregnant women and new mothers accessing PMTCT between June 2012 and March 2014 across both study arms participated in facility based Psychosocial Wellbeing surveys. Bivariate and multivariate inferential statistical analysis was done using STATA 12. Propensity Score Matching was used to investigate the net effect attributable to the m2m standard-of-care.

**Results:** Comparison of the intervention and control sites indicated that clients in m2m-supported health facilities showed improved uptake of PMTCT services (see Table 1), The m2m model was further associated with increased coping self-efficacy (86.6% vs. 64.5%, p < 0.001); coping behaviour (69.4% vs. 56.9%, p < 0.001); HIV disclosure and safer sex self-efficacy (71.7% vs. 50.7%, p < 0.001); and reduction in the experience of depression (83.5% vs. 78.1%, p = 0.028).

**Conclusions:** m2m has developed and refined a simple, scalable, adaptable and sustainable model of peer education and psychosocial support that improves uptake of PMTCT services and addresses the challenges facing HIV-positive pregnant women and mothers. The evidence shows that m2m’s psychosocial peer support helps HIV-positive pregnant women and new mothers and their families cope more effectively with HIV and enhances their psychosocial wellbeing. Integration of peer education and psychosocial support into clinical PMTCT standard-of-care is recommended.

http://dx.doi.org/10.7448/IAS.18.5.20388

**TUAD0202**

**Effectiveness of conditional cash transfers to increase retention in care and adherence to PMTCT services: a randomized controlled trial**

Marcel Yotebieng1; 2; Harsha Thirumurthy1; Kathryn Elizabeth Moracco3; Bienvenu Kawende1; Jean Lambert Chalachala1; Landry Kipula Wenz1; Noro Lantoniaina Rosa Ravelomanana2; Andrew Edmonds1; 2; Deidre Thompson1; Emile Oktolonda2 and Frieda Behets2

1: College of Public Health, Ohio State University, Columbus, United States. 2: Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, United States. 3: Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, United States. 4: School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo. Presenting author email: yotebieng.2@osu.edu

**Introduction:** Novel strategies are needed to increase retention in, and adherence to prevention of mother-to-child HIV transmission (PMTCT) services, and ultimately enhance PMTCT implementation effectiveness in sub-Saharan Africa.

**Objective:** To determine whether small, increasing cash payments conditioned on attending scheduled clinic visits and receiving proposed services can increase the proportion of HIV-infected pregnant women who attend PMTCT visits and adhere to available PMTCT services through six weeks postpartum.

**Methods:** Newly diagnosed HIV-infected women, ≤32 weeks pregnant, were recruited at antenatal care clinics in Kinshasa, Democratic Republic of Congo, and randomly assigned in a 1:1 ratio to an intervention group that received compensation on the condition they attended scheduled clinic visits and accept offered PMTCT services ($5 plus $1 increment at each subsequent visit) or to a control group that received usual care. Outcomes assessed included: retention in care measured by loss-to-follow-up (LTFU), and adherence to PMTCT services (attend all scheduled clinic visits and accept proposed services) through six weeks postpartum. Analysis was by intention to treat. The study is registered with clinicaltrials.gov: NCT01838005.

**Results:** Between April 2013 and August 2014, 612 potential participants were identified, 545 were screened and 433 were enrolled and randomized (Figure 1). Participants in the two groups had similar...
characteristics at baseline. As of January 5, 2015, 407 had completed their six weeks postpartum visit or were no longer in care. Analysis of complete data showed that by six weeks postpartum, a lower proportion of participants in the intervention group (17.7%) than the control group (27.0%) were LTFU (unadjusted odds ratio (OR), 0.58; 95% confidence interval (CI), 0.36–0.94). Similarly, a higher proportion of participants in the intervention group (70.0%) than the control group (54.5%) attended all scheduled visits and accepted proposed services.

Abstract TUAD0202 - Table 1. Effect of conditional cash compensation

|                     | Study group | Odds ratio (95% CI) |
|---------------------|-------------|---------------------|
|                     | Overall n (%) | Intervention n (%) | Control n (%) | Unadjusted | p     | Adjusted | p     |
| Loss to follow-up   |              |                     |               |            |       |          |       |
| Yes                 | 91 (22.36)   | 36 (17.73)          | 55 (26.96)    | 0.58       | 0.0255 | 0.58 (0.36, 0.93) | 0.0235 |
| No                  | 316 (77.64)  | 167 (82.27)         | 149 (73.04)   |            |        |          |       |
| Attendance of each clinic visit and received services | | | | | |
| Yes                 | 254 (63.41)  | 142 (69.95)         | 112 (54.90)   | 1.91       | 0.0017 | 1.97 (1.30, 2.97) | 0.0013 |
| No                  | 153 (37.59)  | 61 (30.05)          | 92 (45.10)    |            |        |          |       |
(OR = 1.91; 95% CI, 1.21–2.87). Results were similar after adjusting for marital status, age and education (Table 1).

**Conclusions:** Among newly diagnosed HIV-infected women, small, incremental cash incentives resulted in increased retention along the PMTCT cascade and adherence to available services. The overall effects of these incentives on HIV-free survival and cost-effectiveness warrant further investigation.

http://dx.doi.org/10.7448/IAS.18.5.20389

**TUAD0203**

Using the critical path for rapid expansion and optimization of a PMTCT programme towards elimination of new HIV infections in children

Reuben Musarandega1; Agnes Mahomva1; Joanna Robinson1; Esther Tumbare1; Phiri Dave Sen1; Anna Hakobyan1 and Angela Mushavi2

1Technical Department, Elizabeth Glaser Pediatric AIDS Foundation, Harare, Zimbabwe. 2Elizabeth Glaser Pediatric AIDS Foundation, Global, Washington, DC, United States. 3Health Portfolio, Children’s Investment Fund Foundation, London, United Kingdom.

Introduction: Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) partnered with the Children’s Investment Fund Foundation (CIFF) and Zimbabwe Ministry of Health and Child Care (MOHCC) to roll out the WHO 2010 and later 2013 prevention of mother-to-child HIV transmission (PMTCT) guidelines. EGPAF, MOHCC and CIFF developed a “critical path” with a prioritized set of performance indicators, with population-based targets, that are the main drivers of impact. The indicators are reviewed quarterly, as they largely draw on routine monitoring data. If performance is lagging in a particular indicator, a diagnosis is undertaken to identify the reason and corrective action explored. Critical path indicators and results for quarter 2, 2012 are in Figure 1. The EGPAF-CIFF goal was to reduce mother-to-child transmission (MTCT) of HIV from about 25% in 2009 to less ~ 9% by 2015.

**Methods:** Health facilities (HFs) were supported to implement the guidelines through training and mentoring during site support visits, among other assistance. PMTCT data were collected quarterly from all supported HFs, and performance of each indicator compared with established targets during data-driven programme reviews held by EGPAF, partner programme officers and MOHCC district staff. Reasons for under-performance and improvement strategies were identified and implemented in subsequent quarters through mentoring and coaching of HF staff to improve service provision and patient follow-up.

**Results:** By October 2014, EGPAF was supporting 1480 out of 1560 sites to provide WHO 2013 PMTCT guidelines (Option B+). Service uptake in all critical path indicators increased significantly (p < 0.001) from 2009/10 to 2013/14 as follows: ANC bookings 68%–100%, HIV testing 85%–98%, AZT prophylaxis 32%–91%, CD4 testing 41%–67%, ART initiation for pregnant mothers 18%–85%, EID 13%–71%, mothers’ adherence on ARV prophylaxis 34%–77%. The national MTCT rate fell to ~ 9.0% in 2013.

**Conclusions:** Through use of the critical path cascade, EGPAF and CIFF supported the MOHCC to achieve a rapid scale-up of PMTCT services. There is a need to maintain coverage and quality PMTCT services and ensure that children needing ART are actively identified,
Attrition from antiretroviral treatment services among pregnant and non-pregnant patients following adoption of Option B+ in Haiti

Jean Wysler Domercant 1; Nancy Puttkammer 2; Lydia Lu 3; Reynold Grand’Pierre 4; David Lowrance 5 and Michelle Adler 6

1Centers for Disease Control and Prevention, Port au Prince, Haiti.
2International Training and Education Center for Health, Seattle, United States.
3Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, United States.
4Ministry of Health of the Government of Haiti, Port au Prince, Haiti.
5Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Port au Prince, Haiti.
6Centers for Disease Control and Prevention, Port au Prince, Haiti.

Abstract TUAD0204

Attrition from antiretroviral treatment services among pregnant and non-pregnant patients following adoption of Option B+ in Haiti

Introduction: Attrition from antiretroviral treatment (ART) services is an important determinant of HIV treatment outcomes. This study assessed factors associated with attrition among pregnant and non-pregnant patients initiating ART following adoption of Option B+ (universal ART eligibility for HIV-infected pregnant women) in October 2012 in Haiti.

Methods: Electronic medical records of adult patients initiated on ART from October 2012 to August 2014 at 73 health facilities (HF) from 8 of 10 Haitian administrative departments were analyzed. Within a survival analysis framework, attrition was defined as the first instance of failure to attend a HF visit for 90 days after a missed clinical or pharmacy-dispensing appointment, or an officially-recorded programme discontinuation, whichever came first. Known transfers to alternative HF were treated as censored observations, not attrition cases. ART initiations during or within 12 weeks after pregnancy were deemed Option B+ cases. The Kaplan-Meier method and Cox proportional hazards regression, stratified by HF, were used to determine attrition and associated factors.

Results: Among 17,084 patients who initiated ART, 7719 (45.2%) were non-pregnant women, 5920 (34.7%) were men and 3445 (20.2%) were pregnant women. At six months, attrition was 15.6% (95% confidence interval (CI): 14.8–16.4) for non-pregnant women, 17.0% (16.1–18.0) for men and 33.0% (32.2–33.9) and 50.8% (49.0–52.6) respectively. Adjusted for patient-level factors and HF, attrition risk was 63% higher among pregnant women and 16% higher among men, compared to non-pregnant women (p < 0.001). Significant protective factors included: receiving psychosocial counselling (hazard ratio (HR): 0.84, p < 0.001); cotrimoxazole prophylaxis (HR: 0.83, p < 0.001); tuberculosis treatment (HR: 0.88, p < 0.001) before ART initiation; having an HIV-positive household member (HR: 0.80, p < 0.05); living in the same commune as the HF (HR: 0.94, p < 0.01), and greater duration of pre-ART enrolment (HR: 0.99 for each 30-day increase, p < 0.001).

Conclusions: Following adoption of Option B+, ART attrition in Haiti was higher than that described in published reports from other resource-limited settings. Early, sustained and tailored interventions are urgently needed to reduce ART attrition in Haiti, particularly among pregnant women.

http://dx.doi.org/10.7448/IAS.18.5.20390
to-child-transmission. Results will guide subsequent phases of the national rollout.

**Methods:** From October, 2013, to June, 2014, we recruited participants from 22 purposefully selected health facilities in the Northwest and Southwest Regions for an observational cohort evaluation. HIV-positive pregnant and breastfeeding women, not currently on antiretrovirals (prophylaxis or treatment), were eligible to participate in the assessment. Option B+ was offered to all eligible participants, and a descriptive analysis was performed.

**Results:** Of 1267 HIV-positive pregnant or breastfeeding women identified, 669 (53%) were eligible for the evaluation. Of those who were offered Option B+, 666 (99%) accepted life-long ART and 3 (<1%) accepted ART only during pregnancy and breastfeeding. As of October 2014, 569 (85%) women remained alive and on treatment; 8 (1.2%) died, 17 (3%) discontinued ART and 34 (5%) were lost to follow-up (LTFU). Fifty-six (8%) did not return for their first refill after ART initiation; this percentage varied from 2 to 8% between facilities. The six month retention for monthly cohorts of women initiating Option B+ was 77–91% (Figure 1). Of 409 infants born to the 669 women enrolled, 8 (2%) died, 3 (<1%) were LTFU. Four hundred and three (99%) received NVP prophylaxis within 72 hours of birth. By eight weeks post-partum, 342 (89%) were tested for HIV deoxyribonucleic-acid, 9 (3%) received a positive result. The remaining infants are not yet old enough for HIV status determination. All HIV-infected infants initiated ART.

**Conclusions:** In Cameroon, Option B+ is highly accepted by HIV-positive pregnant and breastfeeding women and can achieve a high six month retention rate. Long-term retention, mortality and final mother-to-child-transmission after cessation of breastfeeding need further evaluation.

http://dx.doi.org/10.7448/IAS.18.5.20392

**TUAD0206LB**

**Improving early ANC attendance through community engagement and dialogue: project ACCLAIM in three African countries**

Mary Pat Kieffer1; Godfrey Woelk1,2; Daphne Mpofu3; Rebecca Cathcart1 and ACCLAIM Study Group

1Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States. 2Department of Health Behavior and Health Education, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, United States. 3Elizabeth Glaser Pediatric AIDS Foundation, Mtshweni, Swaziland.

**Introduction:** Timing of first antenatal clinic (ANC) attendance in sub-Saharan Africa averages 24–25 weeks; however, to effectively prevent HIV transmission to infants, earlier ANC attendance and initiation of antiretroviral therapy are necessary. Advancing Community Level Action for Improving Maternal and Child Health (MCH)/Prevention of Mother-to-Child HIV Transmission (PMTCT), known as ACCLAIM, a three-arm randomized trial in 45 clusters across Swaziland, Uganda and Zimbabwe, aims to improve access, uptake and retention in MCH/PMTCT services.

**Methods:** The study randomized clusters and evaluated three interventions: 1) community leader engagement (participation in the Community Leaders Institute, mentoring to engage in community action); 2) Community Days and dialogues (community event with structured dialogues on MNCH/PMTCT, and provision of health services) and 3) male and female MCH classes (set of four structured sessions led by peer facilitators).

This sub-study analyzed early ACCLAIM results on earlier access to ANC services. Baseline gestational age (GA) data at first ANC visit were collected from health facilities before implementation and quarterly after implementation. We compared proportions of women attending ANC during first half of pregnancy (<20 weeks’ gestation) at baseline and 6–12 months after interventions.

**Results:** A total of 277 trained community leaders held >7000 community meetings and engaged >27,000 individuals in dialogues at Community Days, identifying and addressing barriers, misperceptions and harmful gender norms. The proportion of women attending ANC ≤20 weeks’ gestation across the three countries increased by 36% from baseline; this trend was significant across the quarters observed (p < 0.0001).

Attendance during the first trimester (<12 weeks) also increased, from 11.7% (84/719) to 14.1% (102/721) in Swaziland (p = 0.163), and from 3.4% (24/705) to 12.0% (97/809) (p < 0.0001) in Zimbabwe (Uganda data not available). Community dialogues actively focused on the benefits of early ANC and addressed norms of waiting until the woman “shows” before seeking ANC.

**Conclusions:** In our study, community based interventions have resulted in significant greater than one-third increase in ANC ≤20 weeks’ gestation in three African countries. On-going data analysis will provide data on the full potential of open community dialogues by trained community leaders to change community norms and health-seeking behaviours such as early access to ANC and MCH/PMTCT services.

http://dx.doi.org/10.7448/IAS.18.5.20554

**WE – WEDNESDAY**

**WEAA0101**

**Comparison of HIV-1 envelope specific IgA and IgG antiviral ability to prevent HIV-1 infection: additive, inhibitory and synergistic effects**

Sandra Gerda Okala1; Deborah F King1,2 and Robin J Shattock1

1International AIDS Vaccine Initiative, London, United Kingdom. 2International AIDS Vaccine Initiative, London, United Kingdom.

**Introduction:** Despite the crucial role of IgA in mucosal immunity, very little is known about how IgG and IgA isotypes interact to prevent HIV-1 infection. This gap in the current knowledge was highlighted in the HIV-1 RV144 vaccine trial in which specific monomeric (m)IgA mitigated IgG effectors functions and correlated with increased risk of HIV-1 acquisition. Both IgG and dimeric (d)IgA are present in the female and male genital tracts, which are the main

Abstract TUAD0206LB– Table 1. Change in gestational age at first antenatal care

| Gestational age at first ANC | Baseline July - September 2013 (January - March 2014, Uganda) n = 5071 | 6 - 12 months of implementation October – December, 2014 n = 4799 | p-value |
|-----------------------------|-------------------------------------------------|-------------------------------------------------|---------|
| ≤ 20 weeks                  | 1532 (30.2%)                                    | 1975 (41.2%)                                    | < 0.0001|
| 21 + weeks                  | 3539 (69.8%)                                    | 2824 (58.8%)                                    |         |
site of viral entry. However, the ratio of IgG to IgA varies between compartments. In this study, we compared the antiviral properties of IgG and IgA antibodies with the same epitope specificity at ratios found in genital secretions. Subsequently, we investigated whether the combination of antibody recognizing discrete epitopes but from the same isotype resulted in improved antiviral activities.

**Methods:** CHS1, b12, 2F5 and 782 mAbs binding to soluble HIV-1env gp140 Env and kinetics parameters of these interactions were determined by competitive enzyme-linked immunosorbent assay and Bio-Layer Interferometry (BLI). HIV-1env virus capture by the panel of mAbs was quantified by p24 ELISA, antibody mediated viral aggregation (AMVA) was determined using Nanoparticle Tracking Analysis (NTA) and neutralization activity by TZM-bl neutralization assay.

**Results:** We demonstrated that IgGs captured significantly more virions than IgAs, and this was correlated with higher association rate constants whereas dIgA presented the ability to mediate viral aggregation. Strikingly, the combination of dIgA and IgG recognizing the same epitope did not elicit any additive effects. In contrast, IgG prevented dIgA binding to soluble HIV-1env gp140 Env and its ability to capture and aggregate HIV-1env virions. However, mixtures of IgGs or dIgAs recognizing distinct epitopes but from the same isotype resulted in synergistic effects with higher proportions of captured viruses; antibody mediated viral aggregates and neutralization activities.

**Conclusions:** This study compared the ability of IgG and dIgA to prevent HIV-1 infection with respect to the ratio IgG and dIgA found in genital secretions. Collectively, these results suggest that the combination of antibody targeting different epitopes provides enhanced general antiviral activities. Nonetheless, antibody binding to the same epitope but of different isotypes may lead to competition and inhibition of antiviral functions.

http://dx.doi.org/10.7448/IAS.18.5.20393

**WEAA0102**

Anti-V3/glycan and anti-MPER neutralizing antibodies, but not anti-V2/glycan-site antibodies are strongly associated with higher anti-HIV-1 neutralization breadth and potency

Rajesh Abraham Jacob1,2; Thandeka Moyo1,2; Michael Schomaker3; Fatima Abrahams3; Berta Grau Pujo1 and Jeffrey Dorfman1,2

1International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa. 2Division of Immunology, University of Cape Town, Cape Town, South Africa. 3Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.

Presenting author email: jeffrey.dorfman@icgeb.org

Introduction: Previous candidate HIV vaccines have failed to either induce wide-coverage neutralizing antibodies or substantially protecting vaccinees. Therefore, current efforts focus on novel approaches never before successfully used in vaccine design, including modelling epitopes. Candidate immunogen models identified by broadly neutralizing antibodies include the membrane proximal external region (MPER, recognized by 4E10, 2F5 and 10E8 monoclonal antibodies (mAbs)), V3/glycans (typified by PGT121-128 mAbs) and the V2/glycan site (initially defined by PG9 and PG16 mAbs). Anti-MPER and anti-V3/glycan antibodies are often autoreactive or polyreactive, and this is thought to pose both direct and indirect barriers to achieving neutralization breadth. Recent evidence shows that antibodies with moderate neutralization breadth are frequently attainable, with 50% of sera from chronically-infected individuals neutralizing ≥50% of a large, diverse set of viruses. Such moderately neutralizing antibodies may be more attainable in vaccinees. Despite these findings, there is little systematic information addressing which specificities are preferentially targeted among such commonly found, moderately broad neutralizing sera.

**Methods:** We explored associations between neutralization breadth and potency and presence of neutralizing antibodies targeting MPER, V2/glycan site and V3/glycans in sera from 177 antiretroviral therapy-naive HIV-1-infected (±1 year) individuals recruited in Cape Town, South Africa.

**Results:** Recognition of both MPER and V3/glycans was associated with increased breadth and potency. MPER-recognizing sera neutralized 4.62 more panel viruses than MPER-negative sera (95% prediction interval (PI) 4.41, 5.20), and V3/glycan-recognizing sera neutralized 3.24 more panel viruses than V3/glycan-negative sera (95% PI 3.15, 3.52). In contrast, V2/glycan site-recognizing sera neutralized only 0.38 more panel viruses (95% PI 0.20, 0.45) than V2/glycan site-negative sera and no association between V2/glycan site recognition and breadth or potency was observed.

**Abstract WEAA0102**

**Table 1. Broad/potent neutralization and target recognized**

| Category                   | Less potent (geo mean ID50 < 220) | Potently neutralizing (geo mean ID50 ≥ 220) | Relative risk (95% CI) p (X²) | Less broad (neutralizes < 18/24 viruses) | Broadly neutralizing (neutralizes ≥ 18/24 viruses) | Relative risk (95% CI) p (X²) |
|----------------------------|---------------------------------|---------------------------------|--------------------------------|---------------------------------|---------------------------------|--------------------------------|
| Anti-MPER negative         | 124                             | 20                             | 1.00 (reference)              | 122                             | 22                             | 1.00 (reference)              |
| Anti-MPER positive         | 24                              | 9                              | 1.96 (0.99, 3.91)             | 0.061                           | 23                             | 1.00 (reference)              | 1.98 (1.04, 3.78)             | 0.043 |
| Anti-V2 glycan site negative | 63                             | 21                             | 1.00 (reference)              | 62                             | 22                             | 1.00 (reference)              |
| Anti-V2 glycan site positive | 29                             | 5                              | 0.59 (0.24, 1.43)             | 0.222                           | 27                             | 0.79 (0.37, 1.67)             | 0.522 |
| Anti V3/glycans negative   | 75                              | 17                             | 1.00 (reference)              | 73                             | 19                             | 1.00 (reference)              |
| Anti-V3/glycans positive   | 12                              | 9                              | 2.32 (1.21, 4.46)             | 0.017                           | 12                             | 2.08 (1.10, 3.92)             | 0.033 |
Conclusions: Despite autoreactivity of many neutralizing antibodies recognizing MPER and V3/glycans, antibodies to these sites are major contributors to neutralization breadth and potency in this cohort. This suggests that the autoreactivity effect is not critical and that the MPER and the V3/glycans should remain high priority vaccine candidates. The V2/glycan site result is surprising because broadly neutralizing antibodies to this site have been repeatedly observed. It may therefore be appropriate to focus on developing immunogens based upon the MPER and V2/glycans.

http://dx.doi.org/10.7448/IAS.18.5.20394

WEAA0103 Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central America
Humberto Valenzuela-Ponce1; Santiago Ávila-Rios3; Daniela Garrido-Rodríguez3; Thalia García-Tellez3; Maribel Soto-Nava3; Tania Escamilla-Gómez5; Claudia García-Morales3; Jonathan Cortés-Alvarezb; Ramón Hernández-Juan2; Akio Murakami-Ogasawaram; Carlos Mejía-Villatorob; Juan Pascale2; Guillermo Porrasa; Carlos Quanta; Ivette Lorenzoana; Rita Meza3; Elsa Palou3; Marvin Manzanerob; Gustavo Reyes-Teran9 and Mesoamerican HIV Project Group
1Center for Research on Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico. 2Hospital Roosevelt, Guatemala City, Guatemala. 3Instituto Commemorativo Gorgas la Salud, Panama City, Panama. 4Hospital Metropolitano Vivian Pellans, Managua, Nicaragua. 5HIV National Program, Tegucigalpa, Honduras. 6Ministry of Health, Belize, Belize.

Introduction: HLA-B*35 alleles have been classified into two groups, PY and Px, based on residues 114/116 in the HLA peptide binding groove, defining the amino acid preference at position 9 of the peptides they present. B*35:02/03, part of the Px group, have been associated with rapid HIV disease progression in the context of HIV-1 B clade infection. As B*35 is the most prevalent HLA-B allelic group in Mexico and Central America (expressed in 41.4% of individuals), including a number of relatively unstudied B*35 alleles, we investigated HIV disease outcome in this cohort.

Methods: HLA sequence-based typing was performed on 1971 chronically HIV-1 clade B infected, ART-naïve individuals from Mexico (n = 1058), Guatemala (n = 396), Nicaragua (n = 218), Honduras (n = 165), Panama (n = 85) and Belize (n = 49). Associations between HIV plasma viral load (pVL) and CD4 T cell count (CD4 count) with B*35 expression were evaluated using Mann–Whitney U-tests and Storey q values. Only HLA-B heterozygous individuals were compared in order to exclude confounding effects resulting from HLA homozgyosity.

Results: We observed 10 different B*35 alleles (n > 5). Based on residues 114 and 116, B*35:01/08/14/16/17/20/43 were classified as PY, and B*35:02/03/12 as Px. Ranking HLA-B*35 alleles according to median pVL or CD4 count showed a wide spectrum of associated HIV disease outcomes. B*35:01 (PY) and B*35:12 (Px), which are not considered disease-susceptible alleles, were associated with higher pVL and lower CD4 count (p < 0.05, q < 0.05). B*35:12 detrimental effect was stronger in Guatemala and Nicaragua than in Mexico, and the magnitude of B*35:01 effect in each country was frequency-dependent. B*35:08 (PY) had a modest protective effect on disease outcome (although not statistically significant). No significant impact on median pVL or CD4 count was observed in HLA-B*35 heterozygous persons on cART (n = 359) and Px (n = 134) groups.

Conclusions: These results challenge the B*35-PY/Px hypothesis, indicating that PX alleles can be disease-susceptible. Moreover, the previous observation that the negative effect of the B*35 group is due to all Px alleles is not supported by these data. Interestingly, differences in the detrimental effect of some B*35 alleles in different countries seemed to be frequency-associated, warranting further studies on HIV HLA-associated adaptation in previously uncharacterized populations.

http://dx.doi.org/10.7448/IAS.18.5.20395

WEAA0104 Type-1 programmed dendritic cells induce primary CTL capable of effectively targeting the HIV-1 reservoir
Robbie B Mailiard1; Kellei N Smith3; Paolo Piazza2; James I Mullins2,3 and Charles R Rinaldo1
1Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, United States. 2Department of Microbiology, University of Washington, Seattle, United States. 3Department of Medicine, University of Washington, Seattle, United States.

Presenting author email: rbm19@pitt.edu

Introduction: The “kick and kill” strategy for the cure of chronic HIV-1 infection involves unmasking cells harbouring the latent viral reservoir following their immune elimination. We hypothesize that a broad priming of de novo rather than memory HIV-1 specific cytotoxic T-lymphocytes (CTL) will be required to effectively target the autologous HIV-1 reservoir, and that this “kill” can be best achieved using specifically programmed type-1 dendritic cells (DC1).

Methods: Mature, IL-12p70 producing DC1 were generated using a combination of either TNFa, IL-1b, poly IC, IFNa and IFNg or CD40L and IFNg. Mature, IL-12 deficient DC were generated using either a combination of TNFa, IL-1b, IL-6 and PGE2 or CD40L alone. CD8+ T cells were purified from HIV-1 negative donors, and both naive (primary) and memory CD8+ T cells were isolated from HIV-1 infected Multicenter AIDS Cohort Study participants who were on virus-suppressive CART for several years. These cells were stimulated with autologous DC loaded with HIV-1 Gag peptides or autologous AT2-inactivated HIV-1. Resulting CTL activity was assessed by IFNg ELISPOT and antiviral cytotoxicity assays targeting autologous HIV-1 infected CD4+ T cells.

Results: DC1 proved far superior to the IL-12-deficient DC for inducing primary CTL responses in both infected and uninfected donors. Importantly, DC1 required CD40L "help" at the onset of priming cultures for successful CTL induction and expansion. Both primary and memory CTL each responded to distinct autologous HIV-1 Gag peptides with robust IFNg production. However, a broader targeting of known MHC class I-restricted epitopes was achieved by the primary CTL responders than the memory cells. Importantly, despite substantial IFNg production by both T cell subsets, the primary CD8+ T cells were significantly superior to restimulated memory T cells in eradicated HIV-1 infected CD4+ T cells in the CTL assays.

Conclusions: We demonstrate that naïve T cells from HIV-1 infected persons on cART have the repertoire and ability to be primed by high IL-12p70-producing DC1 to effectively target the HIV-1 reservoir, while memory CTL responses are suboptimal. These findings highlight the importance of directing HIV-1 curative strategies towards the induction of de novo rather than memory HIV-1-specific CTL responses.

http://dx.doi.org/10.7448/IAS.18.5.20396
Introduction: Infants bear a high burden of HIV-1 and tuberculosis (TB) infections, especially in sub-Saharan Africa. We previously demonstrated that the double auxotroph Mycobacterium tuberculosis (Mtb) strain mc6435, engineered to co-express SIV Gag, was safe and immunogenic in neonatal macaques. Here, we tested the efficacy of an oral mc6435 prime/intramuscular MVA-SIV boost regimen to protect against repeated low-dose oral SIVmac251 challenge in infant macaques. Methods: The study included 75 infant rhesus macaques. Mock-vaccinated infants (n = 15) received saline. Vaccinated animals (n = 60) received attenuated auxotrophic Mtb-vaccines with or without SIV gag/env inserts (n = 53) orally, or BCG (n = 7) intradermally at birth. Before nine weeks, infants were exposed to a once-weekly low-dose oral SIVmac251 challenge regimen. Plasma viraemia was determined by real-time PCR. Cellular immune activation was determined by flow cytometric analysis in blood and tissues, soluble plasma markers were measured with a Procarta 37plex. Statistical analysis for risk-per-SIV exposure was determined by SAS and Kaplan-Meier plots. Immune parameters were analyzed using Kruskal-Wallis with multiple Dunn’s comparison.

Results: A single administration of the mc6435 vaccine at birth induced persistent immune activation that was associated with oral SIV acquisition after fewer challenges compared to mock-vaccinated infants. The human BCG vaccine resulted in similar enhanced acquisition of SIV, and BCG-vaccinated infants showed higher peak viraemia compared to mock- and Mtb-vaccinated infant macaques. The potential for enhanced oral SIV acquisition was independent of the mycobacterial vaccine strain, immunization route and boost regimen. Analysis of blood and tissue samples revealed that both Mtb and BCG vaccines induced immune activation of myeloid cell populations and CD4+ T cells, potential target cells of SIV. Immune activation was detected as early as three weeks post-vaccination and persisted for several months.

Conclusions: Our results in the infant macaque model are consistent with BCG-induced immune activation of CD4+ T cells in human infants, reports of persistent monocyte activation in BCG-vaccinated human adults, and increased HIV-1 infection rates in human CD4+ T cells exposed to Mtb complex in vitro. Thus, in areas of high HIV-1 prevalence, TB vaccines need to be tested for their risk of enhancing HIV-1 susceptibility in human infants.
Introduction: Early initiation of long-term antiretroviral therapy (ART) may lead to viral control after treatment discontinuation. Recent evidence indicates that ART initiated within seroconversion limits the HIV-1 reservoir size. Insight into the reservoir in patients with different timings of ART as well as those who can control HIV-1 without therapy should further inform new treatment strategies.

Methods: A cross-sectional study of HIV-1 reservoir size (total and integrated HIV-1 DNA) and dynamics (2-LTR circles and cell-associated HIV-1 unspliced RNA (usRNA)) was performed in peripheral blood mononuclear cells (PBMCs) in 84 HIV-1 infected patients from four cohorts in two clinical centres (London, UK and Ghent, BE): long-term treated patients with ART initiated during seroconversion (SRCV on ART; n = 25) or chronic infection (Chronic ART; n = 32), long-term non-progressors (LTNP; n = 17) and ART-naive recent seroconverters (Recent SRCV; n = 10). Total HIV-1 DNA, 2-LTR and usRNA were measured by ddPCR and integrated HIV-1 DNA by Alu-HIV PCR. Clinical parameters including time on ART and aviremia, CD4 count and CD4/CD8 ratio were collected.

Results: Median total HIV-1 DNA copies were: 92, 48, 137 and 1901 c/10^6 PBMC in SRCV on ART, LTNP, Chronic ART and Recent SRCV, respectively. Significantly lower levels of total (p = 0.041) and integrated HIV-1 DNA (p = 0.003) were detected in early as compared to chronic infection. Differences between the cohorts were determined by Wilcoxon Signed Rank test.

Abstract WEAB0101 - Figure 1. Total HIV-1 DNA (a) and integrated HIV-1 DNA (b) levels in four patient cohorts. Data is shown as log_{10} copies/million (c/M) PBMC and significant p-values are indicated by *. Differences between the cohorts were determined by Wilcoxon Signed Rank test.
churnedly treated patients, however these were lower than those found in LTNP (Figure 1a and 1b). Interestingly, similar levels of integrated HIV-1 DNA were found in Recent SRCV compared to the Chronic ART cohort (p = 0.104), confirming very fast seeding of the reservoir (Figure 1b). Levels of usRNA were significantly lower in early compared to chronically treated cohort (p = 0.007), indicating a lower transcriptional activity in early treated patients and similar to LTNP (p = 0.615). Furthermore, early treated patients exhibited a higher CD4/CD8 ratio as compared to chronically treated patients (p = 0.009), suggesting lower levels of residual immune activation.

Conclusions: Our data demonstrate that long-term early treated patients have smaller reservoir size as compared to patients treated during chronic infection, however not reaching levels found in LTNP. Interestingly, the reservoir dynamics in terms of 2-LTR and usRNA as well as the CD4/CD8 ratio in early treated patients are comparable to LTNP.

http://dx.doi.org/10.7448/IAS.18.5.20398

WEAB0102

High rates of non-reactive HIV serology after antiretroviral treatment initiated in acute HIV infection

James L K Fletcher1; Suteaporn Pinyakorn2; Mark de Souza1; Shirawat Akapirat1; Rapee Trichavaro1; Tippawan Pankam2; Eugene Kroon1,2; Donn Colby3; Peeriya Prueksakakool1; Duanghatiali Suttichom1; Jerome H Kim2,3; Praphan Phanuphak4,5; Nittaya Panuphak4,5; Jintanat Ananworanich2,6 and The SEARCH010/RV254 Study Group

1The Thai Red Cross AIDS Research Centre, SEARCH, Bangkok, Thailand. 2U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States. 3Department of Retrovirology, Armed Forces Research Institute of Medical Sciences – United States Component, Bangkok, Thailand. 4The Thai Red Cross Anonymous Clinic, Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 5Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 6Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States.

Presenting author email: james.f@searchthailand.org

Introduction: Non-reactive HIV serology may be a marker of low HIV viral burden. We examined the evolution of HIV antibody in a cohort of individuals treated during acute HIV infection (AHI).

Methods: Between April 2009 and December 2014, adults attending voluntary HIV testing in Bangkok, Thailand, were screened for AHI, by either pooled nucleic acid testing (4th generation immunoassay (4G IA) non-reactive samples or by 3rd (3G) or 2nd generation (2G) enzyme immunoassay (EIA) of 4G IA reactive samples. Immediate antiretroviral therapy (ART) was offered. Western blot and p24 quantification were performed for Fiebig staging. HIV serology at baseline, weeks 12 and 24 were performed.

Results: Two hundred and thirty-three Thai adults were enrolled from 130,164 samples screened; three individuals did not initiate ART and were excluded from analysis. The median age of the volunteers was 27 years, and 95% were male. Median time from history of HIV exposure to enrolment was 18 days, and median time from enrolment to ART initiation was one day. Of 207 baseline 2G EIA non-reactive subjects, results were available for 150 at week 12 and 135 at week 24 (Table 1). At week 12, 34% were non-reactive by 2G, 3% by 3G and 20% by 4G IA; at week 24, 39% were non-reactive by 2G, 5% by 3G and 18% by 4G. Baseline HIV RNA < 5 log copies/mL (p = 0.02), CD4 count > 350 cells/μL (p = 0.01) and Fiebig stage 1 or 2 (p = 0.03) were predictive of non-reactive 2G EIA at week 24. Lower AUC0-24 week for HIV RNA was also associated with non-reactive 2G EIA at week 24 (p ≤ 0.001, Figure 1). Seroreversion was uncommon. One of 23 individuals with reactive 2G EIA at baseline was non-reactive at week 24; 11 of 207 demonstrated transient 2G EIA reactivity at week 12.

Conclusions: Approximately 40% of individuals who initiated treatment in AHI maintained non-reactivity to 2G EIA after 24 weeks of ART. Rapid ART initiation and HIV RNA decline as well as low HIV RNA and high CD4 at baseline predicted subsequent serological non-reactivity. HIV serologic non-reactivity is likely due to low viral burden, further supporting the benefits of early initiation of ART.

http://dx.doi.org/10.7448/IAS.18.5.20399

WEAB0103

Twenty-four weeks is too short to assess virological success in primary HIV infection treatment

Anne Vandendriessche1; Thomas Mourouzis2,3; Veronique Lemée2; Yasmine Debab2; Gilles Peytavin4,5; Joel Ladner6; François Caron1,3; Jean-Christophe Plantier5,8 and Jeremie Leporrier1

1Rouen University Hospital, Infectious Diseases, Rouen, France. 2Rouen University Hospital, Virology, Rouen, France. 3Université de Rouen, Institut de Recherche et d’Innovation Biomédicale (IRIB), Rouen, France. 4APHP-Bichat Hospital, Pharmacoc-Toxicology, Paris, France. 5Université Paris 7, IAME Inserm 1137, Paris, France. 6Rouen University Hospital, Epidemiology & Public Health, Rouen, France.

Presenting author email: anne.vandendriessche@chu-rouen.fr

Abstract WEAB0102 - Table 1. Non-reactivity to enzyme immunoassay

|                        | Non-reactivity to HIV enzyme immunoassay, N (%) |
|------------------------|-----------------------------------------------|
|                        | Baseline (N = 207)                               | Week 12 (N = 150)                   | Week 24 (N = 135)                   |
| 2nd generation EIA     | 207 (100)                                      | 51 (34)*                          | 53 (39)*                            |
| 3rd generation EIA     | 99 (48)                                       | 5 (3)*                            | 7 (5)*                              |
| 4th generation IA      | 43 (21)                                       | 30 (20)                           | 24 (18)                             |

*McNemar’s test, p < 0.001, compared to baseline (Note: no significant difference between week 12 and 24).
Introduction: The goal of HAART, in established HIV infection, is to obtain virological success (plasma HIV-RNA level (pVL) < 40 copies/mL) associated with CD4 increase at 24 weeks of treatment (W24). Therefore, we analyzed whether such W24 end-point is also pertinent for patients treated for primary HIV infection (PHI).

Methods: We conducted a 10-year retrospective analysis of the immuno-virological response in 55 adults receiving HAART within three months after diagnosis of PHI. Genotypic resistance tests were performed before HAART and at W24 for patients with virological failure (VF) as well as HAART plasma concentrations.

Results: Patients were mostly men (n = 48, 87%), White European (n = 50, 91%), MSM (n = 29, 52%) and mean age 35.9 years. At baseline, mean pVL was 2.6·10^6 cp/mL (8·10^5 to > 10^7) and mean CD4 count 479/mm^3 (77–1003). Patients were mostly infected with subtype B HIV-1 (n = 30, 54%). Due to the evolution of treatment recommendations over the 10-year study period, nine different combinations of HAART were used, including mostly TDF/FTC (n = 38, 69%) and a protease inhibitor as third agent (n = 49, 89%). At W24, 44/55 (80%) patients had pVL < 40cp/mL, whereas 11/55 (20%) had low residual pVL (45–391 cp/ml; mean: 155). In these latter patients, we observed neither mutation associated with resistance nor inefficient drug concentration. VF was correlated in univariate analysis with a significantly higher mean baseline pVL (p = 0.03) and a significantly lower mean baseline CD4 count (p = 0.04) than patients with undetectable pVL at W24. There was no relationship between age, sex, ethnicity, source of contamination, HAART combination or VF at W24.

Conclusions: Our results show that 24 weeks is too short to achieve virological success in patients with high pre-treatment pVL associated with low CD4 count. These data highlight that the usual W24 end-point to conclude virological success may not be appropriate in PHI.

http://dx.doi.org/10.7448/IAS.18.5.20400

WEAB0104
HIV transmitted drug resistance declined from 2009 to 2014 among acutely infected MSM in Bangkok, Thailand
Donn Colby1; Nittaya Phanuphak2; Sunee Srivichayakul1; Peeriya Priekackew1; Putthachard Saengtawan1; Rapee Trichavaroj1; Trevor Crowell2; Jerome Kim3; Jintanat Ananworanich3; Praphan Phanuphak1 and RV254/SEARCH010 Study Group
1Thai Red Cross AIDS Research Center, SEARCH, Bangkok, Thailand. 2Chulalongkorn University Hospital, Bangkok, Thailand. 3Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand. 4U.S. Military HIV Research Program, Bethesda, United States. 5Thai Red Cross AIDS Research Center, Bangkok, Thailand.

Abstract WEAB0104 - Table 1. Transmitted drug resistance among MSM in Bangkok

| Total | 2009–2010 | 2011–2012 | 2013–2014 | p |
|-------|-----------|-----------|-----------|---|
|       | n (%)     | n (%)     | n (%)     | n (%) |
| N enrolled | 184       | 32        | 52        | 100 |
| Any resistance | 13 (7.1) | 4 (12.5) | 5 (9.6) | 4 (4.0) | 0.07 |
| N with RT genotype | 183 | 32 | 51 | 100 |
| NRTI mutations | 6 (3.3) | 2 (6.3) | 2 (3.9) | 2 (2.0) | 0.23 |
| NNRTI mutations | 4 (2.2) | 3 (9.4) | 1 (2.0) | 0 (0) | 0.03 |
| N with PR genotype | 180 | 32 | 50 | 98 |
| PI mutations | 6 (3.3) | 1 (3.1) | 3 (6.0) | 2 (2.0) | 0.52 |

Introduction: Rates of transmitted drug resistance (TDR) have been reported to be 11–21% in the USA and Europe, where baseline genotype resistance testing prior to antiretroviral therapy (ART) is routine. In resource limited settings, baseline resistance testing is not the standard of care, but TDR data can ensure that first-line treatment regimens used in national HIV treatment programs remain effective.

Methods: The RV254/SEARCH010 cohort has enrolled patients with acute HIV infection from the largest HIV testing and counselling centre in Thailand, since 2009. Patients have baseline genotype testing prior to initiating ART: TRUGENE HIV-1 (Siemens Healthcare Diagnostics, Australia) was used for the first 66 patients and a validated in-house method for the remainder. Mutations were categorized following the World Health Organization surveillance drug resistance mutation (SDRM) list. Prevalence of resistance was calculated by dividing the number of subjects with mutations by the number enrolled during each time period. Change in prevalence over time was assessed by chi-square test for trend. Time periods were combined into two-year blocks for analysis.

Results: Genotype resistance test results were available from 184 of the first 186 subjects enrolled in the study; virus from two patients could not be amplified. Median age was 28 years, 95% were male and 92% were men who have sex with men (MSM). Median time (interquartile range, IQR) from HIV exposure to diagnosis was 18 (14–24) days. Median IQR HIV RNA was 5.7 (5.1–6.7) log_{10} copies/mL and was not significantly different between patients with and without resistance mutations. Median IQR CD4 was 352 (260–486) cells/mm^3. Prevalence rates for resistance mutations are shown in the table. Overall TDR was 7.1%, declining from 12.5% in 2009–2011 to 4% in 2013–2014, although the change was not statistically significant (p = 0.07). The mutations most commonly found were the M46I (n = 3), K103N (n = 2), Y181C (n = 2) and M41L (n = 2).

Conclusions: TDR does not appear to be increasing among MSM in Thailand and may be declining. Routine genotype testing prior to initiating ART may not currently be necessary in this population, but surveillance for TDR should continue to monitor for any future changes.

http://dx.doi.org/10.7448/IAS.18.5.20401

WEAC0101
Social cohesion among sex workers has an independent effect on reduced client condom refusal in a Canadian setting
Elena Argento1; Putu Duft2,3; Brittany Bingham1,3; Paul Nguyen1; Steffanie Strathdee4 and Kate Shannon2,3
1Gender & Sexual Health Initiative, BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2School of Population and Public Health, University of British Columbia, Vancouver, Canada. 3Brock University, St. Catharines, Canada. 4Department of Family Medicine, University of British Columbia, Vancouver, Canada.
Health, University of British Columbia, Vancouver, Canada. 5Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 6Division of Global Health, Department of Medicine, University of California, San Diego, United States. Presenting author email: eargento@cfenet.ubc.ca

**Introduction:** Despite substantial evidence in low and middle-income settings that community-led empowerment and collectivization can be a powerful determinant of successful HIV prevention, there is limited understanding of the impact of connectedness among sex workers on HIV risk in the global north. This study longitudinally modelled the impact of social cohesion on client condom refusal among street and off-street sex workers in Vancouver, Canada.

**Methods:** Longitudinal data were drawn from an open prospective cohort of female (trans*-inclusive) sex workers, AESHIA (An Evaluation of Sex Workers Health Access), in Metro Vancouver (2010–2013). Participants were recruited through outreach to outdoor locations and hidden indoor and online venues and completed bi-annual interview questionnaires and HIV/STI testing by a project nurse. Lippman and colleagues’ Social Cohesion Scale measured community connectedness (i.e. perception of mutual aid, trust and support) among sex workers. Bivariable and multivariable logistic regression using generalized estimating equations (GEE) were used to examine the independent effect of social cohesion on client condom refusal over three-year follow-up.

**Results:** Of 654 sex workers, one-third (n = 221) reported client condom refusal over three-year follow-up. On average, a medium level of social cohesion was reported; median social cohesion scores were 24 (IQR 20–29, range = 4–45). In the final multivariable confounder model, for every one point increase in the social cohesion score, the odds of client condom refusal decreased by 3%, (adjusted odds ratio = 0.97; 95% CI: 0.95–0.99) after adjusting for age, injection drug use and place of solicitation.

**Conclusions:** This is the first study to examine the independent effect of social cohesion on client condom refusal among sex workers in the global north. Findings suggest that community collectivization and sex worker-led empowerment efforts can have a direct protective effect on HIV risk reduction and shifting social norms among clients in the sex industry. Given public health and human rights concerns around new Canadian laws introduced this year to further criminalize sex workers’ ability to work together (C-36), these findings highlight the urgent need for legal reforms and a structural framework that better promotes sex workers’ ability to more formally collectivize, including sex worker-led efforts in the HIV response.

http://dx.doi.org/10.7448/IAS.18.5.20402

**WEACO103**

High utilization of health services and low ART uptake among female sex workers (FSW) in three South African cities: results from the South Africa health monitoring study (SAHMS-FSW)

Tim Lane1; Maria Sibanyoni2; Albert Manyuchi3; Thomas Osmand4; Alexander Marr5; Mike Grasso6; Zach Isdahl7; Nyaradzo Mutanha8; Phakamile Makhubela9; Mpho Silma3; Nkosinathi Zuma3; Helen Struthers5; James McIntyre3; Helen Rees2 and Francois Venter2

1Center for AIDS Prevention Studies, University of California, San Francisco, United States. 2Wits Reproductive Health & HIV Institute, Johannesburg, South Africa. 3Anova Health Institute, Johannesburg, South Africa. 4Center for AIDS Prevention Studies, University of California, San Francisco, United States. Presenting author email: tim.lane@wits.ac.za

**Introduction:** The 2012–2016 South Africa HIV National Strategic Plan calls for integrated behavioural and biological surveillance with female sex workers (FSW) to address critical HIV epidemiological and programmatic data gaps. In 2013–2014, we conducted the SAHMS-FSW in three metropolitan areas to estimate prevalence of HIV, syphilis and associated risk factors and assess current utilization of health and HIV services.

**Methods:** We recruited 764 FSW in Johannesburg, 650 in Cape Town and 766 in Durban using respondent-driven sampling (RDS) to take behavioural surveys, access voluntary counselling and testing and provide blood samples for HIV and syphilis surveillance. Serological testing followed national standards. We used RDSAT (version 7.1) to estimate population-adjusted prevalence for HIV, syphilis, selected behavioural and programmatic indicators; and SPSS (version 18.0) for multivariate logistic regressions with selected RDS-adjusted behavioural and programmatic indicators to identify site-specific significant associations with HIV-infection. We report adjusted odds ratios (aOR) and 95% Confidence Intervals (95% CI) in...
Abstract WEAC0103 - Table 1. Predictors of HIV – South African Health Monitoring Study, 2014, and current ART utilization

| Venue of sex work (street based is reference) | Johannesburg | Cape Town | Durban |
|-----------------------------------------------|--------------|-----------|--------|
| Brothel based only                            | 0.59         | 2.13      | 2.31   |
| Street and brothel based only                 | 3.01         | 0.01      | 0.18   |
| Health care utilization                       | 1.35         | 1.63      | 1.26   |
| ANC utilization                               | 0.28         | 0.31      | 1.8    |
| Peer education exposure                       | 3.1          | 0.31      | –      |
| UAI with non-paying partner                   | –            | 28.55     | 10.52  |
| Age                                           | 1.13         | 1.19      | 1.15   |

Introduction: Female sex workers (FSW) are a hard-to-reach key population in sub-Saharan Africa with high HIV prevalence, infrequent access to HIV care services, and low uptake of antiretroviral therapy (ART). We describe HIV seroprevalence, HIV status awareness, and ART eligibility and use for venue-based FSW in Lilongwe, Malawi. Although FSW accessing healthcare services are more likely to be HIV-positive, current ART utilization demonstrates a substantial gap to be addressed as South Africa begins implementing universal treatment. Identification and expansion of effective outreach models are needed to increase utilization of ART, as well as effectively target prevention services for HIV-negative FSW. Health outreach strategies must account for behavioural and structural factors in specific sex-work environments.

http://dx.doi.org/10.7448/IAS.18.5.20404
Injection drug use among female sex workers in Iran: findings of the first national bio-behavioural study

Abbas Sedaghat1; Mohammad Karamouzian2; Hamid Sharifi2; Ali Mirzaee2; Mostafa Shokoohi2 and Aliakbar Haghdoost2

Introduction: While the prevalence of HIV among female sex workers (FSW) in Iran is approximately 4.5%, FSW who have ever injected drugs are believed to have a significantly higher HIV prevalence. This study tries to assess the determinants of injection drug use among FSW through Iran’s first and only national bio-behavioural surveillance survey.

Methods: This survey was conducted in 2010, by recruiting 827 FSW through facility-based sampling from 21 sites in 14 cities in Iran. Data were collected through face-to-face interviews using a pilot-tested standardized risk assessment questionnaire. All analyses were weighted based on the response rate and adjusted for the clustering effect of the sampling sites. A predictive multivariable logistic regression model was constructed to investigate the determinants of injection drug use among FSW in Iran.

Results: Mean age of participants was 32, 50% had primary school education, 36% were married and most of them reported sex work as their primary source of income. Of all participants, 71.6% (95% CI: 68.5–74.6) had ever used drugs and 14.6% (95% CI: 12.2–16.9) had ever injected drugs. The most frequently injected drugs were methadone, crystal methamphetamine and crack. Among those who had ever injected drugs, 36.6% reported that they had a drug injection during the previous month and the prevalence of HIV was 11.2% (95% CI: 5.4–21.5). In the multivariable model, history of HIV testing (AOR = 1.79, 95% CI: 1.19–2.69), duration of sex work (AOR = 1.08, 95% CI: 1.04–1.12), drug use before sex in the past month (AOR = 2.70, 95% CI: 1.79–4.10) and alcohol use before sex in the past month (AOR = 2.07, 95% CI: 1.35–3.17) were significant predictors of injection drug use.

Conclusions: The prevalence of injection drug use among FSWs in Iran is concerning which calls for special attention to be paid to FSWs who inject drugs. As selling sex to cover drug habit expenses is a likely practice among female drug users, a part of harm reduction programs for drug users should try to target this population in order to reduce their sex work practices.

http://dx.doi.org/10.7448/IAS.18.5.20406
Abstract WEAC0106LB - Table 1. Predictors of ART use among ART-eligible FSW

| Predictors                           | Prevalence ratio | Adjusted prevalence ratio |
|--------------------------------------|------------------|---------------------------|
|                                      | [95% CI]         | [95% CI]                  | p-value |
| Age [REF ≥ 30 years]                 |                  |                           |         |
| 18–29 years                          | 0.78 [0.60–1.02] | 0.87 [0.66–1.16]          | 0.346   |
| Number of clients past 30 days       |                  |                           |         |
| 0–10                                 | REF              | REF                       |         |
| 11 or more                           | 1.24 [0.98–1.57] | 1.29 [1.02–1.63]          | 0.032   |
| Partnership and disclosure           |                  |                           |         |
| No non-paying intimate partner       | REF              | REF                       |         |
| Disclosed to some or all intimate partners | 0.87 [0.69–1.09] | 0.86 [0.69–1.08]          | 0.188   |
| Has not disclosed to intimate partners | 0.41 [0.19–0.87] | 0.47 [0.23–0.95]          | 0.036   |
| Mother                               |                  |                           |         |
| No                                   | REF              | REF                       |         |
| Yes                                  | 0.82 [0.62–1.08] | 0.76 [0.58–0.99]          | 0.047   |

Univariate analyses also assessed age, race, education, mobility, violence and depression. The adjusted model includes variables statistically significant at p < 0.20 in univariate analyses, including variables listed, age and time since HIV diagnosis.

Methods: FSW ≥ 18 years were recruited through respondent driven sampling into a cross-sectional study in Port Elizabeth, South Africa. Socio-demographics, reproductive, behavioural and healthcare history were assessed through interview-administered questionnaires. All FSW were tested for HIV, and CD4 counts were assessed among women living with HIV. Engagement in the HIV care cascade is described, and predictors of self-reported antiretroviral therapy (ART) uptake among treatment-eligible, previously diagnosed FSW were estimated using robust Poisson regression. As ART eligibility thresholds changed from ≤ 350 to ≤ 500 cells/mm³ during the study period, eligibility was determined based on CD4 count and current guidelines at time of study participation.

Results: Between October 2014 and April 2015, 410 FSW participated in study activities. Overall, 261/410 (63.7%) were living with HIV. Prior history of HIV testing and diagnosis were relatively high (>80%), however, self-reported ART coverage among HIV-positive FSW was just 39% (Figure 1). After adjusting for time since HIV diagnosis, women who had intimate partners and had not disclosed their HIV status to them were over 50% less likely to be on ART than FSW not in relationships (Table 1). Mothers and women with fewer clients per month were also statistically significantly less likely to be on treatment than non-mothers or FSW with more clients in the adjusted analyses.

Conclusions: HIV testing was common among FSW in this setting, and awareness of HIV status was relatively high, however, efforts are needed to improve ART uptake and retention in this population. Though viral suppression data were not available, this likely represents additional fall-out from the care cascade. Disclosure to partners and family appear to be key barriers to treatment uptake. Building HIV disclosure skills and efficacy may help to improve health outcomes for FSW living with HIV and prevent onward transmission.

http://dx.doi.org/10.7448/IAS.18.5.20556

WEAD0101

Community-based adherence clubs improve outcomes for stable antiretroviral therapy patients: findings from Gugulethu, South Africa

Anna Grimsrud1; Maia Lesosky1,2; Cathy Kalombo3; Linda-Gail Bekker2,4 and Landon Myer2

1Division of Epidemiology and Biostatistics, University of Cape Town, Cape Town, South Africa. 2Department of Medicine, University of Cape Town, Cape Town, South Africa. 3Gugulethu Community Health Centre, Provincial Government of the Western Cape, Cape Town, South Africa. 4The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Introduction: There are few data on patient outcomes from community-based models to deliver antiretroviral therapy (ART), with previous research focused on models for home-based delivery. We describe outcomes of ART patients decentralized to community-based adherence clubs (CACs) and compare outcomes with patients managed within a facility-based model.

Methods: This analysis included 8150 adults initiating ART from 2002–2012 at a public sector clinic in Gugulethu, South Africa, followed until the end of 2013. From June 2012, stable patients (ART > 12 months, suppressed viral load) were referred to CACs. Kaplan-Meier methods estimated time to outcomes among CACs stratified by gender and age (youth: 15–24 years of age and older patients: >25 years of age). Long-term follow-up (LTFU) was compared between CACs and facility-based care using proportional hazards models with time-varying covariates and inverse probability weights of CAC participation.

Results: Of the 2113 patients (68.8% female, 7.4% youth) decentralized to a CAC, 94% were retained on ART after 12-months. After the first CAC visit, LTFU among CAC patients was 5.6% and 6.4% at 12-months (Figure 1a) and viral rebound 2.2 and 1.5% (Figure 1c), for men and women, respectively. LTFU was higher in CACs among youth compared to older patients (Figure 1b). Youth were twice as likely to be LTFU (adjusted hazard ratio) aHR: 2.17, 95% CI 1.26–3.73) and experience viral rebound (aHR 2.24, 95% CI 1.00–5.04) in a CAC compared to older patients. Overall, CAC participation reduced LTFU by 67% (aHR: 0.33, 95% CI 0.27–0.40) compared to facility-based care, and this reduction persisted when stratified by patient demographic and clinic characteristics. Patients initiating ART most recently, in 2010 or 2011, had a 90% reduction in LTFU in a CAC compared to facility-based care (95% CI 0.05–0.21). Youth were the only sub-set of patients that did not have a significant decrease in risk of LTFU in CACs compared to the community health centre (CHC) (aHR 0.68, 95% CI 0.37–1.22).

Conclusions: Community-based Adherence Clubs appear to be associated with a decreased risk of LTFU compared to facility-based care. More research is needed on how to expand the role of community-based ART services and what components of these delivery models support long-term retention.

http://dx.doi.org/10.7448/IAS.18.5.20407

WEAD0102

Sustained viral suppression in persons living with HIV/AIDS receiving HAART in Peru

Patricia Caballero1,2; Cosme Marcelo Da Silva3 and Marly Da Cruz4

1National Institute of Health and Social Protection, Ministry of Health, Health Services, Family Planning, Integrated Maternal Health Services, Lima, Peru. 2Flaum Foundation, University of Pennsylvania, Philadelphia, PA, USA. 3Healthcare Foundation, Lima, Peru. 4Faculty of Medicine, University of Lima, Lima, Peru.
Introduction: Successful treatment for HIV infection requires sustained viral suppression (SVS). Patients with undetectable HIV-RNA levels have a significantly lower risk of clinical disease progression. And at community level viral suppression is important to reduce HIV transmission and the emergence of resistant strains. The study aimed to analyze the frequency and duration of viral suppression (VS) in the first cohort of people living with HIV/AIDS (PLWHA) under treatment.

Methods: We retrospectively evaluated data from all PLWHA uninsured adults who initiated HAART through the National Program during 2004-2006 and followed-up until 2012. Patients with complete records in the National Laboratory Reporting System Data Base were included. The duration of VS was analyzed using survival analysis (Kaplan-Meier) in PLWHA who achieved viral suppression. Survival time was measured between the first control with viral load ≤400 copies/ml until the presence of first interruption or failure of viral suppression (FSV) with viral load >400 copies/ml. Persons lost to follow up and those without FSV were censored. R Software 3.0.3 was used.

Results: During the study period a total of 6289 PLWHA had access to health care settings for initial evaluation and only 5142 received HAART. Of these, 4530(88%) achieved VS for variable time (responders) and 612 never presented VS (non-responders). Cumulative survival rate was analyzed in responders: 91.1% maintained VS up to one year, 84.6% up to two years, 80.2% to three years, 77.1% to four years, 74.1% to five years and 70.1% to six years. According to survival analysis, Kaplan-Meier curves presented lower duration of VS in young adult patients, females, persons in prisons and those who did not increase their CD4 above baseline. No differences were observed with baseline CD4 and viral load (p < 0.05).

Conclusions: This findings suggest that SVS as a programme indicator is feasible and useful for monitoring health care settings and ranking them like a control quality measure. SVS could also be included as another parameter in cascade of treatment measures.

http://dx.doi.org/10.7448/IAS.18.5.20408

WEAD0103

Entry into care following universal home-based HIV testing in rural KwaZulu-Natal, South Africa: the ANRS TasP 12249 cluster-randomized trial

Melanie Plazy1,2; Kamal ElFarouki3,4; Collins Iwuji3,6; Nonhlanhla Okesola5; Joanna Orne-Gliemann1,2; Joseph Larmarange5,7; Marie-Louise Newell8; Deenan Pillay5,9; François Dabis1,2; Rosemary Dray-Spira1,4 and for the ANRS 12249 TasP Study Group

1INSERM U 897 – Centre Inserm Épidémiologie et Biostatistique, Bordeaux, France. 2Université Bordeaux, Institut de Santé Publique, d’Épidémiologie et de Développement (ISPED), Bordeaux, France.
**WEAD0104**

**Assessing the HIV care continuum in The Caribbean, Central and South America network for HIV epidemiology (CCASAnet); progress in clinical retention, cART use and viral suppression**

Peter F Rebeiro1; Carina Cesar2; Bryan E Shepherd3; Raquel B De Bono4; Claudia Cortés5; Fernanda Rodrigues6; Pablo Belaunzarán-Zamudio7; Jean W Pape8; Denis Padgett9; Daniel Hoces10; Catherine C McGowan11 and Pedro Cahn12

1School of Medicine, Vanderbilt University, Nashville, United States.
2Fundación Huesped, Buenos Aires, Argentina.
3Instituto Nacional de Infectología Evando ChagasFundación Oswaldo Cruz, Rio de Janeiro, Brazil.
4Fundación Arriarán, Universidad de Chile, Santiago, Chile.
5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
6Le Groupe Haltien d’Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince (GHESKIO), Port-au-Prince, Haiti.
7Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras.
8Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

**Introduction:** Retention, combination antiretroviral therapy (cART) use and viral suppression are key stages in the HIV Care Continuum associated with delayed disease progression and reduced transmission. We assessed trends in these indicators within the large and diverse CCASAnet cohort over a decade.

**Methods:** Adults from CCASAnet clinical cohorts in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru contributed data from first visit between 2003 and 2012 until final visit, death, or the end of 2012. Retention was ≥ 2 HIV care visits in a year, > 90 days apart. cART use was prescription of a regimen of ≥ 3 active antiretroviral agents in a year. Viral suppression was HIV-1 RNA < 200 copies/mL at last measurement in the year. cART use and viral suppression denominators were subjects with ≥ 1 visit in the year. Multivariable modified Poisson regression models were used to assess temporal trends and predict percentages meeting each indicator in each year, adjusting for age, sex, HIV transmission mode, cohort, calendar year and total time in care.

**Results:** Among 18,799 individuals contributing to retention analyses, 14,380 to cART use analyses and 13,330 to viral suppression analyses.
analyses, there were differences between those meeting indicator definitions versus not by most characteristics (Table 1). There were significant improvements in the indicators from 2003 to 2012: from 63 to 80% retained, 74 to 91% using cART, and 53 to 82% virally suppressed (p < 0.05, each). Predicted values from adjusted models revealed similar trends (Figure 1).

Female sex (risk ratio (RR) = 0.96; 95% confidence interval (CI): 0.93, 0.99 vs. males) and injection drug use (IDU) as HIV transmission mode (RR = 0.84; 95% CI: 0.74, 0.94 vs. male sexual contact with males (MSM)) were associated with lower retention, but unrelated with cART use or viral suppression. MSM transmission (RR = 0.96; 95% CI: 0.92, 0.99) decreased probability of cART use versus heterosexual transmission.

Conclusions: HIV Care Continuum outcomes have improved over time. However, efforts must be made to improve retention, particularly among females and IDUs, and cART use must be improved among MSM. Additional research is needed to sustain progress by identifying impediments to achieving positive Care Continuum outcomes, and their causes, in these settings.

http://dx.doi.org/10.7448/IAS.18.5.20410

WEAD0105LB
Providing same day, observed ART to newly diagnosed HIV+ outpatients is associated with improved virologic suppression

Christopher Pilcher1; Hiroyu Hatano1; Aditi Dasgupta2; Diane Jones1; Sandra Torres2; Fabiola Calderon2; Clarissa Osipina-Norvell2; Wendy Hartogensis2; Erin Demicco2; Elvin Geng2; Monica Gandhi1 and Diane Havlir2

1HIV/AIDS Division, Medicine, UCSF, San Francisco, United States. 2Tulane University Medical School, New Orleans, United States.

Presenting author email: cpilcher@php.ucsf.edu

Introduction: Despite known clinical and prevention benefits, ART is typically delayed by weeks-to-months after HIV diagnosis to allow linkage to care, HIV education, social stabilization and laboratory evaluation. The UCSF/San Francisco General Hospital (SGFH) RAPID programme aimed to eliminate this delay by providing same-day/observed ART even as HIV care was being established. We investigated consequences of the RAPID treatment initiation strategy.

Methods: RAPID eligibility included new HIV diagnosis with acute/recent infection, active opportunistic infection or CD4 < 200/mm3. At referral, all RAPID-eligible or -ineligible patients with new diagnosis received a standard package of multidisciplinary services for social support, education, risk and stigma reduction; labs were drawn; and regular provider follow-up was arranged. The RAPID intervention consisted of 1) same-day access to an on-call provider; 2) a five-day ART supply facilitated by and 3) an accelerated process for insurance benefits. Focusing on a July 2013–December 2014 programme period, survival analysis was used to compare time to achieving viral suppression over time by ART initiation strategy.

Abstract WEAD0104–Figure 1. Figure in HIV care continuum outcomes in CCASAnet.

Abstract WEAD0105LB–Figure 1. Viral suppression over time by ART initiation strategy.
WEAD0201
Targeted HIV testing in home or clinic for older children of HIV-infected adults in care increases paediatric HIV testing rates and reveals high prevalence of previously undiagnosed HIV infection

Anjuli Wagner1; Irene Njuguna2; Cyrus Mugo3; Irene Inwani3; Elizabeth Maleche-Obimbo2; Kenneth Sherr4; Dalton Wamalwa2; Grace John-Stewart5,6,7 and Jennifer Slyker4
1Department of Epidemiology, University of Washington, Seattle, United States. 2Department of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya. 3Kenyatta National Hospital, Nairobi, Kenya. 4Department of Global Health, University of Washington, Seattle, United States. 5Department of Global Health, University of Washington, Seattle, United States. 6Department of Pediatrics, University of Washington, Seattle, United States. 7Department of Medicine, University of Washington, Seattle, United States. Presenting author email:anjuliwagner@gmail.com

Introduction: Health systems offer infant HIV testing as part of prevention of mother-to-child HIV transmission (PMTCT) programs, but are not built to systematically diagnose HIV infection in older children before symptomatic illness. Offering HIV-infected adults attending HIV treatment programs targeted testing in home or clinic may increase early diagnosis of paediatric HIV.

Methods: HIV-infected parents attending HIV care clinic at Kenyatta National Hospital (KNH) in Nairobi, Kenya were asked about their children’s HIV status. Adults with untested children ≤ 12 years old chose to test children either at home (HBT) or in a clinic (CBT). Multinomial relative risk regression was used to identify cofactors of testing acceptance.

Results: During the 9-month period when targeted testing was routinely offered, approximately four times as many children were tested per month as in the previous 10-month period (13.6 vs 3.5 per month, RR: 3.9, 95% CI: 2.8–5.5). Among 116 enrolled adults, 23 (20%) chose HBT and had 46 children tested, 48 (41%) chose CBT and had 58 children tested, and 45 (39%) did not complete testing. More adults chose CBT than HBT (median age: 8 years (IQR: 2–11)).

Compared to adults who chose CBT, adults who chose HBT were more likely to have higher income, more education, be male, have a partner, have an unemployed partner and have a partner known to be HIV negative (p < 0.05), while adults who did not test their children were more likely to have higher income and have a partner who was known to be HIV negative or of unknown HIV status (p < 0.05). In multivariate analyses, income and partner status remained significantly associated with testing choice.

Conclusions: Targeting HIV-infected parents in care increased the rate of paediatric testing and found high prevalence of paediatric HIV. CBT was preferred over HBT at this urban referral hospital. Efforts to increase paediatric HIV testing and to understand parental characteristics are important to provide timely diagnosis and linkage to care.

http://dx.doi.org/10.7448/IAS.18.5.20411

Abstract WEAD0201—Figure 1. Active referral increases paediatric HIV testing.
Moving towards targeted HIV testing in older children at risk of vertically transmitted HIV

Tsitsi Bandason1; Grace Mchugh1; Rashida Ferrand1; Shungu Munyati2; Katharina Kranzer3 and Prosper Chonzi4

1Biomedical Research and Training Institute, ZENITH, Harare, Zimbabwe. 2Biomedical Research and Training Institute, Harare, Zimbabwe. 3London School of Hygiene and Tropical Medicine, London, United Kingdom. 4Harare City Health, Harare, Zimbabwe.

Presenting author email: tbandason@brti.co.zw

Introduction: WHO recommends PITC to all in high-burden countries. Symptom screening algorithms have been used widely for other diseases like tuberculosis. Prompt identification of undiagnosed HIV infection remains a priority in Southern Africa. We previously proposed a simple algorithm where a child is asked to respond to any of the four questions, namely, whether child 1) has previously been admitted to hospital, 2) has had recurring skin problems, 3) is a single or double orphan 4) has experienced poor health in the past three months which can be asked by any cadre at primary care level for screening older children at risk of HIV infection and requiring an HIV test. The objective of this study was to validate the performance of this algorithm in a primary care setting.

Methods: All previously untested children, aged 6–15 years attending seven selected Primary Health Care Clinics of Harare, Zimbabwe, with parental/guardian consent were tested for HIV infection and asked to respond to four algorithm questions. Each positive response was scored as one.

Results: A total of 6102 (74%) children with median age 9 (IQR: 7 to 11) years, 3138 (51%) of them male, consented to an HIV test. HIV prevalence was 4.8% (95% CI: 4.2–5.3) and positivity increased successively as the score increased with those who scored zero, 55/3830 (1%); scored one, 110/1609 (7%); scored two, 80/489(16%); scored three, 26/96 (27%); scored four, 10/16(63%).

A child with a score of one or more had eight times odds (95% CI: 6.6–11) of testing HIV positive with a sensitivity of 80% (95% CI: 75–85), specificity of 66% (95% CI: 64–67). Sensitivity was higher in those aged 10 years or more (86% vs. 70%, p = 0.001). Overall, we needed to test 11 children to identify one HIV positive.

Conclusions: The algorithm maintained its integrity and demonstrated that it is a sensitive tool screening older children at risk of HIV infection. The algorithm can be used by lower cadre healthcare workers and can help prioritize limited resources.

Impact of implementing “Test and Treat” policy on paediatric ART enrolments and coverage in Uganda

Peter Elyanu1,2; Eleanor Magongo1; Barbara Asire1; Ivan Lukabwe1; Harriet Bitimwine1; Cordelia Katureebe1; Pamela Achi1; Vivienne Mulema1; Eric Dziuban2; Nandita Sugandhi2; Victor Musiime2; Nora Namuwenge1 and Joshua Musinguzi1

1STD/AIDS Control Program, Ministry of Health, Kampala, Uganda. 2School of Public Health, University of Texas, Houston, United States. 3Baylor College of Medicine Children’s Foundation-Uganda, Kampala, Uganda. 4Pharmacy Division, Ministry of Health/Management Sciences for Health, Kampala, Uganda. 5Clinton Health Access Initiative (CHAI), Kampala, Uganda. 6CDC, Atlanta, Uganda. 7Clinton Health Access Initiative (CHAI), Boston, United States. 8Makerere University College of Health Sciences, Pediatrics and Child Health, Kampala, Uganda.

Presenting author email: eleanormagongo@gmail.com

Introduction: In 2013, it was estimated that 193,500 of children under 15 years were living with HIV in Uganda and 83% would be eligible for treatment according to WHO guidelines; recommending lifelong treatment for all children under five years and all older patient based on clinical or immunologic staging. However, despite efforts to scale up paediatric treatment, coverage remained low at 22% in 2013. Programmatic barriers to ART initiation in children include the perception that paediatric ART is complicated, unavailability of CD4 testing and difficulty in accurate clinical staging. In September 2013, Uganda adopted a “test and treat” antiretroviral therapy (ART) policy for all HIV infected children under 15 years of age to simplify recommendations and remove programmatic barriers to ART initiation in children.

Methods: The MOH launched and disseminated these guidelines to all stakeholders through three day health facility based trainings and mentoring during the period January to December 2014. To evaluate the impact of this new policy a comparison was made between the number of children initiated between June and December 2013 and those initiated between January and June 2014.
Results: By December 2014, 1340 (84%) of 1600 ART providing health facilities and 17,238 health workers were trained on the new guidelines. There was a 1.4-fold increase in the number of HIV-infected children newly initiated on ART from 5540 in June–Dec 2013 to 9145 in Jan–June 2014. The increase was greater among children aged 5–14 years and 2–4 years (2.4 and 1.4 fold, respectively); however, there was no change among the under two year old’s (see Figure 1). Pregnant adolescents constituted 2.5% (1229/4145) of children less than 15 years of age enrolled on ART in Jan–June 2014. Paediatric ART coverage has increased from 22% (43,481/193,500) in December 2013 to 27% (51,305/193,500) in June 2014.

Conclusions: Expanding eligibility criteria increases initiation of older children on ART to enrol those who are at higher risk of disease progression/mortality, more work needs to be done to improve early infant diagnosis (EID) and early case detection.

http://dx.doi.org/10.7448/IAS.18.5.20413

WEAD0204

Immunization practice and vaccine safety perception in centres caring for children with perinatally acquired HIV: results from the Pediatric European Network for Treatment of AIDS survey

Emma Concetta Mannò1; Alasdair Bamford2; Pablo Rojo Conejo3; Laura Marquez4; Maria Jose Mellado5; MA ´ngeles Mun˜oz-Doporto6; Emma Concetta Manno1; Alasdair Bamford2; Pablo Rojo Conejo3; Laura Marquez4; Maria Jose Mellado5; MA ´ngeles Mun˜oz-Doporto6; Eeva Salo20; Alla Volokha21; Henriette J Scherpbier22; Delane Shingadia20; Antonio Di Biagio3; Vanja Giacomett17; Rosenfeldt Vibeke18; Helena Helena de Sousa Marques19; Eva Salo20; Alia Volokha21; Henriette J Scherpbier22; Tim Niehues23; Jack Levy24; Magdalena Marczynska25; Mariana Mardarescu26; Veronique Reliquet27; Carlo Giacquito28; Stefania Bernardi29 and Paolo Palma30

1Unit of Immune and Infectious Diseases, DPUO, University Department of Pediatrics, Children’s Hospital “Bambino Gesu”, Rome, Italy. 2Department of Paediatric Infectious Diseases and Immunology, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom. 3Hospital Universitario Doce de Octubre, Unidad de Inmunodeficiencias paediatricos, Servicio de Pediatría, Madrid, Spain. 4Centro Hospitalar do Porto, Pediatric Infectious Diseases and Immunodeficiencies Unit, Porto, Portugal. 5Hospital Universitario Infantil La Paz, Madrid, Spain. 6Center Hospitalar do Porto, Pediatric Infectious Diseases and Immunodeficiencies Unit, Porto, Portugal. 7Hospital Universitario Infantil La Paz, Madrid, Spain. 8Infectious Diseases and Microbiology Unit, Institute of Child Health, University College London, London, United Kingdom. 9U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States. 10Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States. 11Instituto de Infectologia Emilio Ribas, São Paulo, Brazil. 12Department of Immunology and Infectious Diseases, School of Medicine, University of Padova, Padova, Italy. 13Department of Pediatric Infectious Disease and Immunology, Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom. 14Imperial College Healthcare NHS Trust, London, United Kingdom. 15Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 16Infectious Diseases Unit, IRCSS San Martino University Hospital-IST, University of Genoa, Genoa, Italy. 17Department of Paediatrics, I Sacco University Hospital, Milan, Italy. 18Department of Paediatrics, Hvidovre University Hospital, Copenhagen, Denmark. 19Instituto da Criança, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. 20Children’s Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. 21Children Center of Clinical Immunology, Kiev, Ukraine. 22Department of Pediatric Haematology, Immunology and Infectious Diseases, Academic Medical Center, Emma Children’s Hospital, Amsterdam, The Netherlands. 23Department of Pediatrics, Helios Clinic Krefeld, Krefeld, Germany. 24Saint-Pierre University Hospital, Brussels, Belgium. 25Pediatric Department of Infectious Diseases, Medical University of Warsaw; Warszawa, Poland. 26Department of Paediatric Immunodepression, Prof. Dr. Matei Bal, National Institute for Infectious Diseases, Bucharest, Romania. 27Department of Infectious Diseases, CHU Nantes, Nantes, France. 28Department of Paediatrics, University of Padova, Padova, Italy. 29Presenting author email: emma_m@hotmail.it

Introduction: Perinatally HIV-infected children are more susceptible to vaccine preventable infections and vaccine induced immunity is less robust than in healthy children because of precarious waning of protective immunity. For this high risk population it is important to design specific vaccine schedules to define correct dosing and to set accurate correlates of protection. This survey was performed to give an overview of current vaccination practices among paediatricians looking after vertically HIV-infected children.

Methods: An online questionnaire regarding vaccination practices in HIV-infected children was completed by investigators from the PENTA network. Data were collected between November 2013 and March 2014.

Results: A total of 88 experts in the management of paediatric HIV-infection from 46 different units looking after 2465 patients completed the questionnaire. The majority of units (72%) did not perform routine childhood immunizations in HIV centres. Vaccination histories were incomplete for 40% of the studied population. Influenza, pneumococcal conjugate vaccine and human papilloma vaccine immunizations are widely administered (93, 89 and 83% of units, respectively). Varicella and Rotavirus vaccinations are less recommended (61 and 24% of the units, respectively). Monitoring of vaccine responses is employed in 72% of centres. Serology appears to be the most feasible assay among the different centres (90%), mostly performed with immuno-enzymatic assays.

Conclusions: Vaccination practices for perinatally HIV-infected children still vary widely between countries. A crucial issue is the incomplete adherence to varicella vaccine. Indeed only in few countries varicella vaccination is universally recommended for children at national. More efforts should be made to standardize mandatory and recommended vaccinations, as well as to guide timing of serological assays. The majority of units carry out immuno-enzymatic tests to evaluate specific antibody levels. However, methods vary with different cut-offs of protection and units of measurement employed. Moreover, especially in high risk groups (e.g. children who started late HAART or performed vaccinations before treatment), researches on the development of novel methods to assess protective immunity and accurate correlates of protection are needed. The ultimate goal will be to design individualized vaccine schedules, developed on therapeutic and immunological features of individual patients, optimizing the chances of them gaining robust long-term vaccine induced protection.

http://dx.doi.org/10.7448/IAS.18.5.20414

WEAD0205LB

Lower ANC attendance and PMTCT uptake in adolescent versus adult pregnant women in Kenya

Keshet Ronen1,2; Christine Mcgrath3; Agnes Langat4; John Kinuthia5; Danvers Omolo6; Benson Singa5; Abraham Katana5; Lucy Nganga4 and Grace John-Stewart7

1Fred Hutchinson Cancer Research Center, Seattle, United States. 2University of Washington, Seattle, United States. 3University of Texas Medical Branch, Galveston, United States. 4Centers for Disease Control and Prevention, Atlanta, United States. 5Infectious Diseases and Clinical Research, Nyeri, Kenya. 6Infectious Diseases and Medical Research, Kisumu, Kenya. 7Department of Internal Medicine, University of Chicago, Chicago, United States.
Control and Prevention, Nairobi, Kenya. 3Kenya Medical Research Institute, Nairobi, Kenya. Presenting author email: kronen@fhcrc.org

Introduction: Although rates of pregnancy and HIV infection are high among Kenyan adolescent women, their engagement in Prevention of Mother-to-Child HIV Transmission (PMTCT) services is poorly characterized. We hypothesized that adolescent women show lower engagement in the PMTCT cascade than adult women, from prenatal care (ANC) attendance to HIV testing and antiretroviral (ARV) uptake.

Methods: We conducted a nationally representative cross-sectional survey of mothers attending 120 maternal child health clinics selected by probability-proportionate-to-size-sampling in Kenya in July–December 2013, with a secondary survey oversampling HIV-positive mothers in 30 clinics. Self-report questionnaires verified by clinic booklets recorded ANC attendance, HIV testing, ARV use and maternal characteristics. Data were compared between adolescent (age <20) and adult mothers. Differences in maternal characteristics were assessed by Chi-square test. Logistic regression was used to analyze ANC attendance and HIV testing among all women and ARV uptake among HIV-positive women.

Results: Among 2521 mothers surveyed, 278 (12.8%) were adolescents. Adolescents were less likely than adults to have above primary education (25.0% vs. 42.9%, p < 0.001), intended pregnancy (40.5% vs. 58.6%, p < 0.001) and a current partner (73.1% vs. 90.9%, p < 0.001). Overall, 2471 (97.8%) reported attending ≥1 ANC visit. Among 1859 women with verified ANC visits, 898 (44.7%) attended ≥4 visits. Adolescents were less likely than adults to attend ≥4 ANC visits (35.2% vs. 45.6%, OR[95% CI] = 0.65 [0.49–0.86]). This effect remained significant when adjusting for education, primigravida, pregnancy intention and HIV status (OR[95% CI] = 0.59 [0.36–0.97]). Among 2359 women who attended ≥1 ANC visit and were not known to be HIV-positive prior to pregnancy, 2298 (96.1%) received HIV testing during pregnancy. Testing rates were not significantly different between adolescents and adults. Among 288 HIV-positive women who attended ≥1 ANC visit and were not on HAART prior to pregnancy, 20 (6.9%) were adolescents, and 243 (84.4%) used any ARVs for PMTCT. Adolescents were less likely to use ARVs than adults (65.0% vs. 85.8%, OR[95% CI] = 0.31 [0.12–0.81]).

Conclusions: Adolescent mothers showed poorer ANC attendance and lower uptake of ARVs for PMTCT. Adolescents were less likely to use ARVs than adults (65.0% vs. 85.8%, OR[95% CI] = 0.31 [0.12–0.81]).

WEAD0301

Health resource use pattern analysis to inform targeted interventions alongside the HIV cascade of care and optimize the effect of treatment as prevention

Emanuel Krebs1; Jeong Eun Min2; Rolando Barrios2; Julio Montaner1,3; Bohdan Nosyk1,3 and STOP HIV/AIDS Study Group

1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada. 3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. Presenting author email: ekrebs@cfenet.ubc.ca

Introduction: Identifying patterns of health resource utilization (HRU) of people living with HIV/AIDS (PLHIV) can allow for comparison of their effects on longer-term health outcomes and costs. Further, identification of patterns associated with greater risk of attrition between stages of the cascade of care can help in the development of targeted interventions to effectively increase patient retention.

Methods: We conducted a population-level analysis of HRU for individuals having received a CD4 test after HIV diagnosis. All individuals 18 years or older in British-Columbia in the modern HAART-era (post-September 2006) were included. Using linked comprehensive administrative health databases in a probabilistic model-based clustering analysis with 14 HRU measures, we estimated parameters by maximum likelihood using the expectation maximization (EM) algorithm. Individuals with estimated parameters maximizing the probability of belonging to a similar HRU cluster were classified with each other, and the optimal number of clusters was estimated by the Bayesian Information Criterion. The analysis was conducted across CD4 count stratification (> 200 cells/mm2; < 200 cells/mm2).

Results: Our study included 941 individuals with at least one year follow-up (median age 40, 21% female) and with a CD4 count obtained between September 1st, 2006 and March 31st, 2011. Individuals with CD4 < 200 clustered in two HRU patterns. The high cost cluster (N = 68; mean $18,169($2521,432)), driven by lengthy HIV-related emergency hospitalizations (76.5% with > 7 days), had costs more than double the low cost cluster (N = 147; $6811($13,592)). Individuals with CD4 > 200 were best classified in four clusters. The high cost cluster (N = 74; $15,831($19,180)) was characterized by non-HIV ER hospitalizations (100% ≥ 1 day, 55.4% > 7 days) and high prevalence of mental health issues. The second highest cost cluster (N = 60; $5058($5152)) was characterized by short-term non-HIV elective hospitalizations (48.3% ≥ 1 day). The two lower cost clusters both had no hospitalizations; the higher (N = 425; $3378($6454)) with much more frequent physician visits and medication use than the lowest cost cluster (N = 167; $1291($7969)).

Conclusions: Even within relatively homogeneous cohorts in terms of disease progress at time of linkage to HIV care, individuals were found to have heterogeneous HRU patterns. Identifying classes of individuals according to HRU can help inform clinical response, as well as the design of public health interventions to optimize HIV care.

http://dx.doi.org/10.7448/IAS.18.5.20415

WEAD0302

Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining seasonal labour migrant programs

Sherrie Kelly1; Andrew Shattuck2; Clif Kent2,3; Robyn Stuart2,3; Arshak Papoyan4; Trdat Grigoryan5; Ruben Hovhannisyan6; Samvel Grigoryan6 and David Wilson1

1The Kirby Institute, UNSW, Sydney Australia. 2School of Physics, University of Sydney, Sydney, Australia. 3Department of Mathematical SciencesUniversity of Copenhagen, Copenhagen, Denmark. 4National Center for AIDS Prevention, Yerevan, Armenia. Presenting author email: skelly@gmail.com

Background: HIV prevalence is declining in all key affected populations in Armenia (people who inject drugs, men who have sex with men, prisoners and female sex workers); however, there are increases among labour groups who seasonally migrate to countries of higher HIV prevalence. We conducted a modelling study to assess the impact of optimizing the national strategic plan to minimize HIV incidence and AIDS-related deaths by 2020. We determined optimal funding levels for all programs to best achieve the strategic plan and, in particular, examined the outcomes required for migrant programs to warrant increased funding.

Methods: We used the Optima model to perform epidemiological and economic analyses. Demographic, epidemiological, behavioural and HIV programme cost data were obtained for Armenia from 2000 to 2014 and used to inform the model. Through internal and external consultations, assumptions were generated on what coverage levels among targeted populations could be attained for different investments, as well as their expected outcomes. A sensitivity analysis on
migrant HIV testing and counselling programs was conducted around assumptions based on observed data. Results: According to Optima's optimization algorithm, shifts in funding allocations are required to minimize incidence and deaths by 2020. The largest emphasis should be on antiretroviral therapy (ART), as optimal allocations nearly doubled the investment in treatment from 17 to 24% of the total budget. This is projected to avert almost 25% of new infections and 50% of AIDS-related deaths by 2020 compared to levels if 2013 spending were maintained. We show that funding for seasonal migrant programs should be maintained through to 2020 at 5% of the total budget. Sensitivity analysis demonstrated that these programs are cost-effective to fund if the coverage threshold for HIV testing and counselling for seasonal migrants, as illustrated in Figure 1B, can be achieved.

Conclusions: Optimization of HIV/AIDS investment in Armenia could significantly reduce HIV incidence and AIDS-related deaths by 2020, particularly by focusing more on antiretroviral therapy. We have also identified thresholds for programme performance, prior to their scale-up, which can be used to evaluate whether they should be scaled-up or down in the future.
Country of research: Armenia
Key Population: People living with HIV (PLHIV), Migrants/displaced persons/mobile populations

http://dx.doi.org/10.7448/IAS.18.5.20416

WEAD0303
Has performance-based financing accelerated progress towards controlling the HIV epidemic? An impact evaluation of Mozambique’s HIV-focused PBF programme
Yogesh Rajkotia; Omer Zang; Pierre Nguimkeu and Iva Djurovic
ThinkWell, Maputo, Mozambique.
Presenting author email: yrajkotia@collaborativedev.com

Introduction: As performance-based financing (PBF) gains global traction, evidence around its effectiveness to accelerate the elimination of HIV is needed. We evaluated the impact of a PBF programme implemented by Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), on the provision of HIV, PMTCT and MCH services. We also examined the temporal effects of PBF to better understand its lifecycle both in terms of onset and duration of effect. Finally, we evaluated the impact of PBF on non-incentivized services.

Methods: The impacts of PBF in Gaza (South) and Nampula (North) provinces were analyzed using a retrospective observational study design in which PBF provinces were matched with control provinces. Eighteen indicators related to HIV, PMTCT and MCH services were reviewed. Due to regional heterogeneity, we evaluated the North and South as separate experiments. Beginning January 2011, up to eleven quarters of data from 134 PBF facilities after matching (84 North and 50 South) were used. Data sources include PBF programme data and health management information system data. Our econometric framework employed a multi-period, multi-group programme data and health management information system data. The model allows the user to vary key input parameters, including annual numbers of patients starting ART, delay duration of patients on ART and roll-out of viral load monitoring. We aimed to estimate the need of second-line ART in sub-Saharan Africa between 2015 and 2030 under various scenarios.

Methods: We developed a mathematical simulation model of HIV progression on ART to project second-line needs up to 2030 for individual countries. The model allows the user to vary key input parameters, including annual numbers of patients starting ART, delay

Abstract WEAD0304 - Table 1.  Projected number of patients on first- and second-line ART in 2020 and 2030 under various scenarios

| Future scale-up of ART initiation | Treatment interruptions and switching | 2020 | 2030 |
|----------------------------------|-------------------------------------|------|------|
|                                  |                                     | Universal routine viral load monitoring | Targeted or routine viral load monitoring depending on country | Universal routine viral load monitoring | Targeted or routine viral load monitoring depending on country |
|                                  |                                     | 1st-line | 2nd-line | 1st-line | 2nd-line | 1st-line | 2nd-line | 1st-line | 2nd-line |
| Accelerated scale-up until universal coverage reached | No interruptions, immediate switching | 18,272,800 | 2,480,100 | 19,143,300 | 1,672,400 | 19,561,700 | 4,144,300 | 20,730,300 | 2,992,200 |
|                                  | Interruptions included, delayed switching | 18,334,300 | 1,771,300 | 18,869,600 | 1,221,200 | 20,161,000 | 3,561,500 | 21,143,100 | 2,539,400 |
| Stable scale-up                  | No interruptions, immediate switching | 13,306,000 | 1,899,200 | 13,807,300 | 1,387,100 | 15,717,400 | 3,239,100 | 16,397,400 | 2,555,600 |
|                                  | Interruptions included, delayed switching | 12,598,600 | 1,445,300 | 12,970,000 | 1,056,600 | 15,892,600 | 2,758,100 | 16,462,900 | 2,166,900 |
| No future scale-up               | No interruptions, immediate switching | 7,655,600 | 1,397,200 | 7,447,200 | 987,100 | 7,305,900 | 1,757,000 | 7,082,000 | 1,352,300 |
|                                  | Interruptions included, delayed switching | 7,697,300 | 1,186,700 | 8,009,900 | 872,700 | 7,314,800 | 1,569,200 | 7,619,000 | 1,262,700 |

Conclusions: The PBF programme in Mozambique has shown to produce large, sustained increases in the provision of PMTCT, paediatric HIV and MCH and should be considered as a powerful alternative to traditional input-based financing.

http://dx.doi.org/10.7448/IAS.18.5.20417

WEAD0304
The estimated need of second-line antiretroviral therapy in sub-Saharan Africa 2015 – 2030: mathematical modelling study
Janne Estill1; Nathan Ford2; Luísa Salazar-Vizcaya3; Andreas Haas3; Nello Blaser3; Matthias Egger1; Vincent H Abayambere3; Olivia Keiser3 and IeDEA Southern Africa
1Institut für Sozial- und Präventivmedizin (ISPm), University of Bern, Bern, Switzerland. 2World Health Organisation, Geneva, Switzerland. 3Institute of Health Policy, University of Geneva, Geneva, Switzerland.

Presenting author email: olivia.keiser@ispm.unibe.ch

Introduction: At the end of 2013, about 300,000 patients were on second-line antiretroviral therapy (ART) in sub-Saharan Africa. The need for second-line ART may increase substantially with increasing duration of patients on ART and roll-out of viral load monitoring. We aimed to estimate the need of second-line ART in sub-Saharan Africa between 2015 and 2030 under various scenarios.

Methods: We developed a mathematical simulation model of HIV progression on ART to project second-line needs up to 2030 for individual countries. The model allows the user to vary key input parameters, including annual numbers of patients starting ART, delay

Abstract WEAD0304 - Table 1.  Projected number of patients on first- and second-line ART in 2020 and 2030 under various scenarios

| Future scale-up of ART initiation | Treatment interruptions and switching | 2020 | 2030 |
|----------------------------------|-------------------------------------|------|------|
|                                  |                                     | Universal routine viral load monitoring | Targeted or routine viral load monitoring depending on country | Universal routine viral load monitoring | Targeted or routine viral load monitoring depending on country |
|                                  |                                     | 1st-line | 2nd-line | 1st-line | 2nd-line | 1st-line | 2nd-line | 1st-line | 2nd-line |
| Accelerated scale-up until universal coverage reached | No interruptions, immediate switching | 18,272,800 | 2,480,100 | 19,143,300 | 1,672,400 | 19,561,700 | 4,144,300 | 20,730,300 | 2,992,200 |
|                                  | Interruptions included, delayed switching | 18,334,300 | 1,771,300 | 18,869,600 | 1,221,200 | 20,161,000 | 3,561,500 | 21,143,100 | 2,539,400 |
| Stable scale-up                  | No interruptions, immediate switching | 13,306,000 | 1,899,200 | 13,807,300 | 1,387,100 | 15,717,400 | 3,239,100 | 16,397,400 | 2,555,600 |
|                                  | Interruptions included, delayed switching | 12,598,600 | 1,445,300 | 12,970,000 | 1,056,600 | 15,892,600 | 2,758,100 | 16,462,900 | 2,166,900 |
| No future scale-up               | No interruptions, immediate switching | 7,655,600 | 1,397,200 | 7,447,200 | 987,100 | 7,305,900 | 1,757,000 | 7,082,000 | 1,352,300 |
|                                  | Interruptions included, delayed switching | 7,697,300 | 1,186,700 | 8,009,900 | 872,700 | 7,314,800 | 1,569,200 | 7,619,000 | 1,262,700 |

Conclusions: The PBF programme in Mozambique has shown to produce large, sustained increases in the provision of PMTCT, paediatric HIV and MCH and should be considered as a powerful alternative to traditional input-based financing.

http://dx.doi.org/10.7448/IAS.18.5.20417
We applied the model to all countries in sub-Saharan Africa assuming 12 scenarios that combine different future ART scale-up scenarios (accelerated until universal coverage; stable; no future scale-up), monitoring (routine viral load monitoring in all or only selected countries), and retention and switching (including or excluding possibility of treatment drop-out and delayed switching). The input parameters were chosen to fit the numbers of patients on first- and second-line ART in 2005 to observed estimates.

**Results:** If the scale-up of ART is accelerated across the region, patients are retained in care, switching is immediate, and all countries implement routine viral load monitoring, the number of patients on second-line ART will increase to 4.1 million by 2030 (17% of all patients on ART). In a scenario with a stable scale-up and realistic drop-out and switching delay, the corresponding numbers were 2.8 million (15%) with universal routine viral load monitoring, and 2.2 million (12%) with routine viral load monitoring only in selected countries.

**Conclusions:** We expect that by 2030, 2–3 million people will receive second-line ART in sub-Saharan Africa, but the number of patients in need may be over four million. Routine viral load monitoring, timely switching and minimizing treatment interruptions will further increase the number of patients on second-line ART.

http://dx.doi.org/10.7448/IAS.18.5.20418

**WEAD0304**

Kenya private health sector HIV care services costing using the management accounting system for hospitals framework

Benson Chuma¹; Sayaka Koseki²; Stephen Musau³; Ben Johns³ and Agnes Gatome-Munyua³

¹Abt Associates, International Health, Nairobi, Kenya. ²Abt Associates, Washington, United States. ³Abt Associates, Washington, United States.

Presenting author email: bensonchuma@gmail.com

**Introduction:** The private sector is a key HIV service provider in Kenya, but few data on the cost of private service provision are available. The lack of cost data has inhibited the design of reimbursement mechanisms and health insurance packages, as well as policy decisions on private sector financing. This study estimated unit costs for private sector HIV services disaggregated by facility type and level, as a contribution to ongoing efforts to implement health insurance products covering HIV services.

**Methods:** Cost and service volume data were collected from 149 private sector facilities in 2013 as part of a nationwide systematic sampling of public and private healthcare costing study supported by GIZ, the USAID-funded Strengthening Health Outcomes Through the Private Sector (SHOPS) Project Kenya, and the Ministry of Health. The MASH (Management Accounting System for Hospitals) tool was used to analyze data. Multiple facilities were eliminated due to lack of complete data with only 60 used.

**Results:** Average unit costs per inpatient day and per outpatient visit were generated by sector and facility levels 2–4 (as defined by Kenya Norms and Standards 2006). HIV specific unit costs estimated included for HIV counselling and testing (HCT) services and provision of ART. The authors estimated operational costs, but were unable to estimate capital costs following lack of data. Average outpatient visits ranged from Ksh. 689 to 1036 in level 2 and level 4, respectively. ART visit costs ranged from Ksh. 1575 to 3660 across the facilities sampled. HCT visit services ranged from Ksh. 537 to 1151 across level 2 and 4 facilities, respectively.

**Conclusions:** The study contributed to health financing policy discussions in the provision and financing of HIV services in Kenya. Data generated was presented to insurers and providers who expressed intentions of using it for decision making. Possible applications include design of
HIV care inclusive insurance products and advising reimbursement decisions regarding the same. Providers offering HIV services can also use it to benchmark their efficiency. Due to poor record keeping in most facilities, only 60 of the 149 facilities had enough data for analysis. There’s a need to support facilities to improve record keeping.

http://dx.doi.org/10.7448/IAS.18.5.20419

WEAD0306LB

The PEPFAR COPs allocation database: a comprehensive database to monitor PEPFAR spending, increase data transparency, and improve civil society engagement in country operational plans

Brian Honermann; Gregorio Millett; Kali Lindsey; Sandhira Wijayaratne; Jennifer Sherwood and Jack MacAllister

Public Policy Office, amfAR, Washington, DC, United States.

Presenting author email: brian.honermann@amfar.org

Introduction: A total of $29.5 billion has been allocated by PEPFAR from 2007 to 2014 through the annual country operational plan (COP) process. COPs serve as a planning tool for activities of US government and in-country partners funded by PEPFAR. Historically, utilizing data from COPs has been difficult due to their inflexible PDF/RTF format hindering the ability to query and manipulate data, create graphical representations of the financial data or identify trends in PEPFAR allocations over time. As PEPFAR moves towards greater civil society engagement during COPs’ development, it is increasingly important that COPs’ data are readily accessible, categorizable and interpretable for civil society organizations (CSOs).

Methods: Utilizing standard open source tools, amfAR – funded by MAC AIDS – created a navigable database and website of all allocation data contained in published COPs from 2007 through 2014. Data are categorized and can be graphically represented and disaggregated by year, primary partner, host country, strategic area, budget code and organizational type of recipient. Text narratives of individual budgetary mechanisms captured directly from the COPs are also included in the database and provide users with detailed information for specific allocations. In addition, epidemiological profiles and PEPFAR targets are available by country to provide context for the public health impact of investments.

Results: From 2007 through 2014, $29.5 billion was allocated through the COPs process. By organizational type, the primary recipients of PEPFAR funds were NGOs ($8.3 billion), private contractors ($5.4 billion) and universities ($3.5 billion). Another $5.5 billion was not allocated to an identifiable partner or programme. Trends varied substantially by country. In Rwanda, resources shifted dramatically to Rwandan government agencies (from 7.6% of PEPFAR resources in 2011 to 34.2% of PEPFAR resources in 2013). Comparatively, PEPFAR 2013 host government funding was lower for Kenya (10.72%), Malawi (3.66%), Nigeria (2.64%) and South Africa (0.8%).

Conclusions: amfAR’s COPs database provides corresponding financial and graphical information about progress towards country ownership and gives the most granular view to date of PEPFAR budgets. The database will be an invaluable tool to help CSOs and others digest and utilize PEPFAR budgetary information. The database is available at http://copsdata.amfar.org

http://dx.doi.org/10.7448/IAS.18.5.20559
MOPDA0101
Within-host evolution of X4 HIV-1 in a rare transmission pair revealed by phylogenetic reconstruction of deep-sequence data
Anh Le1; Jeremy Taylor2; Winnie Dong3; Rosemary McCloskey2; Conan Woods5; Kanna Hayashi3; M-I Milloy4; P Richard Harrigan3; Art Fy Poon3 and Zabrina L Brumme1,2
1Health Sciences, Simon Fraser University, Burnaby, Canada. 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Presenting author email: qal@sfu.ca
Introduction: A putative case of transmission of an X4 HIV strain from a CCR5wt/wt donor to a homozygous CCR5 donor was retrospectively identified in the Vancouver Injection Drug Users Study. We collected longitudinal intrahost deep-sequence data and applied ancestral phylogenetic reconstruction methods to characterize HIV transmission and evolution in this rare event.
Methods: Pairwise genetic distances separating donor and recipient bulk plasma gag, pol, env and env-V3 sequences were the lowest in the cohort (e.g. 0.0027 substitutions/nuc site in Gag vs. cohort bulk plasma HIV gag, pol, nef and env-V3 sequences). In the donor, reversion of Env-V3 from plasma- and PBMC-DNA were tricaps amplified, pooled equally and deep-sequenced (Roche 454). BEAST and HyPhy were used to reconstruct phylogenies, estimate multiplicity of infection and reconstruct transmitted/founder (T/F) viruses from plasma-derived deep sequences from donor and recipient.
Results: Despite infection with the same X4 HIV strain, donor CD4 count was 20 cells/mm3 within 1.5 years of infection whereas the recipient’s remained 270 cells/mm3. Donor/recipient plasma viral loads were comparable (~4.5 Log). All 10 ancestral reconstructions were consistent with transmission of a single X4 T/F virus between May and August 2001. The estimated T/F virus sequence was identical to the co-dominant variant (36%) observed in the recipient’s first (+5 month) timepoint. This sequence was also observed in 0.09% of donor plasma and 33.5% of PBMC at month -1, suggesting minority variant transmission. In the donor, reversion of ~60% of the total plasma virus population to an R5 phenotype occurred by 50 months post-infection; in contrast, the recipient’s dominant V3 sequence steadily diversified over time but remained consistently X4.
Conclusions: Results highlight the utility of phylogenetic reconstruction applied to deep-sequence data to characterize T/F viruses and intra-host evolution in transmission pairs. Differential CD4 depletion and V3 evolution in these individuals, despite acquisition of a near-identical X4 strain, underscores the critical role of host genetics on HIV evolution/pathogenesis.

http://dx.doi.org/10.7448/IAS.18.5.20420

MOPDA0102
Genetic ancestry component proportions are correlated with HIV disease progression
Daniela Garrido-Rodriguez1; Santiago Avila-Rios5; Humberto Valenzuela-Ponce1; Thalia Garcia-Tellez1; Verónica Quiroz-Morales1; Claudia García-Morales1; Maribel Soto-Nava1; Akio Murakami-Ogasawara1; Juan Carlos Fernandez-Lopez2 and Gustavo Reyes Terán1
1Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico. 2National Institute of Genomic Medicine, Mexico City, Mexico.
Presenting author email: danni.garrido@gmail.com
Introduction: Genetic stratification within specific populations may explain differences in HIV control. We explore the influence of genetic diversity on HIV disease progression in a cohort of mestizo individuals with different proportions of European (EUR), Amerindian (AMI) and African (AFR) genetic ancestry components.
Methods: We estimated individual ancestry proportions in a cohort of 565 HIV-clade B-infected, antiretroviral treatment-naïve Mexican individuals using a panel of 128 ancestry informative markers. HLA alleles and KIR genes were genotyped for each participant in order to control for already known associations with HIV control and to describe putative novel associations in different genetic context.
Results: The mean ancestral component proportions in the study cohort were 0.594 AMI, 0.38 EUR and 0.026 AFR, as previously observed in Mexican mestizo populations. We observed a negative correlation between the proportion of AMI ancestry component (p = 0.0014) and a positive correlation between the proportion of EUR ancestry component (p = 0.0004) and CD4 T cell counts. To try to explain these observations, we evaluated differences in frequency and effects on CD4 T cell counts of specific HLA alleles, KIR genes or HLA-KIR combinations in EUR 60% vs. AMI 60% individuals. A*31:01, B*39:05, B*44:03 and C*07:02 showed protective effects in individuals with high EUR component, but risk effects in individuals with high AMI component (p < 0.05). Most KIR genes were more protective for EUR individuals than for AMI individuals. KIR+ HLA-Bw4 combinations were more frequent in individuals with EUR component (p < 0.05) while KIR + HLA-C1 combinations were more frequent in AMI individuals (p < 0.05). Interestingly, the previously observed protective associations KIRDS1/3DL1 + HLA-Bw4 were not evident, neither in the entire cohort, nor in EUR individuals. KIRDS4 in combination with HLA-C1 seemed to be protective for individuals with higher EUR component.
Conclusions: This is the first time that differences in HIV disease progression associated with genetic stratification are shown in a single population. Further studies involving fine stratification of genetically diverse populations, exploring expression of other genes involved in HIV control are warranted to understand differences observed in this study.
http://dx.doi.org/10.7448/IAS.18.5.20421

MOPDA0103
Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7
Jose Alcamip; Mercedes Bermejo1; Benjamin Descours2; Elena Mateos1; Michael M Lederman3; Monsef Benkirane2 and Mayte Coiras1
1Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain. 2Institute of Human Genetics, Montpellier, France. 3Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, United States.
Presenting author email: ppalcam@isciii.es
Introduction: HIV-1 post-integration latency in quiescent CD4+ T cells is responsible for viral persistence despite antiretroviral treatment. It was proposed that the increase in proviral load in HIV-infected patients after IL-7 treatment was due to homeostatic proliferation of memory CD4+ T cells. We determined previously that IL-7 increased HIV-1 infection through phosphorylation and subsequent inactivation of the restriction factor SAMHD1. Now we analyzed SAMHD1 phosphorylation in PBMCs from patients enrolled in ACTG 5214 study (NCT00099671), in order to elucidate the role of IL-7 in HIV-1 proviral integration and persistence and whether this could be related to SAMHD1 inactivation. In addition, we determined that the tyrosine-kinase inhibitor Dasatinib preserved SAMHD1 antiviral activity, avoiding IL-7-mediated HIV-1 infection.

Methods: PBMC samples obtained from 10 patients enrolled in ACTG 5214 study (NCT00099671), collected before (day 0) and 4 after administration of IL-7. PBMCs obtained from two patients diagnosed with chronic myeloid leukemia (CML), on chronic treatment with Dasatinib. Resting CD4+ T cells from healthy donors obtained by negative selection from PBMCs. Phosphorylation of SAMHD1 at T592 was determined by immunoblotting and flow cytometry. Proviral integration was analyzed by TaqMan qPCR. Dasatinib (BMS-354825, Sprycel) was provided by Bristol-Meyers Squibb.

Results: 1) IL-7 (1 nM) induced SAMHD1 phosphorylation, interfering with HIV-1 latency. 2) IL-7-mediated SAMHD1 phosphorylation greatly increased HIV-1 infection in purified CD4+ T cells, increasing early and late retrotranscription, as well as proviral integration. 3) A significant increase in pSAMHD1 was observed in central memory CD4+ T cells from HIV-infected patients treated with IL-7 (ACTG 5214).

4) Dasatinib completely inhibited SAMHD1 phosphorylation at 75 nM, interfering with HIV-1 retrotranscription and consequently, with proviral integration. 5) CD4+ T cells from patients with CML treated with Dasatinib showed lower expression of SAMHD1 phosphorylated.

Conclusions: By inducing SAMHD1 phosphorylation, IL-7 increases susceptibility of resting CD4+ T lymphocytes to infection, leading to HIV persistence. SAMHD1 regulation plays a central role in the establishment of HIV-1 reservoirs and represents a major target for therapeutic intervention. Dasatinib is the first compound currently used in clinic that has been described to preserve the antiviral function of an innate factor such as SAMHD1.

http://dx.doi.org/10.7448/IAS.18.5.20422
Results: The patient had undetectable plasma HIV and achieved 100% donor chimerism at week 12 post-alloHSCT, but then became non-adherent with ART. At five months, the patient presented with fever and meningoencephalitis. Plasma and CSF HIV levels were 25,500 and 17,000 copies/mL, respectively. Before alloHSCT, 31 sequences were isolated from the VOA. At rebound, 14,645 and 5003 sequence reads were obtained from CSF and blood respectively and were combined into consensus sequences using a cut-off of >0.2% of total sequence reads. An identical sequence found at both pre-alloHSCT timepoints accounted for 9/31 (29%) of independent VOA sequences. This sequence grouped with the plasma and CSF viral rebound sequences in a monophyletic clade with high sequence homology.

Conclusions: Despite 100% donor chimerism in peripheral blood, ART interruption led to HIV rebound in plasma and CSF. Rebound virus was identical to a pre-alloHSCT isolate which compromised nearly 1/3 of the latent CD4+ T-cell reservoir sampled. This unique case suggests that recipient cells persist at early time-points after alloHSCT and that a single viral population latent in resting memory CD4+ T cells can re-establish infection.

http://dx.doi.org/10.7448/IAS.18.5.20424

MOPDA0106LB
Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencing

Sook-Kyung Lee1; Shuntai Zhou1; Nancie Archin2; David Margolis2 and Ronald Swanstrom1

1Department of Biochemistry and Biophysics, UNC Center for AIDS Research, University of North Carolina, Chapel Hill, United States.
2Department of Medicine, University of North Carolina, Chapel Hill, United States.

Presenting author email: sooklee@med.unc.edu

Introduction: Viral outgrowth assay (VOA) is a widely used culture assay to measure the latent HIV-1 reservoir harbouring replication-competent HIV-1 in resting CD4+ T cells in patients on HAART. However, the assay is costly, and both labour and resource intensive. To overcome some of these issues with the VOA, we designed an assay using ultra deep sequencing (UDS), which directly analyzes the number of different sequences of the induced viruses to score the number of latently HIV-infected resting CD4+ T cells. In this study, we tested the premise whether the viral sequences derived from two
different proviruses are genetically distinct, since the assay involves a bulk culture.

**Methods:** To analyze viruses derived from different VOA culture wells scored as p24 positive, the viral samples derived from different culture wells were assigned with a specific Barcode and subjected to sequence analysis of the V1–V3 region of env sequences using the Primer ID-based paired-end MiSeq platform. A total of nine patient samples, two acute and seven chronic, were analyzed by UDS. Phylogenetic trees were generated by using consensus sequences created from sequences with the identical Primer ID and were used to detect distinct viral lineages present in the individual culture supernatant. For chronic patient samples, IUPM values were determined by using distinct viral lineages detected and the adjusted number of patient-derived resting CD4+ T cells used for VOA.

**Results:** Approximately 50% of the viral lineages derived from each chronic patient were distinct. In contrast, all viral lineages derived from each acute patient were homogeneous. When IUPM values determined by UDS analysis were compared to the IUPM values obtained from VOA, we observed approximately twofold higher IUPM values than the IUPM values determined by VOA. We also observed a significant positive correlation between the number of viral lineages observed per well and the number of resting T cells present per well.

**Conclusions:** The results suggest that approximately 50% of the viral lineages induced from different cells derived from chronic patients were distinct. Thus, the UDS assay is applicable for samples derived from chronic patients. The multiplexing ability of the assay improves the efficiency for the throughput capacity.

http://dx.doi.org/10.7448/IAS.18.5.20560

**MOPDB0101**

**Bacterial vaginosis, intravaginal practices and HIV genital shedding: implications for HIV transmission**

Maria Alcaide1; Maureen Chisembele2; Emeria Malupande2; Kristopher Arheart1; Deborah Jones1 and Margaret Fischl1

1Division of Infectious Diseases, Miller School of Medicine, University of Miami, Miami, United States. 2Obstetrics and Gynecology, University of Zambia, Lusaka, Zambia.

**Presenting author email:** malcaide@med.miami.edu

**Introduction:** Bacterial vaginosis (BV) is associated with an increased risk of HIV transmission, and intravaginal practices (IVP), the practice of cleansing the vagina for hygienic, health or sexuality reasons, is the primary risk factor for developing BV. This study examines the relationship between BV, IVP and lower genital HIV shedding in HIV infected women in Zambia.

**Methods:** Participants were HIV-1 infected women, older than 18 years and living in Lusaka, Zambia. Participants completed audio computer administered self-interviews questionnaires assessing demographic, sexual risk factors and IVP. BV was diagnosed by gram stain of vaginal secretions using Nugent criteria. HIV-1 plasma viremia and genital shedding was assessed by measuring HIV-1 RNA in plasma and cervico vaginal lavages using real time PCR.

**Results:** One hundred and twenty-eight HIV-1 infected women were enrolled. Mean age was 37 years (range 24–60). Most had a stable male sex partner (126; 98%), and the majority of male partners had HIV infection (86%; 67%). About one third (44; 34%) reported more than one partner in the prior year. All participants had engaged in IVP in the prior month, and over 90% used IVP daily. Ninety-eight participants (76%) had abnormal vaginal flora (Nugent score of 4–10); and 80 (62%) had BV (Nugent score 7–10). HIV-1 plasma viremia was detected in 26 participants (20%) (median = 8.4 log copies/ml, range = 3.9–14.5). HIV-1 genital shedding was detected in 18 participants (14%); (median = 6.7 log copies/ml, range = 3.6–12.7). In multivariate analysis, daily IVP were associated with BV (OR = 7.9, CI = 1.54–40.8, p < 0.01) and plasma viremia was associated with HIV-1 genital shedding (OR = 7.23, CI = 2.43–21.37, p < 0.01). Demographic, sexual risk factors, IVP or BV were not associated with HIV genital shedding.

**Conclusions:** BV was common in this sample of women with HIV infection and occurred in women engaging in frequent IVP. Neither BV nor IVP increased HIV genital shedding in women on suppressive antiretrovirals. Effective antiretroviral therapy remains the main strategy to prevent HIV female genital shedding and risk of subsequent HIV transmission. Further research in women with detectable plasma viremia is needed to examine how IVP and BV affect the vaginal mucosa and increase HIV transmission.

Study was funded by NIH, K23HD074489.

http://dx.doi.org/10.7448/IAS.18.5.20425

**MOPDB0102**

**IUD use in HIV-positive women**

Laura Anca Vicol1; Alicia Hornsberger1; Neora Pick2; Julie Van Schalkwyk3; Deina Bloomenthal1; Jan Christlawa4 and Deborah Money2

1Oak Tree Clinic, BCWH, PHSA, Vancouver, Canada. 2WHRI, BCWH, PHSA, Oak Tree Clinic, Vancouver, Canada.

**Presenting author email:** lvicol@cw.bc.ca

**Introduction:** Eighty percent of HIV-positive (HIV+) women are of childbearing age, therefore access to effective, safe contraception is essential. Generally, intrauterine device (IUD) provide safe, effective contraception but historically, IUDs were contraindicated in HIV+ women due to concerns regarding infection. Data in HIV+ women are scarce. The goal was to assess rate of complications for IUS insertion in HIV+ women.

**Methods:** IUDs insertions in HIV+ women were offered at Oak Tree Clinic (the provincial referral centre for HIV+ women and children) since 2009, following strict clinical evaluations for eligibility. Criteria used for insertion were: not planning a pregnancy for at least one year; requesting a reversible contraceptive, wanted/needed to avoid estrogen-based methods and CD4 > 150. STD screening was done in all cases. Demographic information collected included: age, CD4, ARV at insertion and purpose of IUD (contraception vs. cycle control).

**Results:** Data was reviewed from 44 sequential women given IUDs from 2009 to 2014 with ages 17–48. CD4 count 160–1230 (median 590); 32/44 (73%) had viral loads < 40 c/ml; 9 women had detectable VL between 89–126,908 c/ml; 7 were not on ARV therapy; 2 were on ARV but struggled with adherence and were detectable; 3/44 had a copper IUD. 40/44 had a hormonal IUD. 1 had a hormonal followed by a copper IUD. 3 IUDs were inserted for menstrorrhagia. 1 IUD was for combined therapeutic and contraceptive purposes. 5 requested the hormonal IUD removed not related to reproductive plans. 1 refused reinsertion when the expired hormonal IUD was removed. Complications included four IUD expulsions (9%) (three spontaneous; one partial within the cervix). The rate of expulsion in general population is 6%. One IUD was removed by hysteroscopy due to upward migration of strings and myometrial embedment. One IUD accidentally pulled out during intercourse and required emergent reinsertion of a new device. No IUD related infections or other serious complications occurred, regardless of CD4 count.

**Conclusions:** In this small series of HIV+ women, IUDs were safe and well tolerated. This method of contraception should remain an option for HIV+ women if close follow up of short and long term complications can be followed.

http://dx.doi.org/10.7448/IAS.18.5.20426

**MOPDB0103**

**Effectiveness of contraception for HIV-infected women using antiretroviral therapy: combined data from three longitudinal studies**
Abstract MOPDB0103– Table 1. Contraceptive effectiveness, by ART status and type

| Progestin use | ART Use | # Pregnancies | Person-years | Incidence rate (per 100 person-years) | aHR* (95% CI), reference no contraception | p-value for interaction term |
|--------------|---------|---------------|--------------|--------------------------------------|---------------------------------------------|----------------------------|
| No contraception | On ART | 111 | 843.5 | 13.2 | – | – |
| No contraception | No ART | 1067 | 4733.6 | 22.5 | – | – |
| Implant | On ART | 1 | 94.1 | 1.1 | 0.06 (0.01, 0.45) | 0.73 |
| Implant | No ART | 7 | 507.8 | 1.4 | 0.05 (0.02, 0.11) | – |
| Injectable | On ART | 11 | 332.8 | 3.3 | 0.18 (0.094, 0.35) | 0.79 |
| Injectable | No ART | 111 | 2100.2 | 5.3 | 0.20 (0.16, 0.24) | – |
| Oral pills | On ART | 5 | 81.2 | 6.2 | 0.37 (0.15, 0.91) | 0.97 |
| Oral pills | No ART | 63 | 573.1 | 11.0 | 0.36 (0.28, 0.47) | – |
| Total | | 1376 | 9266.3 | 14.8 | – | – |

Maria Pyra1,2; Renee Heffron1,2; Nelly R Mugo1,3,4; Kavita Nanda5; Katherine K Thomas2; Connie Celum1,2,6; Athena P Kourtis5; Jared M Baeten1,2,6 and Partners in Prevention HSV/HIV Transmission Study and Partners PreP Study Teams
1Department of Global Health, University of Washington, Seattle, United States. 2Department of Epidemiology, University of Washington, Seattle, United States. 3Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya. 4Sexual, Reproductive, Adolescent and Child Health Research Program, Kenya Medical Research Institute, Nairobi, Kenya. 5Integrated Health Sciences, FHI 360, Research Triangle Park, United States. 6Department of Medicine, University of Washington, Seattle, United States. 7Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, United States.

Presenting author email: mpyra99@uw.edu

Introduction: Ensuring safe, effective contraception for women with HIV-1 is a public health imperative. Some data suggest that antiretroviral therapy (ART) may diminish the effectiveness of certain contraceptive methods, particularly implants.

Methods: Combining data from 5282 HIV-infected women participating in three longitudinal studies (Partners in Prevention HSV/HIV Transmission Study, Couples Observation Study and Partners PreP Study) from seven countries in Africa between 2004 and 2012, we calculated incident pregnancy rates among women using different contraceptive methods (implant, injectable and oral) and compared those to rates among women not using contraception. Multivariable Cox regression models controlled for confounding factors, and the interaction term was assessed to identify if ART diminished contraceptive effectiveness.

Results: During follow-up (median 1.8 years, IQR 1.2–2.3), 9% of women ever used implant, 41% used injectables (primarily depot medroxyprogesterone acetate (DMPA)), 15% used oral pills and 47% never used hormonal contraception. Additionally, 31% of women ever used ART during follow-up, including 23% using nevirapine and 5% using efavirenz. Among women not using contraception, pregnancy rates were 13.2 and 22.5 per 100 women-years for those on and not on ART, respectively. Use of implants reduced the risk of pregnancy by more than 90%, both among women on ART (aHR 0.06, 95% CI 0.01–0.45) and not on ART (aHR 0.05, 95% CI 0.02–0.11). Likewise, injectables reduced pregnancy risk (aHR 0.18, 95% CI 0.09–0.35 on ART and aHR 0.20, 95% CI 0.16–0.24 not on ART), as did oral contraceptives by a lesser degree (aHR 0.37, 95% CI 0.15–0.91 on ART and aHR 0.36, 95% CI 0.28–0.47 not on ART). We found no statistical evidence that ART use diminished contraceptive effectiveness, including for nevirapine and efavirenz, although sample size was limited for assessing specific ART agents.

Conclusions: In this large prospective evaluation of three studies, modern contraceptive methods were highly effective in reducing pregnancy risk in HIV-infected women, including those concurrently using ART. While limited evidence from other studies suggests that some ART agents could diminish the effectiveness of contraceptive implants, these data emphasize that implantable contraception is highly effective compared to no contraception and more so than shorter-acting methods such as injectables and oral pills.

http://dx.doi.org/10.7448/IAS.18.5.20427

MOPDB0104

Importance of programmatic longitudinal surveillance for identification of congenital anomalies among infants exposed to HIV-1 and antiretrovirals: findings from the Mpepu Study, Botswana

Gbolahan Ajibola1; Roger Shapiro3,2; Rebecca Zash1,3; Lewis Holmes4; Oganne Oganne Batlang1; Kerapetse Ramogothobeng1; Florence Chilisa1;

Abstract MOPDB0104– Table 1. Congenital anomalies

| Case # | Description of congenital anomaly | Presenting symptom | Timing of diagnosis from birth |
|--------|----------------------------------|-------------------|-------------------------------|
| 1      | Anovestibular fistula             | Stool in urine    | 42 days                       |
| 2      | Biliary atresia                  | Jaundice at birth | 48 days                       |
| 3      | Biliary atresia                  | Jaundice at birth | 38 days                       |
| 4      | Congenital Lymphedema            | Bilateral leg swelling | 15 days                      |
| 5      | Jejunal atresia                  | Failure to pass stool with abdominal distension and vomiting | 5 days                      |
| 6      | Macrocephaly                     | Widening of fontanelle and increasing head size | 85 days                      |
| 7      | Pyloric stenosis                 | Projectile vomiting | 25 days                      |
| 8      | Talipes equino valgus            | Concern expressed by mother about position of foot | 60 days                      |
Rhian Twine 1; Amanda Selin 2 and Kathleen Kahn 6,7
University of the Witwatersrand, Johannesburg, South Africa. 5Bennett Statistical Consulting

Introduction: A large and increasing number of HIV-infected women are conceiving while taking antiretrovirals (ARVs) globally. In resource-limited settings, surveillance systems, if present, often are limited to the initial birth exam.

Methods: We used pre-randomization data from May 2011 to December 2014 from an ongoing clinical trial of infant cotrimoxazole prophylaxis in Botswana. Enrolments of live-born infants of HIV-infected women occurred after delivery, so long as the mother consented to infant participation and no infant life-threatening conditions were identified at birth. Infants were examined by study staff at delivery, and monthly in the first three months of life, and congenital anomalies were documented. We present a descriptive analysis of anomalies identified after the initial birth exam.

Results: Of 2935 HIV-infected women enrolled in the Mpepu study who delivered live-born infants, newborn exams were documented on 2900 (99%) infants. ART from conception was documented for 1088 (38%) women; 1147 (40%) started ARVs during pregnancy; 442 (15%) women received AZT monotherapy; and 223 (7%) received no ARVs during pregnancy. A total of 28 congenital anomalies were identified, and 8 (29%) were first diagnosed at a visit after the initial birth exam (Table 1). No differences were identified in the number of infants with or without congenital abnormalities by ARV exposure group in pregnancy, but the study was underpowered to detect differences in rare outcomes. Identification of congenital anomalies after the birth exam occurred either because the anomaly was not readily apparent at birth (e.g. biliary atresia), or because an externally-identifiable anomaly was overlooked at birth but subsequent parental concern led to documentation and management of the anomaly.

Conclusions: ARV use in pregnancy warrants ongoing surveillance monitoring for teratogenicity, particularly for regimens including EFV/ FTC/TDF with insufficient safety data in pregnancy. Nearly one third of infants with or without congenital abnormalities by ARV exposure group in pregnancy, but the study was underpowered to detect differences in rare outcomes. Identification of congenital anomalies after the birth exam occurred either because the anomaly was not readily apparent at birth (e.g. biliary atresia), or because an externally-identifiable anomaly was overlooked at birth but subsequent parental concern led to documentation and management of the anomaly.

Benefits: Of 2935 HIV-infected women enrolled in the Mpepu study who delivered live-born infants, newborn exams were documented on 2900 (99%) infants. ART from conception was documented for 1088 (38%) women; 1147 (40%) started ARVs during pregnancy; 442 (15%) women received AZT monotherapy; and 223 (7%) received no ARVs during pregnancy. A total of 28 congenital anomalies were identified, and 8 (29%) were first diagnosed at a visit after the initial birth exam (Table 1). No differences were identified in the number of infants with or without congenital abnormalities by ARV exposure group in pregnancy, but the study was underpowered to detect differences in rare outcomes. Identification of congenital anomalies after the birth exam occurred either because the anomaly was not readily apparent at birth (e.g. biliary atresia), or because an externally-identifiable anomaly was overlooked at birth but subsequent parental concern led to documentation and management of the anomaly.

http://dx.doi.org/10.7448/IAS.18.5.20428

MOPDC0101
Communities can mobilize to test: findings from a community randomized trial of a theory-based community mobilization intervention in South Africa

Sheri A Lippman 1; Audrey Pettifor Pettifor 2; Torsten B Neiland 1; Catherine MacPhail 3; Dean Peacock; Suzanne Maman 1; Rhian Twine 5; Amanda Sein 6 and Kathleen Kahn 7

1Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, United States. 2Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, United States. 3Wits Reproductive Health and HIV Institute, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4School of Health, University of New England, Armidale, Australia.

http://dx.doi.org/10.7448/IAS.18.5.20429

MOPDC0102
Reducing stigma and increasing HIV testing with a health information intervention, a cluster-randomized trial from Malawi

Laura Derksen 1; Adamson Muula 2; Joep van Oosterhout 2,3; Monique van Lettow 2; Alfred Matengeni 2 and Sumeet Sodhi 2,4

1Department of Economics, London School of Economics, London, United Kingdom. 2College of Medicine, University of Malawi, Blantyre, Malawi. 3Dignitas International, Zomba, Malawi. 4Toronto Western Hospital, University Health Network, Toronto, Canada.

Presenting author email: l.c.derksen@lse.ac.uk

Background: Despite widespread availability of antiretroviral therapy (ART), demand for HIV testing remains low across southern Africa. HIV testing may be viewed as a signal of HIV status. Those who seek an HIV test may be rejected by potential sexual partners who fear contracting HIV. This could discourage HIV testing and encourage...
travel far from home for HIV testing to avoid being seen. Such stigma may be exacerbated by unawareness of the public benefit of ART, that is, its capacity to reduce HIV transmission by 96%. We evaluated an information experiment designed to increase HIV testing rates by reducing stigma.

**Methods:** We conducted a cluster-randomized controlled trial in Malawi. We held community health information meetings in all villages. In control villages (n = 62), we provided information on the private benefits of ART, including its potential to prolong life and reverse AIDS symptoms. In intervention villages (n = 60), the public benefit of ART was discussed in addition to the control message.

**Results:** Among those aged 15–49, there was a significantly larger uptake of HIV testing in the intervention villages (intervention 2.6% vs. control 1.6%; p = 0.0035), according to routinely collected data from 18 health facilities over a period of three months after the intervention. This effect was significant for men and women, and larger when corrected for spill-overs. The intervention led to a large shift in beliefs about ART, as measured by a survey five months after the intervention. Respondents in intervention villages were more likely to report accepting attitudes towards sexual partners on ART. High beliefs about the public benefit of ART were associated with significantly more tests at nearby clinics. HIV testing decisions were predicted by a respondent’s perception of his/her community’s beliefs about ART. These observations strongly suggest that the effect of the intervention on HIV testing uptake is mediated by a reduction in stigma.

**Conclusions:** The results demonstrate that stigma between sexual partners is a significant barrier to HIV testing, and that providing new information on the effect of ART on HIV transmission can increase testing uptake.

http://dx.doi.org/10.7448/IAS.18.5.20430

**MOPDC0103**

HIV self-testing increases HIV testing frequency among high-risk men who have sex with men: a randomized controlled trial

David Katz1,2; Matthew Golden1,2; James Hughes1; Carey Farquhar1 and Joanne Stekler1

1Department of Epidemiology, University of Washington, Seattle, United States. 2Public Health – Seattle & King County, United States, Seattle.

Presenting author email: dkatz7@u.washington.edu

**Background:** HIV self-testing has the potential to increase HIV testing and thereby decrease the time persons living with HIV are unaware of their status, but the absence of counselling may result in increased risk of HIV acquisition.

**Methods:** In Seattle, Washington, we randomly assigned 230 HIV-negative men who have sex with men (MSM) at high risk for HIV acquisition in a 1:1 ratio to have access to HIV self-testing using the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test on oral fluids or to testing as usual for 15 months. Men randomized to self-testing were trained to use the test and provided a self-test at baseline; they could contact the study for additional tests as needed up to once a month. All participants were advised to test quarterly, offered testing reminders and could test through any existing HIV testing source. The primary outcome was self-reported number of HIV tests during follow-up. To evaluate potential adverse effects of self-testing, we compared the following between the two arms: non-concordant condomless anal intercourse (CAI) and number of male CAI partners in the last three months (measured at 9 and 15 months) and diagnosis with a bacterial sexually transmitted infection (STI) at the final study visit (15 months).

**Results:** Men randomized to self-testing reported significantly more HIV tests during follow-up (mean = 5.3, 95% CI = 4.7–6.0) than those in the control arm (3.6, 3.2–4.0; p < 0.0001), representing an average increase of 1.7 tests per participant over 15 months. Men randomized to self-testing reported using an average of 3.9 self-tests during follow-up. Self-testing was non-inferior to clinic-based testing with respect to markers of HIV acquisition risk. At the final study visit, 5.4% of MSM randomized to self-testing were diagnosed with a bacterial STI compared with 12.2% of control participants (risk difference = –6.8%; 95% CI = −16 to +1.6%). There were no significant differences between the two arms in the proportion of men reporting non-concordant CAI or the reported number of male CAI partners in the last three months at 9 and 15 months.

**Conclusions:** Access to free HIV self-testing increased testing frequency among high-risk MSM and did not impact sexual risk behaviour or STI acquisition.

http://dx.doi.org/10.7448/IAS.18.5.20431

**MOPDC0104**

Home HIV testing among transgender women in San Francisco: a pilot feasibility and acceptability study

Sheri A Lippman1; Mary E Moran1; Angel Ventura2; Lesley S Castillo1,2; Susan Buchbinder3; Sarah Treves-Kagan1 and Jae M Sevelius1

1Center for AIDS Prevention Studies, University of California, San Francisco, United States. 2School of Public Health, University of California, Berkeley, United States. 3San Francisco Department of Public Health, Bridge HIV, San Francisco, United States.

Presenting author email: sherilippman@ucsf.edu
Background: Transgender women are the population most impacted by HIV in the United States, with prevalence approximately 40 times higher than the general population. The rates of HIV antibody testing in the transgender community are not commensurate with risk. Development of alternative testing strategies to ensure early detection, care and prevention of infection is critical.

Methods: We conducted a pilot study to explore feasibility and acceptability of offering home-based, self-conducted HIV testing for transwomen. Fifty HIV-negative transwomen in San Francisco were provided with OraQuick oral HIV self-test kits and asked to utilize the tests once a month for three months. Survey data were collected at baseline, one month and three months. In-depth-interviews (IDIs) were conducted with 11 participants at their final visit to learn more about self-testing experiences, barriers to self-testing and how the self-test might fit into an expanded pool of testing options.

Results: Self-testing was both feasible and acceptable: following the first test 94% reported the test easy to use; 93% said the results were easy to read; and 91% said they would recommend the self-test to others. Acceptability remained high at three months. Approximately 25% used the test kit with others present and 68% reported preference for self-tests versus clinic-based testing. IDIs revealed tension between a desire for the privacy afforded by self-testing and a desire for the social and resource support offered at health facilities. While most participants were comfortable accessing services and had been tested recently (88% in the past year), IDIs provided with OraQuick oral HIV self-test kits and asked to utilize the tests once a month for three months. Survey data were collected at baseline, one month and three months. In-depth-interviews (IDIs) were conducted with 11 participants at their final visit to learn more about self-testing experiences, barriers to self-testing and how the self-test might fit into an expanded pool of testing options.

Conclusions: The home-based, self-conducted HIV test provides a viable option for populations who prefer to avoid the clinic environment. To increase acceptability, enhanced linkage strategies to social and resource support should be considered. The current price point is inaccessible for populations that experience disproportionate economic marginalization. Interest in partner testing could represent an opportunity to package tests in pairs and an expanded opportunity for testing uptake. Additional research should focus on expanding delivery options and implementation strategies.

http://dx.doi.org/10.7448/IAS.18.5.20432

MOPDC0105
Supervised HIV self-testing to inform adoption and scale up of self-testing in Zimbabwe
Sue Napierala Mavedzenge 1; Euphemia Sibanda 2; Yvonne Mavengere 2; Karin Hatzold 2; Owen Mugunurungu 2; Getrude Ncube 3 and Frances Cowan 2, 5
1RTI International, Women’s Global Health Imperative, San Francisco, United States. 2Centre for Sexual Health and HIV/AIDS Research, Harare, Zimbabwe. 3Population Services International, Harare, Zimbabwe. 4Centre for Sexual Health and HIV Research, University College London, London, United Kingdom. Presenting author email: smavedzenge@rti.org

Background: HIV self-testing (HIVST) can potentially increase uptake of testing in a low-cost, confidential and non-stigmatizing manner. Rigorous evaluation of instructional materials for accurate self-testing has rarely been conducted. In preparation for implementation and scale-up of HIVST in Zimbabwe, we have adapted and iteratively refined instructional materials to support self-testing. Here we present results from our evaluation of these materials through supervised self-testing.

Methods: Participants were recruited at an HIV testing clinic using convenience sampling. They were given the instructional materials and left alone to complete their self-test and record the result. Confirmatory rapid testing after HIVST, and pre- and post-test questionnaires to evaluate their experience were conducted. The testing process was video recorded and videos analyzed using checklists. Data were evaluated weekly and IEC materials iteratively refined accordingly to optimize accuracy.

Results: We conducted 172 supervised self-tests among participants in urban Harare, with mean age of 30 (range 18–70), 53% female and 20% first-time testers. Overall 93% read their result accurately, in some cases despite failing to follow instructions as determined by video. Six percent were unable to determine their result. One percent got inaccurate results, including one HIV+ individual on antiretroviral therapy (ART) who followed instructions correctly as determined by video. While most (88%) reported the test was not hard to use, 23% said some instructions were unclear, resulting in modifications to the materials. Common sources of confusion were in interpreting results, the purpose of the test kit desiccant and unclear images/language. Low literacy was associated with unsure/invalid results, prompting revision of the materials for a rural, less literate setting. There, among 29 participants, 3% were unable to determine their results and 31% got an inaccurate result. Materials have been further revised making them almost entirely pictorial, and supervised self-testing is ongoing.

Conclusions: Though there is little published research on optimizing HIVST materials, we found that thorough evaluation of materials through supervised self-testing has been critical to optimizing accuracy. Numerous revisions were required, and evaluation in different settings yielded differing results. Rigorous development and testing of HIVST supportive materials appropriate to country and setting is recommended prior to implementation of HIVST programs.

http://dx.doi.org/10.7448/IAS.18.5.20433

MOPDC0106
Integrating partner notification services into PMTCT (Option B+) services in the northwest and southwest regions of Cameroon

Abstract MOPDC0105–Table 1. HIV results among 172 participants in Harare

| Test | Participant-read HIVST | Staff-read HIVST | Confirmatory test |
|------|------------------------|------------------|------------------|
| HIV negative | 146 | 150 (146 + 3 unsure + 1 transcription error*) | 156 (149 + 7 invalid HIVST) |
| HIV positive | 16* | 15 | 16 |
| HIV unsure | 5 | 0 | 0 |
| HIV invalid | 5 | 7 | 0 |

*One was a participant transcription error – she was clear in her post-HIVST interview that she thought she was HIV negative. The second was someone on ART who tested negative via self-test and positive in confirmatory testing.
Abstract MOPDC0106—Figure 1. Uptake of PN services at 22 B + sites.

Pius Tih Muffih1, Eveline Mbho3, Ebua Fang1; Winifred Wainfen1; Mathew Golden4; Pius Tih Muffih1; Eveline Mbho1; Ebua Fang1; Raymond Shields3 and Mathew Golden4
1Cameroon Baptist Convention Health Services, Bamenda, Cameroon. 2Cameroon Baptist Convention Health Board, AIDS Care and Prevention Program, McCall, Idaho, United States. 3Cameroon Baptist Convention Health Services, Bellingham, United States. 4Department of Epidemiology, University of Washington, Seattle, United States.

Presenting author email: piustih@cbchealthservices.org

Background: Partner notification (PN) for control of sexually transmitted infections (STIs) is a public health strategy which notifies the partners of infected individuals of their possible exposure to disease. PN has rarely been used in sub-Saharan Africa as an HIV prevention intervention. In Cameroon, patients newly diagnosed with HIV do not usually receive assistance in notifying their sex partners leading to low partner disclosure and poor partner involvement in prevention of mother-to-child transmission (PMTCT). In 2012, the World Health Organization issued new guidelines in PMTCT including Option B+ which recommends that all HIV positive pregnant women (PW) be placed on antiretroviral treatment for life irrespective of CD4 count. PN was integrated into PMTCT at 22 pilot Option B+ sites as a strategy to increase male partner disclosure, notification, testing and linkage to care.

Methods: Beginning in March 2013, Trained Health Advisors (HA) at the 22 B+ sites interviewed consenting HIV-positive PW about their sexual partners in the last two years and facilitated disclosure or confidentially informed their partners that they had been exposed to HIV. The HAS pre-test counselled the partners and offered HIV testing in the clinic, their home or other location. They then educated both index cases and their partners on HIV prevention and risk reduction and linked all HIV positive partners to care and treatment.

Results: During the 18 months, uptake was monitored monthly and 823 PW tested HIV positive at the 22 option B+ sites (Figure 1). Of the 840 partners they identified, 693 (82.5%) were traced and notified of their exposure to HIV. Of the 693 notified, 421 (60.8%) did their HIV test and received results. A total of 139 (33.0%) of those tested were HIV positive and 138 (99.3%) were linked to appropriate C&T services. HIV negative partners (67.0% of those tested) were counselled on risk reduction. Male partner involvement increased greatly at seven of ten sites monitored.

Conclusions: PN is a feasible HIV prevention strategy in resource-limited settings which can identify and test many partners of HIV positive PW. PN can be integrated into Option B+–PMTCT programs to identify HIV positive partners who are placed on treatment alongside the HIV positive PW.

http://dx.doi.org/10.7448/IAS.18.5.20434

MOPDD0101

The effect of opiate substitution therapy on healthcare utilization and engagement among HIV-infected people who inject drugs in Ukraine

Chethan Bachireddy1; Jacob Izenberg2; Michael Soule3; Sergey Dvoryak4 and Frederick Altice5

1Department of Internal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States. 2Department of Psychiatry, University of California, San Francisco, United States. 3Department of Psychiatry, Massachusetts General Hospital McLean, Harvard Medical School, Boston, United States. 4Ukrainian Institute on Public Health Policy, Kyiv, Ukraine. 5Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.

Presenting author email: chet86@gmail.com

Background: Eastern Europe and Central Asia face a rapidly escalating HIV epidemic driven by injection drug use (IDU). We evaluate the role of opioid substitution treatment (OST) in engaging HIV-infected people who inject drugs (PWID) in care and the effect of OST on utilization of medical services.

Methods: Cross-sectional study of healthcare utilization in the past six months among 296 randomly sampled HIV-infected opioid-dependent PWID conducted in healthcare clinics in 2010 across Ukraine. Participants categorized as therapeutic on OST if on OST for at least three consecutive months prior to the past six months or as not taking OST if not on any OST in the past nine months. Based on this criterion, 24 individuals were excluded.

Results: The 65% on OST (177/272) were less likely to be below the poverty line or live alone and more likely to have been married or have gone to prison (p < 0.05). The two groups did not differ significantly in terms of age, gender, or education. Those on OST had more years of opioid injection but were less likely to have injected in the past 30 days, to have engaged in poly-substance abuse, or to have ever overdosed on drugs (p < 0.01). In the past six months, those on OST were less likely to seek emergency care (72% vs. 84%, p < 0.05) and had fewer mean emergency care visits (2.77 vs. 4.57, p < 0.02) with no significant differences in mean ambulatory visits (1.78 vs. 0.59, p = 0.11) or hospitalizations (0.53 vs. 0.34, p = 0.36). Those on OST were more likely to be engaged in HIV care, as evidenced by higher rates of antiretroviral therapy ART (37% vs. 26%, p = 0.08), recent CD4 testing (82% vs. 60%, p < 0.03), and recent TB testing (95% vs. 71%, p < 0.01). Number of self-reported symptoms was higher in the non-OST group compared to those on OST (10.46 vs. 7.75, p < 0.01). Limitations include cross-sectional design and potential for recall and social desirability biases.

Conclusions: Despite higher rates of incarceration and more years of opioid injection, those therapeutic on OST were less likely to seek emergency care than those not on OST and more likely to be engaged in HIV care with fewer overall symptoms.

http://dx.doi.org/10.7448/IAS.18.5.20435

MOPDD0102

The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among injection drug using people living with HIV/AIDS

Bohdan Nosyk1,2; Jeong Eun Min3; Elizabeth Evans1; Libo Li3; Lei Liu4; Viviane Lima7;5; Evan Wood1,5 and Julio Montaner1,5

1Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2Department of Public Health Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 3Department of Family Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 4Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada. 5Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 6Psychiatry, University of California, San Francisco, United States. 7Psychiatry, University of California, San Francisco, United States.

Presenting author email: chet86@gmail.com

Background: Eastern Europe and Central Asia face a rapidly escalating HIV epidemic driven by injection drug use (IDU). We evaluate the role of opioid substitution treatment (OST) in engaging HIV-infected people who inject drugs (PWID) in care and the effect of OST on utilization of medical services.

Methods: Cross-sectional study of healthcare utilization in the past six months among 296 randomly sampled HIV-infected opioid-dependent PWID conducted in healthcare clinics in 2010 across Ukraine. Participants categorized as therapeutic on OST if on OST for at least three consecutive months prior to the past six months or as not taking OST if not on any OST in the past nine months. Based on this criterion, 24 individuals were excluded.

Results: The 65% on OST (177/272) were less likely to be below the poverty line or live alone and more likely to have been married or have gone to prison (p < 0.05). The two groups did not differ significantly in terms of age, gender, or education. Those on OST had more years of opioid injection but were less likely to have injected in the past 30 days, to have engaged in poly-substance abuse, or to have ever overdosed on drugs (p < 0.01). In the past six months, those on OST were less likely to seek emergency care (72% vs. 84%, p < 0.05) and had fewer mean emergency care visits (2.77 vs. 4.57, p < 0.02) with no significant differences in mean ambulatory visits (1.78 vs. 0.59, p = 0.11) or hospitalizations (0.53 vs. 0.34, p = 0.36). Those on OST were more likely to be engaged in HIV care, as evidenced by higher rates of antiretroviral therapy ART (37% vs. 26%, p = 0.08), recent CD4 testing (82% vs. 60%, p < 0.03), and recent TB testing (95% vs. 71%, p < 0.01). Number of self-reported symptoms was higher in the non-OST group compared to those on OST (10.46 vs. 7.75, p < 0.01). Limitations include cross-sectional design and potential for recall and social desirability biases.

Conclusions: Despite higher rates of incarceration and more years of opioid injection, those therapeutic on OST were less likely to seek emergency care than those not on OST and more likely to be engaged in HIV care with fewer overall symptoms.

http://dx.doi.org/10.7448/IAS.18.5.20435
Background: Prior studies indicate that opioid substitution treatment (OST) reduces the risk of mortality and improves the odds of accessing highly active antiretroviral therapy (HAART), however the relative effects of these treatments for injection drug use are unclear. We aim to determine the independent and joint effects of OST and HAART on mortality, by cause, within a population of injection drug using people living with HIV/AIDS (PLHIV). We used a linked population-level administrative database for British Columbia, Canada (1996–2010) to form a cohort of injection drug using PLHIV. We selected all individuals identified as HIV-positive and either having a history of OST at initial HAART receipt, as indicated by methadone or buprenorphine dispensation records in the BC PharmaNet database or having an indication of injection drug use before HIV infection, as indicated in the HIV testing database. We employed time-to-event analytic methods, including competing risks models, proportional hazards models with time-varying covariates, and marginal structural models, to identify the independent and joint effects of OST and HAART on all-cause, as well as drug- and HIV-related mortality, controlling for covariates.

Methods: This mixed-methods research programme integrated a structured questionnaire and laboratory testing with qualitative interviews assessing legal knowledge, police encounters, drug and sex risk behaviours, and infectious disease status. At baseline, 737 PWID were recruited in Tijuana; 32 participated in qualitative interviews.

Results: Between 2010 and 2013, only 11% of PWID respondents reported being aware of drug decriminalization; virtually none experienced drug treatment diversion or the law's other operational components. Interviews underscored the law's irrelevance to PWID; 699 (98%) characterized police practices as typically inconsistent with formal law. Instead of diversion to addiction treatment, multivariate modelling suggested that police encounters are independently associated with increased HIV risk behaviours such as syringe sharing (OR = 1.26; 95% CI = 1.09–1.46) and poly-drug use (OR = 2.11; 95% CI = 1.38–3.22). Qualitative data underscored the dissonance between the formal legal standards for drug and syringe possession, treatment diversion and other public health-oriented legal provisions on the one hand, and the lived experience of drug users on the other.

Conclusions: Formal drug policy reform may be necessary in many settings to reduce HIV risk among PWID, but appears insufficient as a stand-alone intervention. As policy interventions intended to facilitate HIV prevention gain global momentum, ancillary structural reforms such as police training to improve the rule of law are needed to unlock their public health potential. Operational partnerships with law enforcement are discussed.

http://dx.doi.org/10.7448/IAS.18.5.20437

MOPDD0104

Low threshold services for females who inject drugs: reducing gender inequities in methadone enrolment

Barrot H Lambdin1,2, Cassian Nyandindi3, Doug Bruce3, Norman Sabuni4, Ayoub Magimba4 and Eva Matiko6

1Pangaea Global AIDS, Oakland, United States. 2Department of Epidemiology and Biostatistics, University of California, San Francisco, United States. 3Department of Global Health, University of Washington, Seattle, United States. 4Ministry of Health and Social Welfare, Dar es Salaam, Tanzania, United Republic of Tanzania. 5Department of Medicine, Yale University, New Haven, United States. 6Centers for Disease Control and Prevention, Dar es Salaam, Tanzania, United Republic of Tanzania.

Presenting author email: blambdin@pgaf.org

Abstract MOPDD0104 - Figure 1. Lowess smooth of the percentage of female methadone clients.
Background: In 2011, the government of Tanzania established methadone assisted therapy (MAT) to combat the dual epidemic of HIV and injection drug use. However, enrolment of females who inject drugs into MAT has lagged behind that of males. To address this inequity, the methadone clinic at Mwananyamala Regional Referral Hospital (MRRH) introduced low threshold services for females in January 2013, allowing women to bypass the historically required attendance at community-based organizations prior to enrolment. Furthermore, existing female clients were encouraged to recruit their peers and one-day of the week was set aside for enrolling female clients only.

Methods: We conducted an interrupted time-series study to evaluate the impact of implementing low threshold services for females enrolling into MAT, using de-identified, routinely collected data from November 2012 to October 2014 at MRRH. Prais-winsten regression models were utilized to estimate the mean change in the proportion of clients that were female and the weekly number of females enrolling, adjusting for male enrolment and a period of MAT enrolment interruption form July-November 2013.

Results: Overall, 759 clients enrolled into the methadone clinic during the study period. Of those enrolling, the mean age was 34 years. The mean number of people enrolling into methadone during the study period was 8 clients (95% CI: 7, 9) per week. After implementation of low threshold services, the proportion of female clients increased from 14% (95% CI: 13%, 15%) to 25% (95% CI: 23%, 25%; p = 0.001), but after the enrolment interruption, the proportion of female methadone clients decreased slightly to 22% (21–22%).

Adjusting for male enrolment, the mean number of females enrolling per week was 2 (95% CI: 1–3; p = 0.001) people per week higher as compared to before implementation. Following the enrolment stoppage, the average number of female enrollees was comparable to pre-intervention (mean change: 0; 95% CI: –1, 1; p = 0.442).

Conclusions: Implementation of low threshold services improved enrolment into the methadone programme among women, thereby increasing the proportion of female methadone clients. However, the gains in enrolment were attenuated after an enrolment interruption, highlighting the importance of programme stability with this group of clients.

http://dx.doi.org/10.7448/IAS.18.5.20438

MOPDD0105

Increasing rates of earlier antiretroviral treatment associated with elevated levels of optimal virologic response among HIV-positive illicit drug users during a treatment-as-prevention-based initiative in a Canadian setting

M-J Milloy; Thomas Kerr; Robert Hogg; Silvia Guillemi; Julio Montaner and Evan Wood

British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.

Presenting author email: uhrj-mjsm@cfenet.ubc.ca

Introduction: Among illicit drug users, renewed efforts to reduce high levels of HIV/AIDS-related morbidity and mortality and curb rates of viral transmission rely, in part, on earlier initiation of antiretroviral therapy (ART). However, there are concerns that starting treatment prior to immunosuppression for members of harder-to-treat groups could contribute to lower levels of treatment adherence and lead to impaired virologic response. Thus, we sought to evaluate trends in CD4 cell count at ART initiation over time and rates of subsequent virologic response among HIV-positive illicit drug users during a community-wide Treatment-as-Prevention campaign in Vancouver, Canada.

Methods: We used data from the ACCESS study, an ongoing longitudinal cohort of HIV-positive illicit drug users linked to comprehensive HIV clinical monitoring and pharmacy dispensation records. In this retrospective study, we included all individuals who initiated ART from 2005 onwards. We used multivariable logistic regression to evaluate differences in mean CD4+ cell count at initiation by year of initiation. To estimate time to plasma HIV-1 RNA viral load <50 copies/mL by CD4 cell count at ART initiation, we used Kaplan–Meier and Cox proportional hazards methods.

Results: Between 2005 and 2013, 357 individuals initiated ART. Median CD4 at initiation increased from 130 cells/mL (interquartile range: 60 – 205) in 2005 to 330 (205 – 430) in 2013. In a linear regression analysis adjusted for age, gender and ancestry, year of initiation was positively associated with CD4 cell count at initiation (b = 30.82 cells per year increase, p < 0.001). Among 357 initiates, 184 (52%) reached non-detectable plasma VL within 360 days. In an adjusted Cox proportional hazards model, CD4 cell count at initiation was positively associated with time to viral suppression (adjusted hazard ratio: 1.21 per 100 cell/mL increase; 95% confidence interval: 1.13–1.29).

Conclusions: We observed substantial increases in CD4 cell count at initiation over time coincident with a community-wide TasP-based initiative. Individuals initiating ART earlier in the disease course exhibited higher rates of optimal virologic response. These findings support earlier initiation of ART among illicit drug users to reduce levels of HIV/AIDS-associated morbidity and mortality and rates of viral transmission.

http://dx.doi.org/10.7448/IAS.18.5.20564

TU – TUESDAY

TUPDA0101

Association between CSF and peripheral markers of immune-activation/inflammation and elevated intrathecal HIV-RNA levels in a cohort of HIV-infected antiretroviral naïve individuals

Esther Merlini1; Francesca Iannuzzi1; Francesca Bai2; Mattia Trunfio2; Stefano Bonora2; Andrea Calcagno2; Elvira Stefania Cannizzo2; Matteo Basili2; Teresa Bini2; Antonella d’Arminio Monforte2 and Giulia Marchetti2

1Clinic of Infectious Diseases and Tropical Medicine, University of Milan, Health Sciences, Milan, Italy. 2Department of Infectious Diseases, University of Turin, Turin, Italy.

Presenting author email: esther.merlini@unimi.it

Introduction: Since the association between high HIV-RNA replication in central nervous system and immune activation/inflammation has not yet been established, we aimed to investigate the inflammatory milieu in CSF and peripheral blood of HIV+ antiretroviral naïve subjects with high CSF viremia compared to those with low CSF viremia, in the attempt to identify biomarkers that might be used as diagnostic tools.

Methods: A total of 150 HIV+ eART-naïve pts underwent to lumbar puncture for CSF HIV-RNA quantification and were tested for peripheral T-cell immune-phenotypes (CD38/CD45RA/CD45R0/CD127 on CD4/CD8; flow cytometry). In a subgroup of 64 patients CSF/ plasma TNF-a, IL-6, sCD14, IFNg, MCP-1, IP-10, neopterin, S100beta (ELISA, Luminex) were measured. We defined: high CSF HIV-RNA ≥10,000 cp/mL (H-CSF); low CSF HIV-RNA <10,000 cp/mL (L-CSF), viral escape (VE) CSF/plasma HIV-RNA >1 log10 cp/mL. Statistical analyses: Chi-square, Mann–Whitney test and univariate/multivariate logistic regression.

Results: 48/150 pts (32%) resulted H-CSF. VE was found in 5/150 pts (3%). No differences in gender, risk exposure categories, viral hepatitis co-infections, HIV duration, age and CD4+ nadir were found between
L-CSF and H-CSF. H-CSF pts displayed higher plasma HIV-RNA (p = 0.002) and VE (p = 0.019). The univariate logistic regression showed that H-CSF are characterized by lower central memory CD127+CD40+ (p = 0.026) and naive CD8+CD45RA+ (p = 0.017) and higher activated CD8+CD38+ (p = 0.08) and memory activated CD8+CD38−/CD45RO+ (p = 0.022). In multivariate analysis, lower proportion of CD8+CD45RA+ was the only parameter independently associated with H-CSF (OR 0.934, IC 95% 0.877–0.995, p = 0.035), adjusting for plasma VL, CD4/CD8 ratio, CD127/CD4%, CD8/CD38%. Within the CSF, we found that H-CSF displayed significantly higher sCD14 (p < 0.0001), neopterin (p = 0.006), IL-6 (p = 0.002) and IP-10 (0.035) and no differences in TNFα, MCP-1 and S100beta. Similarly, H-CSF showed higher circulating sCD14 (p < 0.0001), but not TNFα, IL-6 and IFNγ.

Conclusions: The low percentage of naive CD8+ T-cells, independently associated with higher CSF Viral Load, might be included in a panel of biomarkers useful to identify patients at major risk of high CSF replication, if confirmed by larger studies.

Besides, the finding of higher peripheral and CSF activation/inflammation in H-CSF group indicate a more complex scenario, where both districts cooperate in maintaining the inflammation within CNS, possibly affecting neuronal function, and therefore deserves further investigations.

http://dx.doi.org/10.7448/IAS.18.5.20439

\textbf{TUPDA0102} Receptor mediated endocytosis directs subcellular trafficking and TLR signalling of HIV-1 in plasmacytoid dendritic cells

Meagan O’Brien\textsuperscript{1}; Olivier Manches\textsuperscript{2}; Craig Wilen\textsuperscript{3}; Vernon Wu\textsuperscript{1}; Nicole Sunseri\textsuperscript{4} and Nina Bhardwaj\textsuperscript{2}

\textsuperscript{1}Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States. \textsuperscript{2}Department of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, United States. \textsuperscript{3}Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, United States. \textsuperscript{4}Department of Pediatrics, University of Chicago, Chicago, United States.

Presenting author email: mpowersobrien@yahoo.com

\textbf{Introduction:} Dysregulated type I interferon (IFN) responses contribute to immuneopathology in chronic HIV infection, therefore it is critical to dissect the molecular mechanisms underlying HIV-stimulated IFN production. We examined the spatiotemporal regulation of IFN secretion by plasmacytoid dendritic cells (pDC), specialized cells that secrete high levels of IFN upon HIV recognition by Toll-like receptor (TLR) 7. We showed previously that intracellular trafficking of HIV to early endosomes is associated with potent IFN secretion but minimal NF-κB signalling, resulting in suboptimal pDC secretion but minimal NF-κB signalling, resulting in suboptimal pDC maturation; however, how HIV trafficking is determined and the causal link between HIV subcellular localization and differential TLR signalling are currently unknown.

\textbf{Methods:} Human pDC were purified from peripheral blood and were stimulated with GFP labelled: HIV, HIV pseudotyped with influenza hemagglutinin envelope (HA-HIV), and PR8 influenza. TLR7 expressing HEK NF-κB reporter cells, stably transfected with CD4 mutants with cytoplasmic tails directing trafficking to early endosomes (EE) or lysosomes, were activated with HIV and controls. Analysis included ELISA, flow cytometry and florescent microscopy. Cells were imaged using the Advanced Precision imaging system and images were analyzed using ImageJ.

\textbf{Results:} We compared the effects and spatiotemporal trafficking in pDC of HIV, influenza and HA-HIV. We demonstrate that HA-HIV strongly activates maturation pathways (NF-κB) in pDC and traffics rapidly to lysosomes, similarly to influenza but unlike HIV, suggesting that viral envelope directs trafficking and resultant phenotype of ssRNA virions in pDC. We studied HIV-CD4 interactions in a HEK reporter cell system expressing TLR7 with functional NF-κB signalling, which we co-transfected with CD4 mutants whose cytoplasmic tails either directed CD4 trafficking to EE or lysosomes. We show that wild type (WT) CD4 localizes to EE, whereas CD4 mutated with either DEC-205 or LAMP1 tail localizes to lysosomes. HIV traffics to EE in WT CD4 expressing TLR7 HEK cells and fails to stimulate NF-κB signalling, whereas HIV traffics to lysosomes in DEC-205/LAMP1 expressing TLR7 HEK cells and stimulates NF-κB signalling, suggesting that rerouting of HIV (via CD4) to lysosomal compartments triggers NF-κB rather than IFN pathways.

\textbf{Conclusions:} CD4 receptor mediated endocytosis targeting early endosomes determines HIV intracellular localization and observed interferon-producing phenotype of HIV-activated pDCs.

\textbf{http://dx.doi.org/10.7448/IAS.18.5.20440}

\textbf{TUPDA0103} HIV-1 Vpu exploits the crosstalk between BST2 and the ILT7 receptor to inhibit innate sensing of infected T cells by plasmacytoid dendritic cells

Mariana G Bego\textsuperscript{1}; Edouard A Côté\textsuperscript{1}; Nick Ashman\textsuperscript{2}; Johanne Mercier\textsuperscript{3}; Winfried Weih\textsuperscript{4} and Eric A Cohen\textsuperscript{1,3}

\textsuperscript{1}Institut de Recherches Cliniques de Montréal, Montréal, Canada. \textsuperscript{2}Unit of Virus Host Cell Interactions, Université Grenoble Alpes, Grenoble, France. \textsuperscript{3}Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, Canada.

Presenting author email: eric.cohen@ircm.qc.ca

\textbf{Introduction:} Plasmacytoid dendritic cells (pDCs) constitute a major source of type-I interferon (IFN-I) production during acute HIV infection. Their activation results primarily from TLR7-mediated sensing of HIV-infected cells. BST2/Tetherin is a restriction factor that suppresses HIV release by cross-linking virions at the cell-surface. HIV-1 overcomes BST2 antiviral activity through Vpu, which partially downregulates BST2 cell-surface expression. Apart from its direct antiviral activity, BST2 was shown to bind the ILT7 pDC-specific inhibitory receptor and repress IFN-I production by activated pDCs. Here, we examined whether Vpu-mediated BST2 antagonism could modulate innate sensing of HIV-infected cells by pDCs.

\textbf{Methods:} PBMCs or isolated pDCs were co-cultured with T cells infected with wild type or Vpu-defective HIV-1 and innate sensing was evaluated by monitoring IFN-I production. BST2-mediated activation of ILT7 signalling was analyzed using an ILT7-reporter cell system.

\textbf{Results:} We show that Vpu antagonizes the production of IFN-I during sensing of HIV-infected cells by pDCs. This control of innate sensing by Vpu could be prevented by: 1) depletion of BST2 from infected donor cells; 2) depletion of ILT7 in pDCs; or 3) blocking BST2-ILT7 interaction using anti-BST2 antibodies or soluble ILT7. Using a BST2 mutant that cannot cross-link budding virions but yet retains the capacity to repress IFN-I production by pDCs, we show that virion trapping on infected donor cells prevents BST2 from eliciting an inhibition of IFN-I production by pDCs. Interestingly, confocal microscopy analysis of virus producing cells reveals that in presence of Vpu there is a residual pool of surface BST2, which is excluded from viral budding sites and thus potentially accessible for interaction with ILT7 on pDCs. Lastly, using an ILT7 reporter cell system, we provide evidence that Vpu-mediated BST2 antagonism modulates the levels of available surface BST2 capable of engaging and activating ILT7 upon cell-to-cell contact.

\textbf{Conclusions:} Overall, this study sheds light on a novel Vpu-BST2 interaction that allows HIV to control innate sensing of infected cells by pDCs via the negative signalling exerted by the ILT7-BST2 pair. This mechanism of innate immune evasion is likely to be critical for efficient viral dissemination and establishment of viral reservoirs during acute infection.

\textbf{http://dx.doi.org/10.7448/IAS.18.5.20441}
**TUPDA0104**

**HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the promoter**

Filippo Turini1,2, Anna Kajaste-Rudnitski1, Sara S Marelli1, Carine Van Lin5, Aize T Das6, Ben Berkout4 and Elisa Vicenzi1

1Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy. 2Molecular Medicine PhD Program, Vita-Salute San Raffaele University, Milan, Italy. 3Service of Molecular Virology, University of Bruxelles, Gosselies, Belgium. 4Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.

**Presenting author email:** turini.filippo@hsr.it

**Introduction:** HIV-1 latency is a multifactorial process resulting by the interplay between cellular transcription factors and the viral regulatory protein Tat. We have previously described the interferon-inducible restriction factor TRIM22 as a suppressor of basal and phorbol ester-dependent LTR-mediated transcription independently of NF-κB and of Tat/TAR interaction. As basal HIV-1 transcription is mainly driven by the binding of the cellular transcription factor Sp1, we have investigated whether TRIM22 could interfere with such Sp1-driven transcriptional activation of HIV-1 LTR.

**Methods:** 293T cells, lacking of endogenous TRIM22, were co-transfected with a TRIM22-expressing plasmid together with reporters vectors driven by the HIV-1 promoter containing either wild-type or mutated Sp1 binding sites or lacking of either one or two sites; reporter expression was assessed 48 hours post-transfection. Endogenous TRIM22 was knocked-down (KD) in SupT1 cells that were subsequently infected with HIV-1 molecular clones engineered or mutated Sp1 binding sites or lacking of either one or two sites. Virus replication was monitored up to 32 days post-infection. Cell extracts from TRIM22-transfected 293T was subjected to 1) immunoprecipitation, 2) Western blotting, 3) DNA pull-down and 4) chromatin immunoprecipitation (ChIP).

**Results:** TRIM22 overexpression suppressed Sp1-driven transcription of HIV-1, as its inhibitory activity was lost in the absence of Sp1 binding sites. In contrast, TRIM22 KD increased the replication of infectious clones that were exclusively dependent upon Sp1 binding to the promoter. Furthermore, immunoprecipitation experiments showed that TRIM22 and Sp1 can interact physically although this interaction does not affect the level of expression of endogenous Sp1 or its phosphorylation state. TRIM22 did not directly bind to the promoter. Furthermore, immunoprecipitation experiments showed that TRIM22 and Sp1 can interact physically although this interaction does not affect the level of expression of endogenous Sp1 or its phosphorylation state. TRIM22 did not directly bind to the promoter. Furthermore, immunoprecipitation experiments showed that TRIM22 and Sp1 can interact physically although this interaction does not affect the level of expression of endogenous Sp1 or its phosphorylation state.

**Conclusions:** TRIM22 inhibits Sp1-dependent transcription by interacting with Sp1 and preventing its binding to the HIV-1 LTR. Our findings bear relevance for the discovery of new pharmacological approaches aimed at targeting the reservoir of cells latently infected with replication-competent proviruses.

**http://dx.doi.org/10.7448/IAS.18.5.20442**

**TUPDA0105**

**Polymorphisms in TRIM22 are associated with HIV-2 acquisition and disease progression**

Shmona Simpson1, Thushan deSilva1, Louis-Marie Yindom1, Alexandra Legidowicz1, Timothy Vincent2 and Sarah Rowland-Jones3

1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. 2Medical Research Council Unit, The Gambia, Serrekunda, Gambia. 3Presenting author email: shmona.simpson@trinity.ox.ac.uk

**Introduction:** Tripartite motif-containing protein 22 (TRIM22) is an E3 ubiquitin ligase with activity against HIV-1: high levels of TRIM22 expression are associated with reduced viral set-point following acute HIV-1 infection. The TRIM22 gene has been greatly shaped by positive selection, and its expression is sensitive to retroviral infection, Type I and Type 2 interferon. The mechanism by which TRIM22 exerts its antiviral effect is poorly understood. Further, the impact of TRIM22 genetic variation in the context of HIV-2 disease is unknown.

**Methods:** To test the hypotheses that TRIM22 expression antagonizes HIV-2 infection and that polymorphisms in TRIM22 significantly modulate this effect, we conducted three studies. Firstly, TRIM22 was genotyped in 60 HIV-2 patients, comparing viral controllers and rapid progressors, and a similar number of age and sex matched controls from the same community in rural Guinea-Bissau. Using regression modelling, polymorphisms were analysed alongside immunological and virological data. Secondly, a model of TRIM22 was constructed using computational methods and the polymorphisms observed in vivo were mapped and analysed. Finally, baseline CD4 and protein levels of TRIM22 from C8166 cells were measured using quantitative RT-PCR and flow cytometry respectively. The cells were subsequently infected with HIV-2, and measurements repeated to determine whether TRIM22 gene expression is sensitive to HIV-2 infection.

**Results:** The data show that TRIM22 polymorphisms rs1063303 and rs7935564 are significantly associated with HIV-2 acquisition and disease progression. Further, polymorphisms observed in vivo cluster in functional regions that our modelling studies suggest may interact with the HIV-2 capsid. Finally, we show that TRIM22 gene expression is upregulated in the presence of HIV-2, in a lymphocyte cell line.

**Conclusions:** Taken together, our data show that TRIM22 expression is sensitive to HIV-2 infection and that polymorphisms in TRIM22 genes are significantly associated with HIV-2 acquisition and disease progression. Further, the study has computationally characterized positively selected polymorphisms observed in vivo and the data show that these polymorphisms have the potential to significantly alter protein structure and function. These data provide the first analysis of TRIM genetic variation in the context of HIV-2 infection.

**http://dx.doi.org/10.7448/IAS.18.5.20443**

**TUPDA0106LB**

**The negative checkpoint receptor TIGIT marks exhausted T cells during SIV infection and correlates with SIV disease progression**

Gabriela M Webb1, Glen M Chew2, Tsuyoshi Fujita3, Benjamin J Burwitz3, Helen L Wu4, Jason S Reed2, Katherine B Hammond2, Scott G Hansen2, Mark Maurer2, Alan J Korman2, Lishomwa C Nhllov2 and Jonah B Sacha1

1Vaccine & Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, United States. 2Department of Tropical Medicine, Hawaii Center for HIV/AIDS, John A. Burns School of Medicine, University of Hawaii, Honolulu, United States. 3Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan. 4Biologics Discovery California, Bristol-Myers Squibb, Redwood City, United States.

**Presenting author email:** moring@ohsu.edu

**Introduction:** During chronic viral infections, high antigenic load continually stimulates T cells resulting in T-cell exhaustion. Exhausted T cells increase the expression of negative checkpoint inhibitors such as PD-1, which raise the threshold for activation and contribute to suppressed immune responses. Another recently discovered immune checkpoint receptor, TIGIT, is upregulated on T cells in neoplasms and chronic CMV infection. We hypothesize that TIGIT functions as a negative checkpoint receptor marking dysfunctional T cells during SIV infection.
infection and that modulation of TIGIT would restore anti-SIV-specific T-cell responses. **Methods:** Spleen, lymph node (LN) and PBMCs from SIV-naïve and SIV-infected rhesus macaques (RMs) were examined for surface expression of TIGIT. In vitro cytokine production was assessed via intracellular cytokine staining. Proliferative capacity was determined through CFSE dilution assays in the presence of antibodies blocking TIGIT and PD-1 pathways (anti-TIGIT mAb and anti-PD-L1 mAb). **Results:** TIGIT expression was significantly upregulated on CD8⁺ T cells derived from the spleen and LN but not on PBMC in SIV-infected animals. The frequency of TIGIT⁻/CD8⁺ T cells in the LN significantly correlated with SIV viral load, and TIGIT expression was driven primarily by g-chain cytokines such as IL-2. TIGIT was expressed on approximately 40% of SIV-specific CD8⁺ T cells, even in animals with full ART suppression of viral replication. While IκB expression did not differ between TIGIT⁻ and TIGIT⁺ CD8⁺ T cells, TIGIT CD8⁺ T cells produced significantly more IFN-γ compared to TIGIT⁻ CD8⁺ T cells. Single and dual blockade of TIGIT and/or PD-1 signalling pathways restored proliferative capacity of SIV-specific T cells in vitro. **Conclusions:** TIGIT is a negative checkpoint receptor that marks a novel population of functionally exhausted SIV-specific CD8⁺ T cells and is associated with SIV disease progression. The enhancement of virus-specific T-cell proliferative responses in the presence of single or dual blockade of TIGIT and/or PD-1 suggests that targeting the TIGIT pathway is a viable therapeutic approach to reverse T-cell dysfunction. Given the high sequence homology of rhesus and human TIGIT, this provides a platform to further investigate TIGIT, along with other checkpoint inhibitors, as potential targets for mediating a functional cure for HIV.

http://dx.doi.org/10.7448/IAS.18.5.20561

**TUPDB0102**

Prolongation of QTc interval in HIV-infected individuals compared to the general population is not caused by antiretroviral therapy

Stefan Esser¹; Marie Henrike M Geisel²; Marina Arendt²; Christina Schulze³; Volker Holzendorf²; Anna Warneke²; Norbert H Brockmeyer⁴; Martin Howler⁵; Dirk Schadenfroh⁵; Till Neumann⁶; Lewin Eisele⁷; Raimund Erbel³; Susanne Moebus²; Karl-Heinz Jöckel²; Nico Reinsch² and HIV HEART Study Group and Heinz Nixdorf Recall Investigative Group

¹Department of Dermatology and Venerology, University of Duisburg Essen, Essen, Germany. ²Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg Essen, Essen, Germany. ³Department of Cardiology, West German Heart Centre, University of Duisburg Essen, Essen, Germany. ⁴Clinical Trial Centre Leipzig, University Leipzig, Coordination Centre for Clinical Trials (ZKS Leipzig – KKS), Leipzig, Germany. ⁵Department of Sexual Health and Medicine, Clinic of Dermatology, Venerology and Allergology, Ruhr University Bochum, Bochum, Germany. ⁶Department of Internal Medicine, City Hospital Dortmund, Dortmund, Germany.

Presenting author email: stefan.esser@uk-essen.de

Introduction: Prolongation of the QT interval (QTc) increases the risk of cardiovascular events (CVE). The incidence of CVE is higher in HIV-infected (HIV⁺) patients compared with the general population. The impact of different antiretroviral therapies (ART), co-medication and HIV-infection on the electrical activity of the heart is rarely investigated in large HIV⁺ cohorts.

Methods: We compared QTc of HIV⁺ outpatients of the HIV HEART study (HIVH) and of controls of the population-based Heinz Nixdorf Recall study (HNR), both recruited from the German Ruhr area since 2000. HIVH cases were age- and sex-matched with HNR controls in a 1:2 ratio. QTc was measured and corrected using the Bazett’s formula. We used crude and adjusted linear mixed models to account for the matched design and adjusted for QTc interval prolonging medication (QTc-PM, no ART). Differences in QTc between HIV specific factors and ART were evaluated using ANOVA in the HIVH subpopulation. All analyses were stratified by sex.

Results: 496 HIVH participants (83.3% male, aged 54.5 ± 6.7) were matched with 992 HNR controls. We observed a longer QTc in HIVH subjects compared with HNR controls: 424 ± 23 ms versus 411 ± 15 ms for male and 435 ± 20 ms versus 416 ± 17 ms for female subjects (p < 0.0001 for both sexes). HIVH males used QTc-PM more often (22.3% vs. 17.6% for HNR) than HIVH females (13.3% vs. 24.7% for HNR). However, adjusting for QTc-PM the mean differences in QTc remained significant with 13 (95% CI: 11, 15) ms for male and 19 (95% CI: 14, 24) ms for female subjects. Prolongation of QTc (male > 440 ms, female > 460 ms) was pathologic in 22.8% versus 3.9% of HIVH and HNR males and in 12.1% versus 1.8% of the females. No differences in the QTc were observed within the HIVH population for different ART medications, for the clinical and immunological HIV status and for the route of HIV infection in both sexes.

Conclusions: HIV⁺ patients have longer mean QTc and more often pathological prolonged QTc compared with age- and sex-matched controls from the general population even after adjustment for intake of non-antiretroviral QTc-PM. ART, HIV stage and HIV transmission route are not associated with QTc prolongation.

http://dx.doi.org/10.7448/IAS.18.5.20444

**TUPDB0102**

Favourable effect on vitamin D and bone after switching from Atripla to darunavir/ritonavir: a randomised controlled clinical trial

Lisa Hamzah¹; Juan Manuel Tiraboschi²; Martina Toby³; Helen Nesson⁴; Christine Manτ; Cason John⁵; Keith Burling⁶; Ranjababu Kulasegaram⁷; Alasdair Teague⁸; Frank A Post⁹; Julie Fox² and MIDAS Study Group

¹Renal Sciences, King's College London, London, United Kingdom. ²Department of Nuclear Medicine, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom. ³Renal Sciences, King's College London, London, United Kingdom. ⁴King's Centre for Global Health, King’s College Hospital NHS Foundation Trust, London, United Kingdom.

Presenting author email: lisa.hamzah@kcl.ac.uk

Introduction: Efavirenz has been associated with reductions in vitamin D (25(OH)D) and Tenofovir with increased bone turnover, reductions in bone mineral density (BMD) and renal tubular dysfunction (RTD). We hypothesized that switching from Atripla to Darunavir/Ritonavir monotherapy (DRV/r) might increase 25(OH)D, and improve BMD and RTD.

Methods: Patients with HIV RNA <50 copies/mL on Atripla for > six months were randomized 1:1 to receive ongoing Atripla or DRV/r (800/100 mg once daily) for 48 weeks. Primary endpoint was change from baseline in 25(OH)D at week 48. Secondary endpoints included changes in BMD, bone turnover markers and RTD. Linear regression estimated the mean difference in 25(OH)D in patients on Atripla versus DRV/r. Secondary endpoints were expressed as the mean (95% CI) observed between-arm difference from baseline.

Results: 70 subjects (86% male, 66% white, mean (SD) CD4 cell count 537.3 (191.5) per mm³) were randomized, of whom 26 (DRV/r) and 31 (Atripla) completed the 48 week study on the allocated treatment. The mean (SD) difference between baseline and week 48 25(OH)D was 5.0 (5.9) ng/ml for DRV/r and 1.2 (6.0) for Atripla. After adjustment for baseline 25(OH)D and demographics, at week 48 DRV/r monotherapy was associated with a + 3.5 (95% CI: 0.5, 6.4)
Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals

Philip Grant1; Doug Kitch2; Grace McComsey3; Ann Collier4; Sue Koletar5; Kristine Erlandson6; Michael Yin7; Benedetta Bartali8; Belinda Ha9; Kathy Melbourne10 and Todd Brown11

1Infectious Diseases, Stanford University, Stanford, United States. 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, Harvard School of Public Health, Boston, United States. 3Department for Pediatrics and Medicine, Case Western Reserve University, Cleveland, United States. 4Division of Allergy and Infectious Diseases, University of Washington, Seattle, United States. 5Division of Internal Medicine, Ohio State University, Columbus, United States. 6Division of Infectious Diseases, University of Colorado, Denver, United States. 7Division of Infectious Diseases, Columbia University, New York, United States. 8New England Research Institute, Watertown, United States. 9ViiV, Research Triangle Park, United States. 10Medical Sciences, Gilead Sciences, Foster City, United States. 11The Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, United States.

Presenting author email: pmgrant72@gmail.com

Introduction: Accelerated bone mineral density (BMD) loss occurs during the first two years of ART. Few studies have evaluated sub- sequential changes in BMD, especially compared to uninfected controls.

Methods: ACTG A5318 performed one follow-up visit site-specific dual-energy x-ray absorptiometry (DXA) in HIV-infected individuals who had received baseline and follow-up DXAs during the randomized treatment trial A5202/A5224. As controls, we obtained DXA results from uninfected participants enrolled in BACH/Bone and WIHS cohorts. Repeated measures analyses compared BMD change rate between HIV-infected and uninfected, adjusting for age, sex, race and body mass index (BMI). In the HIV-infected group, we performed multivariable analyses evaluating association of HIV-specific (baseline and time-updated CD4 and viral load), HIV treatment-related (randomized ART regimen, cumulative tenofovir (TDF) exposure) and non-HIV related factors (age, sex, race, relevant concomitant medication use, BMI, total lean body mass) on BMD change rate.

Results: Baseline characteristics between HIV infected (n = 97) and HIV-uninfected (n = 630) participants were generally similar: median age, 40 versus 46; % female, 14 versus 14; % black, 34 versus 35; median BMI, 24 versus 29; and median years between first and last DXA, 7.5 versus 6.9. Seventy-one percent of HIV-infected participants were on TDF at last DXA. Compared to controls, HIV-infected individuals had significantly greater adjusted BMD decline rate at lumbar spine (LS) and total hip (TH) during the first 96 weeks of ART (both p < 0.001). Subsequently, on follow-up DXA, HIV infection remained significantly associated with greater adjusted BMD decline rate at LS (−0.29%/year; 95% CI: −0.49; −0.09; p = 0.005) but not at TH (p = 0.63). In the HIV group, the rate of BMD decline slowed after the first 96 weeks of ART (0–96 weeks vs. Late Change: LS: −0.75%/year vs. −0.13%/year, p = 0.04; TH: −1.29%/year vs. −0.30%/year, p < 0.001). During the late period, no HIV-related characteristic was associated with BMD loss, but lower total lean body mass (and not BMI) was associated with greater BMD loss at LS and TH (both p < 0.001).

Conclusions: Although the rate of BMD decline slowed after the first 96 weeks after ART initiation in HIV-infected persons, the rate of bone loss at the lumbar spine was still significantly greater than HIV-uninfected controls.

http://dx.doi.org/10.7448/IAS.18.5.20445

TUPDB0104

Prevalence of non-alcoholic fatty liver disease and liver fibrosis among perinatally HIV-infected Asian adolescents with history of transaminis

Taviyti Sudjardiruk1,2,3, Torsak Bunupuradhan5, Linda Auripibal5, Pope Kosalarksa5, Nia Kurniati5 and Thanyaweey Puthanakrit6,7

1Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 2Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 3HIV-NAT, Thai Red Cross – AIDS Research Centre, Bangkok, Thailand. 4Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand. 5Department of Child Health, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. 6Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Presenting author email: tavitiya@gmail.com

Introduction: Liver disease is an important non-AIDS related morbidity in HIV-infected adults. Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological syndrome which may progress toward liver fibrosis and cirrhosis. The study objective was to determine the prevalence of NAFLD and liver fibrosis among perinatally HIV-infected adolescents with a history of transaminis.

Methods: A cross-sectional study was conducted at 4 paediatric HIV centres in Thailand (Bangkok, Chiang Mai, Khon Kaen) and Indonesia (Jakarta). HIV-infected adolescents aged 10 to 25 years with virologic suppression and had transaminis to uninfected controls.

Results: From August to December 2014, 39 adolescents were enrolled. Median (IQR) age was 17.2 (14.6–19.4) years; 47% were male. Median (IQR) duration of ART was 7.8 (4.4–11.2) years, of which 54% currently received non-nucleoside reverse transcriptase (NNRTI)-based regimen. Median (IQR) current CD4 cells count was 691 (535–797) cells/mm3. Fatty liver was observed in 6 (15%) adolescents, of which 2 (5%) had severe fatty liver (Table 1). Seventeen (46%) adolescents had any liver fibrosis and 6 (15%) had significant liver fibrosis (Table 1). Median (IQR) of ALT and AST were 30 (21–39) and 25 (20–31) U/L, respectively. Four (11%) had mild/moderate fibrosis by APRI. The APRI was moderately positively correlated with

http://dx.doi.org/10.7448/IAS.18.5.20446
Abstract TUPDB0104—Table 1. Characteristics of perinatally HIV-infected adolescents with non-alcoholic fatty liver disease or liver fibrosis

| Sex | Age (yrs) | BMI (kg/m²) | ALT (U/L) | AST (U/L) | Fatty Liver by USG | TE (kPa) | APRI |
|-----|-----------|-------------|-----------|-----------|-------------------|----------|-------|
| M   | 23        | 36.2        | 160       | 87        | Severe            | 14.0     | 0.63  |
| F   | 17        | 21.3        | 36        | 24        | Severe            | 5.7      | 0.21  |
| M   | 15        | 17.6        | 36        | 42        | Mild              | 5.9      | 0.39  |
| F   | 12        | 15.4        | 36        | 31        | Mild              | 5.7      | 0.42  |
| F   | 20        | 17.8        | 46        | 35        | Mild              | 4.3      | 0.47  |
| F   | 20        | 20.5        | 71        | 33        | Mild              | 3.3      | 0.33  |
| M   | 17        | 25.8        | 50        | 45        | Normal            | 8.6      | 0.60  |
| F   | 18        | 19.4        | 23        | 25        | Normal            | 8.0      | 0.34  |
| M   | 14        | 17.8        | 23        | 32        | Normal            | 7.9      | 0.27  |
| M   | 18        | 18.5        | 29        | 22        | Normal            | 7.8      | 0.17  |
| F   | 23        | 18.0        | 19        | 18        | Normal            | 7.7      | 0.34  |

M = male; F = female; BMI = body mass index; ALT = alanine aminotransferase; AST = aspartate aminotransferase; USG = ultrasonography; TE = transient elastography; APRI = aspartate aminotransferase-to-platelet ratio index; The bold text indicates abnormal values for each test.

Liver stiffness evaluated by TE (Pearson’s correlation coefficient = 0.51; p = 0.001).

Conclusions: About one-third of perinatally HIV-infected adolescents with a history of transaminisits met criteria of fatty liver or liver fibrosis. Longitudinal follow-up to monitor for progression and provide appropriate interventions in a timely manner is needed.

Remark: This study is funded by CIPHER Grants (2014), International AIDS Society.

Abstract TUPDB0105

Fixed dose combination EVG/COBI/TDF/FTC does not affect insulin resistance: the STRIBILD-IR study

Christoph D Spinner¹; Kristina E Kern¹; Sebastian Noe¹; Alexander von Werder²; Christiane Schwerdtfeger²; Roland Schmidt²; Alexander Zink²; Eva Wolf² and Roman Jakoubov³

¹Department of Medicine II, University Hospital Klinikum rechts der Isar, Munich, Germany. ²Department of Dermatology and Allergology, University Hospital Klinikum rechts der Isar, Munich, Germany. ³Clinical Research, Muc Research GmbH, Munich, Germany.

Presenting author email: christoph.spinner@tum.de

Introduction: The incidence of insulin resistance (IR) and diabetes mellitus in HIV-patients, both contributing to cardiovascular morbidity and mortality, has been associated with antiretroviral therapy (ART). Only limited data exists on metabolic effects of regimens including newer drugs such as fixed dose combination drugs, particularly concerning IR.

Methods: In this prospective, open-label, randomized phase-I-study we investigated the effects of the recently available fixed dose combination of tenofovir disoproxil fumarate, emtricitabine, elvitegravir and cobicistat (TDF/FTC/EVG/cobi, group I) on IR, in comparison to established ART with TDF/FTC + lopinavir/ritonavir (LPV/r, group II) and TDF/FTC + darunavir/ritonavir (DRV/r, group III). N = 30 healthy, male volunteers were randomly assigned into one of the 3 study arms. IR was measured using golden standard method of hyperinsulinemic euglycemic clamp before and 14 days after initiation of study medication. Briefly, a constant insulin infusion (2 mIU/(kg*min)) was infused over two hours, glucose infusion was adjusted as necessary to achieve stable glucose levels (target 90 ± 5 mg/dl). All volunteers took the study medication, as verified by pill counting. IR was evaluated using the mean glucose disposal rate normalized to body weight (M̄BG (mg glucose/min*kg)), as calculated during the clamp. To test for statistical significance of global and pairwise differences in IR, analyses of variances and the Student’s t-test was used. To test for significant changes in IR within study arms, the paired t-test was used.

Results: The enrolled volunteers were young, non-obese, healthy males; no significant differences were detected concerning baseline characteristics (Table 1). Mean IR did not differ between the groups before treatment (I vs. II vs. III: 11.2 ± 3.2; SD, standard deviation); n = 10 vs. 12.5 ± 3.3; n = 9 vs. 11.6 ± 2.5; n = 9). The medication was well tolerated; 2 patients were excluded from analysis due to medical (hypothyroidism) and technical (insulin pump error) reasons. TDF/FTC alone significantly affected IR after 14 day of treatment as compared to baseline (9.2 ± 1.8 vs. 12.5 ± 3.3; p = 0.037), but neither TDF/FTC/EVG/cobi (11.3 ± 2.5 vs. 11.2 ± 3.2; p = n.s.) nor TDF/FTC/DRV/r (11.3 ± 2.4 vs. 11.6 ± 2.5; p = n.s.) did.

Conclusions: Our study shows for the first time that neither treatment with the fixed dose combination TDF/FTC/EVG/cobi nor with LPV/r had a significant effect on IR.

Abstract TUPDB0105—Table 1. Baseline characteristics

| Group/parameter (Mean ± SD) | I: TDF/FTC/EVG/cobi | II: TDF/FTC + LPV/r | III: TDF/FTC + DRV/r |
|---------------------------|---------------------|---------------------|---------------------|
| Age (years)               | 26.3 (± 4.8)        | 27.3 (± 4.8)        | 27.2 (± 2.3)        |
| Weight (kg)               | 75.3 (± 4.8)        | 70.2 (± 8.3)        | 72.3 (± 7.6)        |
| Body height (cm)          | 183.5 (± 4.2)       | 178.9 (± 5.7)       | 180.0 (± 5.5)       |
| BMI (kg/m²)               | 22.4 (± 1.1)        | 21.9 (± 2.2)        | 22.3 (± 1.5)        |
| Fasting blood glucose (mg/dl) | 82.0 (± 5.1)  | 82.3 (± 6.7)        | 83.3 (± 6.0)        |
Molecular investigation for HIV-1 cross-group transmissions during the outbreak period (2011 - 2014) in Athens metropolitan area: introduction of subtype A from Eastern Europe

Dimitrios Paraskevis1; Georgios Nikolopoulos2; Vana Sypsa3; Minla Psychigou2; Meni Malliori2; Samuel R Friedman3 and Angelos Hatzakis1
1Department of Hygiene Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece. 2Hellenic Center for Diseases Control and Prevention, Athens, Greece. 3Department of Propedeutic Medicine, Laikon General Hospital, Athens, Greece. 4Medical School, University of Athens, Athens, Greece. 5National Development and Research Institutes, (NDRI), New York, United States.

Introduction: New diagnoses of HIV-1 infections among people who inject drugs (PWID) increased in Athens metropolitan area, Greece during 2011. Our aim was to identify potential cross-group transmissions between PWID and other risk groups using molecular methods.

Methods: HIV-1 subtypes were determined for 711 HIV-1 patients (PWID) sampled during 2011-2014. Cross-group transmissions were those that originated from other groups as estimated by phylogenetic trees. Specifically cross-group transmissions corresponded to viral lineages from PWID that didn’t fall into the outbreak transmission networks or the recombinants. Further phylogenetic analyses were conducted for the sequences from cross-group transmissions.

Results: Among the 711 HIV-1 patients (PWID), 630 (88.6%) sequences fell within four IDU transmission networks belonging to CRF14 BG (n = 356, 50.1%), CRF35_AD (n = 123, 17.3%), subtype B (n = 106, 14.9%) and A (n = 45, 6.3%). 48 (6.8%) were recombinants consisting of partial regions originating from the PWID-specific clades. On the other hand, sequences from 33 (4.6%) of the infections in this group are due to cross-group infections. Notably, half of these cross-group infections due to subtype A originate from the large IDU epidemic in Eastern Europe. Conclusions: During the four year period of the HIV-1 outbreak among the PWID in Athens metropolitan area, we estimated that 33 (4.6%) of the infections in this group are due to cross-group infections. Notably, half of these cross-group infections due to subtype A originate from the large IDU epidemic in Eastern Europe (A EEU). For subtype B, however, the majority of cross-group infections originated from Greece.
Conclusions: A comprehensive understanding of HIV transmission in Pakistan will be critical to design strategically targeted HIV prevention programs. Clusters may be indicators of ongoing transmission, and thus an effective strategy for prevention programs could be to target the cities and population groups with high clustering.

http://dx.doi.org/10.7448/IAS.18.5.20450

TUPDC0103
Transmission networks of HIV-1 among men who have sex with men in East and Southeast Asia
Kok Keng Tee;1 Ramli Kantor;2 Somnuek Sungkanuparph;3 Yutaka Takebe;4 Patrick Li;5 Rossana Ditangco;6 Prapan Phanuphak;7 Thira Sirisanthanak;8 Benedit Sim;9 Winai Ratanasuwan10 Pacharee Kantipong11 Mahiran Mustafa12 Tuti Parwati Merati13 Awachana Jiamsakul14 Thida Singtoroj15 Adeeba Kamarulzaman1 and TREAT Asia Studies to Evaluate Resistance - Monitoring (TASER-M) 1Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 2Department of Medicine, Alpert Medical School of Brown University, Providence, United States. 3Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 4AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan. 5Queen Elizabeth Hospital, Hong Kong, China. 6Research Institute for Tropical Medicine, Manila, Philippines. 7HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 8Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 9Hospital Sungai Buloh, Kuala Lumpur, Malaysia. 10Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 11Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 12Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia. 13Faculty of Medicine, Udayana University and Sanglah Hospital, Bali, Indonesia. 14The Kirby Institute, UNSW Australia, Sydney, Australia. 15TREAT Asia, amfAR, Bangkok, Thailand. Presenting author email: k2tee@um.edu.my

Introduction: The HIV epidemic among men who have sex with men (MSM) is expanding at an alarming rate in Asia. Understanding the dynamics of HIV-1 transmission among MSM through viral sequence analyses may provide essential information on the origin of viral lineages and the characteristics of disease spread.

Methods: We determined transmission networks of HIV-1 among MSM across countries in East and Southeast Asia. A total of 1856 HIV-1 polymerase gene sequences were obtained from TREAT Asia Studies to Evaluate Resistance-Monitoring (TASER-M) sites in Hong Kong, Thailand, Malaysia and the Philippines between 2006 and 2011. Time-stamped sequence datasets of HIV-1 subtype B (n = 144) and CRF01_AE (n = 186) from antiretroviral-naive MSM were identified and subjected to spatiotemporal analysis using Bayesian phylodynamic methods. A transmission network was defined as a phylogenetic cluster (≥2 isolates) supported by >90% bootstrap values and Bayesian posterior probability value of 1 at the tree node.

Results: Phylogenetic reconstructions showed that 68% of HIV-1 subtype B and 46% of CRF01_AE sequences were grouped in 50 transmission networks of various sizes (mean size = 5.6, range 2–32 sequences), with subtype B sequences having a higher tendency to form a network (p < 0.0001). With additional representative sequences from China, Mongolia and Myanmar from the Los Alamos National Laboratory HIV Sequence Database, 34 networks involving 154 subtype B-infected individuals and 16 networks involving 125 CRF01_AE-infected individuals were observed. Location mapping showed that the MSM networks in East and Southeast Asia were mostly localized (78%) in their respective countries, with 22% spanned beyond a single country. Genealogy-based analysis to estimate the divergence time for each transmission network indicated the continued emergence of new networks over the past three decades. The uninterrupted growth of sub-epidemics of various cluster sizes suggests the role of transmission networks as a continuous driving force of the epidemic among MSM in Asia.

Conclusions: Despite expanded access to antiretroviral therapy in Asia, our analysis showed continued regional emergence of recent HIV-1 subtype B and CRF01_AE networks among MSM. Strategies such as early diagnosis and treatment as prevention to reduce transmission risks among discordant partners need to be expanded across the region.

http://dx.doi.org/10.7448/IAS.18.5.20451

TUPDC0104
Estimating the size of men who have sex with men (MSM) using modified capture-recapture method based on network sampling in the capital city of Georgia in 2014
Lela Sulaberidze1; Ali Mirzazadeh2,3; Ivdity Chikovani4; Natia Shengelia5; Nino Tsereteli6 and George Gotsadze4 1Curatio International Foundation, Tbilisi, Georgia. 2Global Health Sciences, University of California San Francisco, San Francisco, United States. 3Regional Knowledge Hub and WHO Collaborating Centre for HIV Surveillance, Kerman, Islamic Republic of Iran. 4Center for Information and Counseling on Reproductive Health – Tanadgoma, Tbilisi, Georgia. Presenting author email: l.sulaberidze@curatio.com

Introduction: Estimates of the number of people at high risk for HIV infection are crucial for prevention, treatment and care planning. Taking into consideration that Georgia is the country, where HIV prevalence is concentrated among men who have sex with men (MSM) and information on the size of this key population was lacking, we conducted the study using seven different population size estimation methods in Tbilisi, Georgia. We want to focus on a new method proposed by Dombrowski among methamphetamine users in 2012. This represents capture-recapture using network sampling technique. Among MSM, we first time applied this method with few modifications.

Methods: Modified capture-recapture requires single sample, which for our study was 210 MSM 18 years and older recruited through Respondent Driven Sampling. The study participants were asked about their personal characteristics (approximate height, weight, hair colour and ethnicity) and so called “telefunken codes” derived from the last four digits of their own mobile number. In difference to the original method that used six personal identifiers, we dropped eye

Abstract TUPDC0104 – Table 1. Different MSM population size estimates from various methods implemented in Tbilisi, 2014

| Method                  | Point estimate (18-59y) | Lower bound (18-59y) | Upper bound (18-59y) |
|-------------------------|-------------------------|----------------------|----------------------|
| Modified capture-Recapture | 4385                    | 3115                 | 5654                 |
| MSM size – median of all seven estimates* | 5100                    | 3243                 | 9088                 |
| MSM prevalence in adult population (%) | 1.42                    | 0.90                 | 2.53                 |

*Estimates derived from the following methods: Network Scale-Up, Web- and mob-App Multipliers, Service Multiplier, Unique Object Multipliers, RDS-based Handcock, Wisdom of Crowd, Modified Capture-Recapture.
Network-level factors associated with IPV perpetration among young urban Tanzanian men

Marta Mulawa1; HLM Reyes1; V Foshee2; CT Halpern2; L Kajula3 and S Maman4

1Health Behavior, University of North Carolina at Chapel Hill, Durham, United States. 2Department of Psychiatry and Mental Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania. 3Faculty of Health Sciences, School of Public Health and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California, San Francisco, United States. 4Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, United States.

Introduction: Research suggests that characteristics of an individual’s social network may influence intimate partner violence (IPV) perpetration among men in sub-Saharan Africa. For example, studies indicate that network-level measures of gender norms or IPV acceptance may be associated with IPV perpetration. However, to date, no studies have identified network-level factors associated with IPV among East African youth. We used data from our on-going HIV prevention trial in Dar es Salaam, Tanzania with 1268 men, ages 15–59 years (mean = 26), nested within 60 networks of randomly selected social clubs called “camps.” The purpose of this study was to assess the degree to which variance in men’s IPV perpetration was attributed to camp membership and to determine the effect of camp-level norms (gender norms and IPV attitudes) on IPV perpetration.

Methods: We used 2-level hierarchical linear models to model the relationship between individual and camp-level characteristics and past-year physical IPV perpetration, assessed using an adapted version of the World Health Organization violence against women instrument. Camp-level gender norms were computed by averaging responses among all camp members to an adapted version of the Gender Equitable Men Scale. All individual-level variables were group-mean centred to facilitate decomposition of between and within-camp effects. We estimated an unconditional random effects model to determine the proportion of IPV variance attributable to camp membership. Subsequent models sequentially introduced individual-level demographic/control variables, camp-level norms and individual-level norms.

Results: A significant proportion of variance in IPV perpetration (3.1%) was due to between-camp differences (0.0054, p = 0.01). Increasing levels of camp equitable gender norms were significantly associated with decreasing IPV perpetration (γ = −0.167, p = 0.04), and this association remained after controlling for individual-level gender norms. Camp-level norms regarding IPV acceptance were not associated with IPV perpetration.

Conclusions: Studies have found a strong association between IPV and HIV. We found that membership in social groups with equitable gender norms reduced men’s risk of perpetrating IPV, even after adjusting for their own views about gender norms and the acceptability of violence. This finding highlights the importance of multi-level HIV and IPV interventions that simultaneously address individual risk factors while making gender norms more equitable within social networks.

http://dx.doi.org/10.7448/IAS.18.5.20452

Gender differences in HIV testing behaviours by community-level and individual-level stigma in rural South Africa

Sarah Treves-Kagan1; Alison El Ayadi2; Audrey Pettifor3,4,5; Catherine MacPhail4,6; Rhian Twine5; Suzanne Maman3; Kathleen Kahn7 and Sheri A Lippman1

1Center for AIDS Prevention Studies, University of California, San Francisco, United States. 2Department of Obstetrics, Gynecology and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California, San Francisco, United States. 3Faculty of Health Sciences, School of Clinical Medicine, Wits Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South Africa. 4Faculty of Health Sciences, School of Public Health, Medical Research Council/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa. 5Collaborative Research Network, University of New England, Armidale, Australia.

Introduction: Research suggests that characteristics of an individual’s social network may influence intimate partner violence (IPV) perpetration among men in sub-Saharan Africa. For example, studies indicate that network-level measures of gender norms or IPV acceptance may be associated with IPV perpetration. However, to date, no studies have identified network-level factors associated with IPV among East African youth. We used data from our on-going HIV prevention trial in Dar es Salaam, Tanzania with 1268 men, ages 15–59 years (mean = 26), nested within 60 networks of randomly selected social clubs called “camps.” The purpose of this study was to assess the degree to which variance in men’s IPV perpetration was attributed to camp membership and to determine the effect of camp-level norms (gender norms and IPV attitudes) on IPV perpetration.

Methods: We used 2-level hierarchical linear models to model the relationship between individual and camp-level characteristics and past-year physical IPV perpetration, assessed using an adapted version of the World Health Organization violence against women instrument. Camp-level gender norms were computed by averaging responses among all camp members to an adapted version of the Gender Equitable Men Scale. All individual-level variables were group-mean centred to facilitate decomposition of between and within-camp effects. We estimated an unconditional random effects model to determine the proportion of IPV variance attributable to camp membership. Subsequent models sequentially introduced individual-level demographic/control variables, camp-level norms and individual-level norms.

Results: A significant proportion of variance in IPV perpetration (3.1%) was due to between-camp differences (0.0054, p = 0.01). Increasing levels of camp equitable gender norms were significantly associated with decreasing IPV perpetration (γ = −0.167, p = 0.04), and this association remained after controlling for individual-level gender norms. Camp-level norms regarding IPV acceptance were not associated with IPV perpetration.

Conclusions: Studies have found a strong association between IPV and HIV. We found that membership in social groups with equitable gender norms reduced men’s risk of perpetrating IPV, even after adjusting for their own views about gender norms and the acceptability of violence. This finding highlights the importance of multi-level HIV and IPV interventions that simultaneously address individual risk factors while making gender norms more equitable within social networks.

http://dx.doi.org/10.7448/IAS.18.5.20453

Abstract TUPDD0101 - Figure 1. Testing under various stigma scenarios.
Introduction: Despite national testing campaigns and increased access to HIV treatment, stigma remains a significant barrier to testing in South Africa. A nuanced understanding of stigma and testing is instrumental in refining intervention programming. Stigma can be examined at either the individual or community level and may operate differentially by gender. Further, estimating HIV testing uptake achievable through stigma reduction interventions is critical for understanding potential impact.

Methods: We examined the relationship between anticipated HIV stigma at individual and community levels on recent HIV testing, stratified by gender, using data from a population-based sample of 1126 adults aged 18–35 residing in 22 villages in Mpumalanga, South Africa. Anticipated HIV stigma, or expectations of discrimination should one become HIV positive, was measured using a 9-item scale and dichotomized as any versus no stigma. Community-level stigma was defined as the proportion of individuals within each village reporting any anticipated stigma. We assessed associations of community and individual stigma and HIV testing for men and women. We then used multi-level regression models to estimate the potential effect of changing community-level stigma to improve testing uptake using the g-computation algorithm. Analyses were weighted to account for the survey design.

Results: Men tested less frequently (OR 0.22, 95% CI 0.14–0.33) and reported more individual anticipated stigma (OR 5.1, 95% CI 2.6–10.1) than women. Men reporting no individual-level stigma (vs. some) were 48% more likely to have tested (p = 0.08). For women, testing behaviour was not associated with individual anticipated stigma but for each percentage point reduction in community-level stigma the likelihood of testing increased by 3% (p = 0.03). We modelled gains in HIV testing at different levels of community stigma (Figure 1). For example, results indicate a potential 15% intervention gain in HIV testing among women if community-level stigma decreased by 5%. Changing community-level stigma did not result in significant gains for men.

Conclusions: Our data indicates that HIV-related stigma influences HIV testing for men and women through different pathways. Stigma reduction programs may need to consider gender differences and tailor activities to the target population. Longitudinal research is needed to confirm projections and direction of effect.

http://dx.doi.org/10.7448/IAS.18.5.20454

Abstract TUPDD0102 - Table 1. Illustrative Quotes

Entrenched gender norms

- “Men are generally lazy . . . I am already infected and still want to show my male ego without considering my family‘ . . . many men as well are not ready to take up HIV test and would push their partners to go first and rely on their results.” – Male youth Focus Group Discussion (FGD) participant, Sena
- “As men we have a lot of fear . . . Men also like giving excuses, that they are ever busy in the name of searching for the family, even if they have gotten this food that they are ever looking for [laughter].” – Male adult FGD participant, Sena
- “Many men believe that medical issues are women’s affairs.” – Male adult FGD participant, Ongo
- “Men are people with hardened hearts. They will hardly rush for any programme. They can release their wives and children first to go and rely on their results, and for him, he assesses before going.” – Female adult FGD participant, Kameke

Signs of changing gender norms

- Interviewer: “You have mentioned that most people do not test as couples; please tell me more about this?”
- “A good percentage of men are not faithful. It is men who would even end up enrolling for HIV care at a very far facility. Men should change and be free to test as couples so as to build trust. They should stop frustrating their women as well.” – Female adult FGD participant
- “Gender based violence is real and rampant in this community. This is so because there is no family dialogue to discuss family issues. I do dialogue in my house but when I introduced the HIV topics, many started avoiding the dialogue.” – [Male adult participant, FGD Tom Mboya]
served as barriers to HIV testing. Men often tested “by proxy,” inferring their HIV status from the test results of wives. Yet debates about HIV risks were vigorous, with many men questioning traditional masculine gender norms; moreover, the promise of antiretroviral therapy (ART) to prolong health appeared to motivate many men to participate in testing.

Conclusions: Mobile testing reduces but does not eliminate barriers to men’s participation; however, the promise of ART may be enabling changes in male gender norms related to testing. Findings may be useful for developing novel strategies to improve male engagement in test and treat efforts.

http://dx.doi.org/10.7448/IAS.18.5.20455

TUPDD0103
Examining the relationship between paediatric PMTCT outcomes and knowledge of partner status
Anne Schlegl; Ewa Skowronska; Emeka Okonji and Esca Scheepers
Department of Programs and Technical Support, mothers2mothers, Cape Town, South Africa.

Introduction: The mothers2mothers’ (m2m) Mentor Mother programme empowers pregnant women and new mothers to make informed decisions about their maternal and reproductive health as well as their infants’ health, through provision of peer education and psychosocial support. The m2m’s 2013 annual evaluation showed that discordancy was negatively associated with the uptake of paediatric prevention of mother-to-child transmission (PMTCT) services. HIV-positive mothers who knew their male partners were HIV-negative were less likely to bring their infants for PCR testing at 6–8 weeks (OR = 0.60, p = 0.005), or for a follow-up test at 18 months (OR = 0.75, p = 0.017), compared to mothers who knew their partners were HIV-positive. The aim of this study is to further investigate the role that knowledge of one’s partner’s HIV status plays in the uptake of paediatric PMTCT services.

Methods: Secondary analysis of m2m’s 2013 internal programme evaluation data was conducted. Data comprised of a representative random sample of 5592 HIV-positive clients’ longitudinal records (routinely maintained by Mentor Mothers), enrolled from March through May 2012 in six African countries. The relationship between knowledge of partner status and uptake of paediatric PMTCT services was investigated through bivariate analysis (chi-square) and binary logistic regression analysis using STATA 12.

Results: Knowledge of partner HIV status was significantly associated with uptake of paediatric PMTCT services. Mothers who knew their partner’s HIV status were more likely to take up paediatric PMTCT services compared to those who did not know their partner’s status. The likelihood of improved uptake of PMTCT services was the highest among mothers who knew they were in a concordant relationship. There was no significant relationship between knowledge of partner status and uptake of infant ART.

Conclusions: Additional primary research on the effects of concordancy and discordancy on PMTCT outcomes is recommended. Our secondary analysis suggests that uptake of paediatric PMTCT services is more likely to occur amongst clients who know that they are in a concordant relationship. This evidence supports m2m’s inclusion of a tailored serodiscordant couples education and support intervention to facilitate mutual disclosure of HIV status in partners, especially in the context of Option B+, thus improving outcomes in the postnatal care cascade.

http://dx.doi.org/10.7448/IAS.18.5.20456

TUPDD0104
Who benefits from partner services in Mozambique?
Results from a pilot programme in a public, urban clinic
Caryl Feldacker; Serene Myers; Freide Cesar; Zulmira Parades; Catarina Ferrao; Sinesia Citoa Citoa; Florindo Mudender and Matthew Golden
1Global Health, International Training and Education Center for Health, University of Washington, Seattle, United States.
2International Training and Education Center for Health, Maputo, Mozambique. 3Ariel Glaser Foundation, Maputo, Mozambique. 4Department of Health, Maputo, Mozambique. 5Division of Allergy and Infectious Diseases, University of Washington Harborview Medical Center, Seattle, United States.

Introduction: Notifying partners of persons newly diagnosed with HIV can help identify undiagnosed infections and link people to care. Assisted partner services (APS) offers persons with newly diagnosed HIV infection help notifying and getting sex partners tested. APS is not widely available in sub-Saharan Africa, including Mozambique. We explore who benefits from APS as compared to passive services through a pilot programme in an urban, public clinic in Maputo, Mozambique.

Methods: Between June and September 2014, four community health workers (CHWs) offered APS to 223 index patients (IPs) with recently diagnosed HIV: 220 accepted and 206 (94%) were retained at eight weeks. CHWs used structured interviews to collect data at baseline, four and eight weeks. At baseline, CHWs counselled IPs to notify partners and encourage their HIV testing, but did not offer to notify partners directly. At four weeks, with consent, CHWs notified partners to encourage testing. We used logistic regression, adjusted for clustering, to define the odds that APS increased HIV testing uptake and identified new HIV infections, setting significance at p ≤ 0.05.

Results: Of 206 IPs, 79% were female, 73% were married and 31% named >1 sex partner. IPs named 283 partners, 278 had complete data: 59% are spouses. Of 192 people tested, 103 (53.6%) tested after APS at four weeks. Of 103 HIV positive diagnoses, 55 (53.4)
**Abstract TUPDD0104: Table 1. Factors associated with uptake of assisted partner services for HIV testing and HIV diagnosis**

| Tested Prior to | Tested at 8 | OR HIV | OR HIV | APS* (Univariate) | APS** (Multivariate) |
|-----------------|-------------|--------|--------|-------------------|----------------------|
| HIV testing     | HIV testing |        |        |                   |                      |
| Male partner    | Male partner| 1.61   | 0.91   | 0.59              | 0.39                 |
| Male partner    | Female      | 2.84   | 1.70   | 1.39              | 1.21                 |
| 1 sex partner   | 4 sex partners | 0.43   | 0.72   | 0.52              | 0.59                 |
| Has continuing sexual relations | | 2.78   | 1.44 | 3.17              | 2.77                 |
| IP reason for HIV testing | | 0.99 | 0.58 | 0.52              | 0.59                 |
| IP reason for testing symptoms | | 0.52 | 0.26 | 0.31              | 0.39                 |
| IP reason for testing prenatal | | 0.52 | 0.26 | 0.31              | 0.39                 |

Results from logistic regression models using the (cluster) option in STATA. 95% CI presented in parentheses. *Results from univariate models. **Results from multivariate models.

**Conclusions:** APS significantly improves HIV testing uptake and case-finding among current sex partners: those in monogamous pairs benefit most. These findings suggest that the model of APS piloted in Mozambique might be most profitably focused on persons in ongoing partnerships and highlights the need for better interventions for persons with multiple sex partners.

http://dx.doi.org/10.7448/IAS.18.5.20457

**TUPDD0105**

**Male partner acceptance of home-based syphilis and HIV testing offered to couples during pregnancy**

Jennifer Mark\(^1\); John Kinuthia\(^2\); Alfred Osoti\(^3\); Molly Gone\(^4\); Victor Auma\(^4\); Saloni Parikh\(^5\); Daisy Krackowki\(^6\); Bourke Betz\(^7\); Barbra Richardson\(^8\); Alison Roxby\(^9\) and Carey Farquhar\(^10\)

\(^1\)Epidemiology, University of Washington, Seattle, United States. \(^2\)Kenyatta National Hospital, Nairobi, Kenya. \(^3\)Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya. \(^4\)School of Public Health and Community Medicine, University of Washington, Seattle, United States. Presenting author email: jmark55@uw.edu

**Introduction:** Testing partners for HIV in the antenatal period is an effective way to bring HIV services to couples. Leveraging antenatal HIV testing with point of care (POC) diagnostics for other sexually transmitted infections (STI) may improve male partner treatment services among couples.

**Methods:** We conducted a prospective study among male partners of pregnant women who received home-based couple HIV testing and education (HOPE) following a first antenatal visit in Kisumu, Kenya. From April to July 2014, rapid POC syphilis testing (SD Bioline Syphilis 3.0) was added to the package of services for men and those with positive results were referred to the clinic for treatment. We assessed men’s acceptance of testing and intention to seek clinic-based treatment and calculated an odds ratio to examine correlation between uptake of syphilis and HIV testing.

**Results:** Data were available for 73 (83%) couples receiving a HOPE visit. Men were on average 26 years of age (IQR: 22, 29). At study entry, most men reported having previously tested for HIV (93%, n = 68), of whom 7% reported being of known HIV positive status (n = 5) and 80% reported knowing their female partner’s HIV status (n = 59). Of 73 men, 67 accepted syphilis testing (92%) among whom 64 intended to attend clinic STI treatment if they received a positive syphilis result (95%). HIV prevalence among the men was 14.7% and 64 intended to attend clinic STI treatment if they received a positive syphilis result (95%). HIV prevalence among the men was 14.7% and one man (<1%) was syphilis positive. In this group, 61 (83%) accepted both syphilis and HIV tests. Three men (4%) refused both tests and three men (4%) accepted HIV alone. Six men (8%) accepted syphilis alone, of whom two reported having been previously tested as HIV-positive. If a man accepted HIV testing, he was 10-fold as likely to accept syphilis testing, compared to a man who refused HIV testing (OR: 10.2; 95% CI: 1.05–89.3; p = 0.02).

**Conclusions:** In a high HIV and low syphilis setting, home-based education and POC syphilis testing of male partners during pregnancy is highly acceptable when coupled with HIV testing and may encourage men to seek clinic-based STI services. Integration with HIV testing appears feasible, and syphilis test uptake is highly correlated with HIV test uptake.

http://dx.doi.org/10.7448/IAS.18.5.20458
TUPDDD0106
Antiretroviral treatment uptake and correlates of adherence among men who have sex with men and transgender women in Mumbai, India
Christopher Pina1; Alpana Dange2; Shruti Neytra2; Harish Kambli2; Santosh Karambe2; Rosy Chhabra3 and Viraj Patel1,3
1Albert Einstein College of Medicine, Bronx, United States. 2Montefiore Medical Center, Bronx, United States. 3Humsafar Trust, Mumbai, India.
Presenting author email: christopher.pina@med.einstein.yu.edu

Introduction: Understanding factors influencing ART adherence is needed to optimize treatment responses for HIV-infected men who have sex with men (MSM) and Hijra/transgender women (TGW) in India. The objective of this formative study was to determine rates of ART uptake and adherence and explore potential factors associated with adherence in Indian MSM and TGW.

Methods: We conducted a cross-sectional survey in Hindi among all HIV positive MSM and TGW on ART accessing support services at a LGBT community based organization in Mumbai between July and September 2014. Non-adherence was measured by self-report and defined as missing any doses (i.e. <100% adherence) in the past one month and three months. Potential correlates of adherence assessed were sociodemographics, medication side-effects, depression (CES-D-10), self-efficacy (GSE), internalized homophobia/stigma and medication beliefs using chi-square or t-tests.

Results: Of the 300 individuals registered in the organization’s HIV support programme, 28.3% (65/300) were eligible for ART by current country standards (e.g. CD4=350 or having an OI) with 22% (65/300) currently on ART. Of those on ART, 83% (54/65) were MSM and 17% (11/65) TGW; 40% (25/65) were married to women, and most (97%) received free ART through government clinics. Overall, 32% (21/65) were non-adherent in the past one month and 45% (29/65) in past three months. Correlates (p<0.05) of non-adherence were similar for one month and three months and were associated with younger age, non-Kothi identity (MSM subgroup), alcohol use, having sex with women, feeling healthy and negative medication beliefs but was not directly associated with depression, internalized homophobia, or medication self-efficacy.

Conclusions: In one of the first studies of adherence among MSM and TGW in India, ART treatment uptake and adherence were suboptimal. Modifiable factors associated with adherence may serve as targets for interventions to support adherence. Further work is however needed to verify self-report measures with biological outcomes and confirm findings in other samples of Indian MSM and TGW.

http://dx.doi.org/10.7448/IAS.18.5.20459

WE – WEDNESDAY

WEPDA0101
Evolution of neutralizing antibodies in HIV-1 subtype C infection
Bongwa Ndlovu1; Tandile Hermanus2; Nancy Tumba2; Penny Moore3; Manjeeta Jaggiarnath4; Bruce D Walker5; Lynn Morris2 and Thumbi Ndung’u2
1HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa. 2AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa. 3Ragon Institute of MGH, University of Cambridge, MIT & Harvard, Boston, United States. Presenting author email: bongiwendlovu4@ukzn.ac.za

Introduction: The development of a preventative HIV-1 vaccine will most likely require induction of broadly neutralizing antibodies (BCN). Neutralizing antibodies develop in almost all HIV-1 infected individuals, however they develop months following HIV-1 infection and they are strain-specific. The development of BCN antibodies occurs only in 20–30% of HIV-1 infected individuals. However, the mechanism that leads to the development of BCN is unknown and not all epitopes have been identified. The aim of the study was to evaluate pathways and mechanisms that lead to the development of broadly neutralizing antibodies.

Methods: Twenty individuals with acute HIV-1 infection were identified and followed longitudinally for three years in Durban, KwaZulu-Natal. A panel of 18 viruses (6 subtype A, 6B and 6C) was used to screen the patients for neutralizing antibodies at 2–3 years post-infection using the TZM-bl neutralization assay. The patients that developed broadly neutralizing antibodies were followed up longitudinally at 8, 10, 14, 16, 18, 71, 88, 100, 124, 150, 200 weeks to determine the timing of emergence of the BCNs. Specificity of BCNs was determined using single point mutagenesis at 3 years post-infection.

Results: Three out of 20 individuals (AS3-268, AS2-1037, AS2-358) developed broadly neutralizing antibodies. AS3-268 developed potent BCN activity peaking at three years post-infection and it targets N276A glycan on the CD4 binding site of gp120. AS2-1037 developed potent broadly neutralizing activity peaking at two years post-infection and it targets N332A glycan on the V3 loop of gp120. AS2-358 developed BCNs peaking at two years post-infection and it did not map to any known specific epitope.

Conclusions: Broadly neutralizing antibodies could be detected at approximately one year post-infection and they targeted different epitopes on the viral envelope. Work is currently in progress to assess the maturation of breadth and to assess antibody-virus co-evolution.

http://dx.doi.org/10.7448/IAS.18.5.20460

WEPDA0102
HLA-B*58:02-specific benefit of MRKAd5 Gag/Pol/Nef vaccine in an African population
Ellen Michelle Leitman1; Jacob Hurst2; Masahiko Mori3; Philippa C Matthews3; Nicole Frahm3; James Kublin2; Glenda E Gray4 and PhilipJR Goulder1,5
1Department of Paediatrics, University of Oxford, Oxford, United Kingdom. 2Department of Medicine, University of Oxford, Nuffield Oxford, United Kingdom. 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, HIV Vaccine Trials Network, Seattle, United States. 4South African Medical Research Council, Cape Town, South Africa. 5HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Presenting author email: ellen.leitman@st-hughs.ox.ac.uk

Introduction: The MRKAd5 Gag/Pol/Nef vaccine increased the risk of HIV acquisition. However, the Step study suggested an HLA-specific benefit in viral setpoint to vaccinees who subsequently became infected. The Phambili trial, using the same MRKAd5 vaccine, presented an opportunity to investigate the existence of an HLA-specific effect in a genetically distinct South African population. Gag-specific CD8 T-cell responses restricted by protective South African HLA alleles such as HLA-B*57 are associated with successful control of infection, while disease-susceptible alleles such as HLA-B*58 present non-Gag epitopes and are associated with rapid progression. We hypothesized that the MRKAd5 Gag/Pol/Nef vaccine might redirect responses towards Gag in HLA-B*58:02 + Phambili subjects who would not target it naturally.
HIV-1 subtype C is significantly more infectious than other subtypes.

Methods: Viral loads (VL), CD4 T-cell counts, HIV-1 subtypes, and ELISpot anti-HIV CD8 T-cell responses were analyzed in subjects blinded to vaccine/placebo assignment. All data analyzed were from ART-naive subjects.

Results: HLA-B*58:02 was the most prevalent allele (population frequency 23%). HLA-B*58:02+/+ vaccinees (n = 7) had lower viral setpoints than placebo-recipients (n = 7) (25,670 vs. 215,500, p = 0.03), a 0.8 log lower VL calculated using all longitudinal pre-ART data via a mixed effects model (p < 0.001, Figure 1a), reached CD4 < 350 cells/μl slower (p = 0.002, Figure 1b) and showed an increase in Gag breadth in ELISpot assays (p = 0.04) compared to HLA-B*58:02+/− placebo-recipients.

Conclusions: In addition to the known increased risk of HIV acquisition resulting from the MRKAd5 Gag/Pol/Nef vaccine, these current data suggest a therapeutic effect of the same vaccine in subjects expressing HLA-B*58:02, an African HLA allele strongly associated with rapid progression in natural HIV infection. HLA-B*58:02+/+ vaccinees showed a lower viral setpoint and slower time to CD4 < 350 cells/μl, associated with increased Gag-specific ELISpot responses. Caveats to the study include limitation of ELISpot assays to only 60 of 100 study subjects, selected based on cell availability; and of HLA typing to 79 subjects, based on material availability. These factors potentially introduced unintended selection bias effects. Nonetheless, these data on ART-naive subjects are consistent with Step studies, indicating a beneficial therapeutic MRKAd5 HLA-specific effect that in South Africa includes the most prevalent HLA-B allele, HLA-B*58:02.

http://dx.doi.org/10.7448/IAS.18.5.20461

WEPDA0103
HIV-1 subtype C is significantly more infectious than other subtypes

Todd Demarco1; Wes Rountree1; Bhavana Hora1; Yue Chen2; Sarah Keinonen1; Laura Racz1; Lily Daniell1; Raul Louzao1; Ana Sanchez2; Michael Busch3; Thomas Denny4 and Feng Gao2

1Departments of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Durham, United States. 2Blood Systems Research Institute, San Francisco, United States. Presenting author email: todd.demarco@dm.duke.edu

Introduction: HIV-1 subtype C accounts for about 50% of the global HIV-1 infections. It is the predominant subtype in India, Ethiopia and countries in southern Africa. However, virological attributes to this unique epidemiological pattern have not yet been fully defined.

Methods: A total of 207 HIV-1 positive plasma or established strains were cultured and expanded to higher titre stocks by culturing in PBMCs from HIV-1 negative donors. Near-full-length genome (NFLG) sequences were obtained by amplifying two overlapping half genomes. The newly obtained sequences were aligned to the HIV-1 whole genome reference sequences for subtyping. Viral genome copy numbers, tissue culture infection doses (TCID) and p24 concentrations were determined for virus stocks and compared via linear regression among major subtypes. Mann-Whitney U tests were used for the infectivity comparisons at the alpha 0.05 level.

Results: Analysis of NFLG sequences showed that these viruses belonged to subtype A1 (16), subtype B (48), subtype C (53), subtype D (10), CRF01_AE (12), other subtypes and CRFs (F1, F2, G, CRF02, CRF02F1, CRF02G, CRF02F2) each with ≤8 sequences and URFs (45). Only subtypes with ≥10 NFLG sequences were subjected to further analysis. No biologically relevant differences (a 0.3 log10 difference) among all compared subtypes were observed for three measurements: viral genome copy numbers, TCID, and p24 concentrations. The only exception was that the TCID of subtype C was 0.51 log higher than that of CRF01 (p = 0.04). The infectivity per viral genome (TCID/RNA copy) was the highest for subtype C (0.00452 TCID/RNA copy) and was significantly higher than those of all four compared subtypes (A1, B, D and CRF01_AE; p = 0.0286, p = 0.0004, p < 0.001 and p = 0.0205, respectively). The p24/RNA copy ratios of subtypes C and B (0.13 and 0.12 pg/RNA copy, respectively) were the highest and were significantly higher than those of subtypes A1 and D (p < 0.05), but similar to that of CRF01_AE.

Conclusions: The high infectivity of HIV-1 subtype C may give it more replication advantages and allow it to disseminate faster in HIV-1 infected populations in some geographic areas compared to other subtypes. High infectivity may play a critical role in the global epidemic of subtype C.

http://dx.doi.org/10.7448/IAS.18.5.20462

WEPDA0104
Functional differences in the viral accessory protein Nef between major HIV-1 subtypes

Aaron Johnson; Rajesh Jacob; Mansour Haeryfar and Jimmy Dikeakos

Department of Microbiology and Immunology, University of Western Ontario, London, Canada. Presenting author email: aaronjohnson13@gmail.com

Introduction: The HIV-1 accessory protein Nef is essential for HIV-1 pathogenesis and progression to AIDS. By hijacking the cellular trafficking machinery Nef is able to alter T cell activation, increase viral replication and permit viral immune evasion via downregulation of the cell-surface receptors CD28, CD4 and MHC I, respectively. However, only recently have these functions been studied outside of...
laboratory-adapted strains of HIV-1. This proposal aims to investigate how the high degree of HIV-1 genetic diversity impacts Nef function.

**Methods:** An HIV-1 based lentiviral expression system was used to express Nef proteins from 10 group M subtypes (A1, A2, B, C, F1, F2, G, H, J and K) in the context of an HIV-1 infection. T cell lines were infected with pseudoviruses encoding Nef proteins and analyzed for surface levels of CD28 and MHC-I using fluorescent antibody staining and flow cytometry. Alternatively, CD4 cell surface levels were measured by transfecting CD4+ Hela cells with expression plasmids encoding Nef-GFP fusion proteins followed by fluorescent antibody staining and flow cytometry. Nef expression was determined by a combination of western blot analysis and flow cytometry to measure fluorophore fused Nef proteins.

**Results:** Our results demonstrate that MHC I, CD28 and CD4 are differentially downregulated between HIV-1 subtypes. Notably, subtype C Nef, the most common subtype globally, was significantly less efficient at downregulating all three cell surface receptors. Differences in down-regulation efficiency for all three receptors were attributed to variations in Nef protein expression.

**Conclusions:** This study represents a comprehensive analysis of Nef function among 10 HIV-1 subtypes and adds to the growing evidence that HIV-1 genetic diversity impacts viral protein function. Due to the pathogenic role Nef plays in an HIV-1 infection, these results may help explain recent studies that show differences in disease progression in individuals infected with different HIV-1 subtypes. Finally, these findings support further study of all major HIV-1 subtypes and emphasize the need to consider subtype differences when developing alternative treatment options.

http://dx.doi.org/10.7448/IAS.18.5.20463

**WEPDA0105**

Characterization of HIV-1C gp120 in recently and chronically infected individuals in Botswana

Terence Mohammed; Simani Gaseitsiwe; Keikantse Matlhagela; Matshwanele Matsheka; Sihkhile Moyo; Rosemary Musonda

**Introduction:** Viral diversity provides a major challenge in the development of a vaccine against HIV-1. A potential target for HIV-1 vaccines is gp120 envelope protein, which is involved in viral entry and is a target of the host immune system. It has been shown that Envelope characteristics have a role to play in disease progression. However some studies have demonstrated conflicting results. In this study, we aim to analyze HIV-1gp120 characteristics, specifically: potential N-glycosylation sites, amino acid sequence length and net electric charge in cell associated and cell free RNA derived from recently and chronically infected individuals in Botswana.

**Methods:** This was a retrospective study using stored samples collected from treatment naïve HIV-1C infected cohorts at Botswana Harvard AIDS Institute Partnership, representing recently infected and long term infection as determined by serological assays for recency and longitudinal follow up. A 1200 base pairs fragment of V1 to V5 region of gp120 was amplified by nested PCR and sequenced on both strands using Big Dye Technology in proviral DNA and cell free RNA. Potential N-glycosylation sites were determined using Los Alamos HIV sequence database while subtype was assigned using REGA HIV subtyping tool.

**Results:** There was a significant increase in amino acid sequence length of V2 (p = 0.027) and V4 (p = 0.0099) in proviral DNA in the chronic stage as compared to the recent stage of infection. Similar changes were also observed in cell free RNA in V4 (p = 0.0074). In addition, the number of potential N-linked glycosylation sites in proviral DNA was significantly increased in chronic infection in V4 (p = 0.0253). No significant changes in net electric charges were observed. There was an association between viral load and V4 region (p < 0.001). All samples were classified as subtype C.

**Conclusions:** The increase in amino acid sequence length and potential N-Glycosylation sites in the V2 and V4 region may be essential in disease progression. The changes observed in V2 and V4 warrant further investigation. A clear understanding of envelope characteristics is important for development and design of new vaccine and therapeutics.

http://dx.doi.org/10.7448/IAS.18.5.20464

**WEPDA0106LB**

Early loss of splenic Tfh cells in SIV-infected rhesus macaques

Felicien Moukambi; Henintsoa Rabezanahary; Vasco Rodrigues; and Jerôme Estaquier

**Introduction:** Follicular T helper cells (Tfh), a subset of CD4 T lymphocytes, are essential for B-cell activation and provide help to B cells in the production of antigen-specific antibodies. Although several studies have analyzed the dynamics of Tfh cells in the context of AIDS by analyzing peripheral blood and LNs of HIV-infected patients, paradoxically, none of these studies in HIV/SIV infection have addressed the role of Tfh cells in the primary organ of B-cell activation, the spleen.

**Methods:** To address these questions, we have infected rhesus macaques with SIVmac251 (20 AID50). Animals were killed at different time points post-infection and lymphoid organs were recovered. Tfh cells (PD-1highCXCR5+ and CD4+ T cell subsets were monitored by flow cytometry. Concomitantly, B-cell subsets were also analyzed. CD4 T-cell subsets were sorted and SIV DNA was quantified by RT-PCR.

**Results:** Herein, we demonstrated for the first time that the percentages and numbers of splenic Tfh cells decrease early during the acute phase in macaques infected with SIV. This profound loss and abnormal differentiation of Tfh is also associated with the loss of memory B-cell subsets. Moreover, SIV DNA is detected in splenic Tfh cells early after infection. Finally, our results showed that the frequency of splenic Tfh and memory B cells are higher in slow-progressor compared to rapid progressor RMs at the chronic phase.

**Conclusions:** Altogether, our results demonstrate the drastic depletion of splenic memory B cells, which might be related to the loss of fully matured Tfh cells.

http://dx.doi.org/10.7448/IAS.18.5.20562
Introduction: Point-of-care or “rapid” serologic assays for HIV are widely used in resources-limited setting. Their evaluation in the field carried out independently of the manufacturer is crucial to assess their capability to accurately detect non-B subtypes or circulating recombinant form (CRF) of HIV-1.

Our objective was to evaluate the HIV-1/HIV-2 INSTI® test (distributed by Nephrotec, Rungis, France) for the diagnosis of non-B subtypes and CRF of HIV-1 circulating in Gabon, a country of wide genetic diversity.

Methods: A panel of 250 HIV-positive and 250 HIV-negative plasma was prospectively collected after informed consent in adult patients attending the Laboratoire National de Référence des MST et du SIDA, Libreville, as recommended by the WHO (Service delivery approaches to HIV testing and counselling: A strategic policy framework; 2012). The reference HIV serology consisted of Immuno-Comb II HIV1&2 BiSpot (Inverness Medical Innovations, Yavne, Israel) as screening test followed by confirmatory Western blot (New Lav Blot I, Bio-Rad, Marnes-la-Coquette, France). All HIV-positive plasma were furthermore subjected to HIV genotyping by nested PCR, amplicons sequencing, and analysis of resulting FASTA sequences by Genotyping software from NCBI. A subgroup of 1 out of 10 patients was also tested in parallel with finger-stick whole blood INSTI® test.

Results: All HIV-1 belong to HIV-1 group M with broad HIV-1 genetic diversity as assessed using pol sequences (CRF02_AG (53%), CRF14 (18%), CRF15 (12%), CRF01_AE (8%), A1 (4%), G (2%), K (2%), B (1%)). Among 250 HIV-infected and 250 HIV-negative plasma, 250 and 249, respectively, were positive or negative by INSTI®. Thus, INSTI® test sensitivity and specificity were 100% and 99.6%, respectively; positive and negative predictive values in Gabon were 91.5% and 100%, respectively. For the major subtype CRF_02AG, sensitivity and specificity were 100% and 99.6%, respectively; positive and negative predictive values in Gabon were 91.5% and 100%, respectively. For the major subtype CRF_02AG, sensitivity and specificity were 100% and 99.6%, respectively; positive and negative predictive values in Gabon were 91.5% and 100%, respectively. For the major subtype CRF_02AG, sensitivity and specificity were 100% and 99.6%, respectively; positive and negative predictive values in Gabon were 91.5% and 100%, respectively.

Conclusions: HIV-1/HIV-2 INSTI® test is highly reliable for the detection of various non-B HIV-1 antibodies, both in plasma and capillary blood; and it fulfills the WHO criteria for HIV test prequalification. The rapid INSTI® test could be useful for HIV screening in Gabon, as well as in other sub-Saharan African countries.

http://dx.doi.org/10.7448/IAS.18.5.20465

WEPDB0102 Evaluation of the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 assay on whole blood using specimens with unknown ARV exposure

Raquel Viana1; Thabisile Xaba2; Teja Stojiljkovic3; Nico Gunther4 and Carole Wallis5

1Department of Molecular Pathology, Lancet Laboratories and BARC-SA, Johannesburg, South Africa. 2Diagnostics Division, Roche Products (PTY) LTD, Johannesburg, South Africa. Presenting author email: carole.wallis@lancet.co.za

Abstract WEPDB0102 Table 1. Diagnostic Sensitivity and Specificity of the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 compared to the Roche Amplicor HIV-1 DNA PCR assay v1.5

| Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 sample type | Sensitivity | Specificity |
|-------------------------------------------------|-------------|------------|
| Whole blood                                      | 98.5%       | 100%       |
| Plasma                                           | 87.0%       | 100%       |
| Dried blood spot                                 | 98.5%       | 100%       |

Introduction: Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Qualitative version 2 (TaqMan v2 qual) has recently been released for testing of dried blood spot (DBS) for infants and plasma for adults that are antiretroviral (ARV) naïve; however, ARV status of patients is often unknown. This study evaluated the use of whole blood (WB) for HIV-1 detection using TaqMan v2 qual.

Methods: 133 samples (125 EDTA, 8 Virology Quality Assurance (VQA) WB) were used with known HIV-1 status (positive, n = 75; negative, n = 58) as per Roche Amplicor HIV-1 DNA PCR assay v1.5 (Roche v1.5). EDTA samples were split: 1 mL plasma, 100 µL WB and 70 µL WB. Samples were processed using TaqMan v2 qual according to manufacturer’s instructions and results compared to Roche v1.5. Sensitivity and specificity were determined for each sample type and compared to EDTA plasma viral load. Seven WB samples (HIV-1 positive, n = 4; HIV-1 negative, n = 3) were evaluated for reproducibility and precision using the TaqMan v2 qual.

Results: Of the 69 Roche v1.5 HIV-1 positive samples, 68 were detected using TaqMan v2 qual DBS or WB; whereas only 60 were detected using TaqMan v2 qual plasma. HIV-1 positive samples missed had either a viral load of not detected or <20 RNA copies/mL. The TaqMan v2 qual plasma samples missed 13% of HIV-1 positive samples. No false positives were observed across the three different matrices evaluated. Of the 8 VQA WB samples tested on TaqMan v2 qual and Roche v1.5, 100% concordance was observed (n = 6, HIV-1 positive; n = 2, HIV-1 negative). Diagnostic sensitivity and specificity are detailed in the table below. Reproducibility and precision was 100% for all samples tested.

Conclusions: TaqMan v2 qual using DBS or WB had the highest sensitivity when compared to Roche v1.5 (98.5%). Plasma samples on TaqMan v2 qual missed 13% of HIV-1 positive samples. With the increase of microphone use, pre-exposure prophylaxis and reported poor disclosure of prior ARV use, this study indicates that plasma samples are not the ideal sample matrix for testing adults when ARV exposure is unknown. The high percentage of adult samples that were missed would have serious implications for decreasing HIV-1 transmission rates.

http://dx.doi.org/10.7448/IAS.18.5.20466

WEPDB0103 CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study

Anna Grimsrud1; Morna Cornell1,2; Michael Schomaker1,2; Matthew P Fox1,3; Catherine Orrell1; Hans Prozesky1,4; Kathryn Stinson5,9; Frank Tanser10; Matthias Egger1,7; Landon Myer2,12 and International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration (IeDEA-SA)

1Division of Epidemiology & Biostatistics, University of Cape Town, Cape Town, South Africa. 2Centre for Infectious Disease Epidemiology & Research, University of Cape Town, Cape Town, South Africa. 3Center for Global Health & Development, Boston University, Boston, United States. 4Health Economics and Epidemiology Research Office, University of the Witwatersrand, Johannesburg, South Africa. 5Department of Epidemiology, Boston University, Boston, United States. 6Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. 7Division of Infectious Diseases, Department of Medicine, University of Stellenbosch, Stellenbosch, South Africa. 8Tygerberg Academic Hospital, Cape Town, South Africa. 9Me´decins Sans Frontie`res, Cape Town, South Africa. 10Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa. 11Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Switzerland. 12Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa.
Abstract WEPDB0103—Figure 1. Adjusted 12-month log hazard ratios of observed and corrected LTFU from Cox’s proportional hazards models by CD4 count at ART initiation.

University of Bern, Bern, Switzerland. Division of Epidemiology and Biostatistics, University of Cape Town, Cape Town, South Africa.

Presenting author email: agrimsrud@gmail.com

Introduction: Over the past decade of antiretroviral therapy (ART) scale-up, median CD4 counts at ART initiation have increased and ART initiation is recommended at progressively higher CD4 thresholds. However data on the relationship between CD4 count at ART initiation and loss to follow-up (LTFU) are limited and conflicting. We investigated the association between higher CD4 counts at ART initiation and LTFU in South Africa (SA).

Methods: All adults initiating ART between 2008 and 2012 at 3 public sector sites in SA were included. LTFU was defined as no clinic visit in the six months before database closure. The Kaplan-Meier estimator and Cox’s models examined the relationship between CD4 count at ART initiation and 24-month LTFU. Estimates of corrected LTFU were generated adjusting observed LTFU for unascertained deaths through linkage via identification numbers (IDs) with the SA National Population Register. Final models were adjusted for patient demographics, year of ART initiation, and programme expansion.

Results: Among 17,038 patients, the median CD4 at initiation increased from 119 (interquartile range (IQR): 54–180) in 2008 to 257 (IQR: 175–318) in 2012. In unadjusted models, observed LTFU was associated with both CD4 counts \( <100 \) cells/mL and CD4 counts \( \geq 300 \) cells/mL compared to those with a CD4 count 150–199 cells/mL. After adjustment, patients with CD4 counts \( \geq 300 \) cells/mL were 1.35 (95% CI: 1.12–1.63) times as likely to be LTFU after 24 months compared to those with a CD4 count 150–199 cells/mL.

Correction for unascertained deaths attenuated the association between CD4 counts \( \leq 100 \) cells/mL and LTFU while the association between CD4 counts \( \geq 300 \) cells/mL and LTFU persisted (Figure 1).

Conclusions: Patients initiating ART at higher CD4 counts may be at increased risk for LTFU, particularly early after ART initiation. With programmes initiating patients at progressively higher CD4 counts models of ART delivery need to be reoriented to support long-term retention.

http://dx.doi.org/10.7448/IAS.18.5.20467

WEPDB0104

Clinical decision and outcomes of patients suspected of treatment failure and tested for HIV-viral load at the Infectious Diseases Institute (IDI), Kampala, Uganda

Mark Steven Nsumba 1,2; Castelnuovo Barbara 1; Rachel Zimaze Musomba 3; Arvind Kaimal 4; Kalule Ivan 5; Iwanga Isaac 6; John Laurence 7; Parkes-Ratansi Rosalind 8 and Kambugu Andrew 1

1Research Department, Infectious Disease Institute, Kampala, Uganda. 2Makerere University, Kampala, Uganda. 3Infectious Disease Institute, Kampala, Uganda. 4PCT, Infectious Disease Institute, Kampala, Uganda. 5PCT, Infectious Disease Institute, Kampala, Uganda.

Presenting author email: mnsumba@idi.co.ug

Introduction: WHO now recommends routine viral load (VL) monitoring, and the scale up of this has started in sub-Saharan Africa. Recent publications from the region suggest that often patients with detectable VL delay switching to second line ART or are not switched.

Objective: To evaluate the outcome of patients with a VL >1000 copies/ml accessing care at a large urban HIV Centre in Kampala, Uganda.

Methods: At IDI VL tests have been available since 2005. Until December 2014 these were reserved for patients with documented immunological or clinical failure. Those patients with detectable VL are managed through a treatment failure path-way consisting of: 1) review of the results by the clinician, 2) case discussion in the weekly multidisciplinary “switch-meeting” 3) follow up by a clinician and counsellor based on the decision reached during the “switch-meeting.” We performed a retrospective audit of a sample of patients on first line ART with VL >1000 in 2014; data was extracted from 95 randomly sampled clinic files and the clinic database.
Results: 1093 patients on first line ART were tested for VL in 2014, of which 365 (33.4%) had a detectable VL; of these 95 (26%) clinical files were sampled. Median log_{10} VL was 4.9 (IQR: 4.7–5.3).

The diagram summarizes the action taken for the 95 sampled patients stratified by referral to the treatment failure path-way. 60/95 (63.1%) were switched to 2nd-line after a median time of 49 days (IQR: 14–84). Of note an action was taken for all patients referred to the treatment failure path-way.

Conclusions: The majority (65%) of patients with a detectable VL were switched to 2nd-line, and an additional 28% had an action taken. This is a favourable outcome compared to outcomes in other treatment centres around SSA, and we believe that the “switch meeting” model has helped to ensure that action is taken. We advocate that this additional step be considered in WHO and national guidelines to ensure adherence strengthening and prompt switch to second line in patients failing ART.

http://dx.doi.org/10.7448/IAS.18.5.20468

Abstract WEPDB0104 - Figure 1. Action taken for the sampled patients with viral failure stratified by referral to the treatment failure path-way.

Introduction: In resource limited settings, timely plasma separation and transportation to centralized laboratories is a major challenge to the scale-up of viral load (VL) testing. Whole blood (WB) collection and testing through either dried blood spots (DBS) or point-of-care VL assays are potential solutions. However, there is limited evidence on the performance of WB-based VL assays.

Methods: We evaluated three WB VL testing platforms, Alere q HIV-1/2, DBS Abbott RealTime HIV-1 and Roche CAP/CTM HIV-1 (DBS, free virus elution protocol) using routine clinical samples across a wide viral load spectrum chosen from South African public sector patients on combination antiretroviral therapy. Abbott RealTime HIV-1 was used as gold standard and virological failure (VF) was defined for plasma at 1000 copies/mL.

Results: Of the 299 samples selected, 153 (51%) had plasma VL >1000 copies/mL. Abbott DBS VL had the best overall VL correlation with its plasma counterpart ($r^2 = 0.76$), followed by the Roche DBS VL ($r^2 = 0.62$) and Alere q HIV-1/2 ($r^2 = 0.46$).
Abstract WEPDC0101

Geographic origin trends among HIV+ mothers and children in Canada and impact on vertical HIV transmission rates

Jason Brophy1,2; Terry Lee1; Laura Sauve4,5; Ari Bitnun6,7; Joel Singer3; Fatima Kakkar8,9; Normand Lapointe8,9; Ariane Alimenti4,5; Deborah Money6,10,11; Wendy Vaudry7; Fatima Kakkar9; and for the Canadian Pediatric and Perinatal AIDS Research Group

1Children’s Hospital of Eastern Ontario, Ottawa, Canada. 2Department of Pediatrics, University of Ottawa, Ottawa, Canada. 3CHIR – Canadian HIV Trials Network, Vancouver, Canada. 4BC Women’s Hospital and Health Centre, Vancouver, Canada. 5Department of Pediatrics, University of British Columbia, Vancouver, Canada. 6The Hospital for Sick Children, Toronto, Canada. 7Department of Pediatrics, University of Toronto, Toronto, Canada. 8CHU Ste-Justine, Montréal, Canada. 9Department of Pediatrics, Université de Montréal, Montréal, Canada. 10Department of Obstetrics, University of British Columbia, Vancouver, Canada. 11Women’s Health Research Institute, Vancouver, Canada. 12Stollery Children’s Hospital, Edmonton, Canada. 13Department of Pediatrics, University of Alberta, Edmonton, Canada. 14Presenting author email: jbrophy@cheo.on.ca

Introduction: Migration contributes significantly to new HIV cases in Canada. This study describes geographic origin trends among HIV+ mothers and perinatally infected children and the impact of geographic origin on vertical HIV transmission (VT) rates among HIV+ mother-infant pairs (MIP) in Canada from 1990 to 2013.

Methods: The Canadian Perinatal HIV Surveillance Program collects data at 22 centres. The primary focus is on MIP with an infant born in Canada and identified prior to/within three months of birth; MIP with Canadian-born infants identified after three months and HIV+ children born abroad are also tracked. Data reviewed for this study included: maternal country of origin, clinical characteristics, antiretroviral usage and infant outcome. Logistic regression determined VT rate differences for foreign-born (FBM) versus Canadian-born mothers (CBM).

Results: Among 3877 MIP, 2089 (53.9%) mothers were FBM. Of 1481 (70.9%) African mothers, 30.7%, 20.1%, 17.7% and 16.7% came from East, Central, Horn and West Africa, respectively. CBM accounted for 66.7% (971/1456) in Western/Central Canada, whereas FBM predominated in Ontario (945/1357, 69.6%; greatest proportion East African, 25.0%) and Quebec (713/1020, 69.9%; greatest proportion Caribbean, 36.2%). The largest numbers of FBM originated from Haiti (12.5%), Ethiopia (8.7%), Congo (7.0%), Zimbabwe (5.4%) and Nigeria (4.6%). In the pre-cART era (1990–1996), Haiti contributed 29.9% (90/301) of FBM, decreasing to 13.0% (119/918) in 1997–2007 and 6.6% (52/782) in 2008–2013. Since 2008, Ethiopia (80/782, 10.2%), Congo (64/782, 8.2%) and Nigeria (62/782, 7.9%) predominated. VT rate among Canadian-born children from 1990 to 2013 was 3.8% (3.0% among FBM) and 1.2% from 2008 to 2013 (0.7% among FBM). African mothers had lower risk of VT (1990–2013: OR = 0.45, 95% CI 0.29–0.71; 2008–2013: OR = 0.35, 95% CI 0.12–1.08) compared to CBM; no differences were seen for other regions. Of 353 HIV+ children (born in Canada or abroad) with FBM, the greatest numbers came from Haiti (48, 13.6%), Ethiopia (33, 9.3%), Burundi (30, 8.5%) and Congo (15, 4.2%).

Conclusions: Geographic origins of HIV+ FBM in Canada have changed over time, shifting from predominantly Haitian in the pre-cART era to predominantly African more recently. African mothers have lower VT rates than CBM. Understanding country-specific cultural and obstetrical/ paediatric health issues is imperative to providing optimal care.

http://dx.doi.org/10.7448/IAS.18.5.20470

Abstract WEPDC0102

The Canadian perinatal HIV surveillance programme (CPHSP): programme description and trends in demographics, treatment and transmission

Joel Singer1,2; Ari Bitnun3; Terry Lee1; Lindsay Samson1; Jason Brophy1; Deborah Money6,10,11; Wendy Vaudry2; Fatima Kakkar9; Normand Lapointe8; Laura Sauve4 and Canadian Pediatric & Perinatal AIDS Research Group

1Methodology and Statistics, School of Population and Public Health, University of British Columbia, Vancouver, Canada. 2CHIR Canadian HIV Trials Network, Vancouver, Canada. 3Hospital for Sick Children, University of Toronto, Toronto, Canada. 4CHIR Canadian HIV Clinical Trials Network, Vancouver, Canada. 5Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada. 6BC Women’s Hospital and Health Centre, University of British Columbia, Vancouver, Canada. 7Stollery Children’s Hospital, University of Alberta, Edmonton, Canada. 8Hospital Ste-Justine, University of Montreal, Montreal, Canada. 9Presenting author email: singerjoel@hotmail.com

Introduction: The Canadian perinatal HIV Surveillance Programme (CPHSP) was established in 1990 to monitor the impact of maternal HIV infection on vertical transmission of HIV in Canada. The programme aims to identify the characteristics of HIV infection in mothers and their newborn infants, the transmission routes of HIV infection, and the impact of care and treatment on maternal and infant health outcomes. The programme collects data from 22 centres across Canada, including hospitals, clinics, and community-based organizations. The data collected includes demographic information, maternal risk factors, infant outcomes, and treatment regimens. The programme also provides a platform for researchers to study the epidemiology of perinatal HIV transmission in Canada.

Methods: The Canadian perinatal HIV Surveillance Programme collects data on all HIV+ mothers and their infants born in Canada, regardless of the country of origin of the mother or the infant. The programme collects data on maternal risk factors, such as age, race, and country of birth, as well as information on the infant, including gender, birth weight, and mode of delivery. The programme also collects data on the treatment regimens used during pregnancy and the outcomes of the infants, including HIV infection status and death.

Results: Since the establishment of the programme in 1990, there has been a significant increase in the number of HIV+ mothers and their infants. In 1990, there were 10 cases of perinatal transmission, and by 2013, this number had increased to 3877 cases. The programme has also provided valuable insights into the epidemiology of perinatal transmission, including the impact of maternal risk factors on transmission, the effectiveness of antiretroviral treatment, and the outcomes of infants born to HIV+ mothers.

Conclusions: The Canadian perinatal HIV Surveillance Programme has provided valuable data on the impact of maternal HIV infection on vertical transmission of HIV in Canada. The programme has also provided insights into the epidemiology of perinatal transmission, including the effectiveness of antiretroviral treatment and the outcomes of infants born to HIV+ mothers. The programme continues to provide valuable data to inform research and policy initiatives aimed at reducing perinatal transmission of HIV in Canada.

http://dx.doi.org/10.7448/IAS.18.5.20470
Introduction: The Canadian Perinatal HIV Surveillance Program (CPHSP) is an active surveillance program generating national data HIV+ women and their infants in Canada since 1990. We describe the CPHSP’s evolving methodology and analyze mother-infant pair (MIP) demographics, antiretroviral treatment and vertical transmission (VT) rates in Canada from 1990 to 2013.

Methods: MIPs are identified at 22 centres following obstetric or paediatric referral for care. Data is entered via a secure web-based Oracle database, which is managed and analyzed by the CHIR-Canadian HIV Trials Network. A nationally representative steering committee provides direction and oversight. Data collected include maternal characteristics, antiretroviral therapy (ART) and infant outcome. VT rates are based on data of MIP delivered in Canada and identified within three months after birth; infants identified beyond three months of birth are tracked separately.

Results: Among 2914 MIP from the combination ART (cART) era (1997–2013), the overall VT rate was 2.1% but only 0.7% in MIP receiving cART and 0.1% in women receiving >4 weeks of ART. Of 200 identified HIV+ women giving birth in Canada in 2013, 76% acquired HIV heterosexually, 17% through injection drug use (IDU) and 2% perinatally; 53% of mothers were Black and 23% Aboriginal. The proportion untreated steadily decreased from 20.3% in 1997 to 3.0% in 2013. Aboriginal women (7%) continued to have the highest VT rates (3.4%) compared to Black (0.8%), White (0.4%) and Asian (0.0%). The proportion untreated steadily decreased from 20.3% in 1997 to 3.0% in 2013. Aboriginal women (7%) continued to have the highest VT rates (3.4%).

Conclusions: The CPHSP allows for comprehensive identification of perinatal HIV exposure and outcome trends in Canada. Ongoing challenges include ensuring all MIPs are captured given Canada’s evolving methodology and analyze mother-infant pair (MIP) demographics, antiretroviral treatment and vertical transmission (VT) rates in Canada, resulting in two children becoming infected.

Methods: The CPHSP allows for comprehensive identification of perinatal HIV exposure and outcome trends in Canada. Ongoing challenges include ensuring all MIPs are captured given Canada’s geographically and demographically diverse population and low HIV prevalence. Despite continued improvement in treatment access for pregnant HIV+ women, VT continues to occur with Aboriginal women being at greater risk of inadequate treatment and VT.

http://dx.doi.org/10.7448/IAS.18.5.20471

WEPDC0103 HIV acquisition after arrival in France among sub-Saharan African migrants living with HIV in Paris area. Estimations from the ANRS PARCOURS study

Annabel Desgrees du Lou1; Julie Pannetier1; Andrainolo Ravalihasy1; Anne Gosset1; Virginie Supervie2; Nathalie Bajos3; France Lert3; Nathalie Lydie1 and Rosemary Dray-Spira1

1IRD, CEPED, Paris, France. 2INSERM, ILESP, Paris, France. 3INSERM, CESPI, Le Kremlin Bicêtre, France. 4INSERM, CESPI, Villejuif, France. 5INPES, Saint Denis, France.

Presenting author email: julie.pannetier@ceped.org

Introduction: HIV acquisition among sub-Saharan migrants living in Europe has long been considered to predominantly occur before migration because of generalized HIV epidemics in sub-Saharan African countries. Recent evidence suggests that a substantial proportion have acquired HIV while they were living in Europe. In the UK, this proportion was recently estimated at 31% using a CD4-based modelling approach. Such an estimate is not currently available for France.

Methods: We estimated the proportion of sub-Saharan migrants who acquired HIV infection after their arrival in France using life-event and clinical information on a random sample of HIV-infected hospital outpatients born in sub-Saharan Africa in Paris region. We assumed that HIV infection had probably been acquired in France if at least one of the following life-event criterion was fulfilled: 1) HIV diagnosis >10 years after arrival in France, 2) ≥1 negative HIV test in France, and 3) sexual debut after arrival in France. If none of these criteria was fulfilled, we estimated the duration from HIV infection based on first CD4 count measurement using statistical modelling. Infection was assigned in France if, out of 500 durations estimated for each individual, >50% (median scenario) or >95% (conservative scenario) fell within the period while individuals were living in France.

Results: Of the 898 HIV-infected adults born in sub-Saharan Africa included in the analysis, we estimated that 49% (95% confidence interval: 45–53) in the median scenario and 35% (31–39) in the conservative scenario acquired HIV while living in France. This proportion was lower for women than men (30% [25–35] vs. 44% [37–51] in the conservative scenario) and increased with duration in France.

Conclusions: The proportion of sub-Saharan African migrants having acquired HIV infection while living in France is high, highlighting the need for improved focused HIV prevention. This requires a better understanding of the determinants of HIV infection in France in this population.

http://dx.doi.org/10.7448/IAS.18.5.20472

WEPDC0104 Evidence of local HIV transmission in the African community of King County, Washington

Roxane Kerani1,2; Joshua Herbeck3; Susan Buskin4; Julia Dombrowski1,4; Amy Bennett4; Elizabeth Barash1; Lindley Barbee1,2 and Matthew Golden1,2

1Medicine, University of Washington, Seattle, United States. 2HIV/STD Program, Public Health - Seattle and King County, Seattle, United States. 3Global Health, University of Washington, Seattle, United States. 4Communicable Disease Epidemiology, Public Health - Seattle and King County, Seattle, United States.

Presenting author email: rkernan@uw.edu

Introduction: In many parts of the U.S., immigrants from sub-Saharan Africa comprise a large proportion of heterosexual HIV cases. However, little is known about the frequency of ongoing HIV transmission within these communities.

Methods: Public Health-Seattle and King County staff routinely interview patients newly reported with HIV infection, and attempt to contact sex partners to ensure notification and HIV testing. We describe the characteristics, testing history and partner outcomes for African-born persons newly reported with HIV infection in King County (KC), WA from 1/1/2010 to 12/31/2013. Additionally, we reconstructed an HIV-1 pol phylogeny for 1430 cases diagnosed in KC 2008–2014, with 100 sequences each from Kenya and Ethiopia added for African references.

Results: During the study period, 1148 adults were reported with HIV in KC, including 101 (8.8%) born in Africa. Of 63 cases in African-born individuals with new HIV diagnoses, 49 (77.8%) were interviewed for partner services. Seven reported being diagnosed with HIV-infection before U.S. arrival and were excluded from further analysis, leaving 42 individuals. Median time from U.S. arrival to HIV diagnosis was 7.0 years (range: 8 days–26.7 years). Most were born in East African countries (N = 34, 81.0%). Twenty-seven (64.3%) were women; mean age was 42.6 years (range: 24.9–62.2). Sixteen (38.1%) cases reported at least one negative test prior to HIV diagnosis, and 11 (31.4%) reported >1 negative HIV test after U.S. arrival. Pol genotypes were available for seven of these 11 cases; for six of these seven, a local case was the nearest phylogenetic neighbour, and two were infected with subtype B virus. This suggests local transmission sources for these six cases. The 42 newly diagnosed
individuals identified 47 partners; six (12.8%) partners had been diagnosed with HIV infection prior to the investigation. Thirteen partners were newly HIV tested as a result of index patients’ HIV diagnoses; five (38.5%) were HIV-infected. Of the 11 partners who were previously positive (6) or newly diagnosed (5), seven were interviewed and six were African-born.

Conclusions: We found substantial evidence of ongoing HIV transmission in the African community of KC. Additional efforts are needed to increase HIV testing and prevention among African immigrants in the U.S.

http://dx.doi.org/10.7448/IAS.18.5.20473
Heterogeneity of the HIV epidemic in rural Africa: findings from a geospatially informed study of HIV epidemiology in fishing, trading, and agrarian communities in Rakai, Uganda

Larry Chang, Mary K Grabowski, Robert Ssekubugu, Fred Nalugoda, Justin Lessler, Sean Moore, Ronald Gray, David Serwadda, Maria Wawer

1Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, United States. 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States. 3Rakai Health Sciences Program, Kalisizo, Uganda. 4Laboratory of Immunoregulation, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.

Presenting author email: mgrabows@jhsph.edu

Introduction: National and district level HIV prevalence rates may obscure substantial variation of HIV disease burden at the community level. Understanding the extent to which HIV differs across communities and the drivers of disparities and similarities within individual districts may offer opportunities for a more effective, targeted HIV response.

Methods: HIV prevalence and risk behaviours were assessed among 17,109 individuals (53.8% female vs. 46.2% male) in 40 communities in Rakai District, Uganda between August 2011 and October 2013 through the population-based Rakai Community Cohort Study. Communities were classified as lakeside fish landing sites (n = 30), agrarian (n = 27) or trading communities (n = 9) based upon occupation analysis. HIV prevalence was geospatially mapped using Bayesian methods and variability across and within community classifications was characterized. Differences in risk behaviours between communities were assessed using modified Poisson regression models.

Results: There was large variation in HIV prevalence, ranging from 9 to 43%, across communities (see Figure below). Fish landing sites had a mean HIV prevalence of 41% (range: 37–43%). Mean HIV prevalence in trading communities was 17% with substantial variability (range: 11–22%) and 14% in agrarian communities, also with substantial variability (range: 9–26%). Agrarian and trading communities in close proximity (<18 km) to fishing landing sites had HIV prevalence ranging from 11 to 26%. Overall, HIV prevalence was higher among women than men (p < 0.001), and the disparity was greatest in the fish landing sites (49% vs. 34%). The proportion of males and females reporting ≥4 sex partners in the last year was 6.4 (95% CI: 4.1–11.0) and 3.2 (95% CI: 2.7–3.8) times higher in fishing communities than in the agrarian/trading population, respectively. Levels of consistent condom use with non-marital partners were significantly lower in the fish landing sites (RR = 0.80, 95% CI: 0.69–0.94).

Conclusions: Large variations in HIV prevalence and risk factors across communities in rural Rakai underscores the need for a granular approach to HIV prevention and response based on local assessment of HIV burden and risks and locally tailored interventions that may include targeting of high risk groups such as those in fish landing sites.

http://dx.doi.org/10.7448/IAS.18.5.20474
WEPDD0101
Cost-effectiveness of implementing CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda
Anu Ramachandran1; Yukari Manabe2; Radha Rajasingham3 and Maunak Shah4
1Johns Hopkins University School of Medicine, Baltimore, United States. 2Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, United States. 3Minneapolis, University of Minnesota, United States. Presenting author email: aramach7@jhmi.edu
Introduction: Cryptococcal meningitis (CM) constitutes a significant source of morbidity and mortality in resource-limited regions. One million cases occur annually, representing 10–30% of HIV-related death in prevalent regions. Optimal interventions for CM prevention remain unclear. The recently developed serum cryptococcal antigen lateral-flow assay (CRAG-LFA) is highly sensitive and specific, and may allow early detection of subclinical cryptococccemia in those at risk of developing CM. We sought to determine the cost-effectiveness of implementing CRAG-LFA screening for people living with HIV in Uganda compared to other interventions for CM prevention.
Methods: A decision-tree model was constructed to compare three strategies for cryptococcal prevention among people living with HIV (PLWH) with CD4 < 100: Standard of care (SOC, i.e. no cryptococcal screening), CRAG-LFA screening followed by evaluation and treatment of cryptococccemia or universal primary prophylaxis (UPP) with fluconazole for all patients and no CRAG-LFA screening. Primary outcomes were expected costs, DALY's and incremental cost-effectiveness ratios (ICERs). In sensitivity analysis, we analyzed the impact of costs, prevalence and alternative clinical algorithms on the cost-effectiveness of CRAG-LFA screening.
Results: CRAG-LFA screening was associated with an ICER of $5.88 per DALY averted compared to SOC, and was highly cost-effective at current willingness to pay thresholds for Uganda. CRAG-LFA screening dominated the UPP intervention (i.e. both cheaper and more effective). Overall, implementation of CRAG-LFA screening was projected to cost $1.46 more per person than SOC, and could reduce the relative risk of cryptococcal-associated mortality by over 40%. When including the cost of lifetime ART, the ICER for CRAG-LFA screening was $557 compared to SOC and still considered cost-effective. In sensitivity analysis, prevalence of baseline CM and cost of the CRAG-LFA influenced cost-effectiveness. In probabilistic sensitivity analysis, the CRAG-LFA screening intervention was cost-effective in 100% of simulations, and cost-saving in 30% of simulations.
Conclusions: CRAG-LFA screening is extremely cost-effective with the potential to prevent significant morbidity and mortality from CM in vulnerable populations, and represents excellent value for money as a screening intervention for HIV programs in Uganda.

http://dx.doi.org/10.7448/IAS.18.5.20475

Abstract WEPDD0101 - Table 1. Cost-effectiveness projection results

| Intervention                         | Total Cost | Incremental Cost | Incremental Cost (including lifetime ART) | DALYs Accumulated | Incremental Effectiveness (DALYs averted) | Incremental Cost-Effectiveness Ratio (ICER) | Incremental Cost-Effectiveness Ratio (ICER) including lifetime ART |
|--------------------------------------|------------|-----------------|------------------------------------------|-------------------|------------------------------------------|---------------------------------------------|------------------------------------------------|
| Standard of Care (SOC)               | 9.12       | REFERENCE       | REFERENCE                                 | 8.55              | REFERENCE                                 | REFERENCE                                  | REFERENCE                                      |
| CRAG-LFA Screening                   | 10.58      | 1.46            | 139.48                                   | 8.30              | 0.25                                     | 5.88                                       | 557.60                                        |
| Universal Primary Prophylaxis (UPP)  | 236.23     | 227.10          | 332.19                                   | 8.35              | 0.20                                     | 1141.96                                    | 1660.95                                       |

WEPDD0102
Lost opportunities to identify and treat HIV-infected patients: results from a comprehensive study of provider-initiated HIV testing and counselling (PITC) in Malawi
Monica Schwarz1; Robbie Flick2,3; Mwelura Harawa2; Katie Simon2,4; Maria Kim4; Jeff Robison5; and Saeed Ahmed2,4
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States. 2Baylor College of Medicine – Abbott Fund Children’s Clinical Center of Excellence, Lilongwe, Malawi. 3Infectious Diseases, University of Colorado School of Medicine, Denver, United States. 4Baylor International Pediatric AIDS Initiative at Texas Children’s Hospital, Baylor College of Medicine, Houston, United States. 5Department of Pediatrics, University of Utah, Salt Lake City, United States. Presenting author email: monica.schwarz@gmail.com
Introduction: Early diagnosis and treatment of HIV improves patient outcomes and minimizes risk of transmission. Provider-initiated testing and counselling (PITC) is an effective case-finding strategy, but implementation models vary. Malawi Ministry of Health (MOH) guidelines recommend routine opt-out PITC, in line with WHO recommendations for countries with generalized epidemics, but little is known about its implementation. Our objective was to assess PITC implementation in Malawi.
Methods: We conducted a cross-sectional study of PITC implementation at 118 clinics and wards within 12 MOH facilities in central Malawi during June–July 2014. Qualitative data detailing PITC practices was collected through structured interviews with 71 providers who conduct HIV testing at their facility, and characterized using standardized definitions (Figure 1). Quantitative data describing patient visits and HIV tests recorded during 2013 was abstracted from MOH HIV testing reports.
Results: Variable models of PITC were reported across facilities and departments (Table 1). Overall, symptom-based PITC was most commonly reported. Only antenatal and maternity (20/24) departments reported implementing routine opt-out testing. Use of a PITC register varied significantly according to department type. Only 7.7% (86,657/1,102,802) of patient visits in 2013 included an HIV test. Subgroup analysis of TB and antenatal clinics with available data demonstrated that HIV status was ascertained in 94.3% (5293/5616) and 86.8% (26,831/30,961) of patients, respectively. Providers most commonly cited test kit shortages (71/71 providers), inadequate physical space (58/71) and inadequate number of HIV counsellors (32/71) as challenges in PITC implementation. Providers from inpatient units cited the inability to test on weekends (8/16).
Conclusions: Various models of PITC concurrently exist at MOH facilities in Malawi. Only antenatal and maternity clinics demonstrated high rates of routine opt-out PITC. The low ratio of facility visits that included an HIV test suggest missed opportunities for HIV
Abstract WEPDD0101—Figure 1. Decision-analysis model schematic.

Abbreviations: SOC—Standard of care, UPP—Universal fluconazole primary prophylaxis, CRAG-LFA—cryptococcal antigen lateral flow assay, CM—cryptococcal meningitis, WTP—WHO pre-emptive therapy.

Decision-analytic model schematic. We modeled progression or relapse of CM over a 5 year time-horizon for a cohort of PLWH with CD4 < 100. In all model arms symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and treatment if diagnosed with CM. We assumed ART initiation in all arms. The model explores three interventions for prevention of cryptococcal morbidity for those without a baseline diagnosis of CM: 1) SOC, in which patients receive no CM screening or prophylaxis 2) UPP, in which all asymptomatic patients (and symptomatic patients without CM diagnosis * as noted in the model) receive primary prophylaxis with 200 mg of fluconazole. 3) CRAG-LFA, in which all patients receive serum CRAG-LFA screening. Individuals with positive CRAG were assumed to receive the WHO preemptive treatment for cryptococcemia with fluconazole 800 mg for two weeks, followed by fluconazole 400 mg for eight weeks. CRAG-negative individuals receive no further antifungal therapy.

testing. However, the high proportion of patients at TB and antenatal clinics with known HIV status suggest routine testing is feasible. These results underscore the need to develop clear, standardized PITC protocols and tools, and to address obstacles of limited health commodities, infrastructure and human resources.

http://dx.doi.org/10.7448/IAS.18.5.20476

Evaluation of HIV PIMA™CD4 point-of-care test operation by trained non-health workers in rural health centres in Chiradzulu District, Malawi

Birgit Schramm; Aliaa Tayea; Liselotte Wolters; Sarala Nicholas; Charlie Willy Masiku; Dawie Baxter Zolowere; Eustice Mhango;
Abstract WEPDD0102 – Figure 1: Definitions of PITC models.

James Raphael Kandulu 1, Jean-Francois Etard 1, 2, 5; Isabel Amaros 3;
Elisabeth Szumilin 4 and Monique Gueguen 7

1Epicentre, Paris, France. 2Medecins sans Frontieres, Chiradzulu, Malawi. 3Medecins sans Frontieres, Lilongwe, Malawi. 4Ministry of Health, Chiradzulu, Malawi. 5Ministry of Health, Lilongwe, Malawi.

Abstract: Four non-health workers received a one-week structured training on PIMA CD4 test operation. Between June 2014 and January 2015, 331 venous blood samples of pre-ART and ART-patients attending routine CD4-testing in two rural HCs were included. Each sample was assessed on site with PIMA by a lab technician (LT) and a trained community worker (TCW), and measured with PartecCyflow® counter at district hospital. Kappa-coefficient and percent agreement for CD4-classification below and above relevant thresholds were obtained. Bias and limits of agreement (LOA) were assessed for absolute CD4 counts. PIMA error-rates and failed runs (2 consecutive errors) were recorded and TCW-operator acceptability assessed.

Results: Three-hundred-twenty-eight venous blood samples (85% ART-patients, 68.5% female) were included. Median CD4 count (LT PIMA) was 425 cells/µL (IQR: 323, 570). Error rates were low (LT: 1.2% vs. TCW: 2.4%, p = 0.34) and no failed runs occurred. Good agreement was achieved for PIMA results by LTs versus TCWs for CD4 threshold 350 cells/µL (91.7% (95% CI: 88.2–94.5); kappa = 0.80) and 500 cells/µL (91.1% (95% CI: 87.5–93.9); kappa = 0.80). The mean bias (TCW-PIMA minus LT-PIMA) was low (−2.2 cells/µL (LOA: 137.4, −141.9)). Bias and LOA comparing PIMA results by LTs or TCW versus Partec was similar (LT-PIMA minus Partec: −46.4 cells/µL (95.9, −188.8); (TCW-PIMA minus Partec: −46.5 cells/µL (118.0 – 211.0)). TCWs rated PIMA operation as very easy.

Conclusions: Adequately trained community workers delivered CD4 results equivalent to lab technicians with PIMA POC in health centre laboratories. Task shifting of simplified CD4 POC-technologies to trained non-health care staff can serve as a key strategy to ensure sustainable provision of CD4-testing in support of ART-initiation in rural facilities.

http://dx.doi.org/10.7448/IAS.18.5.20477

WEPDD0104
Improving dried blood spot transport logistics for early infant diagnosis in Nigeria: the SPEEiD model

Nwoledi Ndulue 6; Andrew Esetuowaghan 7; Chiema Gabriel 7 and Jimoh Ibrahim 7

1Clinical Unit, Management Sciences for Health, Abuja, Nigeria. 2Laboratory System Strengthening, Management Sciences for Health, Ilorin, Nigeria. 3Nigerian Postal Service, Expedited Mail Service, Ilorin, Nigeria.

Abstract: Who recommends that all children exposed to HIV be tested within four to six weeks of birth to ensure that all infected infants are identified and initiated on treatment early. One major challenge with early infant diagnosis (EID) of HIV in Nigeria remains the absence of standardized logistic sample transfer systems, resulting in long turnaround times between date of sample collection and date of return of result to the mother. To address this challenge, the

Table 1. Reported PITC model and use of PITC register

| Department type | Routine opt-out | Routine opt-in | Symptom-based | PITC register in use, n (%) |
|----------------|-----------------|----------------|---------------|--------------------------|
| TB Clinic      | 5/12 (42)       | 7/12 (58)      | 0/12 (0)      | 12/12 (100)             |
| Antenatal clinic and maternity ward | 20/24 (83) | 4/24 (17) | 0/24 (0) | 24/24 (100) |
| Family planning clinic | 1/11 (9) | 7/11 (64) | 3/11 (27) | 8/11 (73) |
| STI clinic     | 3/6 (50)        | 3/6 (50)       | 0/6 (0)       | 6/6 (100)               |
| Outpatient Department, Under-5 clinic, and immunization clinic | 4/36 (11) | 4/36 (11) | 28/36 (78) | 9/36 (25) |
| Malnutrition clinic | 7/10 (7) | 2/10 (20) | 1/10 (10) | 5/10 (50) |
| Adult and paediatric inpatient wards | 1/19 (5) | 3/19 (16) | 15/19 (79) | 5/19 (26) |
| Totals         | 41/118 (35)     | 30/118 (25)    | 47/118 (40)   | 69/118 (59)             |
USAID-funded ProACT project implemented by MSH, pioneered the Strengthening the Process and Efficiencies for Early infant Diagnosis (SPEEiD) model, which involves the transportation of dried blood spot (DBS) samples from remote HIV clinics to regional PCR labs using the Nigerian Postal Service (NIPOST) Express Mail Service (EMS) platform, which has a network of over 3900 post offices and agencies spread across the country, ensuring penetrance to remote HIV clinics. The objective of this study was to review the effect of utilizing an innovative DBS transport model in improving DBS transportation.

Methods: We carried out a retrospective analysis of logistic data from 177 samples transferred from 28 PMTCT sites using the SPEEiD model over a 12 month period from March 2013 to February 2014 in Kwara state, North Central Nigeria.

Results: A review of the data showed a reduction in turnaround time for return of results from 3-6 months to 3-4 weeks utilizing the SPEEiD Model. Results were received for 97% of samples (171/177) transported with this model, compared to 51% previously. The average cost of sample transfer was estimated at between $20 and $40 per batch and remains comparatively less expensive to other models by at least 30%.

Conclusions: The MSH SPEEiD model remains an indigenous, cost effective, sustainable and time-sensitive sample transfer model which ensures that exposed infants are able to receive their EID test results quickly. This approach may be easily replicated by other partners working in similar resource limited settings, as it provides a practical solution for DBS sample transfer, which remains one of the major challenges affecting EID of HIV in Nigeria.

http://dx.doi.org/10.7448/IAS.18.5.20478

WEPDD0105

Trends in early infant HIV diagnosis and treatment services in rural southwest Uganda (2011-2014)
Juan Seclen-Palacin1; Eliab Natumanya2; Linda Nabitaka3; Edward Bitarakwate2 and Shabbir Ismail1
1Elizabeth Glaser Pediatrics AIDS Foundation, Washington, United States. 2Elizabeth Glaser Pediatrics AIDS Foundation Uganda, Mbarara, Uganda. 3Ministry of Health of Uganda, AIDS Control Program, Kampala, Uganda.

Introduction: In Uganda, 39% of HIV-exposed infants (HEI) were HIV tested within two months and <30% of children accessed to ARVs (UNAIDS, 2014), which reveal challenges to reach to early infant diagnosis (EID) programs.

Abstract WEPDD0105 - Figure 1. Trends of EID for HIV in southwestern Uganda: 2011-2014.
HIV diagnosis and treatment services (EIDT) services. Through implementation of Strengthening TB and HIV/AIDS response in Uganda Southwestern Region (STAR-SW) project, Elizabeth Glaser Pediatrics AIDS Foundation (EGPAF) provides support to districts and sites to strengthen and increase access to EIDT services. This includes training and mentoring site-based healthcare workers (nurses, clinicians) on proper utilization of EIDT guidelines (counselling and testing manuals, treatment protocols), optimizing patient care flow, expanding points of care, strengthening laboratory capacity, utilization of EIDT clinical registers and reporting and conducting regular data reviews for continuous improvement. This report describes trends of accessing EIDT services under this project.

Methods: Using HIV programme data from the Uganda Health System for January 2011 to June 2014, we conducted an EIDT analysis covering all 192 supported sites. Indicators analyzed were number of HIV-positive pregnant women identified during antenatal care, HIV-positive mothers delivered at health institutions, HEI received ARV at birth, exposed infants tested for HIV within two months after birth. ARV uptake and HIV testing coverage were estimated by dividing number of HEI-received ARVs at birth and who were tested within two months between HIV-positive pregnant women in antenatal care (ANC), respectively. Descriptive and trends analysis were conducted.

Results: By January 2011, HEI testing coverage was 17.8%, which increased to 47.5% in December 2012. With the rollout of the Option B+ in early 2013, HEI testing continued to increase and reached around 63% in mid-2014 (trend R² = 0.8174). Simultaneously, HEI receiving ARVs at maternity progressively increased over time from 17% (312/1799) in January 2011 to 32% at the end of 2012, peaking around 63% in mid-2014 (trend R² = 0.8174). Simultaneously, HEI receiving ARVs at maternity progressively increased over time from 17% (312/1799) in January 2011 to 32% at the end of 2012, peaking around 63% in mid-2014 (trend R² = 0.8174). Simultaneously, HEI receiving ARVs at maternity progressively increased over time from 17% (312/1799) in January 2011 to 32% at the end of 2012, peaking around 63% in mid-2014 (trend R² = 0.8174).

Conclusions: HIV testing and ARV uptake for HEI have progressively improved in STAR-SW catchment area. The various site level of support provided by EGPAF seems to have contributed to these results. EGPAF will continue supporting the national and district health systems in further expansion of EIDT services as well as on further analysis of disaggregated data, informing quality improvement interventions and planning additional operational research studies.

http://dx.doi.org/10.7448/IAS.18.5.20565

Abstract WEPDD0106  Table 1. Summary of INSTI™ test results on Commercial HIV-1 Seroconversion Samples before and after IgM removal

| Number of seroconversion (SC) samples | Before IgM removal | After IgM removal |
|--------------------------------------|--------------------|------------------|
|                                      | INSTI positive     | INSTI test dot became negative |
| 15 early SC, IgM positives           | 15                 | 8                |
| 6 early SC, IgM not determined       | 6                  | 2                |
| 5 late SC, IgG                       | 5                  | –                |
| Total = 26                           | 26                 | 10               |

Biolytical Laboratories, Richmond, Canada.
Presenting author email: n.mosh@gmail.com

Introduction: HIV-IgM antibody is detectable within two weeks following infection and is therefore an important immunoassay target for early HIV antibody detection. The objective of this study is to determine if the proven early HIV antibody sensitivity of the 60-second INSTI HIV-1/HIV-2 antibody test is due to its ability to detect HIV-IgM antibodies.

Methods: The INSTI HIV-1 gp41 recombinant antigen was applied to a HIV-IgM ELISA to demonstrate its ability to capture HIV gp41 IgM antibody. This HIV-IgM ELISA assay was run on six commercial early seroconversion samples, known to be HIV-IgM positive, and five long-term HIV-positive serum samples. A separate experiment to demonstrate that the dye-labelled recombinant Protein A-based colour developer (CD) used in the INSTI assay has affinity to human IgM was conducted. A quantity of 0.5 µg of purified human immunoglobulins (IgM, IgD, IgA, IgE and IgG) were blotted onto nitrocellulose (NC) and probed with the CD to observe for spot development. Finally, to determine if INSTI performance is affected by IgM removal, IgM was removed by human anti-IgM MicroBeads on 21 early seroconversion samples with known or undetermined levels of HIV-IgM and with five samples from long-term HIV-positive samples. INSTI results were observed for reduced test spot intensity following IgM removal.

Results: The gp41-based HIV-IgM ELISA was positive for the six early seroconversion samples that were known INSTI and HIV-IgM positive, and negative for the five long-term HIV-positive samples indicating the assay signal was due to HIV-IgM capture by the immobilized gp41 antigen. The dye-labelled recombinant Protein-A used in the INSTI colour developer produced distinct spots for purified IgM, IgA and IgG blotted on the NC membrane. Following IgM removal from 21 seroconversion samples with known or undetermined levels of HIV-IgM and with five samples from long-term HIV-positive samples INSTI results were observed for reduced test spot intensity following IgM removal.

Conclusions: The INSTI HIV-1/HIV-2 Antibody Test is shown to detect HIV gp41-specific IgM antibodies in early HIV infection, which enhances its utility in early HIV infection.

http://dx.doi.org/10.7448/IAS.18.5.20563
### AUTHOR INDEX

#### A

| Name                  | Organization       | Code          |
|-----------------------|--------------------|---------------|
| Abdel-Mohsen, M       | TUAA0204LB         |               |
| Abdool Karim, S       | TUAC0101LB         |               |
| Abimiku, A            | MOAA0205           |               |
| Abrahams, F           | WEAA0102           |               |
| Abram, M              | TUAB0103           |               |
| Abrams, EJ            | MOAB0107LB         |               |
| Achii, P              | WEAD0203           |               |
| Achu, MN              | TUAD0205           |               |
| Adams, R              | MOAA0101           |               |
| Adler, M              | TUAD0204           |               |
| Agot, K               | MOAC0302LB, TUAC0102 |
| Agyei, Y              | TUAC0106LB         |               |
| Ahlers, J             | MOAA0104           |               |
| Ahmed, S              | WEPDD0102          |               |
| Ajibola, G            | MOPDB0104*         |               |
| Akapirat, S           | WEAA0102           |               |
| Akello, I             | MOAC0302LB         |               |
| Akelo, V              | MOAC0106LB         |               |
| Alave, J              | MOAB0205LB         |               |
| Alcaide, M            | MOPDC0101*         |               |
| Alcami, J             | MOPA0103*          |               |
| Alimenti, A           | WEPDC0101, WEPDC0102 |
| Allegre, T            | TUAB0207LB         |               |
| Allison, S            | TUAC0106LB         |               |
| Altice, F             | MOPDD0101          |               |
| Amaros, I             | WEPDD0103          |               |
| Ambinder, RF          | MOPDA0105          |               |
| Amede, E              | WEAA0106LB         |               |
| Amico, KR             | MOAC0305LB, MOAC0306LB |
| Amzal, B              | MOAC0204           |               |
| Ananworanich, J       | WEAB0102, WEAB0104, WEAD00204, MOAB0105 |
| Anastos, K            | MOA0203            |               |
| Anato, S              | TUAC0304           |               |
| Ancuta, P             | WEAA0105           |               |
| Anderson, P           | TUAC0202           |               |
| Anderson, PL          | MOAC0306LB         |               |
| Andrade, J            | TUAB0102           |               |
| Andrew, K             | WEPDD0104          |               |
| Andrew, P             | TUAC0106LB         |               |
| Angin, M              | MOAA0105LB         |               |
| Ansari, A             | MOAA0202           |               |
| Anstett, K            | TUAA0104           |               |
| Antonini-Michelle, T  | TUAB0207LB         |               |
| Apornpong, T          | TUAB0101           |               |
| Apps, R               | TUAA0106LB         |               |
| Arasteh, K            | TUAA0104           |               |
| Archin, N             | MOAP0106LB         |               |
| Arendt, M             | TUPD0101           |               |
| Argento, E            | WEAC0101*          |               |
| Arheart, K            | MOPDB0101          |               |
| Arredondo, J          | MOPDD0103          |               |
| Arribas, J            | TUAB0103           |               |
| Arts, E               | TUAA0102           |               |
| Asamoah-Odei, E       | MOAB0102           |               |
| Åsbjörnsdóttir, KH    | MOAB0103*          |               |
| Aschman, N            | TUPD0103           |               |
| Asila, V              | TUPD0105           |               |
| Asired, B             | WEA0102            |               |
| Asmuth, D             | MOAB0204           |               |
| Aumaire, H            | TUAB0207LB         |               |
| Auripobil, L          | TUPD0104           |               |
| Auvert, B             | MOAC0102*          |               |
| Avetfand-Fenoel, V    | MOAB0105LB         |               |
| Avihingsanon, A       | TUAB0101           |               |
| Avila-Rios, S         | MOPDA0102          |               |
| Ávila-Rios, S         | WEAO0103           |               |
| Awa, JC               | TUAD0205           |               |

#### B

| Name                  | Organization       | Code          |
|-----------------------|--------------------|---------------|
| Bacchetti, P          | MOAB0106LB         |               |
| Bachireddy, C         | MOPDD0101*         |               |
| Bacon, O              | TUAB0202           |               |
| Badal-Faesen, S       | MOAB0205LB, MOAC0101LB |
| Baddeley, A           | MOAB0204*          |               |
| Baeten, J             | MOAB0105LB         |               |
| Baeten, JM            | MOPDB0103          |               |
| Bai, F                | TUPD0101           |               |
| Bailer, R             | TUAA0106LB         |               |
| Bajos, N              | WEPDD0103          |               |
| Bakir Timimi, H       | MOAB0204           |               |
| Bamford, A            | WEAB0204           |               |
| Banchongkit, S        | TUAB0101           |               |
| Bandason, T           | WEAB0202*          |               |
| Bangsberg, DR         | TUAB0103           |               |
| Baño, S               | TUAB0204           |               |
| Bao, J                | MOAB0205LB         |               |
| Baral, S              | WEAC0106LB, TUAC0304 |
| Barash, E             | WEPDC0104          |               |
| Barbar, C             | WEPD0104           |               |
| Barbree, L            | WEPDC0104          |               |
| Barnabas, R           | MOAC0105LB*        |               |
| Bärnighausen, T       | TUAC0105           |               |
| Barrios, R            | WEAD0301, MOAC0103 |
| Bartali, B            | TUPD0103           |               |
| Basillo, M            | TUPD0101           |               |
| Bates, D              | TUAB0207LB         |               |
| Batlang, O            | MOPDB0104          |               |
| Bautista-Arredondo, S | TUAC0104, MOAC0205LB |
| Bavinton, BR          | TUAC0306*          |               |
| Baxter, C             | TUAC0101LB         |               |
| Bayus, B              | TUAD0104           |               |
| Bego, MG              | TUPD0103           |               |
| Behets, F             | TUAD0202           |               |
| Bekes, L-G            | WEAD0101, MOAB0104 |
| Belaunzarán-Zamudio, P | WEAD0104           |               |
| Bélec, L              | WEPD0101           |               |
| Beletsky, L           | MOPDD0103*         |               |
| Bellaton, E           | MOAA0105LB         |               |
| Benki-Nugent, S       | MOAB0103           |               |
| Benkirane, M          | MOPDA0103          |               |
| Bennai, Y             | TUAB0207LB         |               |
| Benne, C              | MOAA0102           |               |
| Bennett, A            | TUAC0303, WEPDC0104 |
| Bennett, K            | MOPDB0104          |               |
| Bennett, S            | MOAB0104           |               |
| Benson, P             | TUAB0103           |               |
| Berhanu, R            | MOAB0202           |               |
| Berkout, B            | TUPD0104           |               |
| Bermejo, M            | MOPAD0103          |               |
| Bernardi, G           | MOPAD0104          |               |
| Bernardi, S           | WEAD0204           |               |
| Bershteyn, A          | TUAD0101*          |               |
| Best, J               | TUAD0104           |               |
| Betz, B               | TUPD0105           |               |
| Beusenberg, M         | MOAB0101           |               |
| Bhek lee, S           | TUAB0101           |               |
| Bhardwaj, N           | TUAB0102           |               |
| Bhatti, L             | TUAB0203           |               |
| Bianchi, F            | TUAD0206           |               |
| Billaud, E            | TUAB0207LB         |               |
| Bingham, B            | WEPAD0101          |               |
| Bin, T                | TUPO0101           |               |
| Bisson, G             | MOAB0205LB         |               |
| Bitarakwate, E        | WEPDD0105          |               |
| Bitimwine, H          | WEAD0203           |               |
| Bitun, A              | WEPDC0101, WEPDC0102 |
| Blanchard, JF         | TUPD0102           |               |
| Blom, K               | TUPD0103           |               |
| Bloomenthal, D        | MOPDB0102          |               |
| Blosser, SJ           | MOAC0304LB         |               |
| Bock, N               | MOAC0301LB         |               |
| Bollu, O              | TUAD0205           |               |
| Bonczkowski, P        | WEAB0101           |               |
| Name               | Code     |
|--------------------|----------|
| Walker-Sperling, V  | MOAA0101 |
| Wallis, C           | WEPD0102*|
| Walmsley, S         | TUAB0201 |
| Wamalwa, D          | WEAD0201, MOAB0103 |
| Wambura, M          | MOAC0301LB* |
| Wanicwe, J          | TUAD0103 |
| Wanasi, P           | MOAC0204 |
| Wang, C             | TUAB0203 |
| Wang, J             | TUAD0103 |
| Wang, J             | TUAC0106LB |
| Wang, Z             | TUAC0301 |
| Warnke, A           | TUPD0101 |
| Warszawski, J       | MOAA0105LB |
| Waterhouse, D       | MOAC0303LB |
| Wawer, M            | WEPD0105 |
| Weaver, E           | MOAA0204 |
| Webb, GM            | TUPDA0106LB* |
| Wei, C              | TUAD0103 |
| Wei, X              | TUAB0103 |
| Weidle, P           | MOAC0303LB |
| Weiser, B           | MOAA0203 |
| Weiss, H            | MOAC0301LB |
| Weissenhorn, W      | TUPDA0103 |
| Welty, T            | MOPD0106 |
| Welty, T            | TUAD0205 |
| Wendoh, J           | MOAA0205 |
| Wenski, LK          | TUAD0202 |
| Werb, D             | MOPD0103 |
| Werlinrud Efsen, AM | MOAB0203 |
| Wertheim, IO        | TUPD0102 |
| Westgard, T         | WEPD0106 |
| Wiesner, L          | TUAD0103 |
| Wijayaratne, S      | WEAD0306LB |
| Wilen, C            | TUPD0102 |
| Wilkinson, L        | MOAD0105LB* |
| Williams, T         | TUAC0203 |
| Wilson, CM          | TUAC0204LB |
| Wilson, D           | WEAD0302 |
| Wimonsate, W        | TUAC0302 |
| Wittkop, L          | TUAB0207LB |
| Woelk, G            | TUAD0206LB |
| Wolf, E             | TUPD0105 |
| Wolff, M            | MOAD0103* |
| Wolters, L          | WEPD0103 |
| Wood, E             | MOPD0102, MOPD0105, |
|                     | TUAC0103, TUAC0405 |
| Woods, C            | MOPA0101 |
| Wu, HL              | TUPDA0106LB |
| Wu, V               | TUPD0102 |
| Wyles, D            | TUAB0203* |
| Wylie, JL           | TUPD0102 |
| Xaba, T             | WEPD0102 |
| Xia, G              | MOAC0304LB |
| Xiao, H             | TUAB0106LB |
| Xing, Y             | TUAC0106LB |
| Xu, D               | MOPD0105 |
| Xu, J               | TUAC0301* |
| Xu, X               | TUAB0104 |
| Yang, B             | TUAD0104 |
| Yang, JC            | TUAB0202 |
| Yang, L             | TUAD0104 |
| Yao, KA             | WEAC0102 |
| Yassi, A            | MOAD0104 |
| Yates, N            | TUAA0106LB |
| Yazdanpanah, Y      | TUAC0406LB |
| Yin, M              | TUPD0103 |
| Yindom, L-M         | TUPD0105 |
| Yotebieng, M        | TUDA0202* |
| Young, J            | TUAD0201 |
| Young, P            | TUDA0401 |
| Youngleson, M       | MOAD0105LB |
| Yu, Y               | TUAC0301 |
| Zablotska, I        | TUAC0303 |
| Zamor, P            | TUAB0206LB |
| Zang, O             | WEAD0303 |
| Zash, R             | MOPD0104 |
| Zerbe, A            | MOAB0107LB |
| Zhang, M            | WEPD0106 |
| Zhang, Y            | TUDA0203 |
| Zhang, Y            | TUDA0404 |
| Zhou, S             | MOPD0106LB |
| Zhuang, M           | TUAC0301 |
| Zhuang, M           | WEAD0204 |
| Ziegler, JB         | TUAD0205 |
| Zink, A             | TUPD0105 |
| Zink, C             | MOAA0101 |
| Zolla-Pazner, S     | TUAA0106LB |
| Zolopa, A           | MOAB0205LB |
| Zolowere, DB        | WEPD0103 |
| Zou, H              | TUAC0301 |
| Zuma, N             | WEAC0103 |
About the journal
The Journal of the International AIDS Society, an official journal of the Society, provides a peer-reviewed, open access forum for essential and innovative HIV research, across all disciplines.
All articles published by the Journal of the International AIDS Society are freely accessible online. The editorial decisions are made independently by the journal's editors-in-chief.
Email: editorial@jiasociety.org
Website: http://www.jiasociety.org
eISSN: 1758-2652

Publisher
International AIDS Society
Avenue de France 23
1202 Geneva, Switzerland
Tel: +41 (0) 22 710 0800
Email: info@iasociety.org
Website: http://www.iasociety.org

Indexing/abstracting
The Journal of the International AIDS Society is indexed in a variety of databases including PubMed, PubMed Central, MEDLINE, Science Citation Index Expanded and Google Scholar. The journal’s impact factor is 4.207 (*2013 Journal Citation Report® Science Edition - a Thomson Reuters product).

Advertising, sponsorship and donations
Please contact the editorial office if you are interested in advertising on our journal’s website. We also gladly receive inquiries on sponsorship and donations to support open access publications from authors in low- and middle-income countries.

Supplements
The Journal of the International AIDS Society publishes supplements, special issues and thematic series on own initiative or based on proposals by external organizations or authors. Inquiries can be sent to the editorial office at editorial@jiasociety.org. All articles submitted for publication in supplements are subject to peer review. Published supplements are freely searchable and freely accessible online and can also be produced in print.

Disclaimer
The authors of the articles in this supplement carry the responsibility for the content and opinions expressed therein. The editors have made every effort to ensure that no inaccurate or misleading content or statements appear in this supplement. However, in all cases, the publisher, the editors and editorial board, and employees involved accept no liability for the consequences of any inaccurate or misleading content or statement.

Copyright
The content in this supplement is published under the Creative Commons Attribution 3.0 Unported (http://creativecommons.org/licenses/by/3.0/) license. The license allows third parties to share the published work (copy, distribute, transmit) and to adapt it under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear. Authors retain the copyright of their articles, with first publication rights granted to the Journal of the International AIDS Society.

Editors
Editors-in-Chief: Susan Kippax (Australia), Papa Salif Sow (Senegal), Mark Wainberg (Canada)
Deputy Editors: Martin Holt (Australia), Kayvon Modjarrad (United States), Iryna Zablotska (Australia), Luis Soto-Ramirez (Mexico)
Managing Editor: Marlène Bras (Switzerland)
Editorial Assistant: Helen Etya’ale (Switzerland)

Editorial Board
Quarraisha Abdool Karim (South Africa), Laith J. Abu-Raddad (Qatar), Dennis Altman (Australia), Joseph Amon (United States), Jintanat Ananworanich (Thailand), Judith Auerbach (United States), Françoise Barré-Sinoussi (France), Chris Beyrer (United States), Andrew Boulle (South Africa), Carlos Cáceres (Peru), Elizabeth Connick (United States), Mark Cotton (South Africa), Jocelyn Dejong (Lebanon), Diana Dickinson (Botswana), Sergii Dvoriak (Ukraine), Nathan Ford (South Africa), Omar Galárraga (Mexico), Diane Havlir (United States), Aikichi Iwamoto (Japan), Adeeba Kamarulzaman (Thailand), Rami Kantor (United States), Ely Katabira (Uganda), Sukhontha Kongsin (Thailand), Kathleen MacQueen (United States), Navid Madani (United States), Jacques Mokhbat (Lebanon), Julio Montaner (Canada), Nelly Mugo (Kenya), Paula Munderi (Uganda), Christy Newman (Australia), Héctor Perez (Argentina), Sai Subhasree Raghavan (India), Renata Reis (Brazil), Linda Richter (South Africa), Jürgen Rockstroh (Germany), Naomi Rutenberg (United States), Gabriella Scarlatti (Italy), Tim Spelman (Australia), Ndèye Coumba Touré-Kane (Senegal), Ian Weller (United Kingdom), Alan Whiteside (South Africa), David Wilson (Australia), Iryna Zablotska (Australia)
